<SEC-DOCUMENT>0001140361-24-037067.txt : 20240813
<SEC-HEADER>0001140361-24-037067.hdr.sgml : 20240813
<ACCEPTANCE-DATETIME>20240813160616
ACCESSION NUMBER:		0001140361-24-037067
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240813
DATE AS OF CHANGE:		20240813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PDS Biotechnology Corp
		CENTRAL INDEX KEY:			0001472091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				264231384
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37568
		FILM NUMBER:		241201400

	BUSINESS ADDRESS:	
		STREET 1:		303A COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		800-208-3343

	MAIL ADDRESS:	
		STREET 1:		303A COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Edge Therapeutics, Inc.
		DATE OF NAME CHANGE:	20090911
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ef20030064_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:pdsb="http://pdsbiotech.com/20240630" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_f08a809b29bd48a6a680ed8557f68f14" contextRef="c20240101to20240630" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_c0d138abe17e4862ab752b2867564a46" contextRef="c20240101to20240630" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_072f3b40d75645adba292ef182a05e8f" contextRef="c20240101to20240630">2024</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_4dea9979fc924d1ba45cdaf9691f9c0f" contextRef="c20240101to20240630">Q2</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_f16cd320df8d4a8693e7d3fff1d6d21e" contextRef="c20240101to20240630">0001472091</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Fact_422456f8ef2547ffa808d9e7f65aa170" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember">http://fasb.org/us-gaap/2024#PrimeRateMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Fact_89027c97a3984c949cabb17cf3986c08" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember">http://fasb.org/us-gaap/2024#PrimeRateMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Fact_1d2392fd0bf043fea9df39565196af84" contextRef="c20240630_RangeAxis_MinimumMember">P4Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="pdsb-20240630.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240101to20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220801to20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_DebtInstrumentAxis_LoanFMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_DebtInstrumentAxis_LoanEMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220824to20220824_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-24</xbrli:startDate><xbrli:endDate>2022-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230714_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201208_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141231_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190617_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240122_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220517_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201208_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240630_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>pdsb:Loan</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>pdsb:Lease</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
<div style="line-height: initial;">

  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <!-- base href="file:///C:/Users/SayaP/AppData/Local/Temp/PROfile/ftkylt1r.3y5/expand/content/form10q.htm" -->
      <div></div>

      <!-- Licensed to: Broadridge Financial Solutions
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
      <div>
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
        <div>
          <div style="text-align: center; margin-right: 6.6pt; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">UNITED STATES</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; margin-right: 7.7pt; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">SECURITIES AND EXCHANGE COMMISSION</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_365e905914894c9e87dfc63bc0d433c1" contextRef="c20240101to20240630">10-Q</ix:nonNumeric></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">(Mark One)</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_5ca304fb07da461ca129d06543e993cd" contextRef="c20240101to20240630" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
                  </span> </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="font-weight: bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_7d81142ab3ad40e2949129fd6cbb370f" contextRef="c20240101to20240630" format="ixt:date-monthname-day-year-en">June 30, 2024</ix:nonNumeric></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_00ee2abdf8c8430681efab904ca8da03" contextRef="c20240101to20240630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
                  </span> </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">&#160;<span style="font-weight: bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">For the transition period from ____________ to _____________</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; margin-right: 4.4pt;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">Commission file number <span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_7ddc5e54b9cf466fa1169764ce556209" contextRef="c20240101to20240630">001-37568</ix:nonNumeric></span></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 24pt;">
                  <div style="text-align: center; text-indent: -0.9pt; margin-left: 3.75pt; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_f964a16257724463a8445f1887e2c1d2" contextRef="c20240101to20240630">PDS Biotechnology Corp</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">oration</span></div>
                </td>

    <td style="width: 20.4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Exact name of registrant as specified in its charter)</div>
                </td>

    <td style="width: 20.4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_108477a6b87d42e491b88f5ec1126bba" contextRef="c20240101to20240630" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_a54f2ecdd73e4f5191235f88796cbca0" contextRef="c20240101to20240630">26-4231384</ix:nonNumeric><br/>
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(State or other jurisdiction of incorporation or organization)</div>
                </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(IRS Employer Identification No.)</div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_d6aff782196d4c94a68ccf91f13cbf93" contextRef="c20240101to20240630">303A College Road East</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_4a7f1ed407d44ee2817b8b1928611841" contextRef="c20240101to20240630">Princeton</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_e13ebfad41454ddebb7fbbbc352058cf" contextRef="c20240101to20240630">NJ</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_3494373f1a774d2499fe5604a0e79984" contextRef="c20240101to20240630">08540</ix:nonNumeric></div>
                </td>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 40%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Address of principal executive offices)</div>
                </td>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_c9ad349634274b8bbc9b705b9b76ed96" contextRef="c20240101to20240630">800</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_5ce13dd8645e4ba9b7d5201a109d382a" contextRef="c20240101to20240630">208-3343</ix:nonNumeric></div>
                </td>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Registrant&#8217;s telephone number)</div>
                </td>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 20.42%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20.42%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Former name, former address and former fiscal year, if changed since last report)</div>
                </td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">Securities registered pursuant to Section 12(b) of the Act:</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
                  <div style="font-family: 'Times New Roman';">Title of each class</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; text-align: center; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
                  <div style="font-family: 'Times New Roman';">Trading symbol(s)</div>
                </td>

    <td style="width: 2.19%; vertical-align: bottom; text-align: center; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">Name of each exchange on which registered</div>
                </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_d8e50348cbed49ef98d75054f982159e" contextRef="c20240101to20240630">Common Stock, par value $0.00033 per share</ix:nonNumeric><br/>
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_60d9272f8d054c4da2408f1fb2c4a4c0" contextRef="c20240101to20240630">PDSB</ix:nonNumeric><br/>
                    </span> </div>
                </td>

    <td style="width: 2.19%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">The <ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_96d178427bee42eea07fbee625cea55e" contextRef="c20240101to20240630" format="ixt-sec:exchnameen">Nasdaq Stock Market</ix:nonNumeric> LLC<br/>
                    </span> </div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
            months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_0661ef6d819f41afa5efab5e655a882e" contextRef="c20240101to20240630">Yes</ix:nonNumeric> &#9746; No &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section
            232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_72ac275f41424fea87c6d34a99561711" contextRef="c20240101to20240630">Yes</ix:nonNumeric>
            &#9746; No &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
            company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Large accelerated filer &#9744;</div>
                </td>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Accelerated filer &#9744;</div>
                </td>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_62016895bcd1415d9bc1f508ea7b9d22" contextRef="c20240101to20240630" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> &#9746;</div>
                </td>

    <td style="width: 26.36%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Smaller Reporting Company <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_418a1a222fc545eaa32b66f2d8a1aacd" contextRef="c20240101to20240630" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 100%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_8eeeb46ff3834f038c54e85e0d37d14b" contextRef="c20240101to20240630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">&#160;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
            accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_8e85e7ac1d4f4fa18774ed0f798706ac" contextRef="c20240101to20240630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160; No &#9746;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">The number of shares of the registrant&#8217;s Common Stock, par value $0.00033 per share, outstanding as of August 6, 2024 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_4eff5ee365bd4e319dcd0de8ed2bda73" contextRef="c20240806" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">36,819,810</ix:nonFraction>.</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div>
            <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after:always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          </div>

          <!--PROfilePageNumberReset%Num%2%%%--></div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION</div>

    <div style="text-align: left;"><br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM 10-Q FOR THE QUARTER ENDED June 30, 2024 </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><!--Anchor--><a id="INDEX"><!--Anchor--></a>INDEX</div>

    <div style="text-align: left;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Page</div>
          </td>

  </tr>

  <tr>

    <td colspan="3" style="width: 91.97%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Part I &#8212; Financial Information</span></span></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Financial Statements (Unaudited):</div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#BalanceSheets">Condensed Consolidated Balance Sheets</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ComprehensiveLoss">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#StockholdersEquity">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CashFlows">Condensed Consolidated Statements of Cash Flows</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">6</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#Notes">Notes to Condensed Consolidated Financial Statements</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">7</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#MANAGEMENTSDISCUSSION">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">17</div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#QUANTITATIVE">Quantitative and Qualitative Disclosures About Market Risk</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">32<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CONTROLS">Controls and Procedures</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td colspan="3" style="width: 91.97%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Part II &#8212; <span style="font-family: 'Times New Roman'; font-size: 10pt;">Other Information</span></span></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#LEGALPROCEEDINGS">Legal Proceedings</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1A.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#RISKFACTORS">Risk Factors</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#UNREGISTEREDSALES">Unregistered Sales of Equity Securities and Use of Proceeds</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#DEFAULTSUPON">Defaults Upon Senior Securities</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#MINESAFETY">Mine Safety Disclosures</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 5.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#OTHERINFORMATION">Other Information</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 6.</div>
          </td>

    <td style="width: 78.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#EXHIBITS">Exhibits</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">33<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.19%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">&#160;</td>

    <td style="width: 78.78%; vertical-align: top;">&#160;</td>

    <td style="width: 8.03%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td colspan="3" style="width: 91.97%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#EXHIBITINDEX">EXHIBIT INDEX</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34<br/>
            </div>
          </td>

  </tr>

  <tr>

    <td colspan="3" style="width: 91.97%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#SIGNATURES">SIGNATURES</a></div>
          </td>

    <td style="width: 8.03%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">35<br/>
            </div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
        </div>

      </div>

    </div>

    <!--PROfilePageNumberReset%Num%3%%%--> </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                    <div style="font-weight: bold;"><span style="font-family: 'Times New Roman';">PART 1. &#160;&#160; <br/>
                      </span> </div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="font-weight: bold; font-family: 'Times New Roman';">&#160;FINANCIAL INFORMATION</div>
                  </td>

  </tr>


</table>
          </div>

          <div style="font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                    <div style="text-align: left; font-weight: bold; font-family: 'Times New Roman';">ITEM 1.</div>
                  </td>

    <td style="vertical-align: top; width: auto;">
                    <div style="text-align: left; text-indent: -45pt; margin-left: 45pt; font-weight: bold;"><!--Anchor--><!--Anchor--><span style="font-family: 'Times New Roman';">FINANCIAL STATEMENTS</span></div>
                  </td>

  </tr>


</table>
          </div>

          <div style="text-align: center;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="text-align: center; font-weight: bold;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

          <div><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="text-align: center; color: rgb(0, 0, 0);"><!--Anchor--><span style="font-weight: bold; font-family: 'Times New Roman';"><!--Anchor-->Condensed Consolidated</span><a id="BalanceSheets"><!--Anchor--></a><span style="font-family: 'Times New Roman';"> <span style="font-weight: bold;"><!--Anchor-->Balance Sheets<!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--></span></span><!--Anchor--></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
          </span></div>

          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"><span style="font-family: 'Times New Roman';"><br/>
                  </span> </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2024</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">ASSETS</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &amp;amp;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(unaudited)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Current assets:</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Cash and cash equivalents</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_58cd4bde50064e879484494d9c2b33ff" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">57,733,724</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2c5533225ad44d25b51f3b96b8ebdedf" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,560,517</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt;"><span style="font-family: 'Times New Roman';">Prepaid expenses and other assets<br/>
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_ba5045bb2b1146809daf8b45a5ff6b4d" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,427,752</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_a6f868956f5141c3b6d5dfba703002a3" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,494,558</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total current assets</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_8e82065c38b4463cb75c905e217dc8bd" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,161,476</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_de9ac827d7464354846d0e8450cfce8f" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">59,055,075</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Property and equipment, net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_1610703be8d14131b468dd1feb95d5b8" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">152,938</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_e3123f90e91241e09fb614e4acf21877" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">134,132</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px;">
                  <div style="text-align: left; font-size: 10pt; margin-left: 9pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Financing lease right-to-use assets</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" id="Fact_ec51644928f342fab65fffab15c9344e" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">181,533</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" id="Fact_79bdfa67c2564faea68c946258c3b0f4" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,873</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Total assets</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Assets" id="Fact_4281ffb1886b4fcf81a360ce214507dc" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,495,947</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Assets" id="Fact_9e0f5b2a7aae49e0a944cd5525cb1a74" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">59,390,080</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Current liabilities:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Accounts payable</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_46d1f113f7064383b9c0a53ae3c621cb" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,252,490</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_786bc17e06704462a43e5cc423205c58" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,982,824</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Accrued expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_77f4221a3d974b8d89b110b90f8789c8" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,947,221</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_f5980f0733194e649c543011e04d0352" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,424,692</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;">
                  <div style="text-align: left; font-size: 10pt; margin-left: 18pt; font-family: 'Times New Roman';">Note payable - short term<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:SecuredDebtCurrent" id="Fact_ce14fa90f5494ac79cfdd63233ef9645" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,416,667</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:SecuredDebtCurrent" id="Fact_94d908d2f64f4532b23ca882e0b2309c" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,166,667</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Financing lease obligation-short term</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_c3b204cfdc6b4f5caed50e956c265830" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">58,396</ix:nonFraction><br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_c4ead7d41220453493b668ae358966dc" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">55,794</ix:nonFraction><br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="margin-left: 27pt; font-family: 'Times New Roman';">Total current liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_c9c498fc16054a4aa66ae8b81d8ce318" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">15,674,774</ix:nonFraction><br/>
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_265b5300de1f4c238f300aa6f6149985" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,629,977</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Noncurrent liabilities:</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Note payable, net of debt discount</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:SecuredLongTermDebt" id="Fact_e79f4575e7a24f05a2aa0ae73e620e02" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,810,194</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:SecuredLongTermDebt" id="Fact_b4272ad0792244358be9eed96e8c20d7" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,506,183</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Financing lease obligation-long term</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_68f4c5b4c5504fbdad7e92f20176f50c" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">93,109</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_5099de4cb3a24d3389dd6cb3fde33fbc" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">122,973</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total liabilities:</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_ee4953fdccaa4d9f83a899fd467ecb68" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,578,077</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_d48a783ef7c34207b4346111c6e48cd0" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33,259,133</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);" rowspan="1">
                  <div>Commitments and contingencies (Note 9)<br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);" rowspan="1"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_b89f2e2578874178bf16bcc1e04dd3a1" contextRef="c20240630" unitRef="U002" xsi:nil="true" format="ixt:fixed-empty"/></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);" rowspan="1"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_5aa038bc69c34112a5aef9902797a2cd" contextRef="c20231231" unitRef="U002" xsi:nil="true" format="ixt:fixed-empty"/></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';"><br/>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">STOCKHOLDERS&#8217; EQUITY</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;"><span style="font-family: 'Times New Roman';">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_7fc4e9303fe54351bb936ee19fac6ba4" contextRef="c20231231" unitRef="U003" decimals="5" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_7d30ba7895bd44b5a86d32726ade556b" contextRef="c20240630" unitRef="U003" decimals="5" scale="0" format="ixt:num-dot-decimal">0.00033</ix:nonFraction></ix:nonFraction></span>
                      par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_9ea3813345f04264ae05aad2f019aed8" contextRef="c20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_c1d6edd4a74946dc86d394f8a8266b47" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></span>
                      shares authorized at <span style="text-indent: 0pt;">June 30</span>, <span style="text-indent: 0pt;">2024</span> and December 31, <span style="text-indent: 0pt;">2023</span>, respectively; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_f0f11dbb8be043328c4a902918a9f7f1" contextRef="c20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_60c96c45e048489194d15ac4f738b38d" contextRef="c20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">36,779,275</ix:nonFraction></ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_c505db1117d54edd9e5e1185e5b97229" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_4bb1937319384ea08ca73051de15f9c3" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">33,094,521</ix:nonFraction></ix:nonFraction></span>
                      issued and outstanding at <span style="text-indent: 0pt;">June 30</span>, <span style="text-indent: 0pt;">2024</span> and December 31, <span style="text-indent: 0pt;">2023</span>, respectively</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_a47bde7256bc458086cdb2556c8d25ed" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,137</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_b828a76b6b95439bbd99e74407b29be2" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,921</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Additional paid-in capital</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_50674871eb3e46a584b9df2dbdafd92d" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">194,337,722</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_d9f9ca9030864b54a06a464ad811e628" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">170,620,641</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Accumulated deficit</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_7f6e65f53dea4969ada42ab21649e6c6" contextRef="c20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">163,431,989</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_e5fa26da84dd45efbe0ac5bc5ebaa25f" contextRef="c20231231" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">144,500,615</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total stockholders&#8217; equity</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_08b733a4e2414b378a9aed24878392b1" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">30,917,870</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_89d2a3f6b0aa42899a92a6294c698b6d" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,130,947</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';"><br/>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total liabilities and stockholders&#8217; equity</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_8b3940b36839447b938cbc07d93e5530" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,495,947</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_3180b1082b314039be709c6632793839" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">59,390,080</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="font-family: 'Times New Roman';">See accompanying notes to the condensed consolidated financial statements.</div>

          <div><span style="font-family: 'Times New Roman';"><br/>
          </span></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

            </div>

          </div>

          <!--PROfilePageNumberReset%Num%4%%%--> </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="ComprehensiveLoss"><!--Anchor--></a><span style="font-family: 'Times New Roman';">Condensed Consolidated Statements of
        <!--Anchor-->Operations and Comprehensive Loss<!--Anchor--></span><!--Anchor--><!--Anchor--><!--Anchor--></div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>

    <div style="text-align: left;"><span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Three Months Ended June 30,</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Six Months Ended June 30,</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2024<br/>
              </span></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2023<br/>
              </span></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2024<br/>
              </span></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2023<br/>
              </span></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating expenses:</div>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development expenses</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_8bba540a61a4413faccfea9f3ae4f817" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,527,698</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_fd5627f320894633aa7860de8ca23890" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,004,852</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_60ce88eebee04e13821339f1516a7d49" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,231,862</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_eaa294547e034ac8802375de78cd1af6" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,848,538</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">General and administrative expenses</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_5b78f82529644b048abc0c85b43ae6b2" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,156,606</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_fc09345edcf749d1b39251e3faa13f32" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,691,321</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_e1ac8b1e75134de6be703d1c502e7d8c" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,550,069</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_e4d4eca890a84f02bf8319cba6f1edcb" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,270,049</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total operating expenses</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_9aef51dd433c4069aeff637002eb389b" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,684,304</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_57b4430b66f74d9fb17fe684467c4354" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,696,173</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_96358d707af447a59eed7925afc22495" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,781,931</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_dafa5490aa4641598d8f94925b0d5359" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,118,587</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Loss from operations</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_898151dcf1644cd59b775729f9a90292" contextRef="c20240401to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,684,304</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_5edb96973b724027b45f9390f263a93e" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">12,696,173</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_3f8e84babafc444d940c15e80df89a8a" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">18,781,931</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_55f1ee071a5947a281a65ebef312bba9" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">22,118,587</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%; background-color: #CCEEFF;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Interest income (expenses), net</div>
            </div>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#160;Interest income<br/>
                  </span></div>
              </div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_cfd8d9f4cca14b1f8b89dac2662007fa" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">675,209</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_f546e4c345224266b4572bc952e24ad7" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">750,654</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_c72eb3371158441cb3df2babec54eede" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,344,104</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_14a025f188e74c01b7d1ec46d20657d3" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,479,995</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160; Interest expense</div>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_39b65869a0fc438babeaed2d84f851dd" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,187,971</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_64688066719f4f7982e9c045fd507b57" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">995,397</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_8ffbd5c0a9fa4f50a7ff8cfde83aeb44" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,362,716</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_db6c0fb8bd79405faf92eace357936b8" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,962,242</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%;" rowspan="1">Interest income (expenses), net</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_48abaa1ffa8c41c7ad6a9669ab79c8e0" contextRef="c20240401to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">512,762</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_c71b680948334f36a50bc3ef78b3b47c" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">244,743</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_cf42185cfb204234b631c15914d37691" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,018,612</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_669db3e4ba764a36b50546bf4b19c450" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">482,247</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%;" rowspan="1">Loss before income taxes<br/>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_f3b6d2ac2b544885b1b78ad1cb9eb5ad" contextRef="c20240401to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,197,066</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_7b7e2675a18a4381a66dfdf14bf04af0" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">12,940,916</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_c8a061bd96cd48d590b05fe5911f2dc6" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">19,800,543</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_36345dc525824836b021e79d677f162b" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">22,600,834</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">Benefit for income taxes<br/>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_741a3bc5ce42437ebf5bde3b6ca22418" contextRef="c20240401to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">869,169</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_2fbc1f6ec23f4cab9be6dbe965034b63" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,406,021</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_8875565866f04fad97fede3b00df085b" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">869,169</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_41e3216bba3f491b9fdee385492ef66e" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,406,021</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net loss and comprehensive loss</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_377ea27d197048f5942f829f477da39b" contextRef="c20240401to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c8e74a3f54754ac39f048f57d5655ce4" contextRef="c20240401to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,327,897</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_168c4bd943c74e22990b18bddbaea573" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_26f7a6d1b18248619a757ae546ef3889" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">11,534,895</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_810abc1986434ae3a3079c95e9cddff9" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_31fde16c696c42ba979f6f8f06f778cd" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">18,931,374</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_9de7ba64ee8e4fa182f316fcfb74a14d" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_fa688cb517e6427aa1dfb4e6dfc0cdd1" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">21,194,813</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Per share information:</div>
            </div>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net loss per share, basic and diluted</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_843d6131b1344b5abc58409f48041fad" contextRef="c20240401to20240630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_524e9b25a74a44b499d2bf8b8b6e73f6" contextRef="c20240401to20240630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.23</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_00d43245b3ca4deba80dcfa6b75e1d6e" contextRef="c20230401to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_0f2d6c5a0b3f41c2a504bf9a4dd94a10" contextRef="c20230401to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.37</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_01b8a864ef314062b7cb0c77d1e0cff7" contextRef="c20240101to20240630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_4d64c8a7c73f4f298033d85bb655d9e2" contextRef="c20240101to20240630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.53</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_33ef74912c5b40c697f7297fd319b8ad" contextRef="c20230101to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_d8e5cb42cc494cb89598ace68a4074a5" contextRef="c20230101to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.69</ix:nonFraction></ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted average common shares outstanding, basic, and diluted</div>
            </div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_c191ceb8a4e9404c8a7243fc8090441f" contextRef="c20240401to20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_185868c66f3d4f17bf5677657b204c94" contextRef="c20240401to20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">36,693,561</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_58fa32f85fbf475f99e3641379dcde87" contextRef="c20230401to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_68db77a33a334551993cf150bb508a98" contextRef="c20230401to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,802,498</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_7af4ec41069a445bb2fcfd3f8290a668" contextRef="c20240101to20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_89edddddde5a47439dbc98e49215eb5d" contextRef="c20240101to20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">35,754,715</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_16be6bf8c60f44d19a8ef1f960cd84c3" contextRef="c20230101to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_dfb97dd9234e4da1961c0bbfecef1e66" contextRef="c20230101to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,616,310</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes to the condensed consolidated financial statements.</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="StockholdersEquity"><!--Anchor--></a><span style="font-family: 'Times New Roman';">Condensed Consolidated Statements of Changes in
        <!--Anchor-->Stockholders&#8217; Equity<!--Anchor--></span><!--Anchor--><!--Anchor--><!--Anchor--></div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Common Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-weight: bold; text-align: center;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-weight: bold; text-align: center;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Issued</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Paid-in </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Capital</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Accumulated </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Deficit</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Total Equity</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">January 1, <span style="text-indent: 0pt;">2023</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a17f18e557ee453eb9b345ee86e10817" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,170,317</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6c87cf06e4344f1d9211f5c112e479dc" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,956</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_511f41f42528440ea8325a94861d1ca2" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">145,550,491</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d34bac104ab2426ea302532f79b45316" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">101,558,417</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3a31dea4cc304adab1341e91f0accd27" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">44,002,030</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock-based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_8b4457e26a7b4ffebca507e9cdc2c09c" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_b7cc6b9c7ea74b4f994c8650dcaeebdf" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,080,319</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_1b297cf17dbf4fbbb2aaaf7d27b7277a" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_690ed19515384e1c9157b25169bb7314" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,080,319</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;">Issuances of common stock from the Sales Agreement, net</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_b40f15915a074a118366ae28a34dc4df" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">553,293</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_85dffa3f4df549eb9ab5c8f4d5f53d95" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">183</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_3663bb5de7dc4d5292a36e5b9fb7132f" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,588,339</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_b5033d45247441a2a56c0d7283db88c8" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_9680e474dfb24de897c9bb3db591ef97" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,588,522</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ff7cc99dd1814c8bb80dff7a88d65f26" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8d587fa7eb16423783d2f39dd1e6e0f2" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_426b3e6a049a42128e770a0f1ad0ffa1" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,659,918</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8f9c7a771886444fae5fbfca75bb2256" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,659,918</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - March 31, <span style="text-indent: 0pt;">2023</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f2b6d1fb9ee8400296441c92c3c97e32" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,723,610</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_86cd78018b2e4add888676bb01f5cb1d" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,139</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d413b1cf114a40af8421545e281be822" contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">152,219,149</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_65d0918c4cc84c86a0047b04359965a0" contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">111,218,335</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c85a1a5e4a554f6a96a46409d5b9e36f" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">41,010,953</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_b85c7ec911b3480ebf5444cad3d1d0bd" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_1f3370fc68d14f888eb92a8e8abed6a3" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,105,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_bb7476561dbe46cd954c1ffa0311a444" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_bee912fdb9e74e2d800f3a005cd60d64" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,105,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Issuances of common stock, from exercise of stock options</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_b5e1bccf07d8419b87791f922445e2ab" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,409</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_dc6899b61ec746b4a51cde21f8c57655" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f369d9748bd44041b7ff93f6b3bab9e2" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,848</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_6ade92214ef94d5ca736adc32e0bff2b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_0086ef5ffd6442fa966e61209177fbf4" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,849</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">Issuance of common stock for consulting agreement<br/>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_63510e87950048a68de6da465788a29e" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_96edb979f57a43518642c7423961f938" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_0b8515dc5ce74900b86af418de4b306b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">609,967</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_3cafb53ffece480c9a4769a605221ed4" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_741c3fb923734502ac34386f608b3b70" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">610,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;" rowspan="1">Issuances of common stock from the Sales Agreement, net<br/>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_2c9e059cbabe4a36bf3394344aa007a6" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">43,169</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_e46106bc44ec4ecf96b32b8d97703e74" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_4e1430e0dbfe477aa807b82022c617f4" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">243,729</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_40f0e21ea0ba4d3596d326d2c6148be1" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_b47f196eedb148be8d5c2d5119073abf" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">243,743</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7f502060fb224d63aed8d554784d1dd3" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e41678e80515408c8bbcf24adfb9ab6a" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e786e9af6dc547679a1c10fa8746d577" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">11,534,895</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_449bf0e5bb824f9584f29a3881304880" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">11,534,895</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - June 30, 2023</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_3ceef7e34b454135a68b80a937afd5ed" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,868,188</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_5ba641eef356458187afee7cc0b888d3" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,188</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_db53b31ccb6c419bbba68b32b23752c3" contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">155,187,231</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b3b0f61b06724ac68b273da4d2c64a72" contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">122,753,230</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_40e6a6c748d04c0087ac656e02ac8e7d" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">32,444,189</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Common Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Issued</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Paid-in </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Capital</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Accumulated </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Deficit</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Total Equity</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">January 1, <span style="text-indent: 0pt;">2024</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_072bee52c106457c86537fd1b853f60e" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">33,094,521</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d4b889cfacc346acb1a8e5dfe4b8e3b7" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,921</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c22de3d64b7d4909a6392c3016acac01" contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">170,620,641</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e6d4f19c24454031acd521ec311b58e8" contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">144,500,615</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_aca96ffd59e9401394bb5c370ade91da" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,130,947</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock-based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_d56e24862104405ba96c470b0c5a507e" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_4d56635128854c1e8cddbd744611499b" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,630,011</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_23dba73f6ee84414871e4385d8fb7c7a" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_03688abcd4da4b7aa2305dea2d82322b" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,630,011</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;">Issuances of common stock from the Sales Agreement, net</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_33b829a3541d4a8a86b8158acb78b304" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,428,681</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_4dfa382e0007474085c3b1ad4b320dfb" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,131</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_3a02eb81c3994f40bac63d6a55ce06ff" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,493,342</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_d8b1ee21a0cb42c98450ef64468ea012" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_f150f45c2e50497788e728e25403d1cd" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,494,473</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 40%;" rowspan="1">Issuances of common stock, from exercise of stock options</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_48937b3ee3a54b7c8f4482535451f19a" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">156,073</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f1b973da455f4f12805872dec6d2f301" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">52</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_190d16b1c2484a1c86dc05498b366de2" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">531,039</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_3d1dbb0554d64eecbc503b6b78975a0a" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_407b79332b4d4a62aa0c02901e0f1878" contextRef="c20240101to20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">531,091</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_94d3fd92b5064269bde0299620830d7c" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a794180720ef4128b5b6d4fc2446190a" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b8147a09fd0442e78e62f4df4ed9d3b0" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e157fabb85b745e1932a472cbf7796e5" contextRef="c20240101to20240331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,603,477</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - March 31, <span style="text-indent: 0pt;">2024</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_83f27d7992ca4ce38ae96a66f6d63597" contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">36,679,275</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4c499ff1726c4752b57aa3059e2d7833" contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,104</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6ba72e7db42744c2af96276ec0f7f0e9" contextRef="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">192,275,033</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4821885b92004a529b329ab49377a98f" contextRef="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">155,104,092</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6d2558224bab4ed88eefcd02275acf18" contextRef="c20240331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">37,183,045</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock-based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_55e84919f4d447e6871c51d747267c5b" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_cb691ab584cd41d9bce0e3d5ed1143a4" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,795,722</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_09f20ccd89394565bce47b581e9f910a" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_feba92dd57fa49c381ae4bc87588edd5" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,795,722</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">Issuances of common stock for consulting agreement<br/>
            </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_77c4e1bf646a44b6970417d5b414bd8b" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_f9a8f7d0af8444f0a05172e33d0b5ab1" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_e1e4d1ecb1374d57880d742101331383" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">266,967</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_e796889cbc5148e991f85c5faeafabb1" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_0e871a26d44b4bfda5ebbc687e88f187" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">267,000</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f06854d265a5405f98b10984b0e5c414" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bfd14e1d54624ce1aab7d2dd30f71798" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_25cbc41faaed41c1b338609faac4adbc" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,327,897</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6403afe5eab345149fe7550a2a19a897" contextRef="c20240401to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,327,897</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - June 30, <span style="text-indent: 0pt;">2024</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_9cce72280d284a9599dc859108110d3b" contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">36,779,275</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_fba67b7742be4d77a97121246f69178f" contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,137</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d5a9819ca3984b069f6b69b6182d72e2" contextRef="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">194,337,722</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1b2529990feb492a92e7726e8e52c909" contextRef="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">163,431,989</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4de60f016f7f4195a01e8f656e3da696" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">30,917,870</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    </div>

    <div><span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes to the condensed <span style="font-size: 10pt; color: rgb(0, 0, 0);">consolidated</span> financial statements.</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
      </span> </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

      <div class="BRPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

          <div style="text-align: center;"><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-weight: bold; font-family: 'Times New Roman';">Condensed Consolidated</span><a id="CashFlows"><!--Anchor--></a><span style="font-family: 'Times New Roman';"> <span style="font-weight: bold;"><!--Anchor-->Statements









































                of
                <!--Anchor-->
                <!--Anchor-->
                <!--Anchor-->Cash Flows<!--Anchor--><!--Anchor--><!--Anchor--></span></span><!--Anchor--></div>

          <div style="text-align: center;"><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">(Unaudited)</div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; font-family: 'Times New Roman';">Six Months Ended June 30,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">2023<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman';">Cash flows from operating activities:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Net loss</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d371d6fbe1354307a068ad80d618fff1" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">18,931,374</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_94324c0eb01f4d78ab4b8a7ab7648aa5" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">21,194,813</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Adjustments to reconcile net loss to net cash used in operating activities:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Stock-based compensation expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_19524dc183204ac1b88f093e14182f09" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,425,733</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_7a171c8858d841dbad59a31eb2bc56ed" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,185,857</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-indent: 18pt; width: 76%;" rowspan="1">Issuance of shares in consulting agreement<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" id="Fact_9ce9a1b0760740348462701707abc445" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">267,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" id="Fact_7c38ed89148044379746f406ebb4109b" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">610,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt; font-family: 'Times New Roman';">Amortization of debt discount</div>
                  </div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_37285b0b0389433395bf5663b8bb67de" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">554,010</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_311932628c8646a6a3621521ecbf96f5" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233,523</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Depreciation expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_9fd022416b1f49e79fdbcaed89bec187" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,194</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_5bfa810d6a294d5ba208c0bcac554954" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,891</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Operating lease expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_54f58908287d426daaabae3c8f08cc91" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_75dc8cdf88624289874cc5c58695b644" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">120,514</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;" rowspan="1">
                  <div style="text-align: left; font-size: 10pt; margin-left: 18pt; font-family: 'Times New Roman';">Finance lease depreciation expense</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" id="Fact_f9f9eb8d87ed45ef9b05ab7106143ce6" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,339</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" id="Fact_9cdb85ab45414581b426c66fffd02146" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,627</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Changes in assets and liabilities:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Prepaid expenses and other assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_858f426ff4c74716a781aa7e8902fa7f" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">66,806</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_ab269d9c446b4856834a99390a2a02eb" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">65,728</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="text-align: left; font-size: 10pt; margin-left: 27pt;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="font-family: 'Times New Roman';">Accounts payable<br/>
                      </span></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                  <div>
                    <div><span style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_87b046b4525c476c995ef62d960b674d" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">3,730,334</ix:nonFraction></span></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">
                  <div>
                    <div><span style="font-family: 'Times New Roman';">)</span></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_11bb94511a874f9ea2829ea6780ffdca" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,195,618</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Accrued expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_6364081558654232864d83f82cf9070a" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">477,471</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_05fb6f2adfcd48fbb150347bcfd8059e" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">4,937,383</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Operating lease liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" id="Fact_d7fcc916ba3847ecab7cda9d4a04f771" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" id="Fact_606bab05064b4b0692cae6a09cbd5760" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">179,136</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 43.2pt; font-family: 'Times New Roman';">Net cash used in operating activities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_4e49e35b1f0c44c28361e9edacc7f926" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">18,796,097</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_9cb099844ff24203bf74c4e5bfd94901" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">18,003,030</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1"><br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt; text-indent: -9pt;">
                    <div><span style="font-weight: bold;">Cash flows from investing activities:</span><br/>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-indent: 18pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">Purchase of equipment<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_482967e9f8f3417f868054fa9dc1e163" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">28,999</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_1ef334a8d6ad44f18c0a587db76f62dc" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-indent: 9pt; width: 76%; padding-bottom: 2px;" rowspan="1">
                  <div>Net cash used in investing activities<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_4fd31d7799e54baca82c7034ffbae15c" contextRef="c20240101to20240630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">28,999</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_1f95d420f0244007b8d59ed3792534c0" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;"><br/>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1"><span style="font-weight: bold;">Cash flows from financing activities:</span></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 9pt; margin-left: 9pt;">Proceeds from exercise of stock options</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_cc415224efb04d25ba05cc173d5caabc" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">531,091</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_4ba380215ecf48b8b842cf784e297b25" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,849</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="margin-left: 9pt; text-indent: 9pt;"><span style="font-family: 'Times New Roman';">Payments of finance lease obligations<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_11d1a799fb194ab6936a7c8ece91fa36" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">27,261</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_218e611bada94a729337f19ad71e93a3" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33,253</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman'; text-indent: 9pt;">Proceeds from issuance of common stock, net of issuance costs</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_dba17d320dfc44b99bfb3c92ff3af270" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,494,473</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_be8c38940bc141a8bd95dc5072e3760a" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,832,265</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="font-family: 'Times New Roman'; text-indent: 9pt;">Net cash provided by financing activities</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_445ab690f49748789b8fedc0156e06b0" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,998,303</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_5bc4bc501f644d5bb90284b0e1ae8215" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,807,861</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" rowspan="1"><br/>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman';">Net increase in cash and cash equivalents</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_5ebec0ba6e744fe6866f6d146f5845e7" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,173,207</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_bedab34420c148fab5f78ba13a80b8e8" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">13,195,169</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Cash and cash equivalents at beginning of period</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_16d44bf0396249b5961782ff1359c1bf" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,560,517</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_769d18960d694648b7413513b3783c55" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,820,160</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px;" rowspan="1">Cash and cash equivalents at the end of period</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_da0da21904364fa99772b2598d26579f" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">57,733,724</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2ee0b3c36cbf4ef2bcba60cc7c318854" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,624,991</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;"><br/>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Supplemental information of cash and non-cash transactions:</div>
                  </div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1"><br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: normal;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for interest</div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_31fc71d4c27340618443e63d4280769b" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,362,716</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_cc599f1b77cb4715a59577a5d57ffda0" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,962,241</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="font-family: 'Times New Roman';">See accompanying notes to the condensed consolidated financial statements.</div>

          <div> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div style="text-align: justify;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-weight: bold;">
            <div style="text-align: center;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

            <div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><!--Anchor--><!--Anchor--><!--Anchor--><a id="Notes"><!--Anchor--></a><span style="font-family: 'Times New Roman';"><!--Anchor--><!--Anchor-->Notes to Condensed Consolidated Financial Statements (Unaudited)</span></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

            </div>

          </div>
<ix:nonNumeric name="us-gaap:NatureOfOperations" id="Text_f99c036f06914cada08548bd403cf17e" contextRef="c20240101to20240630" escape="true" continuedAt="Text_a1d0da18dc8e441491ea0b86c96683ba1">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_a1d0da18dc8e441491ea0b86c96683ba1" continuedAt="Text_a1d0da18dc8e441491ea0b86c96683ba2">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"><!--Anchor-->Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211; </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_a1d0da18dc8e441491ea0b86c96683ba2" continuedAt="Text_a1d0da18dc8e441491ea0b86c96683ba3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a1d0da18dc8e441491ea0b86c96683ba3" continuedAt="Text_a1d0da18dc8e441491ea0b86c96683ba4">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br/>
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_a1d0da18dc8e441491ea0b86c96683ba4" continuedAt="Text_a1d0da18dc8e441491ea0b86c96683ba5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt;">
            <div>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                  <div>
                    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                      <div>
                        <ix:continuation id="Text_a1d0da18dc8e441491ea0b86c96683ba5">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">PDS Biotechnology Corporation, a Delaware corporation (the &#8220;Company&#8221; or &#8220;PDS Biotech&#8221;), is a clinical-stage immunotherapy
                            company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome limitations of current immunotherapy and vaccine technologies. The Company develops proprietary platforms designed to train and
                            enable the immune system to attack and destroy disease; Versamune&#174;, and Versamune&#174; in combination with PDS01ADC for treatments in oncology and Infectimune&#174; for treatments in infectious diseases.&#160; When paired with an antigen,
                            which is a disease-related protein that is recognizable by the immune system, Versamune&#174; and Infectimune&#174; have both been shown to induce, <span style="font-style: italic;">in vivo</span>, large quantities of high-quality,
                            highly potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of
                            Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the limitations of cytokine therapy which previously has resulted
                            in high toxicity and limited therapeutic potential.&#160; The Company&#8217;s infectious disease candidate, Infectimune&#174;, is of potential interest for use in universal influenza vaccines. and is designed to promote the induction of
                            disease-specific neutralizing antibodies.&#160; The Company&#8217;s immuno-oncology product candidates are of potential interest for use as a component of combination product candidates (for example in combination with other leading
                            technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage
                            disease.&#160; The Company is developing targeted product candidates to treat several cancer tumors, including Human Papillomavirus (HPV) associated cancer in head and neck squamous cell carcinoma, melanoma, colorectal, lung, breast
                            and prostate<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.<br/>
                            </span></span></div>
</ix:continuation>
                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Text_b2e98eba8f0e4774b2d74a1c8f25a31f" contextRef="c20240101to20240630" escape="true" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be1">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be1" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be2">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 2 &#8211; Summary of Significant Accounting
            Policies</div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be2" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be3" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be4">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be4" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be5"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_ae15636a958f48f590ed8b2b8efa9524" contextRef="c20240101to20240630" escape="true" continuedAt="Text_148adfed4b724dd89cb43f94c1f212bd1">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be5" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be6"><ix:continuation id="Text_148adfed4b724dd89cb43f94c1f212bd1" continuedAt="Text_148adfed4b724dd89cb43f94c1f212bd2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be6" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be7"><ix:continuation id="Text_148adfed4b724dd89cb43f94c1f212bd2" continuedAt="Text_148adfed4b724dd89cb43f94c1f212bd3">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>
</ix:continuation></ix:continuation></div>

        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be7" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be8"><ix:continuation id="Text_148adfed4b724dd89cb43f94c1f212bd3" continuedAt="Text_148adfed4b724dd89cb43f94c1f212bd4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be8" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be9"><ix:continuation id="Text_148adfed4b724dd89cb43f94c1f212bd4" continuedAt="Text_148adfed4b724dd89cb43f94c1f212bd5">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be9" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be10"><ix:continuation id="Text_148adfed4b724dd89cb43f94c1f212bd5" continuedAt="Text_148adfed4b724dd89cb43f94c1f212bd6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be10" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be11"><ix:continuation id="Text_148adfed4b724dd89cb43f94c1f212bd6">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> unaudited financial
                statements for all periods presented are referred to as &#8220;Condensed Consolidated Financial Statements&#8221;, and have been prepared by the Company in United States (&#8220;U.S.&#8221;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. Accordingly, these notes to the unaudited condensed consolidated financial statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities
                and Exchange Commission (&#8220;SEC&#8221;) on March 28, 2024. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited
                consolidated financial statements for the year ended December 31, 2023. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ent of the Company&#8217;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.</span></span></span></span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be11" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be12">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be12" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be13">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be13" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be14">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be14" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be15">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be15" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be16"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_8e8f7dfa7f71490682a0f73c10591bb1" contextRef="c20240101to20240630" escape="true" continuedAt="Text_770e0e2f13fe4b78aedc84544f397aa81">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be16" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be17"><ix:continuation id="Text_770e0e2f13fe4b78aedc84544f397aa81" continuedAt="Text_770e0e2f13fe4b78aedc84544f397aa82">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be17" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be18"><ix:continuation id="Text_770e0e2f13fe4b78aedc84544f397aa82" continuedAt="Text_770e0e2f13fe4b78aedc84544f397aa83">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be18" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be19"><ix:continuation id="Text_770e0e2f13fe4b78aedc84544f397aa83" continuedAt="Text_770e0e2f13fe4b78aedc84544f397aa84">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be19" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be20"><ix:continuation id="Text_770e0e2f13fe4b78aedc84544f397aa84" continuedAt="Text_770e0e2f13fe4b78aedc84544f397aa85">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be20" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be21"><ix:continuation id="Text_770e0e2f13fe4b78aedc84544f397aa85">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the condensed consolidated financial
            statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the condensed consolidated financial statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be21" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be22">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be22" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be23">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be23" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be24"><ix:nonNumeric name="pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" id="Text_c545e5abd9404e599145b2e2902aa2a4" contextRef="c20240101to20240630" escape="true" continuedAt="Text_fd95a7fd41b8403abf20e78acd5dabbc1">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be24" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be25"><ix:continuation id="Text_fd95a7fd41b8403abf20e78acd5dabbc1" continuedAt="Text_fd95a7fd41b8403abf20e78acd5dabbc2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be25" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be26"><ix:continuation id="Text_fd95a7fd41b8403abf20e78acd5dabbc2" continuedAt="Text_fd95a7fd41b8403abf20e78acd5dabbc3">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be26" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be27"><ix:continuation id="Text_fd95a7fd41b8403abf20e78acd5dabbc3" continuedAt="Text_fd95a7fd41b8403abf20e78acd5dabbc4">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>
</ix:continuation></ix:continuation>
                <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div>
                    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                      <div>
                        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be27" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be28"><ix:continuation id="Text_fd95a7fd41b8403abf20e78acd5dabbc4" continuedAt="Text_fd95a7fd41b8403abf20e78acd5dabbc5">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to complete clinical trials necessary to obtain regulatory <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">product licenses, the regulatory approvals needed to pursue </span>development







                          of its clinical and product candidates<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company&#8217;s adherence to covenants under its debt agreement, the Company&#8217;s</span> ability to preserve its cash resources, the Company&#8217;s ability to add clinical and product
                          candidates to its pipeline, the Company&#8217;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.<br/>
                        </div>
</ix:continuation></ix:continuation>
                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be28" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be29"><ix:continuation id="Text_fd95a7fd41b8403abf20e78acd5dabbc5" continuedAt="Text_fd95a7fd41b8403abf20e78acd5dabbc6">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be29" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be30"><ix:continuation id="Text_fd95a7fd41b8403abf20e78acd5dabbc6" continuedAt="Text_fd95a7fd41b8403abf20e78acd5dabbc7">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

            </div>

          </div>

          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be30" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be31"><ix:continuation id="Text_fd95a7fd41b8403abf20e78acd5dabbc7">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be31" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be32">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be32" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be33">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be33" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be34"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_01bbd76af7a6433f8426790f730739da" contextRef="c20240101to20240630" escape="true" continuedAt="Text_71186c6a56394714a59caec039b7d3e81">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be34" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be35"><ix:continuation id="Text_71186c6a56394714a59caec039b7d3e81" continuedAt="Text_71186c6a56394714a59caec039b7d3e82">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be35" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be36"><ix:continuation id="Text_71186c6a56394714a59caec039b7d3e82" continuedAt="Text_71186c6a56394714a59caec039b7d3e83">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be36" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be37"><ix:continuation id="Text_71186c6a56394714a59caec039b7d3e83" continuedAt="Text_71186c6a56394714a59caec039b7d3e84">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be37" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be38"><ix:continuation id="Text_71186c6a56394714a59caec039b7d3e84" continuedAt="Text_71186c6a56394714a59caec039b7d3e85">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be38" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be39"><ix:continuation id="Text_71186c6a56394714a59caec039b7d3e85">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be39" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be40">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be40" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be41">
<div><span style="font-family: 'Times New Roman';"> <br/>
        </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be41" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be42"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_17d0a550b2da44a2a4ae7181cf80533c" contextRef="c20240101to20240630" escape="true" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e1">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be42" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be43"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e1" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be43" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be44"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e2" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e3">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be44" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be45"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e3" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be45" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be46"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e4" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e5">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be46" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be47"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e5" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e6">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be47" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be48"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e6" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e7">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be48" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be49"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e7" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e8">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be49" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be50"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e8" continuedAt="Text_50fda46ead0a46bb88e1fce28c37b02e9">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be50" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be51"><ix:continuation id="Text_50fda46ead0a46bb88e1fce28c37b02e9">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be51" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be52">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be52" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be53">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be53" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be54"><ix:nonNumeric name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Text_d55a0bcd06fb41e088a5e0ddd7a36446" contextRef="c20240101to20240630" escape="true" continuedAt="Text_a85f9623fe324876804861ac1ccd0e381">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be54" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be55"><ix:continuation id="Text_a85f9623fe324876804861ac1ccd0e381" continuedAt="Text_a85f9623fe324876804861ac1ccd0e382">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be55" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be56"><ix:continuation id="Text_a85f9623fe324876804861ac1ccd0e382" continuedAt="Text_a85f9623fe324876804861ac1ccd0e383">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be56" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be57"><ix:continuation id="Text_a85f9623fe324876804861ac1ccd0e383" continuedAt="Text_a85f9623fe324876804861ac1ccd0e384">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be57" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be58"><ix:continuation id="Text_a85f9623fe324876804861ac1ccd0e384" continuedAt="Text_a85f9623fe324876804861ac1ccd0e385">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be58" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be59"><ix:continuation id="Text_a85f9623fe324876804861ac1ccd0e385">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be59" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be60">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be60" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be61">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be61" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be62"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_b1e49b3b2a11499ea3e20799bd91936b" contextRef="c20240101to20240630" escape="true" continuedAt="Text_1826e23d0a9844b19eab6d679b0e2b461">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be62" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be63"><ix:continuation id="Text_1826e23d0a9844b19eab6d679b0e2b461" continuedAt="Text_1826e23d0a9844b19eab6d679b0e2b462">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be63" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be64"><ix:continuation id="Text_1826e23d0a9844b19eab6d679b0e2b462" continuedAt="Text_1826e23d0a9844b19eab6d679b0e2b463">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be64" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be65"><ix:continuation id="Text_1826e23d0a9844b19eab6d679b0e2b463" continuedAt="Text_1826e23d0a9844b19eab6d679b0e2b464">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be65" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be66"><ix:continuation id="Text_1826e23d0a9844b19eab6d679b0e2b464" continuedAt="Text_1826e23d0a9844b19eab6d679b0e2b465">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be66" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be67"><ix:continuation id="Text_1826e23d0a9844b19eab6d679b0e2b465">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.</span> The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they
              occur.</div>
</ix:continuation></ix:continuation>
          </div>
<ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be67" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be68">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be68" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be69">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be69" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be70"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_267cafa3f35f467f880e864ab04514b9" contextRef="c20240101to20240630" escape="true" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c11">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be70" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be71"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c11" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c12">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be71" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be72"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c12" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c13">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be72" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be73"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c13" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c14">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be73" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be74"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c14" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c15">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be74" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be75"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c15" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c16">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be75" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be76"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c16" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c17">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be76" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be77"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c17" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c18">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be77" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be78"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c18" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c19"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_bd6c17c1239342398b7bffdd5d70af4d" contextRef="c20240101to20240630" escape="true" continuedAt="Text_54c3fe09a39f49d9b845f472a45f96761">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be78" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be79"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c19" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c110"><ix:continuation id="Text_54c3fe09a39f49d9b845f472a45f96761" continuedAt="Text_54c3fe09a39f49d9b845f472a45f96762">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be79" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be80"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c110" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c111"><ix:continuation id="Text_54c3fe09a39f49d9b845f472a45f96762" continuedAt="Text_54c3fe09a39f49d9b845f472a45f96763">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be80" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be81"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c111" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c112"><ix:continuation id="Text_54c3fe09a39f49d9b845f472a45f96763" continuedAt="Text_54c3fe09a39f49d9b845f472a45f96764">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be81" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be82"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c112" continuedAt="Text_1aa52c0977d249eb829c5f71b7e499c113"><ix:continuation id="Text_54c3fe09a39f49d9b845f472a45f96764" continuedAt="Text_54c3fe09a39f49d9b845f472a45f96765">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be82" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be83"><ix:continuation id="Text_1aa52c0977d249eb829c5f71b7e499c113"><ix:continuation id="Text_54c3fe09a39f49d9b845f472a45f96765">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="1" colspan="6">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" colspan="1">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_aac1457e1cae4c8797be9a328686ddb5" contextRef="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,563,211</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_3df308594a5642929508521c9449f647" contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,324,402</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" colspan="1">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_053877254e9b4087845f1c3083ffd80a" contextRef="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">466,112</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_053064ddb00f45bdbea9fef6ff02a7f3" contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">506,229</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_3fbb9c257ee148939e9aac3f79f48205" contextRef="c20240101to20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,029,323</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_f77aa823c9474205afaba74a4409de95" contextRef="c20230101to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,830,631</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be83" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be84">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be84" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be85">
<div><br/></div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

              </div>

            </div>

          </div>

          <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be85" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be86">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be86" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be87"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_947124b4214a4a51a357f82d9362a009" contextRef="c20240101to20240630" escape="true" continuedAt="Text_3eaf23da23864b27819610be9348b9881">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be87" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be88"><ix:continuation id="Text_3eaf23da23864b27819610be9348b9881" continuedAt="Text_3eaf23da23864b27819610be9348b9882">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be88" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be89"><ix:continuation id="Text_3eaf23da23864b27819610be9348b9882" continuedAt="Text_3eaf23da23864b27819610be9348b9883">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

            <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be89" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be90"><ix:continuation id="Text_3eaf23da23864b27819610be9348b9883" continuedAt="Text_3eaf23da23864b27819610be9348b9884">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <div>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be90" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be91"><ix:continuation id="Text_3eaf23da23864b27819610be9348b9884" continuedAt="Text_3eaf23da23864b27819610be9348b9885">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation></ix:continuation>
            </div>

            <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be91" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be92"><ix:continuation id="Text_3eaf23da23864b27819610be9348b9885" continuedAt="Text_3eaf23da23864b27819610be9348b9886">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be92" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be93"><ix:continuation id="Text_3eaf23da23864b27819610be9348b9886" continuedAt="Text_3eaf23da23864b27819610be9348b9887">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be93" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be94"><ix:continuation id="Text_3eaf23da23864b27819610be9348b9887">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be94" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be95">
<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

            <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be95" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be96">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be96" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be97">
<div> <br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be97" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be98">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be98" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be99">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be99" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be100">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be100" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be101">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                  <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be101" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be102">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                    <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be102" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be103"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_9d8ae5da59e54622be3ed11c8b60726e" contextRef="c20240101to20240630" escape="true" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
                      <div>
                        <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be103" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be104"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe1" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe2">
<div>
                          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>
</ix:continuation></ix:continuation>
                      </div>

                      <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be104" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be105"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe2" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                    <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be105" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be106"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe3" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
                    <div>
                      <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be106" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be107"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe4" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe5">
<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>
</ix:continuation></ix:continuation>
                    </div>

                    <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be107" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be108"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe5" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
                    <div>
                      <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be108" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be109"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe6" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe7">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>
</ix:continuation></ix:continuation>
                    </div>

                    <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be109" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be110"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe7" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe8">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                  <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be110" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be111"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe8" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe9">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be111" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be112"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe9" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe10">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be112" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be113"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe10" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe11">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <div>
                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be113" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be114"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe11" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe12">
<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be114" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be115"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe12" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe13">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be115" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be116"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe13" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe14">
<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
</ix:continuation></ix:continuation>
              </div>

              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be116" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be117"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe14" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe15">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be117" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be118"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe15" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe16">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be118" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be119"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe16" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe17">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be119" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be120"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe17" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe18">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be120" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be121"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe18" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe19">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be121" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be122"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe19" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe20">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be122" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be123"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe20" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe21">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be123" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be124"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe21" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe22">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be124" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be125"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe22" continuedAt="Text_7d1262f4260e499ab2f5ba923ef041fe23">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be125" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be126"><ix:continuation id="Text_7d1262f4260e499ab2f5ba923ef041fe23">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be126" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be127">
<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be127" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be128">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation>
              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be128" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be129">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be129" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be130">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                <div><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be130" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be131"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="Text_c4f1c03d02eb48d48ca03d4b57b9c3d2" contextRef="c20240101to20240630" escape="true" continuedAt="Text_dab88ce788f04c2caa12f76048e489c01">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric></ix:continuation>
                  <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be131" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be132"><ix:continuation id="Text_dab88ce788f04c2caa12f76048e489c01" continuedAt="Text_dab88ce788f04c2caa12f76048e489c02">
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
                  <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be132" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be133"><ix:continuation id="Text_dab88ce788f04c2caa12f76048e489c02" continuedAt="Text_dab88ce788f04c2caa12f76048e489c03">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be133" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be134"><ix:continuation id="Text_dab88ce788f04c2caa12f76048e489c03" continuedAt="Text_dab88ce788f04c2caa12f76048e489c04">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

              <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be134" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be135"><ix:continuation id="Text_dab88ce788f04c2caa12f76048e489c04" continuedAt="Text_dab88ce788f04c2caa12f76048e489c05">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">
                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be135" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be136"><ix:continuation id="Text_dab88ce788f04c2caa12f76048e489c05" continuedAt="Text_dab88ce788f04c2caa12f76048e489c06">
<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be136" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be137"><ix:continuation id="Text_dab88ce788f04c2caa12f76048e489c06">
<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>
</ix:continuation></ix:continuation>

                <ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be137" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be138">
<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> <br/>
                </div>
</ix:continuation>
                <div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">
                    <div>
                      <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_1ab6e075e98548aa9c38121d7d665840" contextRef="c20240101to20240630" escape="true" continuedAt="Text_2889857456cb4c98868506631a3d87091"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be138" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be139">
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(L)</div>
                            </td>

    <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">New accounting standards:</span></div>
                            </td>

  </tr>


</table>
</ix:continuation></ix:nonNumeric>
                      <ix:continuation id="Text_2889857456cb4c98868506631a3d87091" continuedAt="Text_2889857456cb4c98868506631a3d87092"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be139" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be140">
<div> <br/>
                      </div>
</ix:continuation></ix:continuation>
                      <div>
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d87092" continuedAt="Text_2889857456cb4c98868506631a3d87093"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be140" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be141">
<div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Recently Adopted Accounting Pronouncements</div>
</ix:continuation></ix:continuation>
                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d87093" continuedAt="Text_2889857456cb4c98868506631a3d87094"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be141" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be142">
<div><br/>
                          </div>
</ix:continuation></ix:continuation>
                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d87094" continuedAt="Text_2889857456cb4c98868506631a3d87095"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be142" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be143">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Recently issued accounting pronouncements did not, or are not believed by the Company to, have a material effect on our present or future Condensed Consolidated Financial Statements.</span></div>
</ix:continuation></ix:continuation>
                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d87095" continuedAt="Text_2889857456cb4c98868506631a3d87096"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be143" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be144">
<div><br/>
                          </div>
</ix:continuation></ix:continuation>
                        </div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d87096" continuedAt="Text_2889857456cb4c98868506631a3d87097"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be144" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be145">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none;">Recent Accounting Pronouncements Not Yet
                            Adopted</div>
</ix:continuation></ix:continuation>
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d87097" continuedAt="Text_2889857456cb4c98868506631a3d87098"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be145" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be146">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></div>

                        <ix:continuation id="Text_2889857456cb4c98868506631a3d87098" continuedAt="Text_2889857456cb4c98868506631a3d87099"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be146" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be147">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_2889857456cb4c98868506631a3d87099" continuedAt="Text_2889857456cb4c98868506631a3d870910"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be147" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be148">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d870910" continuedAt="Text_2889857456cb4c98868506631a3d870911"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be148" continuedAt="Text_1ddcc91b5087476c8504ff6c15a1b3be149">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                          </div>
</ix:continuation></ix:continuation>
                          <ix:continuation id="Text_2889857456cb4c98868506631a3d870911"><ix:continuation id="Text_1ddcc91b5087476c8504ff6c15a1b3be149">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023, the FASB issued ASU 2023-09, Improvements to
                              Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative
                              threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that
                              adopting this standard will have on the consolidated financial statements and disclosures.</span></div>
</ix:continuation></ix:continuation>
<div>

                          <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</div>

                        <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

                        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
                          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160; </span></div>

                        </div>

                      </div>

                    </div>

                  </div>

                </div>

              </div>

              <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

            <div><span style="font-family: 'Times New Roman';"> </span></div>

            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

              </div>

            </div>

            <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>
 </div>


  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="pdsb:LiquidityAndCapitalResourcesTextBlock" id="Text_3c4156a7dd5c4ae7a6d201702ce741d3" contextRef="c20240101to20240630" escape="true" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c1" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c2">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 &#8211; Liquidity <span style="font-family: 'Times New Roman'; font-size: 10pt;">and </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Capital Resources</span></span></div>
</ix:continuation>
          <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c2" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c3">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c3" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c4">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c4" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c5">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;">
            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c5" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c6">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">As of June 30, 2024, the
              Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_9955260197d743888d4cca1dd369702a" contextRef="c20240630" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">57.7</ix:nonFraction> million of cash and cash equivalents. The Company&#8217;s primary use of cash is to fund operating expenses, primarily
              research and development expenditures. Cash used to fund operating expenses is impacted by <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">the level of activities undertaken, as well as</span> </span>the timing of when the Company pays these expenses, as reflected in the change to the Company&#8217;s outstanding accounts payable and
              accrued expenses.<span style="font-size: 10pt; font-family: 'Times New Roman';"> Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman';">year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable.<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In addition, the Loan and Security Agreement allows for the lenders to call the outstanding balance of the term loans if the minimum
                cash balances outlined in the Loans and Security Agreement are not maintained.</span></div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c6" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c7">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation>
            </div>

            <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c7" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c8">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company funds its operations through equity and/or debt financings such as the following:</div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c8" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c9">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c9" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c10">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $<ix:nonFraction name="pdsb:ShelfRegistrationStatementAvailableForFutureSale" id="Fact_710c6c366f93414fa1c39e3bff61a838" contextRef="c20220831" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction>
              million, $<ix:nonFraction name="pdsb:PlacementSharesAvailableForFutureSale" id="Fact_6b522faf850b4f94a418be586f4d2c8e" contextRef="c20220831" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million of which covers the offer, issuance and sale by the Company of its common stock under the Sales Agreement (as
              discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.</div>
</ix:continuation>
            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c10" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c11">
<div><br/></div>
</ix:continuation>
            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c11" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c12">
<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
              Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
              having an aggregate offering price of up to $<ix:nonFraction name="pdsb:PlacementSharesAvailableForFutureSale" id="Fact_2665b6875c894711877e6ea794fd90b8" contextRef="c20220831" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million, or the Placement Shares, through or to the Agents, as sales agents or
              principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in
              Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#8217;s common stock. The Agents will use commercially
              reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
              Agents a commission equal to three percent (<ix:nonFraction name="pdsb:CommissionPercentage" id="Fact_50ac525485634764ab592c355f7198f0" contextRef="c20220801to20220831" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%) of the gross sales proceeds of any Placement Shares sold through the Agents under
              the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of Placement
              Sh<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ares pursuant to the Sales Agreement will terminate upon the
                earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. For the year ended December 31, 2023, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_8fa3752f833a45a2b39d68d8c78f1fe1" contextRef="c20230101to20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,642,269</ix:nonFraction> shares of common stock for a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_25d09146f7c84a529f0f9dbade4972e1" contextRef="c20230101to20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.1</ix:nonFraction> million pursuant to the Sales Agreement. During the three and six months ended June 30, 2024, the company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_342229c574364f5796bb42324c157d0a" contextRef="c20240401to20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_7ebc0eb766b54c79a999988fe70a47bd" contextRef="c20240101to20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,428,681</ix:nonFraction> shares, respectively, of its common
                stock with a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_d4b59f780dc04e2bbc03e860cb5f38bc" contextRef="c20240401to20240630" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.0</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_68d4eca5736742ef930c000325165aad" contextRef="c20240101to20240630" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.5</ix:nonFraction> million, respectively, pursuant to the Sales Agreement.</span></div>
</ix:continuation>
            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c12" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c13">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c13" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c14">
<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders. The Loan and Security Agreement provides for the following <ix:nonFraction name="pdsb:DebtInstrumentNumberOfIndependentTermLoans" id="Fact_80bcd4963d084d8ca38b95c1d6988c8c" contextRef="c20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">6</ix:nonFraction> separate and independent term loans: (a) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_a72c635b19fd47bc8440f1c38bb35ab1" contextRef="c20220831_DebtInstrumentAxis_LoanAMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,500,000</ix:nonFraction>,
                or Loan A, (b) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_10ef9d1a844f468b84eb8111885e1a33" contextRef="c20220831_DebtInstrumentAxis_LoanBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>, or Loan B, (c) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_fca85b253a8947579723127eee15bfca" contextRef="c20220831_DebtInstrumentAxis_LoanCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction>, or Loan C, (d) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_27e20ebff30544cb88d718435d5dbaec" contextRef="c20220831_DebtInstrumentAxis_LoanDMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction>, or Loan D, (e) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_f028c1bf3abe447292b5a9d0d57a8b28" contextRef="c20240630_DebtInstrumentAxis_LoanEMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>, or
                Loan E, and (f) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_73a94544ccc74bbd8e4ceb25771a5c05" contextRef="c20240630_DebtInstrumentAxis_LoanFMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>, or Loan F, (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and
                Loan F, individually a Loan and, collectively, the Loans). Loan A, Loan B, Loan C<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">, and Loan D were delivered to the Company on August 24, 2022.<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In total, the Company received $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" id="Fact_c870a63c32cf4e06af15becab34aa190" contextRef="c20220824to20220824_DebtInstrumentAxis_TermLoansMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.6</ix:nonFraction> million in net proceeds.</span> </span>Loan E and Loan F <span style="font-size: 10pt; font-family: 'Times New Roman';">were</span> uncommitted Loans that could have been advanced by the lenders upon the parties agreement prior to July 31, 2023 upon the satisfaction of certain conditions. <span style="font-size: 10pt; font-family: 'Times New Roman';">At</span> this <span style="font-size: 10pt; font-family: 'Times New Roman';">time, the </span>option<span style="font-size: 10pt; font-family: 'Times New Roman';"> to advance
                  Loan E and Loan F has expired and Loan E and Loan F are </span>no <span style="font-size: 10pt; font-family: 'Times New Roman';">longer available</span> to the Company <span style="font-size: 10pt; font-family: 'Times New Roman';">under







                  the Loan and Security Agreement</span>. The Company may only use the proceeds<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> of the Loans for working capital or general corporate purposes. Each Loan matures on the <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_7205ebdef8854f8492ba9bbdab1fa024" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">48</ix:nonNumeric>-month
                  anniversary following the applicable funding date unless accelerated pursuant to certain events of default.</span> Payments on the principal balance begin on October 1, 2024 and are paid monthly over the succeeding <ix:nonNumeric name="pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" id="Fact_0adfb56132e140cba0f3d2c4194ff386" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">24</ix:nonNumeric> months. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) </span>the per annum rate of
                interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;<span style="-sec-ix-hidden:Fact_422456f8ef2547ffa808d9e7f65aa170">prime rate</span>&#8221; then in effect, plus (b) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact_178a4bdbf571470fa22199f7546d883b" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.75</ix:nonFraction>%; provided that, in the event such rate of interest
                is less than <ix:nonFraction name="pdsb:DebtInstrumentMinimumVariableRate" id="Fact_b4828118bc2449d290594ffd59af6bb6" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>%, such rate shall be deemed to be <ix:nonFraction name="pdsb:DebtInstrumentMinimumVariableRate" id="Fact_2ddc8f2e87e3414fb814b97f0f43190c" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>% for purposes of calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding the preceding month. The Company, at its
                option upon at least ten (<ix:nonNumeric name="pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment" id="Fact_f64fd241826842079b8530f30c998727" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" format="ixt-sec:durday">10</ix:nonNumeric>) business days&#8217; written notice to the lenders, may prepay all (and not less than all) of the
                outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an amount equal to (A) if such Loan is prepaid on or before the
                Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod1" id="Fact_aab36050e8b64e34a5b2213be97703b1" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of the then outstanding
                principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan, but on or before the date that is <ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_86915a0f1d9e4c3589ba7497d5f33bc0" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months after such Loan Amortization Date, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod2" id="Fact_daa28246c4fe4146807689479fd27bd6" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>% of the then outstanding principal balance of
                such Loan, or (C) if such Loan is prepaid more than <ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_34abab4d1da74f43952d29b79bab39bd" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months after the Loan Amortization Date but prior to the stated maturity
                date applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod3" id="Fact_b71d39a87b0f4f6185a2c6ea68eb2a67" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iii)
                the outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iv) all other sums, if any, that shall have become due and payable thereunder. <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod4" id="Fact_33c9969ab5e44e80b39cab83536419cf" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.</div>
</ix:continuation>
            </div>

            <div>
              <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c14" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c15">
<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>
</ix:continuation>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

                <div class="BRPFPageHeader" style="width: 100%;">
                  <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
                  </div>

                </div>

              </div>

            </div>

            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c15" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c16">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Loan and Security Agreement contains customary representations, warranties and covenants, including <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">maintenance of minimum cash balances as well as</span> </span>covenants






















              by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates, and
              fundamental changes.</div>
</ix:continuation>
            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c16" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c17">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c17" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c18">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2023, the Company received approximately $<ix:nonFraction name="pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="Fact_b7d2e6593e2e461c96a0808d75382653" contextRef="c20230401to20230430" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction> million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company&#8217;s participation in the New Jersey Technology
                Business Tax Certificate Transfer NOL program for tax year 2021.</div>
</ix:continuation>
              <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c18" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c19">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </div>
</ix:continuation>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c19" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c20">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2024, the Company received approximately $<ix:nonFraction name="pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="Fact_b945e7b0a8224bd4a18d617b95f911ab" contextRef="c20240401to20240430" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to its participation in the New Jersey Technology Business Tax Certificate
                  Transfer of Net Operating Loss (NOL) program for tax year 2022.<br/>
                </div>
</ix:continuation>
              </div>

            </div>

            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c20" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c21">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c21" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c22">
<div><span style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Going Concern</span></div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c22" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c23">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br/>
              </div>
</ix:continuation>
            </div>

            <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c23" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c24">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its
                  ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, the Company has experienced net losses and negative cash
                  flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In addition, the Loan and Security Agreement allows for the lenders to call the outstanding balance of the
                    term loans if the minimum cash balances outlined in the Loan and Security Agreement are not maintained.</span></div>
</ix:continuation>
                <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c24" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c25">
<div><br/>
                </div>
</ix:continuation>
                <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c25" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c26">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s estimated cash requirements in 2024 and beyond include expenses related to continuing development and clinical trials as
                  well as payments on its debt. The Company plans to execute its operating plan by obtaining additional capital, principally through issuance of equity through separate offerings or an at-the-market facility, issuance of debt, or by
                  entering into collaborations, strategic alliances, or license agreements with third parties. However, there is no assurance that sufficient additional capital and/or financing will be available to the Company, and even if available,
                  whether it will be on terms acceptable to the Company or its existing shareholders. The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale
                  of additional equity would result in dilution to the Company&#8217;s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants
                  that would restrict its operations. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects,
                  grant rights to third parties to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself, or cease operations entirely. Any of these actions could harm its business, results of operations
                  and prospects. Failure to obtain adequate financing may also adversely affect the Company&#8217;s ability to operate as a going concern.</div>
</ix:continuation>
                <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c26" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c27">
<div><br/>
                </div>
</ix:continuation>
                <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c27" continuedAt="Text_e374d6d3d0254c08a1ed2ece98073c3c28">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As a result of these uncertainties, and as its plans are outside of management&#8217;s control, the Company has concluded that substantial doubt
                  exists about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements. The unaudited Condensed Consolidated
                  Financial Statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.</div>
</ix:continuation>
              </div>

            </div>

          </div>

          <ix:continuation id="Text_e374d6d3d0254c08a1ed2ece98073c3c28">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

            <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

            <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_73560b82835844c09425c66d391eb93d" contextRef="c20240101to20240630" escape="true" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd1" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd2">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 4 &#8211; Fair Value of Financial Instruments</div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd2" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd3" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd4" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd5" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">There were no transfers among Levels 1, 2, or 3 during the
            three and six months ended June 30, 2024 or 2023.</div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd6" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd7">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd7" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd8">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd8" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd9"><ix:nonNumeric name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Text_95e08fa664cb47879671c705ca11674d" contextRef="c20240101to20240630" escape="true" continuedAt="Text_b0e6df17c0b7409885d80218ff79242e1">
<div><span style="font-family: 'Times New Roman';"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd9" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd10"><ix:continuation id="Text_b0e6df17c0b7409885d80218ff79242e1">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="14">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of June 30, 2024: (unaudited)</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_30262a55937948d5a3ec41762a7e22c5" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">57,733,724</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_1252c83466184058ae8acadff6d4028e" contextRef="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">57,733,724</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_3363e1e1a2044e5bb8311b091ee60d7a" contextRef="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_ab073a35efde4428afb5fbfc4288be23" contextRef="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2023</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_fe569a42a4dd45fb9f2ea547d56daf34" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,560,517</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_668be085eb044880ad9651725c8dd538" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,560,517</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_1f8ae74868454b428ec005c0ed673f37" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_b598ee9dc44e4b8ea534194337c95188" contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd10" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd11">
<div>
           <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd11" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd12">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd12" continuedAt="Text_34fc050a0f9d45eea30a4efbd9b060cd13">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">
            <ix:continuation id="Text_34fc050a0f9d45eea30a4efbd9b060cd13">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;">The carrying value of the <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Loan and Security Agreement</span> approximated its fair value as of June 30, 2024 due to its variable rate.</div>
</ix:continuation>
          </div>
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

            </div>

          </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_ebe6318ebed84497b71801388d219988" contextRef="c20240101to20240630" escape="true" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d21">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d21" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d22">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 5 &#8211; Leases</div>
</ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d22" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d23">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d23" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d24">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d24" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d25">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d25" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d26">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Operating Lease:</span></div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d26" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d27">
<div><span style="font-family: 'Times New Roman';"> <br/>
          </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d27" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d28">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective March 5, 2020, the Company entered into a sublease for approximately <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" id="Fact_7cddf27e8fff4bbebe3595f9943b04f1" contextRef="c20240630" unitRef="U006" decimals="0" scale="0" format="ixt:num-dot-decimal">11,200</ix:nonFraction> square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 with a term of forty (<ix:nonNumeric name="us-gaap:LessorOperatingLeaseTermOfContract" id="Fact_7ffb3691adaa4de892aa46f62cb456dc" contextRef="c20240630" format="ixt-sec:durmonth">40</ix:nonNumeric>) months with an option to renew through October 31, 2027. The sublease term expired on August 31, 2023, and was not renewed. Upon inception of
              the sublease, the Company recognized approximately $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_a8e35e4a7c794dffaa95c6047074ca30" contextRef="c20200501" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_5f36a6ab264545e0af62254dc09deef6" contextRef="c20200501" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction></ix:nonFraction> million of&#160; ROU assets and operating lease liabilities. The discount
              rate used to measure the operating lease liability as of May 1, 2020 was <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" id="Fact_060db95296534a09b19b139870a9fcd0" contextRef="c20200501" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.15</ix:nonFraction>%. Throughout the period described above, the Company
              has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.</div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d28" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d29">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d29" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d210">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d210" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d211"><ix:nonNumeric name="pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" id="Text_e53fc6fae7d04841af06125cd44cb1e0" contextRef="c20240101to20240630" escape="true" continuedAt="Text_9b5218d6aef14732aac359aeebd34cfb1">
<div>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d211" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d212"><ix:continuation id="Text_9b5218d6aef14732aac359aeebd34cfb1" continuedAt="Text_9b5218d6aef14732aac359aeebd34cfb2">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Supplemental cash flow information related to operating
            leases is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d212" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d213"><ix:continuation id="Text_9b5218d6aef14732aac359aeebd34cfb2" continuedAt="Text_9b5218d6aef14732aac359aeebd34cfb3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d213" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d214"><ix:continuation id="Text_9b5218d6aef14732aac359aeebd34cfb3" continuedAt="Text_9b5218d6aef14732aac359aeebd34cfb4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d214" continuedAt="Text_e3d7e3b71ef44f93bc93bd19e54593d215"><ix:continuation id="Text_9b5218d6aef14732aac359aeebd34cfb4" continuedAt="Text_9b5218d6aef14732aac359aeebd34cfb5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e3d7e3b71ef44f93bc93bd19e54593d215"><ix:continuation id="Text_9b5218d6aef14732aac359aeebd34cfb5">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="7" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">Cash paid for operating lease liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_373734314b5f4d689f1d3eae81d11487" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_3bad8866750347ccacc9545e39524ae0" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">179,136</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>
           <span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>

        <div> <span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>

        <div>
<div><span style="font-family: 'Times New Roman';"> </span>  <span style="font-family: 'Times New Roman';"> </span></div>

          <div><ix:nonNumeric name="us-gaap:LesseeFinanceLeasesTextBlock" id="Text_41fd09658afd4ab184eb1cf9960421fd" contextRef="c20240101to20240630" escape="true" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe1" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe2">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Financing Lease:</span></div>
</ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe2" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe3" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe4">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation><ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe4" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe5"><ix:nonNumeric name="pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" id="Text_b073d91e77ab4362937f69077b4cbdb8" contextRef="c20240101to20240630" escape="true" continuedAt="Text_4bee317433294faa9add9a4b0345e4581">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe5" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe6"><ix:continuation id="Text_4bee317433294faa9add9a4b0345e4581" continuedAt="Text_4bee317433294faa9add9a4b0345e4582">
<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe6" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe7"><ix:continuation id="Text_4bee317433294faa9add9a4b0345e4582" continuedAt="Text_4bee317433294faa9add9a4b0345e4583">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe7" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe8"><ix:continuation id="Text_4bee317433294faa9add9a4b0345e4583" continuedAt="Text_4bee317433294faa9add9a4b0345e4584">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe8" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe9"><ix:continuation id="Text_4bee317433294faa9add9a4b0345e4584" continuedAt="Text_4bee317433294faa9add9a4b0345e4585">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe9" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe10"><ix:continuation id="Text_4bee317433294faa9add9a4b0345e4585">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="7" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of June 30,</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                      </span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeasePrincipalAndInterestPayments" id="Fact_0c10c947a5a44051a08fe5806c47b3c5" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">34,925</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">$ <br/>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeasePrincipalAndInterestPayments" id="Fact_1bf5435942e741d080c5f8e845bc79f1" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">43,221</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe10" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe11">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe11" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe12">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation><ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe12" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe13"><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Text_b058af5d7b1f4beda78c3242f6dbdf5d" contextRef="c20240101to20240630" escape="true" continuedAt="Text_c9d4e96cb4884e8386dddcec5b773b5e1">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe13" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe14"><ix:continuation id="Text_c9d4e96cb4884e8386dddcec5b773b5e1" continuedAt="Text_c9d4e96cb4884e8386dddcec5b773b5e2">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liabilities is as follows:</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe14" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe15"><ix:continuation id="Text_c9d4e96cb4884e8386dddcec5b773b5e2" continuedAt="Text_c9d4e96cb4884e8386dddcec5b773b5e3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe15" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe16"><ix:continuation id="Text_c9d4e96cb4884e8386dddcec5b773b5e3" continuedAt="Text_c9d4e96cb4884e8386dddcec5b773b5e4">
<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe16" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe17"><ix:continuation id="Text_c9d4e96cb4884e8386dddcec5b773b5e4" continuedAt="Text_c9d4e96cb4884e8386dddcec5b773b5e5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe17" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe18"><ix:continuation id="Text_c9d4e96cb4884e8386dddcec5b773b5e5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31,</div>
                  </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_67e34b91c5d54def9140387930276a52" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">34,925</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_bb40ccf3945c46ddb566015b44c9e24b" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">69,850</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" id="Fact_dfd0bc168b4644ba9a651749777fe53b" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,108</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" id="Fact_86b681387e7f4961a8b785dd950af103" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,723</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2028 and after</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeaseLiabilityToBePaidYearFourAndThereafter" id="Fact_4094e13f7e754a3e871a092479348f3d" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" id="Fact_a46a17cbf611417b83c0d12cb0b98625" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">171,607</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" id="Fact_5c853d4b574c4fa8ac554e529cd90662" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,102</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" id="Fact_964abaef68fa4215b3a64504b837136c" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,505</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe18" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe19">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe19" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe20">
<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe20" continuedAt="Text_b12a3966800d48798e1baf4dbba1e7fe21">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b12a3966800d48798e1baf4dbba1e7fe21">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company entered into <ix:nonFraction name="pdsb:LesseeFinanceLeaseNumberOfLeases" id="Fact_6d95c0c36aad49c79e15e7f07e043a75" contextRef="c20240101to20240630" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction>
              financing leases for laboratory equipment with a total cost of $<ix:nonFraction name="pdsb:FinanceLeaseCost" id="Fact_05386836a411454985f996e8e94fa755" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">251,959</ix:nonFraction> with <span style="-sec-ix-hidden:Fact_1d2392fd0bf043fea9df39565196af84">four</span> to <ix:nonNumeric name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Fact_e719eb706b0a415c82cc2e8827d3e8b8" contextRef="c20240630_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> terms and a capitalized interest rate of
              <ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" id="Fact_56d50fa0256b4c1d9b4b14666c1f68ec" contextRef="c20240630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.15</ix:nonFraction>%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $<ix:nonFraction name="pdsb:LesseeFinanceLeaseMonthlyRentalExpense" id="Fact_9e8de6d9265b4f919da10405e937ceb0" contextRef="c20240101to20240630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction>,000. During the year ended December 31, 2023, the Company exercised the bargain
              purchase option, which resulted in recognition of property and equipment of $<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" id="Fact_7cbeb32ac61b419b8ee3f58fdc73d8ed" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,490</ix:nonFraction>.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

        </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_32a268bf225b4809b33cf77488db16a5" contextRef="c20240101to20240630" escape="true" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef1" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef2">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 6 &#8211; Accrued Expenses</div>
</ix:continuation>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef2" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef3" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation><ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef4" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef5"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_c8d65d70ec0f4b9390897c4a8e85dfdd" contextRef="c20240101to20240630" escape="true" continuedAt="Text_ea9884bd4a7546379609e7d96a3bfd671">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef5" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef6"><ix:continuation id="Text_ea9884bd4a7546379609e7d96a3bfd671" continuedAt="Text_ea9884bd4a7546379609e7d96a3bfd672">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses consist of the following:</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef6" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef7"><ix:continuation id="Text_ea9884bd4a7546379609e7d96a3bfd672" continuedAt="Text_ea9884bd4a7546379609e7d96a3bfd673">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef7" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef8"><ix:continuation id="Text_ea9884bd4a7546379609e7d96a3bfd673" continuedAt="Text_ea9884bd4a7546379609e7d96a3bfd674">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef8" continuedAt="Text_e70b82ce91144eb692baefc7eca8feef9"><ix:continuation id="Text_ea9884bd4a7546379609e7d96a3bfd674" continuedAt="Text_ea9884bd4a7546379609e7d96a3bfd675">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e70b82ce91144eb692baefc7eca8feef9"><ix:continuation id="Text_ea9884bd4a7546379609e7d96a3bfd675">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="pdsb:AccruedResearchAndDevelopmentCostsCurrent" id="Fact_9f220b571cbc49d2a314ed90b57adbb6" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">200,699</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="pdsb:AccruedResearchAndDevelopmentCostsCurrent" id="Fact_3fb4405d0a1942d09e6809280b787f32" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div>
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_cc894b495b3d4cc6a089474c2af46ff2" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">556,385</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_48edbadd582d4c0990552189f2e90b27" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">827,863</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" id="Fact_c4edf79801a44fe9a7443eb4ef920921" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">892,894</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" id="Fact_15f1a7f50f4b43d88762d0a6165a3ad8" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,289,690</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_8541f296d2f443238b7031adfb98e770" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">296,875</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_2af6bc4ced454a7388ab0cdc477ae675" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">306,771</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="background-color: #CCEEFF; vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">Accrued rent</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AccruedRentCurrent" id="Fact_2729008833b244faaffb5db99728bcc6" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">368</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AccruedRentCurrent" id="Fact_ecd353adc79d4d2791b6b80348f7b45d" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">368</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_bc20ff5666434347b3ab09fb51b9e15a" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,947,221</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                <div>
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_4161dc5efc4647d38716fdb67d903da5" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,424,692</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

        <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_c437c32b26e1418682eb12f87af9e911" contextRef="c20240101to20240630" escape="true" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b91">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b91" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b92">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Note 7 &#8211; Stock-Based Compensation</div>
</ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b92" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b93">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b93" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b94">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b94" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b95">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b95" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b96">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">In 2014, the Company&#8217;s stockholders approved the 2014
              Equity Incentive Plan (the &#8220;Original Plan&#8221;) pursuant to which the Company may grant up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_c6aef12ea95f44d4a7f0a391a79c7dd0" contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">91,367</ix:nonFraction> shares as ISOs, NQs and
              restricted stock units (&#8220;RSUs&#8221;), subject to increases as hereafter described (the &#8220;Plan Limit&#8221;). In addition, on January 1, 2015, and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the
              terms of the Original Plan, the Plan Limit was and shall be increased by the lesser of (x) <ix:nonFraction name="pdsb:PercentageOfCommonStockOutstanding" id="Fact_4112a691f84744918df79867720b18af" contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the number of shares of Common
              Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors (&#8220;Board&#8221;) may determine in its discretion. In March 2019, the Board adopted and the Company&#8217;s stockholders approved the Amended
              and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Prior Plan&#8221;) which amended and restated the Original Plan in order to remove the annual increase component and was limited to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_3c2698f281fd414aaa21a5d25ba0a9f7" contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">826,292</ix:nonFraction> shares.</div>
</ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b96" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b97">
<div style="text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt;">
              <div>
                <div>
                  <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b97" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b98">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;">On </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">December 8, 2020,
                      the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Restated Plan&#8221;), which amended and restated the Prior Plan. The Restated
                      Plan is identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock authorized for issuance under the Restated Plan was increased from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_a8d54a70b2e64630952f1a757c504547" contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">826,292</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_f28c4b6ba18140a2aebd4562ac2d5f0f" contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,165,535</ix:nonFraction> shares, plus the total number of
                      shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on December 7, 2030, unless
                      earlier terminated.&#160; On May 19, 2023, the Board adopted, subject to stockholder approval, the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Third Restated Plan&#8221;). At the 2023 annual meeting
                      of stockholders held on July 14, 2023, the stockholders approved the Third Restated Plan, which amended and restated the Restated Plan to increase the total amount of shares authorized for issuance thereunder. The Third Restated Plan
                      is identical to the Restated Plan in all material respects, except, the number of shares of Common Stock authorized for issuance under the Third Restated Plan increased from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_6964c627afb240a78c987cec7e504a88" contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,165,535</ix:nonFraction> to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_a17a417db0f04da5893bc3fc5fadda59" contextRef="c20230714_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,565,535</ix:nonFraction>. As of June 30, 2024, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_fc157376d4ee4898970544b23f300256" contextRef="c20240630_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,301,167</ix:nonFraction> shares available for grant under the Third Restated Plan.</span></div>
</ix:continuation>
                </div>

              </div>

              <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b98" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b99">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;"> <br/>
              </div>
</ix:continuation>
            </div>

          </div>

          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b99" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b910">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Pursuant to the terms of the Third Restated Plan, stock options have a term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_6d46dfdc4d3b4301b67ba2333c878b09" contextRef="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a
            <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_46129184105842319e19f38fc5754212" contextRef="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period.</div>
</ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b910" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b911">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b911" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b912">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). On December 8, 2020, the Company amended the
                Inducement Plan solely to increase the total number of shares of common stock reserved for issuance under the Inducement Plan from <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_acdb4fa2d2b14ed8aa745b3f2f66507a" contextRef="c20190617_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction>
                shares to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_59f088e58ce0464d8d2ac39892cf38d6" contextRef="c20201208_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> shares. On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number
                of shares of Common Stock reserved for issuance under the Inducement Plan from <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_3a3b958fc2f74c3fa5089c8a9e2c08ec" contextRef="c20201208_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_40e55844e5c040b6b8dcc73950cfc15b" contextRef="c20220517_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,100,000</ix:nonFraction> shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common
                Stock reserved for issuance under the Inducement Plan from 1,100,000 shares to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_096fe0152ad547eab6e0105108614494" contextRef="c20240122_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,100,000</ix:nonFraction> shares. The Inducement Plan provides
                for the grant of non-qualified stock options. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder
                approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.</span></div>
</ix:continuation>
            <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b912" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b913">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>
</ix:continuation>
              <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b913" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b914">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq
                  Listing Rules, non-qualified stock options under the Inducement Plan may only be made to an employee who has not previously been an employee of the Company or member of the Board of Directors of the Company (or any parent or subsidiary of
                  the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into
                  employment with the Company or such subsidiary. As of June 30, 2024, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_031ab312b56340cc90126fa8f65541b2" contextRef="c20240630_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">969,407</ix:nonFraction> shares available for grant under the
                  Inducement Plan.</span></div>
</ix:continuation>
            </div>

          </div>

          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b914" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b915">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b915" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b916">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b916" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b917">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <div><ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b917" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b918"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_0d4ff581aa6d4e7f9a24f2a492e60771" contextRef="c20240101to20240630" escape="true" continuedAt="Text_6df39c60c6644c979e3b20e0730889411">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b918" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b919"><ix:continuation id="Text_6df39c60c6644c979e3b20e0730889411" continuedAt="Text_6df39c60c6644c979e3b20e0730889412">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations and
              comprehensive loss for the three and six months ended June 30, 2024 and 2023:</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b919" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b920"><ix:continuation id="Text_6df39c60c6644c979e3b20e0730889412" continuedAt="Text_6df39c60c6644c979e3b20e0730889413">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b920" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b921"><ix:continuation id="Text_6df39c60c6644c979e3b20e0730889413" continuedAt="Text_6df39c60c6644c979e3b20e0730889414">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b921" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b922"><ix:continuation id="Text_6df39c60c6644c979e3b20e0730889414" continuedAt="Text_6df39c60c6644c979e3b20e0730889415">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b922" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b923"><ix:continuation id="Text_6df39c60c6644c979e3b20e0730889415">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months Ended June 30,<br/>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six months ended June 30,</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2024<br/>
                      </span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2024<br/>
                      </span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock-Based Compensation</div>
                  </td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Research and development</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_b38cc47944d946e89c5643ee4e0c239f" contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">609,828</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d7a18c3cd4084cdc9218b2a3714c908f" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">806,548</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_ecccb889ca024a509a5ba7e22f882240" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,161,746</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_ac36d3e8fb2445828215f8880840b556" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,607,312</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">General and administrative</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_419201a8b7c04b06b383da94655d2680" contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,185,894</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_b75938fa8f334097b7dd2d2c0bd06652" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,298,990</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_074ca782ad564117a2981a188960f3ce" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,263,987</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_3cd0cac24cdd40cb85afd9338e160965" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,578,545</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_7ec2276d54ec4ed08faf6c888eaa0b08" contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,795,722</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_2e7030e205724ae5857338cc2d0f6555" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,105,538</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_2c84403a28554ac38c456ffaf5bf28d4" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,425,733</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_1e4d41af35984ef1a2d0fc6af723e90f" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,185,857</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b923" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b924">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span>
            <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <br class="Apple-interchange-newline"/>
            </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></div>

          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b924" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b925">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b925" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b926">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%14%%%-->
        <div><ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b926" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b927">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <div style="text-align: justify;"><ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b927" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b928">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b928" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b929">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Company granted options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_69ee1788d7c64c50a34e3396151cb8e0" contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">254,000</ix:nonFraction>
              and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_96487fb65f274d8787d08f9a9715bb8e" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,192,648</ix:nonFraction> shares during the three and six month periods ended June 30, 2024, respectively, and granted options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_a041a66a99dd43b4bd56dbdc385d49d4" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">29,900</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_556b98cc356744fcb83a0675a342ae88" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,154,500</ix:nonFraction> shares during
              the three and six month period ended June 30, 2023, respectively. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_d4a54fba219547c5b0abbd8dacdbbc9e" contextRef="c20240101to20240630" escape="true" continuedAt="Text_3678bb391f854ba4ab1ff7cf6149e9481"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400;">The fair value of options granted during the three and six months ended June 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model utilizing the
              following assumptions:</span></ix:nonNumeric></div>
</ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b929" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b930"><ix:continuation id="Text_3678bb391f854ba4ab1ff7cf6149e9481" continuedAt="Text_3678bb391f854ba4ab1ff7cf6149e9482">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b930" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b931"><ix:continuation id="Text_3678bb391f854ba4ab1ff7cf6149e9482" continuedAt="Text_3678bb391f854ba4ab1ff7cf6149e9483">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b931" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b932"><ix:continuation id="Text_3678bb391f854ba4ab1ff7cf6149e9483" continuedAt="Text_3678bb391f854ba4ab1ff7cf6149e9484">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b932" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b933"><ix:continuation id="Text_3678bb391f854ba4ab1ff7cf6149e9484">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months Ended June 30</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six Months Ended June 30,</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2024</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2024</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_73622b901ffc40199b5d2b83695fd94f" contextRef="c20240401to20240630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">106.26</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_1d0c0f5e187f4a9e88269e7aa21cd68f" contextRef="c20230401to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">143.87</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_5eaca980cc4f465ba490e1b729fccf93" contextRef="c20240101to20240630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">137.07</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_692a1462b6924ec79eac451855dbabd4" contextRef="c20230101to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">142.07</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%;">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_dd775fd838eb408b9799a75c8e4d4f80" contextRef="c20240401to20240630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.26</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_65ce4b27490c4c2880eb7cb172c90986" contextRef="c20230401to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.59</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_81db045f554e4a28a310ef860ecd6aea" contextRef="c20240101to20240630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.04</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_ea0a2cb99e6f443595d11302498977ea" contextRef="c20230101to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.05</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_7c76ab7d9e3b41b58c43f775e541e24b" contextRef="c20240401to20240630" format="ixt-sec:duryear">5.96</ix:nonNumeric></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_20bd16180c9d404f8bbb46156077d83b" contextRef="c20230401to20230630" format="ixt-sec:duryear">6.08</ix:nonNumeric></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_0f048e98534b4214b1b3de890ecb3cf8" contextRef="c20240101to20240630" format="ixt-sec:duryear">6.06</ix:nonNumeric></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_fdb0468f70fd41e2a8885ac64d21471c" contextRef="c20230101to20230630" format="ixt-sec:duryear">6.08</ix:nonNumeric></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%;">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_1f400578de334d9c840187a133f579ce" contextRef="c20240401to20240630" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">-</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_70e152a0c2b1442fb6331e1b621923ff" contextRef="c20230401to20230630" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">-</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_45fde375ecf34b45afd6500fcdfde907" contextRef="c20240101to20240630" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">-</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_ed168608831e45019c838f376ccc2f8f" contextRef="c20230101to20230630" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">-</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: #CCEEFF;">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_33107a0632ab4ac7a1b166e875e8131a" contextRef="c20240401to20240630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.86</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_6337f650cd6e4903b0626219468c8c15" contextRef="c20230401to20230630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.09</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_9264aaadb0d641a4b50da31033d6c9bf" contextRef="c20240101to20240630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.71</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_ce7708181dec4d729cf1cf75899088a6" contextRef="c20230101to20230630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.64</ix:nonFraction></div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b933" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b934">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span> </span></div>
</ix:continuation></div>

          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b934" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b935"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_eb6c618c5c0b416c89868fac25211833" contextRef="c20240101to20240630" escape="true" continuedAt="Text_cb865a4a2e2d4e4d9c81d5e67a8299c31">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b935" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b936"><ix:continuation id="Text_cb865a4a2e2d4e4d9c81d5e67a8299c31" continuedAt="Text_cb865a4a2e2d4e4d9c81d5e67a8299c32">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b936" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b937"><ix:continuation id="Text_cb865a4a2e2d4e4d9c81d5e67a8299c32" continuedAt="Text_cb865a4a2e2d4e4d9c81d5e67a8299c33">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b937" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b938"><ix:continuation id="Text_cb865a4a2e2d4e4d9c81d5e67a8299c33" continuedAt="Text_cb865a4a2e2d4e4d9c81d5e67a8299c34">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b938" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b939"><ix:continuation id="Text_cb865a4a2e2d4e4d9c81d5e67a8299c34" continuedAt="Text_cb865a4a2e2d4e4d9c81d5e67a8299c35">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b939" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b940"><ix:continuation id="Text_cb865a4a2e2d4e4d9c81d5e67a8299c35">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_3dd20bac58f0403da7572a3f59eae646" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,029,345</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_d4fcfe57034d4e2a8d07ad2bc03991aa" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.43</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_87239619c2f64f5bb86bd7d3e5e312d2" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.42</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_de5a1dd188134a2f80be658bfbb74bf6" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,395,227</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_0d2a50d28f274e059d0737f958e99ebb" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,192,648</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_ca5a83bb9e92485296629d8fdfe0b320" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.12</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="Fact_3e83006f28cd411eb5321d03e01c8caa" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">9.70</ix:nonNumeric></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" id="Fact_00d006b726e8467db892c02e1eada1a5" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_e92a47b51a9544b4b96861a9a96718b2" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">156,073</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_f67fa6be0add49c88512759e93933567" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.40</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Forfeited and expired</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" id="Fact_c318d1367dc74985a8f1bb10824503e3" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">502,709</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" id="Fact_fbda28039a2e471983f7d83d43c85b18" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">8.68</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_b6651365b81e4cc3a84255f68399c23f" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,563,211</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_cdb9ab2cabec4ebfb5ad1da6e72a5762" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.03</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_253b8a81d7954c2783c63ce97640507c" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.46</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_20c27b33baad4447a9cc3013dace4779" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">899,228</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_05e0c3e590ff4980bf6d3f5073dcbf1d" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,563,211</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_a1ea890e70ea41aaa549c03df5a95b19" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.03</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_250806dfa0ca4930b910b9ecd357d214" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.46</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" id="Fact_25211783475d4d4aace4f3867cb2414c" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">899,228</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_ac186c6db3ec470aaa0489c182741184" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,043,575</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_3c69fce0ae8342bdb77e7deb88ce0619" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.79</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_84a7e0113abf4eb5a64b3549108ffab4" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_ad817bc788c44c32875ccbb51ed49b77" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">837,670</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b940" continuedAt="Text_a466f05a7e4e49a4ba9fc84c20eb39b941">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br class="Apple-interchange-newline"/>
          </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a466f05a7e4e49a4ba9fc84c20eb39b941">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">As of June 30, 2024 there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_f9b4306c2f61451a912edea622bfae4b" contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,042,395</ix:nonFraction> of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_9d7edcc5adc946f39e9abe55dd612e45" contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">2.84</ix:nonNumeric> years.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span>
           <span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>

          <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_860d2874450e4ff6950d5ae9c0b7d227" contextRef="c20240101to20240630" escape="true" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb01">
<div><span style="font-family: 'Times New Roman';"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb01" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb02">
<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 8 &#8211; Income Taxes</div>
</ix:continuation>
          <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb02" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb03">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb03" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb04">
<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb04" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb05">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb05" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb06">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company records a valuation allowance against its deferred tax
                assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized</span>. I</span>n assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and
            negative evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the
            generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for <span style="font-size: 10pt;">2024</span> and therefore there will be <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_7b74f8e6f3dc432db12c79bffdb66310" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span> current income tax expense.&#160; The Company recorded a full valuation allowance against the net deferred tax assets as of June<span style="font-size: 10pt;"> 30,
              2024</span> and December 31, <span style="font-size: 10pt;">2023</span>. Consequently, the Company recorded <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_0dc632c800e04dfb94cfa339ab97b85d" contextRef="c20240101to20240630" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span> income tax benefit due to realization uncertainties.</div>
</ix:continuation>
          <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb06" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb07">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb07" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb08">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb08" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb09">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to a U.S. federal statutory income tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_644149ac2fad41c998494f1685361914" contextRef="c20240401to20240630" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_150aa9db59e94b9d90086c9325dbed09" contextRef="c20240101to20240630" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction>%. The primary factor impacting the effective tax rate for the three and six months ended <span style="font-size: 10pt;">June 30, 2024</span> is the anticipated full year
                operating loss which will require a full valuation allowance against any associated net deferred tax assets.</div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb09" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb010">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb010" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb011">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb011" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb012">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb012" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb013">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Entities are required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their
                income tax returns. The Company has analyzed its tax positions and has concluded that as of <span style="font-size: 10pt;">June 30, 2024</span>, there were <ix:nonFraction name="pdsb:LiabilityForUncertainTaxPositions" id="Fact_d754d07f16e848afb90e73d87b794abf" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date
                because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_82f50ea5cc3f402b91f4ad510a0f9f86" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_238fe5654c6846bf976d007b353e1400" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits and has <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Fact_b5e6c3a52ce24dad89b1a7a50ce42f4a" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Fact_a9c30f66831b4350a2f71b2be9cf54aa" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t accrued any interest or penalties
                for the three and six months ended June<span style="font-size: 10pt;"> 30, 2024</span> or for the year ended December 31, <span style="font-size: 10pt;">2023.<br/>
                </span></div>
</ix:continuation>
              <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb013" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb014">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></span></div>
</ix:continuation>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb014" continuedAt="Text_5b2a39ba3a2148719f8721e81c27fcb015">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In accordance with the State of
                  New Jersey&#8217;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL
                  carryforwards, resulting in the recognition of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_39d231b91f0d4a179688098fed546635" contextRef="c20240101to20240630" unitRef="U002" decimals="-5" sign="-" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_7e243093c14e421fbddf06ab7aa4e0c6" contextRef="c20230101to20230630" unitRef="U002" decimals="-5" sign="-" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction> million of income tax benefit, net of transaction costs in the six months ended June 30, 2024 and 2023, respectively.</div>
</ix:continuation>
                <ix:continuation id="Text_5b2a39ba3a2148719f8721e81c27fcb015">
<div><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
              <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
                </span></div>

            </div>

          </div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_52ee43536ad149dfb48cd95e38b71a8a" contextRef="c20240101to20240630" escape="true" continuedAt="Text_44b80a338afb4764a6974443bc4cbd321">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
      <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd321" continuedAt="Text_44b80a338afb4764a6974443bc4cbd322">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 9 &#8211; Commitments and Contingencies</div>
</ix:continuation>
      <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd322" continuedAt="Text_44b80a338afb4764a6974443bc4cbd323">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd323" continuedAt="Text_44b80a338afb4764a6974443bc4cbd324">
<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>
</ix:continuation>
    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd324" continuedAt="Text_44b80a338afb4764a6974443bc4cbd325">
<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Rent</span></div>
</ix:continuation>
    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd325" continuedAt="Text_44b80a338afb4764a6974443bc4cbd326">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd326" continuedAt="Text_44b80a338afb4764a6974443bc4cbd327">
<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br/>
      </span></div>
</ix:continuation>
    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd327" continuedAt="Text_44b80a338afb4764a6974443bc4cbd328">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
    <div style="font-family: 'Times New Roman';">
      <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd328" continuedAt="Text_44b80a338afb4764a6974443bc4cbd329">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and six months ended June 30, 2024 was $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_0cc599e7eec14e9292f25f7ea1e11749" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">66,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_8a0e82f619704fbe9dcd1cf1f830fe76" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">132,000</ix:nonFraction> respectively, compared to the three and six months ended June 30, 2023 of $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_aa6a6b8e8b3a444cbb32d2e8706e1f80" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">126,532</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_58363d72c87a4c359724dc959bf67ba8" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">253,202</ix:nonFraction>.</span> </div>
</ix:continuation>
      <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd329" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3210">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3210" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3211">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Exclusive License Agreement</span></div>
</ix:continuation>
        <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3211" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3212">
<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3212" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3213">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In January 2023, the Company entered into an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting IL 12 fused antibody drug conjugate, M9241 (the &#8220;Merck KGaA License Agreement&#8221;).
            Pursuant to the Merck KGaA License Agreement, the Company agreed to make (i) development and first commercial sales milestone payments totaling up to $<ix:nonFraction name="pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales" id="Fact_1e7f44d12a9f406d92b600e90b6f38c5" contextRef="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction>
            million upon the achievement of certain milestones, including the dosing of the fifth patient in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up
            to $<ix:nonFraction name="pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels" id="Fact_137cb8f125b54b6aa8f70165da80571d" contextRef="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction> million upon achieving certain aggregate sales levels of the product.</span> </div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3213" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3214">
<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3214" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3215">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of <ix:nonFraction name="pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct" id="Fact_65a9466def21466f91f757b2ab743d3b" contextRef="c20240101to20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) <ix:nonNumeric name="pdsb:TermOfRoyaltyPayment" id="Fact_8fa6563452bb4940a933a76552adad4b" contextRef="c20240101to20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in the event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or if
            the Company obtains a license to any intellectual property owned or controlled by a third-party which, but for such license would be infringed by making, using or selling the compound.</div>
</ix:continuation>
        </div>

      </div>

      <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3215" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3216">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>
</ix:continuation>
    </div>

    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3216" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3217">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> <span style="font-size: 10pt;"> </span> </span></div>
</ix:continuation>
    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3217" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3218">
<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Legal Proceedings</span><br/>
      </span> </div>
</ix:continuation>
    <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3218" continuedAt="Text_44b80a338afb4764a6974443bc4cbd3219">
<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>
</ix:continuation>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
      <ix:continuation id="Text_44b80a338afb4764a6974443bc4cbd3219">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company is currently not a party to,</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and the Company&#8217;s</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> property is not currently the subject of,</span><span style="font-family: 'Times New Roman';"> any <span style="font-size: 10pt;">material </span>pending <span style="font-size: 10pt;">legal proceedings.</span> The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes that may not be predictable with assurance.</span></div>
</ix:continuation>
    </div>
<div><span style="font-family: 'Times New Roman';"> </span>
    <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;"> </span> </span></div>

    <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
      </span> </div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;"> <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_1e66b360307945beae775da6db05f15a" contextRef="c20240101to20240630" escape="true" continuedAt="Text_e5040c05065544b28c5f94232596a6c91">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c91" continuedAt="Text_e5040c05065544b28c5f94232596a6c92">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">Note 10 &#8211; Venture Loan and Security Agreement</div>
</ix:continuation>
      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c92" continuedAt="Text_e5040c05065544b28c5f94232596a6c93">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c93" continuedAt="Text_e5040c05065544b28c5f94232596a6c94">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c94" continuedAt="Text_e5040c05065544b28c5f94232596a6c95">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_e5040c05065544b28c5f94232596a6c95" continuedAt="Text_e5040c05065544b28c5f94232596a6c96">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c96" continuedAt="Text_e5040c05065544b28c5f94232596a6c97">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company entered into a Venture Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Horizon
            Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#8220;Collateral Agent&#8221;), and the other persons party thereto from time to time as lenders (&#8220;Lenders&#8221;).</div>
</ix:continuation>
        </div>

      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c97" continuedAt="Text_e5040c05065544b28c5f94232596a6c98">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c98" continuedAt="Text_e5040c05065544b28c5f94232596a6c99">
<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c99" continuedAt="Text_e5040c05065544b28c5f94232596a6c910">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c910" continuedAt="Text_e5040c05065544b28c5f94232596a6c911">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Term loan Amounts</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for the following <ix:nonFraction name="pdsb:DebtInstrumentNumberOfIndependentTermLoans" id="Fact_20b962accd3141e689bdfbb169e051d6" contextRef="c20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction> (<ix:nonFraction name="pdsb:DebtInstrumentNumberOfIndependentTermLoans" id="Fact_3736d53918fc4c31b65025cdd16a00bd" contextRef="c20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">6</ix:nonFraction>) separate and independent term loans: (a) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_f4d7a72863124a92b63d6636eaecbe62" contextRef="c20220831_DebtInstrumentAxis_LoanAMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,500,000</ix:nonFraction>
            (&#8220;Loan A&#8221;), (b) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_2598f545f00c4d849365747be3cb073d" contextRef="c20220831_DebtInstrumentAxis_LoanBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> (&#8220;Loan B&#8221;), (c) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_fd8f24a09d7e45fda32db3a43fd05c16" contextRef="c20220831_DebtInstrumentAxis_LoanCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction> (&#8220;Loan C&#8221;), (d) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_4e6fa4b7814e4868b94615f1f4977ace" contextRef="c20220831_DebtInstrumentAxis_LoanDMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction>
            (&#8220;Loan D&#8221;), (e) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_d9c43f4090204364b6ea8d2fa54ca47f" contextRef="c20240630_DebtInstrumentAxis_LoanEMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> (&#8220;Loan E&#8221;), and (f) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_c394293bc8a548bf9ae743476745cc12" contextRef="c20240630_DebtInstrumentAxis_LoanFMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> (&#8220;Loan F&#8221;) (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a &#8220;Loan&#8221; and, collectively, the &#8220;Loans&#8221;). </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Loan A, Loan B, Loan C, and Loan D were
            delivered to the Company on August 24, 2022. </span><span style="font-size: 10pt; font-family: 'Times New Roman';">Loan E and Loan F were uncommitted Loans that could have been advanced by the Lenders upon the parties agreement prior to July
            31, 2023 upon the satisfaction by the Company of certain agreed upon conditions. At</span> this <span style="font-size: 10pt; font-family: 'Times New Roman';">time the </span>option<span style="font-size: 10pt; font-family: 'Times New Roman';"> has expired and Loan E and Loan F are</span> no <span style="font-size: 10pt; font-family: 'Times New Roman';">longer available</span> to the Company <span style="font-size: 10pt; font-family: 'Times New Roman';">under the Loan and
            Security Agreement</span>. <span style="font-size: 10pt; font-family: 'Times New Roman';">The Company may only use the proceeds of the Loans for working capital or general corporate purposes.</span></div>
</ix:continuation>
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c911" continuedAt="Text_e5040c05065544b28c5f94232596a6c912">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c912" continuedAt="Text_e5040c05065544b28c5f94232596a6c913">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c913" continuedAt="Text_e5040c05065544b28c5f94232596a6c914">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c914" continuedAt="Text_e5040c05065544b28c5f94232596a6c915">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_e5040c05065544b28c5f94232596a6c915" continuedAt="Text_e5040c05065544b28c5f94232596a6c916">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">
          <div>
            <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c916" continuedAt="Text_e5040c05065544b28c5f94232596a6c917">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-style: italic;">Maturity</span>. Each Loan matures on the <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_98c0875d08c8476abf8fdc195f485bea" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durwordsen">48 month</ix:nonNumeric>
                anniversary following the applicable date on which a Loan is made to or on account of the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>under the Loan and Security Agreement (the &#8220;Maturity Date&#8221;) unless accelerated pursuant to agreed upon events of default. All amounts outstanding under each Loan will be due and payable upon
                the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.</span> Payments on the principal balance begin on October 1, 2024 and are paid monthly in the succeeding <ix:nonNumeric name="pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" id="Fact_2e7a6319159c4e51af4f181dda9b3895" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durwordsen">24 months</ix:nonNumeric><span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">.</span></div>
</ix:continuation>
            <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c917" continuedAt="Text_e5040c05065544b28c5f94232596a6c918">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> <br/>
              </span></div>
</ix:continuation>
          </div>

        </div>

      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c918" continuedAt="Text_e5040c05065544b28c5f94232596a6c919">
<div><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c919" continuedAt="Text_e5040c05065544b28c5f94232596a6c920">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Interest Rate</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall
            Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;<span style="-sec-ix-hidden:Fact_89027c97a3984c949cabb17cf3986c08">prime rate</span>&#8221; then in
            effect, plus (b) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact_ca83be1c21ff459d94c8d76aba7e3692" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.75</ix:nonFraction>%; provided that, in the event such rate of interest is less than <ix:nonFraction name="pdsb:DebtInstrumentMinimumVariableRate" id="Fact_6339d404263c446f9815295df936f308" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>%, such rate shall be deemed to be <ix:nonFraction name="pdsb:DebtInstrumentMinimumVariableRate" id="Fact_ed3682dd8d2e4ea8b224716235316f53" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>% for purposes of
            calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding during the preceding month.</span></div>
</ix:continuation>
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c920" continuedAt="Text_e5040c05065544b28c5f94232596a6c921">
<div style="text-align: justify; color: rgb(0, 0, 0);"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> <br/>
          </span></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c921" continuedAt="Text_e5040c05065544b28c5f94232596a6c922">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Amortization.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;Each Loan shall commence amortization upon the date set forth on the promissory note executed in connection with the respective Loan, upon which the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>is required to commence making equal payments of principal plus accrued interest on the outstanding principal amount of the respective
            Loan (the &#8220;Loan Amortization Date&#8221;), and continuing thereafter on the first business day of each calendar month through the Maturity Date.</span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c922" continuedAt="Text_e5040c05065544b28c5f94232596a6c923">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c923" continuedAt="Text_e5040c05065544b28c5f94232596a6c924">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c924" continuedAt="Text_e5040c05065544b28c5f94232596a6c925">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c925" continuedAt="Text_e5040c05065544b28c5f94232596a6c926">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Prepayment Premium.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;The <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>may, at its option upon at least ten (<ix:nonNumeric name="pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment" id="Fact_2a5e5626da0946349c64a0704271738d" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" format="ixt-sec:durday">10</ix:nonNumeric>) business days&#8217; written
            notice to the Lenders, prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each Lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an
            amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod1" id="Fact_697fd35d900543ad9404f3365000416e" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="-2" format="ixt-sec:numwordsen">three </ix:nonFraction>percent (<ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod1" id="Fact_c4029ad6060643f68be8d73f66bcb90d" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%) of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan,
            but on or before the date that is twelve (<ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_0f5aa54f278a4772af6b1e50e9bebe8a" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric>) months after such Loan Amortization Date, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod2" id="Fact_e6f619f0422843669eae8f93528c42a6" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="-2" format="ixt-sec:numwordsen">two </ix:nonFraction>percent (<ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod2" id="Fact_31cf549d4dbb43429751829ab5c76c64" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) of the then outstanding principal balance of
            such Loan, or (C) if such Loan is prepaid more than twelve (<ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_0bea390f660c404ca08ac7e5b087bf06" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric>) months after the Loan Amortization Date but prior to the stated
            Maturity Date applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod3" id="Fact_24651e45dbe741dd834a0cd540b31cf3" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="-2" format="ixt-sec:numwordsen">one </ix:nonFraction>percent (<ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod3" id="Fact_979dc69d94a14e06a971273c6e72f94a" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>%) of the then outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iii) the outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iv) all other sums, if any, that shall have become due and payable hereunder. <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod4" id="Fact_0e9aee95847d4b66b8a8ad9ace42217a" contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> prepayment premium will be
            applied to any outstanding balance of any Loan paid on the stated Maturity Date.</span></div>
</ix:continuation>
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c926" continuedAt="Text_e5040c05065544b28c5f94232596a6c927">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c927" continuedAt="Text_e5040c05065544b28c5f94232596a6c928">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Security</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">.</span><span style="font-family: 'Times New Roman';"> The Company&#8217;s obligations are secured by a security interest in all of the assets of the Company, subject
            to limited exceptions and excluding the Company&#8217;s intellectual property.</span></div>
</ix:continuation>
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c928" continuedAt="Text_e5040c05065544b28c5f94232596a6c929">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman';"> <br/>
          </span></div>
</ix:continuation>
      </div>
<ix:continuation id="Text_e5040c05065544b28c5f94232596a6c929" continuedAt="Text_e5040c05065544b28c5f94232596a6c930">
<div><span style="font-family: 'Times New Roman';"> </span>
       <span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c930" continuedAt="Text_e5040c05065544b28c5f94232596a6c931">
<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Covenants; Representations and Warranties; Other Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement contains customary representations, warranties and covenants, including
            maintenance of minimum cash balances as well as covenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans,
            certain corporate changes, transactions with affiliates, and fundamental changes. As of June 30, 2024, the Company was in compliance with all covenants in all material respects.</span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c931" continuedAt="Text_e5040c05065544b28c5f94232596a6c932">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c932" continuedAt="Text_e5040c05065544b28c5f94232596a6c933">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c933" continuedAt="Text_e5040c05065544b28c5f94232596a6c934">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 9pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_e5040c05065544b28c5f94232596a6c934" continuedAt="Text_e5040c05065544b28c5f94232596a6c935">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c935" continuedAt="Text_e5040c05065544b28c5f94232596a6c936">
<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Default Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment,
            breaches or defaults in the performance of covenants, insolvency, and bankruptcy by and/or of the Company.</span></div>
</ix:continuation>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">
          <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c936" continuedAt="Text_e5040c05065544b28c5f94232596a6c937">
<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c937" continuedAt="Text_e5040c05065544b28c5f94232596a6c938">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Warrant and Debt Discount.</span><span style="font-family: 'Times New Roman';"> In connection with the Loan and Security Agreement, the Company issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_ed2f30ff2c8542778fb1e7b754510893" contextRef="c20220831" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">381,625</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_7d306780cb664bb39d2fabf80065c90b" contextRef="c20220831" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">3.6685</ix:nonFraction> per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_696abf53c34740be9e514b8cd5f4ae02" contextRef="c20240630" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or
                substantially all of the Company&#8217;s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other
                reorganization) or series of related transactions, in which more than <ix:nonFraction name="pdsb:PercentageOfVotingPowerDisposedOff" id="Fact_a64577487c654e08898a33712b9b40fa" contextRef="c20240101to20240630_RangeAxis_MinimumMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the voting power of the Company is disposed of, in
                each case, for cash or for marketable securities meeting certain requirements as described in the applicable warrants. The key assumptions used in the Black-Scholes option pricing model were (i) expected term of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_6fbeade6f579427f81deb0ca14e26b7a" contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">10</ix:nonNumeric></span>
                years, (ii) a risk-free rate of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_37503b5edd4b4110982a8f67ed265905" contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.11</ix:nonFraction>%</span>, (iii) expected volatility of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_b6fd6cac954c4f4a8941661a2d573458" contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">93.8</ix:nonFraction>%</span>, (iv) and <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_a8de3c7b652d4c0ca73ff79de2aa0388" contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U004" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span> estimated dividend
                yield. In addition, the Company incurred third party and lender fees of $<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" id="Fact_3519c2c4ed944bb998f5e81c9eac0fa2" contextRef="c20220101to20220930" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">449,329</ix:nonFraction> during the nine months ended September 30, 2022.
                These proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrant and fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the
                Loan and Security Agreement using the effective interest method. The unamortized debt discount was $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_f18071a71cff464bb6101c1847ebf1f3" contextRef="c20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,710,639</ix:nonFraction> as of June 30,
                2024.</span></div>
</ix:continuation>
            <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c938" continuedAt="Text_e5040c05065544b28c5f94232596a6c939">
<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman';"> <span style="font-family: 'Times New Roman';"><br/>
                </span></span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
              <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c939" continuedAt="Text_e5040c05065544b28c5f94232596a6c940">
<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company
                recognized interest expense of $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_6f024079c07344daa6048911035ee179" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,184,294</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_3e0bb71891ed462d8cf7c722c04b388d" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,355,053</ix:nonFraction>, and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_ba20457f91744e31b589ab92918e68b2" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">961,753</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_f04b61add8724e5fb4105ce2087612c9" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,952,272</ix:nonFraction> for the three and six months ended June 30, 2024 and 2023, respectively and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_9e1984055b2c4ab4aec36369d170cfc4" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">283,774</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_19173240c273496080b2332af033408a" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">554,010</ix:nonFraction>, and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_a09eddb5e2354ceba4144a9fce5ea34a" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">121,997</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_e50680fe25a742a38d4221d8e69d175c" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233,523</ix:nonFraction> was related to the amortization of
                the debt discount for the three and six months ended June 30, 2024 and 2023, respectively.</div>
</ix:continuation>
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_e5040c05065544b28c5f94232596a6c940">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div style="color: rgb(0, 0, 0); text-align: justify; text-indent: 0px; font-family: 'Times New Roman';"><span style="font-size: 10pt;"> <br/>
          </span></div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Text_a6cabaaa720442fdb8bc1481eada5813" contextRef="c20240101to20240630" escape="true" continuedAt="Text_36f3bd6542c642a38820cdcbb78183f41">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_36f3bd6542c642a38820cdcbb78183f41" continuedAt="Text_36f3bd6542c642a38820cdcbb78183f42">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Note 11 &#8211; Retirement Plan</div>
</ix:continuation>
          <ix:continuation id="Text_36f3bd6542c642a38820cdcbb78183f42" continuedAt="Text_36f3bd6542c642a38820cdcbb78183f43">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_36f3bd6542c642a38820cdcbb78183f43" continuedAt="Text_36f3bd6542c642a38820cdcbb78183f44">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_36f3bd6542c642a38820cdcbb78183f44" continuedAt="Text_36f3bd6542c642a38820cdcbb78183f45">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt;"><ix:continuation id="Text_36f3bd6542c642a38820cdcbb78183f45" continuedAt="Text_36f3bd6542c642a38820cdcbb78183f46">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_36f3bd6542c642a38820cdcbb78183f46">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
                Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_2eb593eb78ab40028861b7fe47008ed4" contextRef="c20240401to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">46,995</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_805668b1ef6e444fbfbffd866e916b0c" contextRef="c20240101to20240630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">113,483</ix:nonFraction> for the three
                and six months ended June 30, 2024, respectively, compared to the three and six months ended June 30, 2023 of $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_5e0c1bd3ea104148ae0635853cf0f140" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">36,863</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_59fcd1af036a4e6f8e1113af5f54f06c" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">131,769</ix:nonFraction>, respectively.<br/>
              </span></div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</div>
<div><span style="font-family: 'Times New Roman';"> </span>
           <br/></div>

        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <a id="MANAGEMENTSDISCUSSION"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><span style="font-style: italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim
          condensed consolidated</span>&#160;<span style="font-style: italic;">financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) and with the audited financial statements and notes
          thereto of the Company as of and for the year ended December 31, 2023 on Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 28, 2024.</span></div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Quarterly Report contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section
        27A of the United States Securities Act of 1933, as amended) concerning the Company and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition,
        or otherwise, based on current beliefs of the Company&#8217;s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend
        upon or refer to future events or conditions, and include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;forecast,&#8221; &#8220;guidance&#8221;, &#8220;outlook&#8221; and other similar
        expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained
        in any forward-looking statement as a result of various factors, including, without limitation:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s ability to protect its intellectual property rights;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s anticipated capital requirements, including the Company&#8217;s anticipated cash runway and the Company&#8217;s current expectations regarding its plans for future equity financings;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s dependence on additional financing to fund its operations and complete the development and commercialization of its clinical and product candidates, and the risks that raising such additional capital
                may restrict the Company&#8217;s operations or require the Company to relinquish rights to the Company&#8217;s technologies or clinical and product candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s limited operating history in the Company&#8217;s current line of business, which makes it difficult to evaluate the Company&#8217;s prospects, the Company&#8217;s business plan or the likelihood of the Company&#8217;s
                successful implementation of such business plan;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><span style="color: #000000;">the timing for the Company or its partners to initiate the planned clinical trials </span>for its Versamune&#174; products, including <span style="color: #000000;">PDS0101, PDS0103, and others, alone or in
                  combination with PDS01ADC, as well as Infectimune&#174; based clinical candidates and the future success of such trials;</span></div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the successful implementation of the Company&#8217;s research and development programs and collaborations, including any collaboration trials concerning the Company&#8217;s Versamune&#174;, PDS01ADC and Infectimune&#174; based clinical
                and product candidates and the Company&#8217;s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company&#8217;s clinical and product candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the success, timing and cost of the Company&#8217;s ongoing clinical trials and anticipated clinical trials for the Company&#8217;s current clinical candidates, including statements regarding the timing of initiation, pace of
                enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data
                reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company&#8217;s ongoing clinical trials;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of the Company&#8217;s clinical and product candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">any Company statements about its understanding of clinical and product candidates&#8217; mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any
                collaboration trials; the acceptance by the market of the Company&#8217;s clinical and product candidates, if approved;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the timing of and the Company&#8217;s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company&#8217;s clinical and product
                candidates; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">other factors, including legislative, regulatory, political and economic developments not within the Company&#8217;s control, including unforeseen circumstances or other disruptions to normal business operations arising
                from or related to those listed under Part II, Item 1A. Risk Factors.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown
        risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Given
        these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, whether as a result of new
        information, future events or otherwise.</div>

      <div style="text-align: justify;"><span style="color: #000000;"> </span><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In this Quarterly Report, unless otherwise stated or the context otherwise indicates, references to &#8220;PDS Biotech,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to
        PDS Biotechnology Corporation, a Delaware corporation.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Company Overview</div>

      <div>
        <div><br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune&#174; T cell activator and
          Versamune&#174; in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC.&#160; In addition, we are developing the Infectimune&#174; T cell-activator in infectious diseases.</div>

        <div><br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">We believe our investigational targeted immunotherapies have the potential to overcome limitations of current immunotherapy approaches through effective conversion of the immune
          suppressive tumor to an immunogenic microenvironment in addition to the induction of the right type, potency and quantity of tumor-targeting killer (CD8) T cells.&#160; Our Versamune&#174; immunotherapies and Versamune&#174; in combination with PDS01ADC, are
          utilized for treatments in oncology, and Infectimune&#174; is utilized for preventive vaccines against infectious agents. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune&#174; and
          Infectimune&#174; have both been shown to induce, in vivo, large quantities of high-quality, highly potent polyfunctional disease-specific CD4 helper and CD8 killer T cells, a specific sub-type of T cell that has shown potential to be more effective
          at killing infected or target cells. Infectimune&#174; is also designed to promote the induction of disease-specific neutralizing antibodies. PDS01ADC is an investigational tumor targeting IL-12 that we believe may enhance the proliferation, potency
          and longevity of T cells in the tumor microenvironment and reduces the prevalence of immune suppressive cells and components within the tumor. We believe that our proprietary combinations of Versamune&#174; and PDS01ADC together with immune checkpoint
          inhibitors or other standards of care, may enhance the proliferation, potency and longevity of antigen specific multifunctional CD8 T cells in the tumor microenvironment and work synergistically to inhibit or treat cancer.</div>

      </div>

      <div>
        <div><br/>
        </div>

        <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Recent Developments</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In December 2022, we executed an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting IL-12 fused antibody drug conjugate, M9241, which joined our pipeline
        as PDS01ADC. PDS01ADC is a novel investigational tumor-targeting fusion protein of Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome
        the limitations of cytokine therapy which today have resulted in high toxicity and limited therapeutic potential. The proprietary combination of Versamune&#174; and PDS01ADC is designed to overcome tumor immune suppression utilizing a different
        mechanism from immune checkpoint inhibitors (ICI). The <span style="color: #000000;">combination of Versamune&#174; and PDS01ADC to overcome immune suppression is patented by us, and we believe our</span> ownership of both assets will streamline the
        clinical development, registrational process and their potential therapeutic use. <span style="color: #000000;">In a Phase 2 National Cancer Institute (NCI)-led clinical trial in ICI resistant patients, the combination of PDS0101 and PDS01ADC
          administered with an investigational bi-functional ICI resulted in a median overall survival of approximately 20 months. The historical median survival reported in ICI resistant HPV-positive cancers when treated with ICIs is 3-4 months, and best
          reported median survival to date with systemic therapy is 8.2 months in ICI resistant head and neck cancer.</span></div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In February 2023, we announced a successful completion of a Type B meeting with the FDA for the triple combination of PDS0101 and PDS01ADC with an FDA-approved immune checkpoint
        inhibitor for the treatment of recurrent/metastatic, ICI resistant head and neck cancer that is positive for the HPV type 16. In recent interactions with the FDA, we confirmed the required contents of a clinical protocol for the potential
        registrational trial.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In June 2023, an abstract was presented at the 2023 American Society of Clinical Oncology: Abstract number 6012, Safety and Efficacy of Immune Checkpoint Inhibitor (ICI) Na&#239;ve Cohort from Study of
        PDS0101 and Pembrolizumab in HPV16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC). The abstract was also selected as one of the featured posters reviewed by an expert panel in the Head and Neck Cancer discussion session.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In September 2023, data on our investigational universal flu vaccine, PDS0202, was presented at the 9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> European
        Scientific Working Group on Influenza (ESWI) conference. This data demonstrated broad neutralization across multiple influenza strains in animals and provided protection against infection after challenging animals not previously exposed to flu with
        lethal doses of the pandemic H1N1 flu virus.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In October 2023, data demonstrating PDS0101 in combination with standard-of-care (SOC) chemoradiotherapy was associated with a rapid decline in human papillomavirus circulating cell-free DNA
        (ctHPV-DNA), a potential predictive biomarker of treatment response. The data from the IMMUNOCERV Phase 2 clinical trial were featured in an oral presentation at the American Society for Radiation Oncology Annual Meeting.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In October 2023, updated interim data based on an August 2, 2023 cut off from our VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 in combination with Merck&#8217;s anti-PD-1
        therapy, Keytruda&#174; (pembrolizumab) which is the FDA-approved standard of care for first-line treatment of recurrent/metastatic head and neck cancer was presented at a key opinion leader roundtable that we sponsored.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In October 2023, interim safety and immune response data was presented for the first-in-human Phase1/2 clinical trial evaluating PDS01ADC in combination with current SOC chemotherapy, docetaxel, to
        treat metastatic castration sensitive and castration resistant prostate cancer. The data was featured in an oral presentation at the 11<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual Meeting of the
        International Cytokine &amp; Interferon Society.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In October 2023, immune response data from a preliminary analysis of a subset of patients in our VERSATILE-002 Phase 2 clinical trial was presented at the European Society for Medical Oncology
        Congress 2023.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In November 2023, we announced updated survival data from our NCI-led Phase 2 trial investigating the triple combination of PDS0101, PDS01ADC and an investigational immune checkpoint inhibitor
        (ICI) in two groups of advanced cancer patients with various types of human papillomavirus (HPV) 16-positive cancers.&#160; The data showed 75% Survival of ICI na&#239;ve patients at 36 months.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In November 2023, preclinical data from our NCI-led trial including PDS0101, PDS01ADC and an HDAC inhibitor in ICI-resistant HPV-16 positive cancer was presented during a poster presentation at the
        Society for Immunotherapy of Cancer 38<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual Meeting.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;"><span style="text-decoration: underline;">Clinical Candidate Pipeline</span></div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic;">VERSATILE-002: PDS0101 + Keytruda&#174;</div>

      <div><br/>
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">In November 2020, our VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 in combination with Merck&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab) which is the FDA-approved
          standard of care for first-line treatment of recurrent/metastatic head and neck cancer commenced. Enrollment in stage 2 of 2 for the ICI na&#239;ve arm and the ICI resistant arms are complete. The clinical trial will evaluate the efficacy and safety
          of this therapeutic combination as a first and second line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection.</div>

      </div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In this trial sponsored by PDS Biotech, patients whose cancer has returned following initial treatment or spread will be treated with the combination of PDS0101 and <span style="color: #000000;">Keytruda&#174;</span>
        to evaluate if the addition of PDS0101 might improve the efficacy reported in published studies of <span style="color: #000000;">Keytruda&#174;</span> alone. Patients in the trial will receive a total of 5 cycles of combination therapy in the context
        of standard of care <span style="color: #000000;">Keytruda&#174;</span> therapy administered every three weeks until disease progression. The primary endpoint of VERSATILE-002 is the objective response rate, or ORR, at six months following initiation
        of treatment.<span style="color: #000000;"> There are two </span>cohorts in the trial. Cohort 1 is for patients who have yet to be treated with an immune checkpoint inhibitor (ICI na&#239;ve) and cohort 2 which consists of patients who have failed
        immune checkpoint inhibitor therapy (ICI resistant).</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In February 2022, we achieved the preliminary efficacy milestone of at least four or more objective responses of the first 17 patients in the ICI na&#239;ve arm that allowed that arm to proceed to full
        enrollment. We also announced detailed preliminary safety data which showed that the combination is well tolerated without evidence of enhanced or significant toxicity in the first 18 patients in the ICI na&#239;ve arm. <span style="color: #000000;">We
          have completed enrollment in Stage 1 of the ICI resistant arm and we are waiting for sufficient follow up to conduct the futility analysis</span>.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In June 2022, we presented additional preliminary efficacy and safety data from this trial at the ASCO Annual Meeting <span style="color: #000000;">(Weiss J et al. J Clin Oncol 40, 2022 (suppl 16;
          abstr 6041))</span>. The abstract provided preliminary data on 19 patients (safety) with available imaging data for 17 of the 19 patients (efficacy). Data on 17 patients was presented. Highlights from the abstract were as follows:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Confirmed and unconfirmed response rates thus far (tumor shrinkage greater than 30%) seen in 7/17 (41.2%) patients in comparison to the published results of approximately 19% for approved ICIs, used as monotherapy for recurrent or
                metastatic head and neck cancer, with 2 of the 7 having complete responses (CR)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Stable disease (SD) was reported in 6/17 (35.3%) patients, with 4 of the 6 (67%) experiencing tumor shrinkage of less than 30%</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Clinical efficacy (ORR + SD) was seen in 13/17 (76.5%) patients</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Progressive/ongoing disease was reported in 4/17 (23.5%) patients</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Patients had received a median of 4/5 doses of PDS0101 (range 1-5) and 9/35 doses of Keytruda&#174;&#160;(range 1-18)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>There were no treatment-related adverse events greater than or equal to Grade 3 (N=19)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>No patients required dose interruption or reduction on the combination treatment</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>No patients discontinued the combination treatment</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>At 9 months of follow up (median not yet achieved):</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 53.3pt;"><br/>
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Progression free survival (PFS) rate was 55.2%</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 53.3pt;"><br/>
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Overall survival (OS) rate was 87.2%</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br/>
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>No control or comparative studies have been conducted between ICIs and PDS0101</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In May 2022, we expanded this trial into Europe and in June 2022, as described above, we received Fast Track designation from the FDA for PDS0101 in combination with <span style="color: #000000;">Keytruda&#174;.</span></div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In August 2022, our independent Data Monitoring Committee (DMC) met and evaluated data from 43 patients and noted there were no Grade 3 or greater treatment-related adverse events attributed to the
        combination. The DMC recommended continuing the trial with no modifications.</div>

      <div><br/>
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">In October 2022, we announced the results of an end-of-phase 2 meeting with the FDA for PDS0101 in combination with Keytruda&#174;. We have completed the plan for a potential Phase 3 clinical program
          that will support the submission of a BLA for PDS0101 and have submitted our plan to the FDA.</div>

        <div><br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In May 2023, we completed enrollment in the ICI na&#239;ve arm. We filed our amended IND with the FDA in the third quarter of 2023. In October 2023, we received feedback from the FDA
          on the amended IND.</div>

        <div><br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">In June 2023, </span>an abstract was presented at the 2023 American Society of Clinical Oncology: Abstract number 6012, Safety and Efficacy of Immune Checkpoint
          Inhibitor (ICI) Na&#239;ve Cohort from Study of PDS0101 and Pembrolizumab in HPV16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC). The abstract was also selected as one of the featured posters to be reviewed by an expert panel in the Head and
          Neck Cancer discussion session. Data on 34 patients was presented. The data from the abstract is as follows:</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in
                    patients with similar PD-L1 levels.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-top: 12pt;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34)</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed and unconfirmed objective response rate is 41.2% (14/34 patients), which is identical to the preliminary response rate data PDS Biotech previously
                    reported at ASCO 2022 (7/17 patients). To date these responses have been confirmed in nine of the 34 patients (26.5%), including one complete response.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15/34 patients (44.1%) had stable disease.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9/34 patients (26.5%) had progressive disease.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.</div>
                </td>

  </tr>


</table>
        </div>

        <div><br/>
        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In October 2023, at a key opinion roundtable updated interim data was presented based on an August 2, 2023 cut-off from our VERSATILE-002 Phase 2 clinical trial evaluating the combination of
        PDS0101 in combination with Merck&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab) which is an FDA-approved standard of care for first-line treatment of recurrent/metastatic head and neck cancer. Data on 52 patients was presented. The data from the
        roundtable based on investigator assessment was as follows:</div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Highlights from the ICI na&#239;ve cohort included:</div>

      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24-month overall survival (OS) rate of 74%; published 24-month survival rate of less than 30% for approved ICI.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12-month OS rate of 80%; published results of 30-50% with approved ICIs.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tumor shrinkage seen in 60% (31/52) of patients.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed overall response rate ORR of 27% (14/52) to date.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median progression-free survival (PFS) of 8.1 months to date; published results of 2-3 months PFS with approved ICIs.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13% (8/62) of patients experienced Grade 3 treatment-related adverse events (TRAE) and 0% (0/62) experienced Grade 4 or 5 TRAE; published results report 13-17%
                  Grade 3-5 TRAE with approved ICI monotherapy.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60% (33/55) of patients had CPS score of 1-19 (who generally have a weaker response to Keytruda&#174;), and 40% (22/55) have CPS score &gt;20 (who generally have a
                  higher response to Keytruda&#174;).</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In May 2024, at a virtual key opinion leader event, updated interim data was presented based on a November 30, 2023 cut-off from our VERSATILE-002 Phase 2 clinical trial evaluating the combination
        of PDS0101 in combination with Merck&#8217;s anti-PD-1 therapy, Keytruda&#174; (pembrolizumab) which is an FDA-approved standard of care for first-line treatment of recurrent/metastatic head and neck cancer. Data from 53 patients was presented. The data from
        the event based on investigator assessment was as follows:</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Highlights from the ICI na&#239;ve cohort with CPS &gt; 1 included:</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">
        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median overall survival of 30 months; published results for ICIs are 7-18 months.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed overall response rate ORR of 34% (18/53) to date; published results for comparable patients receiving treatment with ICIs are less than 20%.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Confirmed complete responses, partial responses and stable disease according to RECIST v1.1 were seen in 75.5% of patients.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Median progression-free survival (PFS) of 6.3 months to date; published results of 2-3 months PFS with approved ICIs.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The combination of PDS0101 and Keytruda&#174; appeared to be well tolerated with 11% (7/62) of patients experienced Grade 3 treatment-related adverse events (TRAE) and
                    2% (1/62) experienced Grade 4 or 5 TRAE; published results report 13-17% Grade 3-5 TRAE with approved ICI monotherapy.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60% (32/53) of patients had CPS score of 1-19 (who generally have a weaker response to Keytruda&#174;), and 40% (21/53) have CPS score &gt;20 (who generally have a
                    higher response to Keytruda&#174;).</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">During the May 2024 event, we also announced an updated clinical strategy with a two-part registrational trial focused on the double combination of Versamune&#174; HPV + pembrolizumab, accompanied by an
        investigation of the triple combination of Versamune&#174; HPV + PDS01ADC + pembrolizumab as a first line treatment in HPV16-positive recurrent/metastatic HNSCC.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In June 2024, we provided a data update from our VERSATILE-002 clinical trial.&#160; Interim data was presented based on a May 17, 2024 cut-off.&#160; The data update was as follows:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 38.15pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Median Overall Survival of 30 months, consistent with data presented our key opinion leader event in May of 2024, which was based on a data cut as of November 30, 2023.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 38.15pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>27 of the censored patients remained alive and were awaiting their next clinical assessment, 6 censored patients had withdrawn consent for further follow-up, and 2 patients had been lost to follow-up, and 18 patients had died.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 38.15pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The lower limit of the 95% confidence interval is 19.7 months, and the upper limit is not yet estimable, as the majority of patients continue to be followed for survival.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: 20.15pt;">In August 2024 we provided an update to our clinical strategy following discussions with the FDA.&#160; During the August 2024 update, we announced our intent to initiate a registrational study in first line treatment in
        HPV16-positive recurrent/metastatic HNSCC with the double combination of Versamune&#174; HPV + pembrolizumab.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic;">National Cancer Institute: PDS0101+ M9241 (now PDS01ADC) +Bintrafusp Alfa</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In June 2020, the first patient was dosed under a PDS0101 Cooperative Research and Development Agreement (CRADA), in the NCI led Phase 2 investigator-initiated trial evaluating PDS0101 with an
        IL-12 ADC now PDS01ADC, and M7824 (Bintrafusp alfa), which is owned by EMD Serono (Merck KGaA) in patients with advanced HPV-positive cancers who have failed prior treatment. In February 2021, the NCI&#8217;s Phase 2 clinical trial of PDS0101 for the
        treatment of advanced HPV-positive cancers had achieved its preliminary objective response target in patients na&#239;ve to check point inhibitors which allowed for full enrollment of approximately 20 patients in this group. In addition, based on
        promising results in the ICI na&#239;ve arm, the trial was amended to allow enrollment of a separate cohort of IC -resistant patients for assessment of safety and activity of the triple combination. The trial has been closed for enrollment. Preliminary
        efficacy assessment of the triple combination in this added group of 29 ICI resistant patients has been completed and evaluation of long-term patient survival is ongoing.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Preclinical study results arising from this CRADA were published in the Journal for ImmunoTherapy of Cancer, <span style="font-style: italic;">Immunomodulation to enhance the efficacy of an HPV
          therapeutic vaccine (Journal for ImmunoTherapy of Cancer2020;8:e000612. Doi:10.1136/ jitc-2020-000612)</span>, and indicate that PDS0101 generated both HPV-specific T cells and an<span style="color: #000000;">&#160;</span>associated<span style="color: #000000;">&#160;</span>antitumor response when used as a monotherapy. When PDS0101 was combined with the two other novel clinical-stage anti-cancer<span style="color: #000000;">&#160;</span>agents, Bintrafusp Alfa and M9241 (which is now owned by us and
        referred to as PDS01ADC), the preclinical data suggested that all three therapeutic agents worked<span style="color: #000000;">&#160;</span>synergistically to provide superior tumor T cell responses and subsequent tumor regression when compared to any
        of the agents alone or the 2-component combinations. The published preclinical data demonstrating powerful activity of the triple<span style="color: #000000;">&#160;</span>combination appears to be corroborated in the Phase 2 trial, and this triple
        combination could form the basis of a unique platform providing improved cancer treatments across multiple cancers.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In June 2022, at the 2022 ASCO Annual Meeting, the NCI provided an update to the preliminary data presented at the 2021 meeting (Strauss J et al. <span style="font-style: italic;">J
          Clin Oncol</span> 40, 2022 [suppl 16; abstr 2518]). This included data from 30 HPV16-positive patients and highlights were as follows:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Objective response (OR = <span style="text-decoration: underline;">&gt;</span>30% tumor reduction) was seen in 88% (7/8) of patients with ICI naive disease; 4/7 (57%) patients&#8217; responses are ongoing (median 17 months).</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">With ICI resistant patients: PDS01ADC dosing appears to affect response rates, with 5/8 (63%) patients receiving PDS01ADC at 16.8 mcg/kg achieving an OR compared to 1/14 (7%) patients who received PDS01ADC at 8
                mcg/kg achieving an OR; 4/6 (67%) patients&#8217; responses are ongoing (median 12 months).</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Tumor reduction was seen in 45% (10/22) of patients with ICI resistant disease, including patients receiving high or low dose PDS01ADC.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">In ICI resistant patients treated with high or low dose PDS01ADC, survival outcomes were similar (p=0.96 by Kaplan Meier analysis). At a median of 12 months of follow up 17/22 (77%) of patients were alive.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">In ICI na&#239;ve patients 6/8 (75%) were alive at median 17 months of follow up.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Similar OR and survival were seen across all types of HPV16-positive cancers.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Preliminary safety data: 13/30 (43%) of patients experienced Grade 3 treatment-related adverse events (AEs), and 2/30 patients (7%) experienced Grade 4 AEs. There were no grade 5 treatment-related AEs.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We believe the trial results to date strongly suggest, in agreement with the published preclinical studies, that all 3 drugs contribute to the clinical outcomes.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In September 2022, we determined, in agreement with the NCI, to select the ICI resistant patients as the preferred treatment group in the on-going PDS0101-based triple combination
        therapy in advanced HPV-positive cancers and the trial was closed to further enrollment given the ICI resistant arm had been fully recruited.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In October 2022, we presented additional interim data as follows:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Survival data:&#160; 66% (19/29) of HPV16-positive ICI resistant patients in the cohort were alive at a median follow up of 16 months.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Safety profile: 48% (24/50) patients experienced Grade 3 treatment-related adverse events (AEs), and 4% (2/50) patients experienced Grade 4 AEs. There were no Grade 5 treatment-related AEs.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">HPV16-positive ICI na&#239;ve patients: 75% (6/8) were alive at a median follow up of 25 months and 38% (3/8) of responders had a complete response.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In December 2022, we presented interim data as follows:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Median OS was 21 months in 29 checkpoint inhibitor resistant patients who received the triple combination. The reported historical median OS in patients with ICI resistant disease is 3-4 months seen with
                checkpoint inhibitors and best reported median survival to date with systemic therapy of 8.2 months in ICI resistant head and neck cancer.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">In ICI na&#239;ve subjects, 75% remain alive at a median follow-up of 27 months.&#160; As a result, median OS had not yet been reached. Historically, median OS for similar patients with platinum experienced ICI na&#239;ve
                disease is 7-11 months.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Objective response rate (ORR) in ICI resistant patients who received the optimal dose of the triple combination is 63% (5/8).&#160; In current approaches ORR is reported to be less than 10%.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">ORR in ICI na&#239;ve patients with the triple combination is 88%. In current approaches ORR is reported to be less than 25% with FDA-approved ICIs in HPV-positive cancers.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Safety data had not changed since October&#8217;s update. 48% (24/50) of patients experienced Grade 3 (moderate) treatment-related adverse events (AEs), and 4% (2/50) patients experienced Grade 4 (severe) AEs, compared
                with approximately 70% of patients receiving the combination of ICIs and chemotherapy reporting Grade 3 and higher treatment-related AEs.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In February 2023, we announced the completion of a Type B meeting with the FDA for the combination therapy of PDS0101, PDS01ADC, and an FDA-approved immune checkpoint inhibitor
          for the treatment of recurrent/metastatic HPV-positive ICI-resistant head and neck cancer. We confirmed the required contents of the trial design for a potential registrational trial of the combination.</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In November 2023, we released updated interim survival data as follows:</div>

      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>75% of immune checkpoint inhibitor (ICI) na&#239;ve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>12-month survival rate in (ICI) resistant patients of 72%</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Median OS in ICI resistant HPV-positive patients of approximately 20 months; published median OS is 3.4 months</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <div>
        <div style="text-align: justify; color: #000000; font-style: italic;">MD Anderson Cancer Center (IMMUNOCERV): PDS0101+ Chemoradiotherapy</div>

        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In October 2020, a PDS0101 Phase 2 IIT was initiated with The University of Texas MD Anderson Cancer Center and is actively recruiting patients. This clinical trial is investigating
        the safety and anti-tumor efficacy of PDS0101 in combination with standard-of-care chemo-radiotherapy, or CRT, and their correlation with critical immunological biomarkers in patients with locally advanced cervical cancer. We believe that
        Versamune&#174; has strong T cell induction with the potential to enhance efficacy of the current standard of care CRT treatment in this indication with the FDA at this meeting.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In November 2022, data from this trial was included in a poster presentation at the 2022 SITC Annual Meeting which included the following:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">9 of the 17 patients had completed a Day 170 post-treatment Positron Emission Tomography, Computed Tomography (PET CT) scan to assess the status of the cancer. This included 78% (7/9) of treated patients with
                advanced cervical cancer (FIGO stage III or IV).</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">100% (9/9) of patients treated with the combination of PDS0101 and CRT had an objective response.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">89% (8/9) of patients treated with the combination of PDS0101 and CRT demonstrated a complete response (CR) on Day 170 by PET CT. One patient who received 3 of the 5 scheduled doses of PDS0101 showed signs of
                residual disease. One patient who had a CR died from an event unrelated to either their underlying disease or treatment.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">1-year disease-free survival and 1-year overall survival of 89% (8/9) in patients treated with the combination of PDS0101 and CRT.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #201F1E;">As previously reported, data confirm PDS0101 treatment activates HPV16-specific CD8 T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells generated by
                the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8 T cells are important mediators of antigen-specific immunity.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #201F1E;">The data affirms that PDS0101 activates Type 1 interferon pathway in humans, mimicking the mechanism previously demonstrated in preclinical studies in animal models.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #201F1E;">Toxicity of PDS0101 remains limited to low-grade local injection site reactions.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In October 2023, data demonstrating PDS0101 in combination with standard-of-care (SOC) chemoradiotherapy was associated with a rapid decline in human papillomavirus circulating cell-free DNA
        (ctHPV-DNA), a potential predictive biomarker of treatment response. The data from the IMMUNOCERV Phase 2 clinical trial was featured in an oral presentation at the American Society for Radiation Oncology Annual Meeting which included the
        following:</div>

      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Earlier and greater proportion of ctDNA clearance with PDS0101 plus chemoradiation (CRT) vs. SOC CRT alone (81.3% clearance after 3 weeks vs. 30.3% with SOC (p=0.0018), and 91.7% of clearance at 5 weeks vs. 53.1% with SOC (p=0.0179).</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Baseline ctDNA levels correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node involvement; 100% of patients treated with PDS0101 had cancer that had spread to the lymph nodes.</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic;">Mayo Clinic: PDS0101 Monotherapy and in combination with Keytruda&#174;</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In February 2022, we initiated an Investigator-Initiated Trial (ITT), MC200710, for PDS0101 alone or in combination with the immune checkpoint inhibitor, Keytruda&#174;, in patients with
        HPV-positive oropharyngeal cancer (HPV(+)OPSCC) at high risk of recurrence. The trial is being led by Drs. David Routman, Katharine Price, Kathryn Van Abel, and Ashish Chintakuntlawar at Mayo Clinic, a nationally and internationally recognized
        center of excellence for the treatment of head and neck cancers. We believe that this trial not only broadens our addressable patient population of those affected by the increasing incidence of HPV(+)OPSCC, but also allows us to better understand
        the activity of PDS0101 alone or in combination with Keytruda&#174; in earlier stages of disease. This trial is currently open for enrollment.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In this trial, treatment will be administered before patients proceed to transoral robotic surgery (TORS) with curative intent. Treatment in this setting is referred to as
        neoadjuvant treatment. PDS0101 has been shown to induce killer T cells that target and kill HPV-positive cancers, either alone or in combination with ICIs in preclinical studies, and in combination in clinical studies of patients with advanced
        recurrent/metastatic HPV-positive cancers. This trial will explore whether PDS0101 with or without checkpoint inhibition may increase HPV-specific anti-tumor responses, potentially resulting in tumor shrinkage, pathologic regression, and decreases
        in circulating tumor DNA (ctDNA).</div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic;">PDS0102</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">PDS0102 is an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) from the NCI. PDS0102
        is designed to treat TARP-associated cancers including, acute myeloid leukemia (AML), prostate and breast cancer. In our preclinical work, in the administration of PDS0102, the Versamune&#174;+TARP antigen combination led to the induction of large
        numbers of tumor targeted killer T cells. In addition, the TARP tumor antigen alone has already been studied at the NCI in men with prostate cancer and has been shown to be safe, and immunogenic with slowing tumor growth rates (NCT00972309).</div>

      <div>
        <div><br/>
        </div>

        <div style="text-align: justify; color: #000000; font-style: italic;">PDS0103</div>

        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In April 2020, the above mentioned CRADA between PDS Biotech and the NCI was expanded beyond PDS0101 to include clinical and preclinical development of PDS0103. PDS0103 is an investigational immune
        therapy owned by PDS Biotech and designed to treat cancers associated with the mucin-1, or MUC1, oncogenic protein. These include cancers such as ovarian, breast, colorectal and lung cancers. PDS0103 combines Versamune&#174; with novel highly
        immunogenic agonist epitopes of MUC1 developed by the NCI and licensed by PDS Biotech. PDS0103 is currently in the tech transfer, clinical scale up and manufacturing stage.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">MUC1 is highly expressed in several types of cancer and has been shown to be associated with drug resistance and poor disease prognosis in breast, colorectal, lung and ovarian cancers, for which
        PDS0103 is being developed. Expression of MUC1 is often associated with poor disease prognosis, due in part to drug resistance. In preclinical studies, and similarly to PDS0101, PDS0103 demonstrated the ability to generate powerful MUC1-specific
        CD8 killer T cells.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In the first quarter of 2022, we held a pre-IND meeting with the FDA on PDS0103 and we plan to submit our IND package by the end of 2024. However, due to prioritization of our resources, the actual
        submission date may be impacted by our decision to pursue initiation of a pivotal trial for Versamune&#174; HPV in combination with pembrolizumab.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div>
        <div style="text-align: justify; font-style: italic;"><span style="text-decoration: underline;">IL-12 Oncology Immunocytokine Pipeline</span></div>

        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">PDS01ADC is a novel investigational IL-12 fused antibody drug conjugate (IgG1), tumor-targeting interleukin 12 (IL-12) immune-cytokine that enhances the proliferation, potency and
          longevity of T cells in the tumor microenvironment. Together with Versamune&#174; based immunotherapies, PDS01ADC works synergistically to overcome tumor immune suppression and to promote a targeted T cell attack against cancers. As with Versamune&#174;,
          PDS01ADC is given by a simple subcutaneous injection. Clinical data suggests the addition of PDS01ADC to Versamune&#174; based immunotherapies may demonstrate significant disease control in advanced cancer patients by shrinking tumors and/or
          prolonging life.</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">With the exclusive global license agreement with Merck KGaA, Darmstadt, Germany for PDS01ADC, we believe we have simplified our registrational pathway for the NCI-led triple combination by owning
          both PDS0101 and PDS01ADC and combining these agents with an FDA approved ICI. PDS01ADC has been designed to overcome the limitations of cytokine therapy as explained above, and based on extensive preclinical studies performed at the NCI
          evaluating PDS01ADC as a monotherapy and also in combinations with established standard of care treatments for cancer, we believe that PDS01ADC has significant potential as a cytokine therapy independent of Versamune&#174;. Based on the informative
          preclinical studies, a number of ITT Phase 2 trials are currently in progress at the NCI, some of which are outlined below:</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Phase II Study Evaluating ICI Na&#239;ve and Resistant Patients with HPV-positive malignancies treated with PDS01ADC, PDS0101 and bintrafusp alfa.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation
                  Therapy</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A Phase I/II Study of PDS01ADC in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate Cancer</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Phase I/II of PDS01ADC going forward as a Monotherapy in Advanced Kaposi Sarcoma</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Phase I/II of PDS01ADC in Combination of with a Histone Deacetylase (HDAC) Inhibitor in ICI resistant MUC1-positive colon and bladder cancers among others</div>
              </td>

  </tr>


</table>
      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">In October 2023, interim safety and immune response data was presented for the first-in-human Phase 1/2 clinical trial evaluating PDS01ADC in combination with current SOC chemotherapy, docetaxel,
          to treat metastatic castration sensitive and castration resistant prostate cancer. The data was featured in an oral presentation at the 11<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual Meeting of the
          International Cytokine &amp; Interferon Society. The data presented included the following:</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Decrease in PSA levels was seen in all patients at all three tested doses of PDS01ADC and 61% of patients had at least a 60% decrease in PSA levels.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Administration of the combination was associated with decreases in T reg cells and increases in activated natural killer (NK) cells, memory CD8 T cells, proliferating CD4 and CD8 T cells and cytokines INF-&#947; and Interleukin 10 (IL-10).</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The changes in immune responses with the combination were independent of the PDS01ADC dose.</div>
              </td>

  </tr>


</table>
      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">We are working closely with the NCI to determine the best pathway forward for the prioritized PDS01ADC studies, as well as evaluating the use of PDS01ADC in combination with other Versamune&#174;
          based clinical candidates.</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: justify; font-weight: bold;">Infectimune&#174; Development Strategy</div>

        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">We believe that the key differentiating attributes of the Infectimune&#174; platform technology are strong induction of CD8 and CD4 T cells as well as antibodies which can be leveraged to improve
        treatment and preventive options in several infectious disease indications. In January 2022, we presented preclinical data on our universal flu program sponsored by the National Institute of Allergy and Infectious Disease (NIAID) demonstrating the
        potential of the Infectimune&#174; technology with computationally designed influenza proteins developed by the laboratory of Dr. Ted Ross at the University of Georgia to generate broadly protective anti-influenza immune responses across multiple
        strains of influenza. This data has provided a unique opportunity to highlight Infectimune&#174;&#8217;s potentially transformative utility in the development of more broadly effective and longer lasting protective vaccines. Current preventive and
        prophylactic vaccine approaches and technologies predominantly focus on creating strong induction of antibody responses. However, the induction of T cell responses, in addition to antibody responses, provides more durable and broad protection
        against infectious diseases.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">Based on the preclinical data with the universal seasonal flu vaccine and the current focus of the NIAID in developing more effective flu vaccines, we have decided to focus our near-term infectious
        disease activities to align with the interests of the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. This will involve development of a universal seasonal flu vaccine and the potential development of a universal pandemic
        influenza vaccine based on similar computationally designed antigens as have shown promise with Infectimune&#174;.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In July 2022, universal flu vaccine preclinical data for PDS0202 at the 41<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> American Society of Virology meeting:
        Abstract number 3733830, Infectimune&#174; enhances antibodies elicited by COBRA hemagglutinin influenza vaccine. We are evaluating the next steps in the clinical development and funding for PDS0202.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The preclinical results for Infectimune&#174; based vaccines were published in two separate articles in the peer reviewed journal <span style="font-style: italic;">Viruses</span> in
        February 2023: 1. preclinical studies demonstrating complete protection against sickness after lethal challenge with live SARS-CoV-2 or influenza viruses (Gandhapudi SK et al. <span style="font-style: italic;">Viruses</span> 2023, <span style="font-style: italic;">15</span>, 432) and 2. Dramatically enhanced CD4 T cell responses to recombinant influenza proteins compared to leading commercial vaccine adjuvants (Henson TR et al. <span style="font-style: italic;">Viruses</span>
        2023, <span style="font-style: italic;">15</span>, 538).</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In September 2023, preclinical data on our investigational universal flu vaccine, PDS0202, was presented at the 9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>
        European Scientific Working Group on Influenza (ESWI) conference. This data demonstrated active neutralization across multiple influenza viruses in animals and provided protection against infection and weight loss after challenging with high doses
        of H1N1 viruses when they were not previously exposed to flu.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; font-weight: bold;">Our current clinical pipeline of Versamune&#174;, and PDS01ADC based therapies is as follows:</div>

      <div><br/>
      </div>

      <div style="text-align: center;"><img src="image01.jpg" alt="graphic"/></div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have never been profitable and have incurred net losses in each year since inception. Our net losses were $18.9 million and $21.2 million for the six months ended June 30, 2024
        and 2023, respectively. As of June 30, 2024, we had an accumulated deficit of $163.4 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and
        administrative costs associated with these operations.</div>

      <div><br/>
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">As of June 30, 2024, we had $57.7 million in cash and cash equivalents.</div>

      </div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our future funding requirements will depend on many factors, including the following:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the timing and costs of our planned clinical trials;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the timing and costs of our planned preclinical studies of our Versamune&#174; platform;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the outcome, timing and costs of seeking regulatory approvals;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other
                intellectual property rights; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the extent to which we license or acquire other products and technologies.</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">SELECTED FINANCIAL OPERATIONS OVERVIEW</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Revenue</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have not generated any revenues from commercial product sales and do not expect to generate any such revenue in the near future. We may generate revenue in the future from a
        combination of research and development payments, license fees and other upfront payments or milestone payments.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Research and development expenses include employee-related expenses, costs to acquire license rights to use certain technology in our research and development projects, costs of
        acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on our behalf. Costs for certain development activities, such as clinical trials,
        are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities
        are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued expenses. Costs incurred in connection with
        research and development activities are expensed as incurred.</div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">We expect that our research and development expenses will increase significantly over the next several years as we advance our Versamune&#174; and PDS01ADC clinical and product
          candidates into and through clinical trials, pursue regulatory approval of our Versamune&#174; and PDS01ADC product candidates and prepare for a possible commercial launch, all of which will also require a significant investment in contract research
          services, manufacturing process validation and inventory related costs.</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The process of conducting human clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for our
        clinical and product candidates.&#160; The probability of successful commercialization of our clinical and product candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability
        and commercial viability.&#160; As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our
        clinical and product candidates.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;"><span style="text-decoration: underline;">Results of Operations</span></div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The following table summarizes the results of our operations for the three months ended June 30, 2024 and 2023:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Three Months Ended</div>
              <div style="text-align: center; color: #000000;">June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Increase ( Decrease)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;"> 2024</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">$ Amount</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">%</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
              <div style="text-align: center; color: #000000;">(in thousands)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Operating expenses:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Research and development expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">4,528</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">8,005</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(3,477</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(43</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">General and administrative expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">4,156</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">4,691</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(535</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(11</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Total operating expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">8,684</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">12,696</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(4,012</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(32</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss from operations</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(8,684</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(12,696</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">4,012</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(32</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest income (expense), net</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(513</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(245</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(268</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">109</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Benefit from income taxes</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">869</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,406</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(537</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(38</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss and comprehensive loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(8,328</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(11,535</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(3,207</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(28</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Research and development expenses decreased to $4.5 million for the three months ended June 30, 2024 from $8.0 million for the three months ended June 30, 2023. The decrease of $3.5
        million was primarily attributable to a decrease of $2.0 million in clinical trials, $0.2 million in personnel costs related to non-cash stock-based compensation and $1.3 million in manufacturing expenses.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">General and Administrative Expenses</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">General and administrative expenses decreased to $4.2 million for the three months ended June 30, 2024 from $4.7 million for the three months ended June 30, 2023. The decrease of
        $0.5 million was primarily attributable to a decrease of $0.3 million in personnel costs, including $0.1 million in non-cash stock-based compensation, and $0.2 million in professional fees.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Benefit from Income Taxes</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">Income tax benefit was $0.9 million for the three months ended June 30, 2024 and $1.4 million for the three months ended June 30, 2023. The decrease of $0.5 million
          was due to a decrease in the amount of </span>New Jersey NOL carryforwards<span style="color: #000000;"> sold when compared to the comparable period.</span></div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Comparison of the Six months June 30, 2024 and 2023</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The following table summarizes the results of our operations for the six months ended June 30, 2024 and 2023:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Six Months Ended</div>
              <div style="text-align: center; color: #000000;">June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Increase (Decrease)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;"> 2024</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">$ Amount</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">%</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
              <div style="text-align: center; color: #000000;">(in thousands)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Operating expenses:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Research and development expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">11,232</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">13,849</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(2,617</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(19</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">General and administrative expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">7,550</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">8,270</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(720</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(9</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Total operating expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">18,782</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">22,119</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(3,337</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(15</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss from operations</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(18,782</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(22,119</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">3,337</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(15</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest income (expense), net</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(1,019</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(482</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(537</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">111</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Benefit from income taxes</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">869</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,406</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(537</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">(38</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss and comprehensive loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(18,932</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(21,195</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(2,264</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(11</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">Research and development expenses decreased to $</span>11.2<span style="color: #000000;"> million </span><span style="color: rgb(0, 0, 0);">for the six months
          ended June 30, 2024</span><span style="color: #000000;"> from $13.</span>8<span style="color: #000000;"> million </span><span style="color: rgb(0, 0, 0);">for the six months ended June 30, 2023</span><span style="color: #000000;">. The decrease
          of $2.6 million was primarily attributable to a decrease of $</span>0.8<span style="color: #000000;"> million in clinical studies and </span>medical affairs, <span style="color: #000000;">a decrease of $0.</span>4<span style="color: #000000;">
          million in personnel costs related to non-cash stock-based compensation</span> and<span style="color: #000000;"> $1.4 million in </span>manufacturing and quality costs<span style="color: #000000;">.</span></div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">General and Administrative Expenses</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">General and administrative expenses </span>decreased<span style="color: #000000;"> to $7.6 million for the six months ended June 30, 202</span>4<span style="color: #000000;"> from $8.3 million for the six months ended June 30, 202</span>3<span style="color: #000000;">. The </span>decrease<span style="color: #000000;"> of $0.</span>7<span style="color: #000000;"> million was primarily attributable to a
          decrease of $0.6 million in personnel costs, a decrease in legal fees of $0.3 million, partially offset by a</span>n increase <span style="color: #000000;">of $0.</span>2<span style="color: #000000;"> million in </span>professional fees<span style="color: #000000;">.</span></div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Liquidity and Capital Resources</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In August 2022, we filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC for the issuance of common stock, preferred stock, warrants, rights,
        debt securities, and units, up to an aggregate amount of $150 million, $50 million of which covers the offer, issuance and sale by us of our common stock under the Sales Agreement (as discussed below). The 2022 Shelf Registration Statement was
        declared effective on September 2, 2022.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In August 2022, we entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the
          Agents, with respect to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $50 million, or the Placement Shares,
          through or to the Agents, as sales agents or principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an
          &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for our common stock. The Agents will
          use commercially reasonable efforts to sell the Placement Shares from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay the Agents a
          commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under the Sales Agreement, and we have also provided the Agents with customary indemnification and contribution rights. We are not
          obligated to make any sales of our common stock under the Sales Agreement.&#160; The offering of Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or
          (ii) the termination of the Sales Agreement in accordance with its terms. For the year ended December 31, 2023, we sold 2,642,269 shares of common stock with a net value of $16.1 million pursuant to the Sales Agreement. During the three and six
          months ended June 30, 2024, we sold 0 shares of our common stock with a net value of $0 million and 3,428,681 shares of our common stock with a net value of $19.5 million, respectively, pursuant to the Sales Agreement. During the three and six
          months ended June 30, 2023, we sold 43,169 shares of our common stock with a net value of $0.2 million and 576,462 share of our common with a net value of $4.8 million, respectively, pursuant to the Sales Agreement.</div>

        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In August 2022, we entered into a venture loan and security agreement, or the Loan and Security Agreement, with Horizon Technology Finance Corporation, as lender and collateral
        agent for itself and the other lenders. The Loan and Security Agreement provides for the following 6 separate and independent term loans: (a) a term loan in the amount of $7,500,000, or Loan A, (b) a term loan in the amount of $10,000,000, or Loan
        B, (c) a term loan in the amount of $3,750,000, or Loan C, (d) a term loan in the amount of $3,750,000, or Loan D, (e) a term loan in the amount of $5,000,000, or Loan E, and (f) a term loan in the amount of $5,000,000, or Loan F, (with each of
        Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a Loan and, collectively, the Loans). Loan A, Loan B, Loan C, and Loan D were delivered to us on August 24, 2022. Loan E and Loan F were uncommitted Loans that could have been
        advanced by the Lenders upon the parties agreement prior to July 31, 2023 upon the satisfaction by the Company of certain agreed upon conditions. At this time the option has expired and Loan E and Loan F are no longer available to the Company under
        the Loan and Security Agreement. We may only use the proceeds of the Loans for working capital or general corporate purposes.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Each Loan matures on the 48-month anniversary following the applicable funding date unless accelerated pursuant to agreed upon events of default. Payments on the principal balance
        begin on October 1, 2024 and are paid monthly in the succeeding 24 months. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum
        rate of interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;prime rate&#8221; then in effect, plus (b) 5.75%; provided that, in the event such
        rate of interest is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of calculating the interest rate.</div>

      <div>
        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Interest is payable on a monthly basis based on each Loan principal amount outstanding the preceding month. We, at our option upon at least ten (10) business days&#8217; written notice to
        the lenders, may prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an amount equal
        to (A) if such Loan is prepaid on or before the Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, 3% of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan
        Amortization Date applicable to such Loan, but on or before the date that is 12 months after such Loan Amortization Date, 2% of the then outstanding principal balance of such Loan, or (C) if such Loan is prepaid more than 12 months after the Loan
        Amortization Date but prior to the stated maturity date applicable to such Loan, 1% of the then outstanding principal balance of such Loan; <span style="font-style: italic;">plus</span> (iii) the outstanding principal balance of such Loan; <span style="font-style: italic;">plus</span> (iv) all other sums, if any, that shall have become due and payable thereunder. No prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.</div>

      <div><br/>
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In connection with the Loan and Security Agreement, we issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of
          381,625 shares of our common stock at an initial exercise price of $3.6685 per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) 10 years from
          the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the our property or business, or (ii) its merger into or consolidation with any other corporation (other
          than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of, in each case, for cash or
          for marketable securities meeting certain requirements as described in the applicable warrants. The key assumptions used in Black-Scholes option pricing model were (i) expected term of 10 years, (ii) a risk-free rate of 3.11%, (iii) expected
          volatility of 93.8%, and (iv) no estimated dividend yield.</div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;"> <br/>
        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In April 2023, we received approximately $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant our participation in the New
          Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2021.</div>

        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In April 2024, we received approximately $0.9 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to its participation in the New
        Jersey Technology Business Tax Certificate Transfer of Net Operating Loss (NOL) program for tax year 2022.</div>

      <div>
        <div><br/>
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">As of June 30, 2024, we had $57.7 million in cash and cash equivalents. Our primary uses of cash are to fund operating expenses, primarily research and development expenditures.
        Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year
        beyond the filing of this Quarterly Report on Form 10-Q.&#160; Our budgeted cash requirements in 2024 and beyond include expenses related to continuing development and clinical studies as well as payments on our debt.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">We plan to continue to fund our operations and capital funding needs through existing cash and additional equity and/or debt financing. However, we cannot be certain
          that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or our existing stockholders. We may also enter into government funding programs and consider selectively
          partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing
          such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate
          our product development or future commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to develop and market ourselves. In addition, the Loan and Security Agreement allows for the lenders
          to call the outstanding balance of the term loans if the minimum cash balances outlined in the Loans and Security Agreement are not maintained. Any of these actions could harm our business, results of operations and prospects. </span>Failure to
        obtain adequate financing also may adversely affect our ability to operate as a going concern.</div>

      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">As a result of these uncertainties, and as its plans are outside of management&#8217;s control, we have concluded that substantial doubt exists about our ability to continue as a going concern for a
        period of at least 12 months from the date of the issuance of these unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements do not include any adjustments to the carrying amounts and
        classifications of assets and liabilities that would result if were unable to continue as a going concern.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Cash Flows</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The following table shows a summary of our cash flows for each of the periods indicated (in thousands):</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Six Months Ended June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;"> 2024</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
              <div>
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash used in operating activities</div>
              </div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(18,796</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(18,003</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash used in investing activities</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(29</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash provided by financing activities</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">19,998</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">4,808</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net increase (decrease) in cash and cash equivalents</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
              <div style="color: #000000;">1,173</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
              <div style="color: #000000;">(13,195</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="font-weight: bold;">Net Cash Used in Operating Activities</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">Net cash used in operating activities was $18.8 million and $18.0 million for the </span><span style="color: rgb(0, 0, 0);">six months ended</span><span style="color: #000000;"> June 30, 2024 and </span><span style="color: rgb(0, 0, 0);">2023</span><span style="color: #000000;">, respectively. The increase in net cash used in operating activities of $0.8 million was primarily </span>due to a decrease in
        accounts payable and accrued expenses of $2.5 million, partially offset by a decrease in net loss adjusted for non-cash items of $1.4 million.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Net Cash Used in Investing Activities</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Net cash used in investing activities for the six months ended June 30, 2024 and 2023 was $0.0 million and $0.0 million, respectively.</div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">Net Cash Provided by Financing Activities</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Net cash provided by financing activities for the six months ended June 30, 2024 and 2023 was primarily due to the receipt of net proceeds of $19.4 million and $ 4.8 million,
        respectively, from the sale of common stock under the Sales Agreement.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Operating Capital Requirements</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">To date, we have not generated any product revenue. We do not know when, or if, we will generate any product revenue and we do not expect to generate significant product revenue
        unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue
        the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to all of the risks incident to the development of new products, and may encounter unforeseen expenses,
        difficulties, complications, delays and other unknown factors that may harm our business. We expect to incur additional costs associated with operating as a public company and anticipate that we will need substantial additional funding in
        connection with our continuing operations.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year
        after the filing of this Quarterly Report. Our budgeted cash requirements in 2024 and beyond include expenses related to continuing development and clinical studies as well as payments on our debt. Until we can generate significant cash from our
        operations, we expect to continue to fund our operations with available financial resources. These financial resources may not be adequate to sustain our operations. While we intend to finance our cash needs principally through equity or debt
        financings, collaborations, strategic alliances, or license agreements with third parties, there is no assurance that new financing will be available to us on commercially acceptable terms or in the amounts required, if at all. In addition, the
        Loan and Security Agreement allows for the lenders to call the outstanding balance of the term loans if the minimum cash balances outlined in the Loans and Security Agreement are not maintained. We have concluded that substantial doubt exists about
        our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated financial statements.</div>

      <div><span style="color: #000000;"> </span><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we
        expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding
        requirements will depend on many factors, including, but not limited to:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the initiation, progress, timing, costs and results of our planned clinical trials;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the effects of health epidemics, pandemics, or outbreaks of infectious diseases, on our business operations, financial condition, results of operations and cash flows;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory
                authorities;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us now or in the future;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the effect of competing technological and market developments;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the cost of establishing sales, marketing and distribution capabilities in regions where we choose to commercialize our products on our own; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the initiation, progress, timing and results of our commercialization of our clinical and product candidates, if approved, for commercial sale.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Please see the section titled &#8220;Risk Factors&#8221; elsewhere in the Quarterly Report and Annual Report for additional risks associated with our operations.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Purchase Commitments</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have no material non-cancelable purchase commitments with service providers as we have generally contracted on a cancelable, purchase order basis.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">31</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">Critical Accounting Policies and Estimates</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S.
        GAAP. Our accounting policies are more fully described in Note 2 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.&#160; As described in Note 2, the preparation of these financial statements requires us
        to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses incurred during the reporting
        periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and
        liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ from these estimates under different assumptions or conditions. We believe that
        the discussion in our management&#8217;s discussion and analysis addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require management&#8217;s most
        difficult, subjective and complex judgments.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">There have been no material changes to our critical accounting policies and estimates during the six months ended June 30, 2024 from those disclosed in our Annual Report on Form 10-K for the year
        ended December 31, 2023.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-weight: bold;">Off-Balance Sheet Arrangements</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-weight: bold;">Smaller Reporting Company</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">As of January 1, 2021, we were no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. However, we remain a &#8220;smaller
        reporting company,&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We will cease to be a smaller reporting company if we have a non-affiliate public float in excess of $250 million and annual revenues in excess of
        $100 million, or a non-affiliate public float in excess of $700 million, determined on an annual basis. As a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to
        other public companies that are not smaller reporting companies. We will continue to take advantage of some or all of the available exemptions.</div>

      <div><br/>
      </div>

      <a id="QUANTITATIVE"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 3:</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>
        <div style="color: #000000; font-style: italic;">Interest Rate Risk</div>

        <div><span style="color: #000000;"> </span><br/>
        </div>

      </div>

      <div>
        <div style="text-indent: 36pt; color: rgb(0, 0, 0); text-align: justify;">We are exposed to market related changes in interest rates. As of June 30, 2024, our cash equivalents consisted of bank deposits and money market accounts. Additionally, the
          principal balance of our Loan and Security agreement with Horizon Technology Finance Corporation bears a floating interest pegged to the prime rate.&#160; Our primary exposure to market risk is interest rate sensitivity, which is affected by changes
          in the general level of U.S. interest rates.&#160; Historically, the net impact of fluctuations in interest rates have not been material to us.</div>

      </div>

      <div>
        <div><span style="color: #000000;"> </span><br/>
        </div>

        <div style="color: #000000; font-style: italic;">Inflation Risk</div>

        <div><span style="color: #000000;"> </span><br/>
        </div>

      </div>

      <div>
        <div style="text-indent: 36pt; color: #000000;">Inflation generally affects us by increasing our cost of labor and pricing of contracts. We do not believe that inflation has had a material effect on our business, financial condition, or results of
          operations during the three months ended June 30, 2024.</div>

      </div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <a id="CONTROLS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 4:</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">CONTROLS AND PROCEDURES</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-weight: bold;">Evaluation of Disclosure Controls and Procedures</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of
        our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934, or the Exchange Act, as of the end of the period covered by this report. Based on the evaluation, our Chief Executive
        Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded,
        processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</div>

      <div><br/>
      </div>

      <div style="font-weight: bold;">Changes in Internal Control over Financial Reporting</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 19.8pt;">There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation identified
        above that occurred during the quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">PART II.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;"><!--Anchor-->OTHER INFORMATION</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <a id="LEGALPROCEEDINGS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 1.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">LEGAL PROCEEDINGS</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The information in Note 9 to the Condensed Consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.
        There are no matters which constitute material pending legal proceedings to which we are a party other than those incorporated into this item by reference from Note 9 to our Condensed Consolidated financial statements for the quarter ended June 30,
        2024 contained in this Quarterly Report on Form 10-Q.</div>

      <div><br/>
      </div>

      <a id="RISKFACTORS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 1A.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">RISK FACTORS</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2023. However, any investment in
        our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our unaudited interim condensed consolidated financial
        statements and accompanying notes, our Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 28, 2024, including our financial statements and related notes contained therein, and the additional information in the other
        reports we file with the Securities and Exchange Commission. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline and you
        could lose part or all of your investment.<span style="font-style: italic;">&#160;</span>Additional risks that we currently believe are immaterial may also impair our business operations. Our business, financial conditions and future prospects and the
        trading price of our common stock could be harmed as a result of any of these risks.</div>

      <div style="text-align: justify; text-indent: 36pt;"><br/>
      </div>

      <a id="UNREGISTEREDSALES"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">There were no unregistered sales of the Company&#8217;s equity securities during the three months ended June 30, 2024.</div>

      <div><br/>
      </div>

      <a id="DEFAULTSUPON"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 3.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">DEFAULTS UPON SENIOR SECURITIES</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">None.</div>

      <div><br/>
      </div>

      <a id="MINESAFETY"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 4.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">MINE SAFETY DISCLOSURES</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">Not applicable.</div>

      <div><br/>
      </div>

      <a id="OTHERINFORMATION"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 5.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">OTHER INFORMATION</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" id="Fact_dd7a3b2cdaeb446fafcba81314d7e6d4" contextRef="c20240401to20240630" format="ixt:fixed-false"><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" id="Fact_c1ab8f79ebcf4a3eb66f08d804e25338" contextRef="c20240401to20240630" format="ixt:fixed-false"><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" id="Fact_92e765a356ea4642b594db621e952dca" contextRef="c20240401to20240630" format="ixt:fixed-false"><ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" id="Fact_23d9d23af62443049bf70dfcce0911cb" contextRef="c20240401to20240630" format="ixt:fixed-false">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</div>

      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <a id="EXHIBITS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-weight: bold;">ITEM 6.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">EXHIBITS</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; color: #000000; font-weight: bold;"><a id="EXHIBITINDEX"><!--Anchor--></a></div>

      <div style="text-align: center; color: #000000; font-weight: bold;"> <br/>
      </div>

      <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">Number</div>
            </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Exhibit Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036124031090/ef20031626_ex10-1.htm">3.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Amendment to the Eighth Amended and Restated Certificate of Incorporation <span style="color: #000000;">(filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on June 24, 2024, and
                  incorporated by reference herein).</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036124026295/ef20026295_ex10-3.htm">10.1+</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Executive Employment Agreement by and between Stephan F. Toutain and PDS Biotechnology Corporation, effective as of May 1, 2024 <span style="color: #000000;">(filed as Exhibit 10.3 to the Registrant&#8217;s
                  Quarterly Report on Form 10-Q filed on May 15, 2024, and incorporated by reference herein)</span>.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="ef20030064_ex31-1.htm">31.1*</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="ef20030064_ex31-2.htm">31.2*</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="ef20030064_ex32-1.htm">32.1 *</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="ef20030064_ex32-2.htm">32.2 *</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.INS*</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.SCH*</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.CAL*</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">XBRL Taxonomy Extension Calculation Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.DEF*</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">XBRL Taxonomy Extension Definition Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.LAB*</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">XBRL Taxonomy Extension Label Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.PRE*</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">XBRL Taxonomy Extension Presentation Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">104</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89.3%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000;">*</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Filed herewith (unless otherwise noted as being furnished herewith)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000;">+</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Indicates management compensatory plan or arrangement.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">34</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div><a href="#INDEX"><span style="font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <div style="text-align: center; font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

      <div><br/>
      </div>

      <div style="text-align: justify;">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">
              <div>PDS Biotechnology Corporation</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="color: #000000;">August 13, 2024</div>
            </td>

    <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>

    <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Frank Bedu-Addo</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Frank Bedu-Addo, Ph.D.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="color: #000000;">August 13, 2024</div>
            </td>

    <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>

    <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ <span style="color: #000000;">Lars Boesgaard</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000;">Lars Boesgaard</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Chief Financial Officer</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>(Principal Financial and Accounting Officer)</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div><br/>
      </div>

      <div style="text-align: center;"> <span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">35</span> </div>

      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>


</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ef20030064_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 31.1</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION OF <a name="z_cp_text_1_331"></a>PRINCIPAL EXECUTIVE <a name="z_cp_text_1_332"></a>AND FINANCIAL OFFICER</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div><font style="color: #000000;">I, </font>Frank Bedu-Addo<font style="color: #000000;">, Ph.D., certify that:</font></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z89396b70bdb04d0f92026f9845f59805" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended June 30, 2024;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3118acb23e7e427dafe0828efad17121" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
                statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zc9656077e6e3493dbb830fce8e12a2d1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Based on my knowledge, the Condensed Consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
                operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z325cdfb282454b25ad682a7f88476c7c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
                over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="za9e4009a368a4100af2972a960d55568" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.2pt;"><br>
            </td>
            <td style="width: 17.8pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including
                its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z126b811a5e174c71bb708f9256d61484" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.2pt;"><br>
            </td>
            <td style="width: 17.8pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
                financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z1188b636ed7c43d888e0c4a6471912a3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.2pt;"><br>
            </td>
            <td style="width: 17.8pt; vertical-align: top; color: #000000;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
                the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z89ef317b42454ce2b7e552a085918a78" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.2pt;"><br>
            </td>
            <td style="width: 17.8pt; vertical-align: top; color: #000000;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably
                likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3dad49074c5244d5bd8551793d075732" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the
                registrant's board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z318d24a8bf774521b2613de1d90c1e28" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record,
                process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z6a97a15842e34ba98e872e3d64561829" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z3d4e03fd23c44eb78ee86004f0b8ed4d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.21%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Dated: August 13, 2024</div>
            </td>
            <td style="width: 29.86%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">/s/ Frank Bedu-Addo</div>
            </td>
            <td style="width: 19.93%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 29.86%; vertical-align: top;">
              <div style="text-align: center;">Frank Bedu-Addo, Ph.D.</div>
            </td>
            <td style="width: 19.93%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 29.86%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">President and Chief Executive Officer</div>
            </td>
            <td style="width: 19.93%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 29.86%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">(Principal Executive Officer)</div>
            </td>
            <td style="width: 19.93%; vertical-align: bottom;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ef20030064_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 31.2</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION OF <a name="z_cp_text_1_335"></a>PRINCIPAL ACCOUNTING OFFICER</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div style="color: #000000;">I, Lars Boesgaard, certify that:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z55ed7ada41564f8db79b13a65f362951" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended June 30, 2024;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z969c129b907c4d84889ae48ad6fbb1e2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
                statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z5a0b7c41b2504422a4fa3151d3e6e890" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Based on my knowledge, the Condensed Consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
                operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zbd127edcd9d24a08b9bc0f425cf5180b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
                over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zed4e02af167e47c6ad301b55654cda40" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including
                its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3813f151c20d4ecbb4882e8057b22a61" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
                financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb8d01c0baaa1452da4a04792fca1820d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
                the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z5c27e781621a43d3b0919552fc2e519b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably
                likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z7b4106c6338f45eb8fe24dbc4c0a2342" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: #000000;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the
                registrant's board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zed937b357e434396b8af9d2ee160eedb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record,
                process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z559dd7a037444985b141389c46c648ce" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z3a3eb0c633cb407cb763bb78f6ac6f09" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.21%; vertical-align: top;">
              <div style="color: #000000;">Dated: August 13, 2024</div>
            </td>
            <td style="width: 34.79%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">/s/ Lars Boesgaard</div>
            </td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 34.79%; vertical-align: top;">
              <div style="text-align: center; color: #000000;">Lars Boesgaard</div>
            </td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 34.79%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">Chief Financial Officer</div>
            </td>
            <td style="width: 15%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 34.79%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">(Principal Financial and Accounting Officer)</div>
            </td>
            <td style="width: 15%; vertical-align: bottom;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ef20030064_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 32.1</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="color: #000000;">In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended </font><font style="color: rgb(0, 0, 0);">June
          30, 2024</font><font style="color: #000000;"> (the &#8220;Report&#8221;), I, </font>Frank Bedu-Addo<font style="color: #000000;">, Ph.D., President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant
          to &#167; 906 of the Sarbanes-Oxley Act of 2002 that:</font></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z9a92f07ff915404ca51b69bab84c3a71" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zcd3ffc2e7bb4449d9101162cdb0f24a4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zed5f438963bb4acf896efa9422e4c8e0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.8%; vertical-align: top;">
              <div style="color: #000000;">Dated: August 13, 2024</div>
            </td>
            <td style="width: 30.14%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">/s/ Frank Bedu-Addo</div>
            </td>
            <td style="width: 20.06%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.8%; vertical-align: top;">&#160;</td>
            <td style="width: 30.14%; vertical-align: top;">
              <div style="text-align: center;">Frank Bedu-Addo, Ph.D.</div>
            </td>
            <td style="width: 20.06%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.8%; vertical-align: top;">&#160;</td>
            <td style="width: 30.14%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">President and Chief Executive Officer</div>
            </td>
            <td style="width: 20.06%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.8%; vertical-align: top;">&#160;</td>
            <td style="width: 30.14%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">(Principal Executive Officer)</div>
            </td>
            <td style="width: 20.06%; vertical-align: bottom;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ef20030064_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 32.2</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000;">In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended June 30, 2024 (the &#8220;Report&#8221;), I, <a name="z_cp_text_1_338"></a>Lars

        Boesgaard, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 that:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd092727d2c084cfebccfddd47ce6fa17" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z92f2656aed6a42ba8f7deb9d567cb975" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z368dbd73a67044efb2f55f64d28c730a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.21%; vertical-align: top;">
              <div style="color: #000000;">Dated: August 13, 2024</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><font style="color: #000000;">/s/ Lars Boesgaard</font></div>
            </td>
            <td style="width: 19.79%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: center; color: #000000;">Lars Boesgaard</div>
            </td>
            <td style="width: 19.79%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">Chief Financial Officer</div>
            </td>
            <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.21%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000;">(Principal Financial and Accounting Officer)</div>
            </td>
            <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
    <!-- base href="file:///C:/Users/nalamk/AppData/Local/Temp/PROfile%20Green/wgeeychd.war/expand/content/ef20030064_ex32-2.htm" -->
    <title></title>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pdsb-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<xs:schema targetNamespace="http://pdsbiotech.com/20240630" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:pdsb="http://pdsbiotech.com/20240630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: Condensed Consolidated Balance Sheets-->
        <link:definition>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>060100 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResources" id="LiquidityAndCapitalResources">
        <link:definition>060300 - Disclosure - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>060400 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/Leases" id="Leases">
        <link:definition>060500 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>060600 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060700 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>060800 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>060900 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" id="VentureLoanAndSecurityAgreement">
        <link:definition>061000 - Disclosure - Venture Loan and Security Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/RetirementPlan" id="RetirementPlan">
        <link:definition>061100 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/InsiderTradingArrangements" id="InsiderTradingArrangements">
        <link:definition>061200 - Disclosure - Insider Trading Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesTables" id="LeasesTables">
        <!--Parent Role: Leases-->
        <link:definition>080500 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>080600 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>080700 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails" id="LiquidityAndCapitalResourcesDetails">
        <!--Parent Role: Liquidity and Capital Resources-->
        <link:definition>090300 - Disclosure - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" id="FairValueOfFinancialInstrumentsDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090400 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" id="LeasesOperatingLeaseDetails">
        <!--Parent Role: Leases-->
        <link:definition>090500 - Disclosure - Leases, Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" id="LeasesFinancingLeaseDetails">
        <!--Parent Role: Leases-->
        <link:definition>090502 - Disclosure - Leases, Financing Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>090600 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" id="StockbasedCompensationEquityCompensationPlansDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" id="StockbasedCompensationStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" id="StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" id="StockbasedCompensationStockOptionActivityDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090800 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>090900 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails" id="VentureLoanAndSecurityAgreementTermLoansDetails">
        <!--Parent Role: Venture Loan and Security Agreement-->
        <link:definition>091000 - Disclosure - Venture Loan and Security Agreement, Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails" id="VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails">
        <!--Parent Role: Venture Loan and Security Agreement-->
        <link:definition>091002 - Disclosure - Venture Loan and Security Agreement, Warrant and Debt Discount (Details) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" id="RetirementPlanDetails">
        <!--Parent Role: Retirement Plan-->
        <link:definition>091100 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xs:element name="FinanceLeasePrincipalAndInterestPayments" id="pdsb_FinanceLeasePrincipalAndInterestPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="FinanceLeaseCost" id="pdsb_FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LesseeFinanceLeaseMonthlyRentalExpense" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LesseeFinanceLeaseNumberOfLeases" id="pdsb_LesseeFinanceLeaseNumberOfLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncentiveStockOptionsMember" id="pdsb_IncentiveStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfCommonStockOutstanding" id="pdsb_PercentageOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EquityCompensationPlansMember" id="pdsb_EquityCompensationPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InducementPlan2019Member" id="pdsb_InducementPlan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2014Member" id="pdsb_EquityIncentivePlan2014Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiquidityAndCapitalResourcesAbstract" id="pdsb_LiquidityAndCapitalResourcesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiquidityAndCapitalResourcesTextBlock" id="pdsb_LiquidityAndCapitalResourcesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CommissionPercentage" id="pdsb_CommissionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod3" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentWrittenNoticePeriodForPrepayment" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentNumberOfIndependentTermLoans" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod1" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod4" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShelfRegistrationStatementAvailableForFutureSale" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DebtInstrumentThresholdPeriod" id="pdsb_DebtInstrumentThresholdPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod2" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentMinimumVariableRate" id="pdsb_DebtInstrumentMinimumVariableRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlacementSharesAvailableForFutureSale" id="pdsb_PlacementSharesAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="TermLoansMember" id="pdsb_TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanFMember" id="pdsb_LoanFMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanAMember" id="pdsb_LoanAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanEMember" id="pdsb_LoanEMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanCMember" id="pdsb_LoanCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanDMember" id="pdsb_LoanDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanBMember" id="pdsb_LoanBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfVotingPowerDisposedOff" id="pdsb_PercentageOfVotingPowerDisposedOff" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedResearchAndDevelopmentCostsCurrent" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LiabilityForUncertainTaxPositions" id="pdsb_LiabilityForUncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="MerckKGaALicenseAgreementMember" id="pdsb_MerckKGaALicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RoyaltyPercentagePaidOnNetSalesOfProduct" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentsDevelopmentAndFirstCommercialSales" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="TermOfRoyaltyPayment" id="pdsb_TermOfRoyaltyPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pdsb-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LeasesFinancingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="SecuredDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to SecuredDebtCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to FinanceLeaseLiabilityCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to FinanceLeaseLiabilityNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SecuredLongTermDebt" xlink:title="calculation: Liabilities to SecuredLongTermDebt" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="FinanceLeaseRightOfUseAsset" xlink:title="calculation: Assets to FinanceLeaseRightOfUseAsset" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: InterestIncomeExpenseNonoperatingNet to InvestmentIncomeInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="InterestExpenseNonoperating" xlink:title="calculation: InterestIncomeExpenseNonoperatingNet to InterestExpenseNonoperating" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestIncomeExpenseNonoperatingNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IssuanceOfStockAndWarrantsForServicesOrClaims" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOperatingLeaseLiability" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="FinanceLeaseRightOfUseAssetAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to FinanceLeaseRightOfUseAssetAmortization" order="7.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="16.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="17.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityToBePaidYearFourAndThereafter" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsDueYearTwo" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentCostsCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedRentCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedRentCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="WorkersCompensationLiabilityCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to WorkersCompensationLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="InterestPayableCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to InterestPayableCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedProfessionalFeesCurrent" order="1.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pdsb-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#RetirementPlanDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#VentureLoanAndSecurityAgreementTermLoansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationEquityCompensationPlansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LeasesFinancingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#FairValueOfFinancialInstrumentsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LeasesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlan" xlink:type="simple" xlink:href="pdsb-20240630.xsd#RetirementPlan" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" xlink:type="simple" xlink:href="pdsb-20240630.xsd#VentureLoanAndSecurityAgreement" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pdsb-20240630.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpenses" xlink:type="simple" xlink:href="pdsb-20240630.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Leases" xlink:type="simple" xlink:href="pdsb-20240630.xsd#Leases" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="pdsb-20240630.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/NatureOfOperations" xlink:type="simple" xlink:href="pdsb-20240630.xsd#NatureOfOperations" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pdsb-20240630.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueIssuedForServices" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/NatureOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResources" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Leases" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpenses" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlan" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="definition: DebtInstrumentLineItems to BusinessCombinationConsiderationTransferredAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: DebtInstrumentLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="definition: DebtInstrumentLineItems to ShelfRegistrationStatementAvailableForFutureSale" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PlacementSharesAvailableForFutureSale" xlink:title="definition: DebtInstrumentLineItems to PlacementSharesAvailableForFutureSale" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CommissionPercentage" xlink:title="definition: DebtInstrumentLineItems to CommissionPercentage" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: DebtInstrumentLineItems to StockIssuedDuringPeriodSharesNewIssues" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromIssuanceOfCommonStock" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentNumberOfIndependentTermLoans" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnusedBorrowingCapacityAmount" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="ProceedsFromIssuanceOfSecuredDebt" xlink:title="ProceedsFromIssuanceOfSecuredDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromIssuanceOfSecuredDebt" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromIssuanceOfSecuredDebt" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTerm" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentMinimumVariableRate" xlink:label="DebtInstrumentMinimumVariableRate" xlink:title="DebtInstrumentMinimumVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMinimumVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMinimumVariableRate" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentWrittenNoticePeriodForPrepayment" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod1" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentThresholdPeriod" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod2" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod3" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod4" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="definition: DebtInstrumentNameDomain to TermLoansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="definition: TermLoansMember to LoanAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="definition: TermLoansMember to LoanBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="definition: TermLoansMember to LoanCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="definition: TermLoansMember to LoanDMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="definition: TermLoansMember to LoanEMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="definition: TermLoansMember to LoanFMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDescriptionAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseNumberOfLeases" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseNumberOfLeases" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="FinanceLeaseCost" xlink:title="definition: LesseeLeaseDescriptionLineItems to FinanceLeaseCost" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseTermOfContract1" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseTermOfContract1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDiscountRate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDiscountRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseMonthlyRentalExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="PropertyPlantAndEquipmentAdditions" xlink:title="PropertyPlantAndEquipmentAdditions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="PropertyPlantAndEquipmentAdditions" xlink:title="definition: LesseeLeaseDescriptionLineItems to PropertyPlantAndEquipmentAdditions" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfCommonStockOutstanding" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PercentageOfCommonStockOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityCompensationPlansMember" xlink:title="definition: PlanNameDomain to EquityCompensationPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2014Member" xlink:title="definition: EquityCompensationPlansMember to EquityIncentivePlan2014Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityCompensationPlansMember" xlink:to="InducementPlan2019Member" xlink:title="definition: EquityCompensationPlansMember to InducementPlan2019Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="definition: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="27.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="OperatingLeaseCost" xlink:title="definition: OtherCommitmentsLineItems to OperatingLeaseCost" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="definition: OtherCommitmentsLineItems to MilestonePaymentsDevelopmentAndFirstCommercialSales" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="definition: OtherCommitmentsLineItems to MilestonePaymentsAchievementOfCertainAggregateSalesLevels" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="definition: OtherCommitmentsLineItems to RoyaltyPercentagePaidOnNetSalesOfProduct" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="TermOfRoyaltyPayment" xlink:title="definition: OtherCommitmentsLineItems to TermOfRoyaltyPayment" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsTable" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsAxis" xlink:title="definition: OtherCommitmentsTable to OtherCommitmentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain_2" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain_2" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsDomain" xlink:to="MerckKGaALicenseAgreementMember" xlink:title="definition: OtherCommitmentsDomain to MerckKGaALicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="definition: OtherCommitmentsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentNumberOfIndependentTermLoans" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnusedBorrowingCapacityAmount" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTerm" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentMinimumVariableRate" xlink:label="DebtInstrumentMinimumVariableRate" xlink:title="DebtInstrumentMinimumVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMinimumVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMinimumVariableRate" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentWrittenNoticePeriodForPrepayment" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentThresholdPeriod" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod2" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod3" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod4" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="definition: DebtInstrumentNameDomain to TermLoansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="definition: TermLoansMember to LoanAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="definition: TermLoansMember to LoanBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="definition: TermLoansMember to LoanCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="definition: TermLoansMember to LoanDMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="definition: TermLoansMember to LoanEMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="definition: TermLoansMember to LoanFMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: DebtInstrumentLineItems to WarrantsAndRightsOutstandingTerm" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PercentageOfVotingPowerDisposedOff" xlink:label="PercentageOfVotingPowerDisposedOff" xlink:title="PercentageOfVotingPowerDisposedOff" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PercentageOfVotingPowerDisposedOff" xlink:title="definition: DebtInstrumentLineItems to PercentageOfVotingPowerDisposedOff" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="definition: DebtInstrumentLineItems to WarrantsAndRightsOutstandingMeasurementInput" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="definition: DebtInstrumentLineItems to PaymentsOfDebtIssuanceCosts" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestExpenseDebt" xlink:title="definition: DebtInstrumentLineItems to InterestExpenseDebt" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfDebtDiscountPremium" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: DebtInstrumentTable to MeasurementInputTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlanDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pdsb-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTradingArrLineItems" xml:lang="en-US" id="ecd_InsiderTradingArrLineItems">Insider Trading Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems" xlink:title="label: InsiderTradingArrLineItems to ecd_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation" xml:lang="en-US" id="us-gaap_Depreciation">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation" xlink:title="label: Depreciation to us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US" id="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">Issuance of shares in consulting agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract">Condensed Consolidated Balance Sheets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic">Net loss per share, basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash Equivalents and Concentration of Cash Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet" xml:lang="en-US" id="us-gaap_InterestPaidNet">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding">Common stock shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue" xml:lang="en-US" id="us-gaap_CommonStockValue">Common stock, $0.00033 par value, 150,000,000 and 75,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 36,779,275 and 33,094,521 issued and outstanding at June 30, 2024 and December 31, 2023, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit">Current income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtDisclosureTextBlock" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock">Venture Loan and Security Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock_lbl1">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount">Face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount">Unamortized debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">Uncommitted loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="label: DebtInstrumentUnusedBorrowingCapacityAmount to us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" xlink:title="label: DebtInstrumentUnusedBorrowingCapacityAmount to us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentsAbstract" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract">Venture Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract_lbl1">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl1" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable" xml:lang="en-US" id="us-gaap_DebtInstrumentTable">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts">Debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted">Net loss per share, diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="label: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation" xml:lang="en-US" id="us-gaap_ShareBasedCompensation">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl1">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract">Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">Accrued interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestAccrued to us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpenseDebt" xml:lang="en-US" id="us-gaap_InterestExpenseDebt">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseDebt_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseDebt_lbl1">Interest Expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl1" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities" xml:lang="en-US" id="us-gaap_Liabilities">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities" xlink:title="label: Liabilities to us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAbstract">LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract" xlink:title="label: LiabilitiesAbstract to us-gaap_LiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAbstract_lbl1">Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl1" xlink:title="label: LiabilitiesAbstract to us-gaap_LiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss" xml:lang="en-US" id="us-gaap_NetIncomeLoss">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss1" xml:lang="en-US" id="us-gaap_NetIncomeLoss1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract">Interest income (expenses), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract">Noncurrent liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract_lbl1">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock1">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="ProceedsFromIssuanceOfSecuredDebt" xlink:title="ProceedsFromIssuanceOfSecuredDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfSecuredDebt">Proceeds from issuance of secured loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:title="label: ProceedsFromIssuanceOfSecuredDebt to us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1">Proceeds from Issuance of Secured Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" xlink:title="label: ProceedsFromIssuanceOfSecuredDebt to us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Purchase of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SecuredDebtCurrent" xml:lang="en-US" id="us-gaap_SecuredDebtCurrent">Note payable - short term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredDebtCurrent" xlink:to="us-gaap_SecuredDebtCurrent" xlink:title="label: SecuredDebtCurrent to us-gaap_SecuredDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredDebtCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecuredDebtCurrent_lbl1" xml:lang="en-US" id="us-gaap_SecuredDebtCurrent_lbl1">Secured Debt, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredDebtCurrent" xlink:to="us-gaap_SecuredDebtCurrent_lbl1" xlink:title="label: SecuredDebtCurrent to us-gaap_SecuredDebtCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecuredLongTermDebt" xml:lang="en-US" id="us-gaap_SecuredLongTermDebt">Notes payable, net of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt" xlink:title="label: SecuredLongTermDebt to us-gaap_SecuredLongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Number of shares authorized for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Shares available for grant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Fair value of option on grant date (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1">Options outstanding, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract">Condensed Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract">Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract1">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Number of shares of common stock that can be purchased with warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract">Supplemental information of cash and non-cash transactions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent" xml:lang="en-US" id="us-gaap_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember" xml:lang="en-US" id="us-gaap_WarrantMember">Warrants to Purchase Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember" xlink:title="label: WarrantMember to us-gaap_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="PropertyPlantAndEquipmentAdditions" xlink:title="PropertyPlantAndEquipmentAdditions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentAdditions" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAdditions">Recognition of property and equipment from bargain purchase option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:title="label: PropertyPlantAndEquipmentAdditions to us-gaap_PropertyPlantAndEquipmentAdditions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1">Property, Plant and Equipment, Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" xlink:title="label: PropertyPlantAndEquipmentAdditions to us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets" xml:lang="en-US" id="us-gaap_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets" xlink:title="label: Assets to us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentIncomeInterest" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest_lbl1" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl1">Investment Income, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl1" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable" xml:lang="en-US" id="us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable" xlink:title="label: StatementTable to us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract" xml:lang="en-US" id="us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems" xml:lang="en-US" id="us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member">Quoted Prices in Inactive Markets (Level 2) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member">Significant Unobservable Inputs (Level 3) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="FairValueByBalanceSheetGroupingTextBlock" xlink:title="FairValueByBalanceSheetGroupingTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xml:lang="en-US" id="us-gaap_FairValueByBalanceSheetGroupingTextBlock">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:title="label: FairValueByBalanceSheetGroupingTextBlock to us-gaap_FairValueByBalanceSheetGroupingTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xlink:title="label: FairValueByBalanceSheetGroupingTextBlock to us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses" xml:lang="en-US" id="us-gaap_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive impact to EPS (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract">Per share information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">Net Loss per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">Common stock reserved for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity" xml:lang="en-US" id="us-gaap_StockholdersEquity">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity1" xml:lang="en-US" id="us-gaap_StockholdersEquity1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity2" xml:lang="en-US" id="us-gaap_StockholdersEquity2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">Income tax benefit due to realization uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit">Benefit for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit1">Benefit for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember" xml:lang="en-US" id="us-gaap_RetainedEarningsMember">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain" xml:lang="en-US" id="us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EmployeeStockOptionMember1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember1">Stock Options to Purchase Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl2" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl2">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl2" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">Forfeited and expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">Forfeited and expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">Patent Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues">Issuances of common stock from the Sales Agreement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Issuances of common stock, from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues">Issuances of common stock from the Sales Agreement, net (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues1">Issuance of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Issuances of common stock, from exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">Vested and expected to vest (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Assumptions Used in Determining Fair Value of Stock Options and Warrants Granted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract" xml:lang="en-US" id="us-gaap_LeasesAbstract">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies">Commitments and contingencies (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NatureOfOperations" xml:lang="en-US" id="us-gaap_NatureOfOperations">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="us-gaap_NatureOfOperations" xlink:title="label: NatureOfOperations to us-gaap_NatureOfOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent1">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl1">Accrued Professional Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedRentCurrent" xml:lang="en-US" id="us-gaap_AccruedRentCurrent">Accrued rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent" xlink:title="label: AccruedRentCurrent to us-gaap_AccruedRentCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPayableCurrent" xml:lang="en-US" id="us-gaap_InterestPayableCurrent">Accrued interest on debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="label: InterestPayableCurrent to us-gaap_InterestPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WorkersCompensationLiabilityCurrent" xml:lang="en-US" id="us-gaap_WorkersCompensationLiabilityCurrent">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" xlink:title="label: WorkersCompensationLiabilityCurrent to us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="label: BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet">Interest income (expenses), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1">Interest Income (Expense), Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">Nature of Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding" xml:lang="en-US" id="us-gaap_SharesOutstanding">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding1" xml:lang="en-US" id="us-gaap_SharesOutstanding1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract">Venture Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US" id="us-gaap_CompensationAndRetirementDisclosureAbstract">Retirement Plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:title="label: CompensationAndRetirementDisclosureAbstract to us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Assumptions Used to Value Stock Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates" xml:lang="en-US" id="us-gaap_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1">Options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock">Unaudited Interim Financial Statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">401(k) employer contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Unamortized stock compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">Unamortized Stock Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis" xml:lang="en-US" id="us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain" xml:lang="en-US" id="us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis" xml:lang="en-US" id="us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices">Issuance of common stock for consulting agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">Issuance of common stock for consulting agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Options outstanding, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Exercisable, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">Vested and expected to vest, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AreaOfRealEstateProperty" xml:lang="en-US" id="us-gaap_AreaOfRealEstateProperty">Area of office space under sublease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:title="label: AreaOfRealEstateProperty to us-gaap_AreaOfRealEstateProperty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AreaOfRealEstateProperty_lbl1" xml:lang="en-US" id="us-gaap_AreaOfRealEstateProperty_lbl1">Area of Real Estate Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl1" xlink:title="label: AreaOfRealEstateProperty to us-gaap_AreaOfRealEstateProperty_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US" id="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">Margin on variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="label: DebtInstrumentBasisSpreadOnVariableRate1 to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" xlink:title="label: DebtInstrumentBasisSpreadOnVariableRate1 to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsTable" xml:lang="en-US" id="us-gaap_OtherCommitmentsTable">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable" xlink:title="label: OtherCommitmentsTable to us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsAxis" xml:lang="en-US" id="us-gaap_OtherCommitmentsAxis">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:title="label: OtherCommitmentsAxis to us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsDomain" xml:lang="en-US" id="us-gaap_OtherCommitmentsDomain">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:title="label: OtherCommitmentsDomain to us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsLineItems" xml:lang="en-US" id="us-gaap_OtherCommitmentsLineItems">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems" xlink:title="label: OtherCommitmentsLineItems to us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherCommitmentsAbstract" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract_lbl1">Other Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">Term of option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTerm" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm">Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost" xml:lang="en-US" id="us-gaap_OperatingLeaseCost">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">Future Payments for Finance Lease Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="label: FinanceLeaseLiabilitiesPaymentsDueAbstract to us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="CashFlowOperatingActivitiesLesseeAbstract" xlink:title="CashFlowOperatingActivitiesLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xml:lang="en-US" id="us-gaap_CashFlowOperatingActivitiesLesseeAbstract">Supplemental Cash Flow Information Related to Operating Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:title="label: CashFlowOperatingActivitiesLesseeAbstract to us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="CashFlowFinancingActivitiesLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xml:lang="en-US" id="us-gaap_CashFlowFinancingActivitiesLesseeAbstract">Supplemental Cash Flow Information Related to Finance Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:title="label: CashFlowFinancingActivitiesLesseeAbstract to us-gaap_CashFlowFinancingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAsset">Financing lease right-to-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" xlink:title="label: FinanceLeaseRightOfUseAsset to us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl1">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDiscountRate">Discount rate used to measure operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:title="label: LesseeOperatingLeaseDiscountRate to us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1">Lessee, Operating Lease, Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" xlink:title="label: LesseeOperatingLeaseDiscountRate to us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseDiscountRate" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDiscountRate">Finance lease liability capitalized interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:title="label: LesseeFinanceLeaseDiscountRate to us-gaap_LesseeFinanceLeaseDiscountRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract">Operating Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDescriptionAbstract">Financing Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:title="label: LesseeFinanceLeaseDescriptionAbstract to us-gaap_LesseeFinanceLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xlink:title="label: LesseeFinanceLeaseDescriptionAbstract to us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1">Cash and cash equivalents at the end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments" xml:lang="en-US" id="us-gaap_OperatingLeasePayments">Cash paid for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments">Payments of finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAssetAmortization">Finance lease depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:title="label: FinanceLeaseRightOfUseAssetAmortization to us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xlink:title="label: FinanceLeaseRightOfUseAssetAmortization to us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiability" xml:lang="en-US" id="us-gaap_FinanceLeaseLiability">Remaining lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability" xlink:title="label: FinanceLeaseLiability to us-gaap_FinanceLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiability_lbl1">Finance Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl1" xlink:title="label: FinanceLeaseLiability to us-gaap_FinanceLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityCurrent">Financing lease obligation-short term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:title="label: FinanceLeaseLiabilityCurrent to us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="label: FinanceLeaseLiabilityUndiscountedExcessAmount to us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: FinanceLeaseLiabilityUndiscountedExcessAmount to us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityNoncurrent">Financing lease obligation-long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:title="label: FinanceLeaseLiabilityNoncurrent to us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDue">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:title="label: FinanceLeaseLiabilityPaymentsDue to us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1">Finance Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDue to us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="label: FinanceLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearThree to us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearThree to us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearTwo to us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearTwo to us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="label: FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">Future Payments for Financing Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="label: FinanceLeaseLiabilityMaturityTableTextBlock to us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:title="label: FinanceLeaseLiabilityMaturityTableTextBlock to us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiability" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Operating Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="LesseeFinanceLeasesTextBlock" xlink:title="LesseeFinanceLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeFinanceLeasesTextBlock" xml:lang="en-US" id="us-gaap_LesseeFinanceLeasesTextBlock">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock" xlink:title="label: LesseeFinanceLeasesTextBlock to us-gaap_LesseeFinanceLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeasesTextBlock_lbl1">Lessee, Finance Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xlink:title="label: LesseeFinanceLeasesTextBlock to us-gaap_LesseeFinanceLeasesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl1">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeAxis" xml:lang="en-US" id="us-gaap_MeasurementInputTypeAxis">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:title="label: MeasurementInputTypeAxis to us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedDividendRateMember">Estimated Dividend Yield [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:title="label: MeasurementInputExpectedDividendRateMember to us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedTermMember">Expected Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:title="label: MeasurementInputExpectedTermMember to us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US" id="us-gaap_MeasurementInputPriceVolatilityMember">Expected Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:title="label: MeasurementInputPriceVolatilityMember to us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US" id="us-gaap_MeasurementInputRiskFreeInterestRateMember">Risk-free Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:title="label: MeasurementInputRiskFreeInterestRateMember to us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeDomain" xml:lang="en-US" id="us-gaap_MeasurementInputTypeDomain">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:title="label: MeasurementInputTypeDomain to us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingMeasurementInput">Warrants measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:title="label: WarrantsAndRightsOutstandingMeasurementInput to us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseTermOfContract1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseTermOfContract1">Term of financing lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:title="label: LesseeFinanceLeaseTermOfContract1 to us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="LessorOperatingLeaseTermOfContract" xlink:title="LessorOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LessorOperatingLeaseTermOfContract" xml:lang="en-US" id="us-gaap_LessorOperatingLeaseTermOfContract">Term of sublease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" xlink:title="label: LessorOperatingLeaseTermOfContract to us-gaap_LessorOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LessorOperatingLeaseTermOfContract_lbl1" xml:lang="en-US" id="us-gaap_LessorOperatingLeaseTermOfContract_lbl1">Lessor, Operating Lease, Term of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl1" xlink:title="label: LessorOperatingLeaseTermOfContract to us-gaap_LessorOperatingLeaseTermOfContract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm">Term of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1">Warrants and Rights Outstanding, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingLeaseLiability">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiability to us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xml:lang="en-US" id="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="label: DebtInstrumentVariableInterestRateTypeExtensibleEnumeration to us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpenseNonoperating" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseNonoperating_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating_lbl1">Interest Expense, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl1" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis" xml:lang="en-US" id="srt_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis" xlink:title="label: RangeAxis to srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember" xml:lang="en-US" id="srt_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember" xlink:title="label: RangeMember to srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember" xml:lang="en-US" id="srt_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember" xlink:title="label: MaximumMember to srt_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember" xml:lang="en-US" id="srt_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember" xlink:title="label: MinimumMember to srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport" xml:lang="en-US" id="dei_DocumentQuarterlyReport">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport" xml:lang="en-US" id="dei_DocumentTransitionReport">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus" xml:lang="en-US" id="dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany" xml:lang="en-US" id="dei_EntityShellCompany">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany" xlink:title="label: EntityShellCompany to dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory" xml:lang="en-US" id="dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness" xml:lang="en-US" id="dei_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:label="FinanceLeasePrincipalAndInterestPayments" xlink:title="FinanceLeasePrincipalAndInterestPayments" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl">Amount of cash outflow for principal and interest payments on finance lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1">Finance Lease, Principal and Interest Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments">Cash paid for finance lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl">Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:title="label: FinanceLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1">Finance Lease, Liability, to be Paid, Year Four and Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xlink:title="label: FinanceLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter">2028 and after</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="label: FinanceLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeaseCost_lbl" xml:lang="en-US" id="pdsb_FinanceLeaseCost_lbl">Amount of lease cost recognized by lessee for finance lease contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost_lbl" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeaseCost_lbl1" xml:lang="en-US" id="pdsb_FinanceLeaseCost_lbl1">Finance Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost_lbl1" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_FinanceLeaseCost" xml:lang="en-US" id="pdsb_FinanceLeaseCost">Total cost of financing leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl">The amount of estimated aggregate monthly rental expense under finance lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1">Lessee, Finance Lease, Monthly Rental Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense">Aggregate monthly rental payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl">The number of finance leases entered into by the lessee during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1">Lessee, Finance Lease, Number of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases">Number of financing leases entered into</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_IncentiveStockOptionsMember_lbl" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember_lbl">Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember_lbl" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_IncentiveStockOptionsMember_lbl1" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember_lbl1">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember_lbl1" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_IncentiveStockOptionsMember" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding_lbl">Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding_lbl" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PercentageOfCommonStockOutstanding_lbl1" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding_lbl1">Percentage of Common Stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding_lbl1" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PercentageOfCommonStockOutstanding" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding">Percentage of Common Stock outstanding used to determine annual increase in the plan limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_EquityCompensationPlansMember_lbl" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember_lbl">Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember_lbl" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_EquityCompensationPlansMember_lbl1" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember_lbl1">Equity Compensation Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember_lbl1" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_EquityCompensationPlansMember" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember">The Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_InducementPlan2019Member_lbl" xml:lang="en-US" id="pdsb_InducementPlan2019Member_lbl">The 2019 Inducement Plan provides for the grant of non-qualified stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member_lbl" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_InducementPlan2019Member_lbl1" xml:lang="en-US" id="pdsb_InducementPlan2019Member_lbl1">Inducement Plan 2019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member_lbl1" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_InducementPlan2019Member" xml:lang="en-US" id="pdsb_InducementPlan2019Member">2019 Inducement Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_EquityIncentivePlan2014Member_lbl" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member_lbl">In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units ("RSUs"), subject to increases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member_lbl" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_EquityIncentivePlan2014Member_lbl1" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member_lbl1">Equity Incentive Plan 2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member_lbl1" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_EquityIncentivePlan2014Member" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member">2014 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1">Liquidity and Capital Resources [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" xlink:title="label: LiquidityAndCapitalResourcesAbstract to pdsb_LiquidityAndCapitalResourcesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl">The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to pdsb_LiquidityAndCapitalResourcesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1">Liquidity and Capital Resources [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to pdsb_LiquidityAndCapitalResourcesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pdsb_LiquidityAndCapitalResourcesTextBlock" xml:lang="en-US" id="pdsb_LiquidityAndCapitalResourcesTextBlock">Liquidity and Capital Resources</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to pdsb_LiquidityAndCapitalResourcesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl">Period after October 1, 2024 for making monthly payments on the principal balance of the debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:to="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" xlink:title="label: DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance to pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1">Debt Instrument, Period for making monthly payments on principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:to="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" xlink:title="label: DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance to pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xml:lang="en-US" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance">Period after October 1, 2024 for making monthly payments on principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:to="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="label: DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance to pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2">Period after October 1, 2024 for making monthly payments on principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:to="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" xlink:title="label: DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance to pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_CommissionPercentage_lbl" xml:lang="en-US" id="pdsb_CommissionPercentage_lbl">Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage_lbl" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_CommissionPercentage_lbl1" xml:lang="en-US" id="pdsb_CommissionPercentage_lbl1">Commission Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage_lbl1" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_CommissionPercentage" xml:lang="en-US" id="pdsb_CommissionPercentage">Commission paid on Placement Shares sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod3" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod3 to pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1">Debt Instrument, Prepayment Premium, Period 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod3" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod3 to pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3">Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod3" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod3 to pdsb_DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl">Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:to="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" xlink:title="label: DebtInstrumentWrittenNoticePeriodForPrepayment to pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1">Debt Instrument, Written Notice Period for Prepayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:to="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" xlink:title="label: DebtInstrumentWrittenNoticePeriodForPrepayment to pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xml:lang="en-US" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment">Written notice period for prepayment of outstanding loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:to="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="label: DebtInstrumentWrittenNoticePeriodForPrepayment to pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl">The number of independent term loans provided for under the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfIndependentTermLoans" xlink:to="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" xlink:title="label: DebtInstrumentNumberOfIndependentTermLoans to pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1">Debt Instrument, Number of Independent Term Loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfIndependentTermLoans" xlink:to="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" xlink:title="label: DebtInstrumentNumberOfIndependentTermLoans to pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentNumberOfIndependentTermLoans" xml:lang="en-US" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans">Number of independent term loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfIndependentTermLoans" xlink:to="pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:title="label: DebtInstrumentNumberOfIndependentTermLoans to pdsb_DebtInstrumentNumberOfIndependentTermLoans" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod1" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod1 to pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1">Debt Instrument, Prepayment Premium, Period 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod1" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod1 to pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1">Prepayment premium paid if loan is prepaid on or before Loan Amortization date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod1" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod1 to pdsb_DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod4" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod4 to pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1">Debt Instrument, Prepayment Premium, Period 4</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod4" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod4 to pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4">Prepayment premium paid if loan is paid on stated maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod4" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod4 to pdsb_DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl">The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the "2020 Shelf Registration Statement") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf Securities") that are available for future sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1">Shelf Registration Statement, Available for future sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale">Registered securities in Shelf Registration Statement available for future sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentThresholdPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentThresholdPeriod_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentThresholdPeriod_lbl">Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentThresholdPeriod" xlink:to="pdsb_DebtInstrumentThresholdPeriod_lbl" xlink:title="label: DebtInstrumentThresholdPeriod to pdsb_DebtInstrumentThresholdPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentThresholdPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentThresholdPeriod_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentThresholdPeriod_lbl1">Debt Instrument, Threshold Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentThresholdPeriod" xlink:to="pdsb_DebtInstrumentThresholdPeriod_lbl1" xlink:title="label: DebtInstrumentThresholdPeriod to pdsb_DebtInstrumentThresholdPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentThresholdPeriod" xml:lang="en-US" id="pdsb_DebtInstrumentThresholdPeriod">Threshold period after Loan Amortization Date used to determine prepayment premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentThresholdPeriod" xlink:to="pdsb_DebtInstrumentThresholdPeriod" xlink:title="label: DebtInstrumentThresholdPeriod to pdsb_DebtInstrumentThresholdPeriod" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl">Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1">Proceeds from Sale of Unused Net Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards">Proceeds from sale of tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod2" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod2 to pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1">Debt Instrument, Prepayment Premium, Period 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod2" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod2 to pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2">Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod2" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod2 to pdsb_DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentMinimumVariableRate" xlink:label="DebtInstrumentMinimumVariableRate" xlink:title="DebtInstrumentMinimumVariableRate" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentMinimumVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentMinimumVariableRate_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentMinimumVariableRate_lbl">Minimum base rate to be used in computing the variable rate on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMinimumVariableRate" xlink:to="pdsb_DebtInstrumentMinimumVariableRate_lbl" xlink:title="label: DebtInstrumentMinimumVariableRate to pdsb_DebtInstrumentMinimumVariableRate_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentMinimumVariableRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentMinimumVariableRate_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentMinimumVariableRate_lbl1">Debt Instrument, Minimum Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMinimumVariableRate" xlink:to="pdsb_DebtInstrumentMinimumVariableRate_lbl1" xlink:title="label: DebtInstrumentMinimumVariableRate to pdsb_DebtInstrumentMinimumVariableRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentMinimumVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentMinimumVariableRate" xml:lang="en-US" id="pdsb_DebtInstrumentMinimumVariableRate">Minimum base rate used to compute floating interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMinimumVariableRate" xlink:to="pdsb_DebtInstrumentMinimumVariableRate" xlink:title="label: DebtInstrumentMinimumVariableRate to pdsb_DebtInstrumentMinimumVariableRate" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PlacementSharesAvailableForFutureSale_lbl" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale_lbl">The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale_lbl" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale_lbl1">Placement Shares, Available for future sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PlacementSharesAvailableForFutureSale" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale">Placement Shares included in at-the-market offering program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_TermLoansMember_lbl" xml:lang="en-US" id="pdsb_TermLoansMember_lbl">On August 24, 2022, the Company, as borrower (the "Borrower"), entered into a Venture Loan and Security Agreement (the "Loan and Security Agreement") by and among Borrower, PDS Operating Corporation, as guarantor ("Guarantor", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the "Loan Parties" and each individually a "Loan Party") , the persons party thereto from time to time as lenders (collectively, the "Lenders"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the "Collateral Agent"). The Loan and Security Agreement provides for six separate and independent term loans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember_lbl" xlink:title="label: TermLoansMember to pdsb_TermLoansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_TermLoansMember_lbl1" xml:lang="en-US" id="pdsb_TermLoansMember_lbl1">Term Loans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember_lbl1" xlink:title="label: TermLoansMember to pdsb_TermLoansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_TermLoansMember" xml:lang="en-US" id="pdsb_TermLoansMember">Term Loans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember" xlink:title="label: TermLoansMember to pdsb_TermLoansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanFMember_lbl" xml:lang="en-US" id="pdsb_LoanFMember_lbl">One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanFMember" xlink:to="pdsb_LoanFMember_lbl" xlink:title="label: LoanFMember to pdsb_LoanFMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanFMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanFMember_lbl1" xml:lang="en-US" id="pdsb_LoanFMember_lbl1">Loan F [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanFMember" xlink:to="pdsb_LoanFMember_lbl1" xlink:title="label: LoanFMember to pdsb_LoanFMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanFMember" xml:lang="en-US" id="pdsb_LoanFMember">Loan F [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanFMember" xlink:to="pdsb_LoanFMember" xlink:title="label: LoanFMember to pdsb_LoanFMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanAMember_lbl" xml:lang="en-US" id="pdsb_LoanAMember_lbl">One of six separate and independent term loans in the amount of $7,500,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAMember" xlink:to="pdsb_LoanAMember_lbl" xlink:title="label: LoanAMember to pdsb_LoanAMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanAMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanAMember_lbl1" xml:lang="en-US" id="pdsb_LoanAMember_lbl1">Loan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAMember" xlink:to="pdsb_LoanAMember_lbl1" xlink:title="label: LoanAMember to pdsb_LoanAMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanAMember" xml:lang="en-US" id="pdsb_LoanAMember">Loan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAMember" xlink:to="pdsb_LoanAMember" xlink:title="label: LoanAMember to pdsb_LoanAMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanEMember_lbl" xml:lang="en-US" id="pdsb_LoanEMember_lbl">One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanEMember" xlink:to="pdsb_LoanEMember_lbl" xlink:title="label: LoanEMember to pdsb_LoanEMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanEMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanEMember_lbl1" xml:lang="en-US" id="pdsb_LoanEMember_lbl1">Loan E [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanEMember" xlink:to="pdsb_LoanEMember_lbl1" xlink:title="label: LoanEMember to pdsb_LoanEMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanEMember" xml:lang="en-US" id="pdsb_LoanEMember">Loan E [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanEMember" xlink:to="pdsb_LoanEMember" xlink:title="label: LoanEMember to pdsb_LoanEMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanCMember_lbl" xml:lang="en-US" id="pdsb_LoanCMember_lbl">One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanCMember" xlink:to="pdsb_LoanCMember_lbl" xlink:title="label: LoanCMember to pdsb_LoanCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanCMember_lbl1" xml:lang="en-US" id="pdsb_LoanCMember_lbl1">Loan C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanCMember" xlink:to="pdsb_LoanCMember_lbl1" xlink:title="label: LoanCMember to pdsb_LoanCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanCMember" xml:lang="en-US" id="pdsb_LoanCMember">Loan C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanCMember" xlink:to="pdsb_LoanCMember" xlink:title="label: LoanCMember to pdsb_LoanCMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanDMember_lbl" xml:lang="en-US" id="pdsb_LoanDMember_lbl">One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanDMember" xlink:to="pdsb_LoanDMember_lbl" xlink:title="label: LoanDMember to pdsb_LoanDMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanDMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanDMember_lbl1" xml:lang="en-US" id="pdsb_LoanDMember_lbl1">Loan D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanDMember" xlink:to="pdsb_LoanDMember_lbl1" xlink:title="label: LoanDMember to pdsb_LoanDMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanDMember" xml:lang="en-US" id="pdsb_LoanDMember">Loan D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanDMember" xlink:to="pdsb_LoanDMember" xlink:title="label: LoanDMember to pdsb_LoanDMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanBMember_lbl" xml:lang="en-US" id="pdsb_LoanBMember_lbl">One of six separate and independent term loans in the amount of $10,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanBMember" xlink:to="pdsb_LoanBMember_lbl" xlink:title="label: LoanBMember to pdsb_LoanBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanBMember_lbl1" xml:lang="en-US" id="pdsb_LoanBMember_lbl1">Loan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanBMember" xlink:to="pdsb_LoanBMember_lbl1" xlink:title="label: LoanBMember to pdsb_LoanBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanBMember" xml:lang="en-US" id="pdsb_LoanBMember">Loan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanBMember" xlink:to="pdsb_LoanBMember" xlink:title="label: LoanBMember to pdsb_LoanBMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl">Disclosure of accounting policy for significant risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1">Significant Risks and Uncertainties, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">Significant Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PercentageOfVotingPowerDisposedOff" xlink:label="PercentageOfVotingPowerDisposedOff" xlink:title="PercentageOfVotingPowerDisposedOff" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfVotingPowerDisposedOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PercentageOfVotingPowerDisposedOff_lbl" xml:lang="en-US" id="pdsb_PercentageOfVotingPowerDisposedOff_lbl">Percentage of voting power disposed of in a transaction (including a merger or other reorganization) or series of related transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfVotingPowerDisposedOff" xlink:to="pdsb_PercentageOfVotingPowerDisposedOff_lbl" xlink:title="label: PercentageOfVotingPowerDisposedOff to pdsb_PercentageOfVotingPowerDisposedOff_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfVotingPowerDisposedOff_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PercentageOfVotingPowerDisposedOff_lbl1" xml:lang="en-US" id="pdsb_PercentageOfVotingPowerDisposedOff_lbl1">Percentage of Voting Power Disposed off</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfVotingPowerDisposedOff" xlink:to="pdsb_PercentageOfVotingPowerDisposedOff_lbl1" xlink:title="label: PercentageOfVotingPowerDisposedOff to pdsb_PercentageOfVotingPowerDisposedOff_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfVotingPowerDisposedOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PercentageOfVotingPowerDisposedOff" xml:lang="en-US" id="pdsb_PercentageOfVotingPowerDisposedOff">Percentage of voting power disposed off</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfVotingPowerDisposedOff" xlink:to="pdsb_PercentageOfVotingPowerDisposedOff" xlink:title="label: PercentageOfVotingPowerDisposedOff to pdsb_PercentageOfVotingPowerDisposedOff" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:label="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl">Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1">Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock">Supplemental Cash Flow Information Related to Financing Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:title="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl">Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock to pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1">Lessee, Operating Lease, Supplemental Cash Flow Information Related to Operating Lease [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" xlink:title="label: LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock to pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock">Supplemental Cash Flow Information Related to Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:title="label: LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock to pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1">Accrued Research and Development Costs, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent">Accrued research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">Granted, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options granted (or share units converted) into shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl1" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue">Granted, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LiabilityForUncertainTaxPositions" xlink:label="LiabilityForUncertainTaxPositions" xlink:title="LiabilityForUncertainTaxPositions" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LiabilityForUncertainTaxPositions_lbl" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions_lbl">The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions_lbl" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiabilityForUncertainTaxPositions_lbl1" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions_lbl1">Liability for Uncertain Tax Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions_lbl1" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LiabilityForUncertainTaxPositions" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MerckKGaALicenseAgreementMember_lbl" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember_lbl">License agreements with each of the Company's executives that generally provide for product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember_lbl" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MerckKGaALicenseAgreementMember_lbl1" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember_lbl1">Merck KGaA License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember_lbl1" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MerckKGaALicenseAgreementMember" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember">Merck KGaA License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl">Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1">Milestone payments, Achievement of Certain Aggregate Sales Levels</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels">Milestone payments for aggregate sales levels of product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl">Royalty percentage paid on net sales of the product detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1">Royalty Percentage Paid on Net Sales of Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct">Royalty percentage paid on net sales of product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl">Payments to be made for development and first commercial sale milestones detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1">Milestone payments, Development and first commercial sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales">Milestone payments for development and first commercial sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_TermOfRoyaltyPayment_lbl" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment_lbl">Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment_lbl" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_TermOfRoyaltyPayment_lbl1" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment_lbl1">Term of Royalty Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment_lbl1" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_TermOfRoyaltyPayment" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment">Term of royalty payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pdsb-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#RetirementPlanDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#VentureLoanAndSecurityAgreementTermLoansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationEquityCompensationPlansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LeasesFinancingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#FairValueOfFinancialInstrumentsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LeasesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="pdsb-20240630.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlan" xlink:type="simple" xlink:href="pdsb-20240630.xsd#RetirementPlan" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" xlink:type="simple" xlink:href="pdsb-20240630.xsd#VentureLoanAndSecurityAgreement" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pdsb-20240630.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="pdsb-20240630.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpenses" xlink:type="simple" xlink:href="pdsb-20240630.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Leases" xlink:type="simple" xlink:href="pdsb-20240630.xsd#Leases" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="pdsb-20240630.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="pdsb-20240630.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="pdsb-20240630.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/NatureOfOperations" xlink:type="simple" xlink:href="pdsb-20240630.xsd#NatureOfOperations" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20240630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pdsb-20240630.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="FinanceLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to FinanceLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtCurrent" xlink:label="SecuredDebtCurrent" xlink:title="SecuredDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="SecuredDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to SecuredDebtCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to FinanceLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="SecuredLongTermDebt" xlink:title="presentation: LiabilitiesNoncurrentAbstract to SecuredLongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to FinanceLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="LiabilitiesNoncurrentAbstract" xlink:title="presentation: LiabilitiesAbstract to LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAbstract to Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestIncomeExpenseNonoperatingNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FinanceLeaseRightOfUseAssetAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FinanceLeaseRightOfUseAssetAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/NatureOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfOperations" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResources">
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="LiquidityAndCapitalResourcesTextBlock" xlink:title="presentation: LiquidityAndCapitalResourcesAbstract to LiquidityAndCapitalResourcesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstruments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Leases">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="LesseeFinanceLeasesTextBlock" xlink:title="LesseeFinanceLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeFinanceLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeFinanceLeasesTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtDisclosureAbstract to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlan">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/InsiderTradingArrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrAdoptedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrAdoptedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrTrmntdFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrTrmntdFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="LesseeLeasesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to LesseeLeasesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="FairValueByBalanceSheetGroupingTextBlock" xlink:title="FairValueByBalanceSheetGroupingTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueByBalanceSheetGroupingTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueByBalanceSheetGroupingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:title="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:label="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to FinanceLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="presentation: TermLoansMember to LoanAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="presentation: TermLoansMember to LoanBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="presentation: TermLoansMember to LoanCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="presentation: TermLoansMember to LoanDMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="presentation: TermLoansMember to LoanEMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="presentation: TermLoansMember to LoanFMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="presentation: DebtInstrumentNameDomain to TermLoansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ShelfRegistrationStatementAvailableForFutureSale" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="PlacementSharesAvailableForFutureSale" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to PlacementSharesAvailableForFutureSale" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="CommissionPercentage" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to CommissionPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentNumberOfIndependentTermLoans" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentFaceAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentUnusedBorrowingCapacityAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="ProceedsFromIssuanceOfSecuredDebt" xlink:title="ProceedsFromIssuanceOfSecuredDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromIssuanceOfSecuredDebt" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromIssuanceOfSecuredDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentBasisSpreadOnVariableRate1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentMinimumVariableRate" xlink:label="DebtInstrumentMinimumVariableRate" xlink:title="DebtInstrumentMinimumVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentMinimumVariableRate" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentMinimumVariableRate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentWrittenNoticePeriodForPrepayment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentThresholdPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod2" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod3" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod4" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="presentation: DebtInstrumentLineItems to BusinessCombinationConsiderationTransferredAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: LiquidityAndCapitalResourcesAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="AreaOfRealEstateProperty" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to AreaOfRealEstateProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="LessorOperatingLeaseTermOfContract" xlink:title="LessorOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LessorOperatingLeaseTermOfContract" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LessorOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseDiscountRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="CashFlowOperatingActivitiesLesseeAbstract" xlink:title="CashFlowOperatingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowOperatingActivitiesLesseeAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: CashFlowOperatingActivitiesLesseeAbstract to OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="CashFlowOperatingActivitiesLesseeAbstract" xlink:title="presentation: LeasesAbstract to CashFlowOperatingActivitiesLesseeAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="CashFlowFinancingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:label="FinanceLeasePrincipalAndInterestPayments" xlink:title="FinanceLeasePrincipalAndInterestPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowFinancingActivitiesLesseeAbstract" xlink:to="FinanceLeasePrincipalAndInterestPayments" xlink:title="presentation: CashFlowFinancingActivitiesLesseeAbstract to FinanceLeasePrincipalAndInterestPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="presentation: LeasesAbstract to CashFlowFinancingActivitiesLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityToBePaidYearFourAndThereafter" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDue" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityUndiscountedExcessAmount" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiability" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to FinanceLeaseLiabilitiesPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseNumberOfLeases" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseNumberOfLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="FinanceLeaseCost" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to FinanceLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseTermOfContract1" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseTermOfContract1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseDiscountRate" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseMonthlyRentalExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="PropertyPlantAndEquipmentAdditions" xlink:title="PropertyPlantAndEquipmentAdditions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="PropertyPlantAndEquipmentAdditions" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to PropertyPlantAndEquipmentAdditions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDescriptionAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: LeasesAbstract to LesseeLeaseDescriptionTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedResearchAndDevelopmentCostsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="WorkersCompensationLiabilityCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to WorkersCompensationLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="InterestPayableCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to InterestPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedRentCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedRentCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2014Member" xlink:title="presentation: EquityCompensationPlansMember to EquityIncentivePlan2014Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityCompensationPlansMember" xlink:to="InducementPlan2019Member" xlink:title="presentation: EquityCompensationPlansMember to InducementPlan2019Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityCompensationPlansMember" xlink:title="presentation: PlanNameDomain to EquityCompensationPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="presentation: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="PercentageOfCommonStockOutstanding" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to PercentageOfCommonStockOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LiabilityForUncertainTaxPositions" xlink:label="LiabilityForUncertainTaxPositions" xlink:title="LiabilityForUncertainTaxPositions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="LiabilityForUncertainTaxPositions" xlink:title="presentation: IncomeTaxDisclosureAbstract to LiabilityForUncertainTaxPositions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExaminationPenaltiesAndInterestAccrued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsDomain" xlink:to="MerckKGaALicenseAgreementMember" xlink:title="presentation: OtherCommitmentsDomain to MerckKGaALicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="presentation: OtherCommitmentsAxis to OtherCommitmentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsAxis" xlink:title="presentation: OtherCommitmentsTable to OtherCommitmentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="presentation: OtherCommitmentsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: OtherCommitmentsAbstract to OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="presentation: OtherCommitmentsAbstract to MilestonePaymentsDevelopmentAndFirstCommercialSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="presentation: OtherCommitmentsAbstract to MilestonePaymentsAchievementOfCertainAggregateSalesLevels" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="presentation: OtherCommitmentsAbstract to RoyaltyPercentagePaidOnNetSalesOfProduct" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="TermOfRoyaltyPayment" xlink:title="presentation: OtherCommitmentsAbstract to TermOfRoyaltyPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="presentation: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsLineItems" xlink:title="presentation: OtherCommitmentsTable to OtherCommitmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="OtherCommitmentsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to OtherCommitmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="presentation: TermLoansMember to LoanAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="presentation: TermLoansMember to LoanBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="presentation: TermLoansMember to LoanCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="presentation: TermLoansMember to LoanDMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="presentation: TermLoansMember to LoanEMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="presentation: TermLoansMember to LoanFMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="presentation: DebtInstrumentNameDomain to TermLoansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentNumberOfIndependentTermLoans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUnusedBorrowingCapacityAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentBasisSpreadOnVariableRate1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentMinimumVariableRate" xlink:label="DebtInstrumentMinimumVariableRate" xlink:title="DebtInstrumentMinimumVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentMinimumVariableRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentMinimumVariableRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentWrittenNoticePeriodForPrepayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentThresholdPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod4" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: DebtInstrumentTable to MeasurementInputTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: DebtInstrumentsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: DebtInstrumentsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: DebtInstrumentsAbstract to WarrantsAndRightsOutstandingTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20240630.xsd#pdsb_PercentageOfVotingPowerDisposedOff" xlink:label="PercentageOfVotingPowerDisposedOff" xlink:title="PercentageOfVotingPowerDisposedOff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PercentageOfVotingPowerDisposedOff" xlink:title="presentation: DebtInstrumentsAbstract to PercentageOfVotingPowerDisposedOff" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="presentation: DebtInstrumentsAbstract to WarrantsAndRightsOutstandingMeasurementInput" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="presentation: DebtInstrumentsAbstract to PaymentsOfDebtIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUnamortizedDiscount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="InterestExpenseDebt" xlink:title="presentation: DebtInstrumentsAbstract to InterestExpenseDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: DebtInstrumentsAbstract to AmortizationOfDebtDiscountPremium" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #  MP# 2(  A$! Q$!_\0
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M ]*,#TH ]Q^UVW_/Q#_WV*/M=M_S\0_]]BO#MN.WZ48'H* /<?M=M_S\0_\
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M%4<\C&/SZT6<=@FI%X9+4(TERKS23<H.0F.>1@]><^M9O_"*:S_SYG_OM?\
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M:_XT 8=%;G_"*:S_ ,^9_P"^U_QH_P"$4UG_ )\S_P!]K_C0!AU87_D'R?\
M75?Y&M3_ (136?\ GS/_ 'VO^-3+X7U<6;I]D.XR*P&X=,'WH ATEK5M+\N[
M,3!9I9-COC)$/R]\_>Q6AI\>G17=C<0?9 WF1O-OFP(AL!^7)_O9]>F*S_\
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M_P"$4UG_ )\S_P!]K_C0!AT5N?\ "*:S_P ^9_[[7_&C_A%-9_Y\S_WVO^-
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MT /OF,6AI;F87+.4E9_-4B( 8"*,YSSS]*Q*V/\ A&=7_P"?,_\ ?:_XT?\
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ME)GB9[_!CZ_HS#HHHJ3Y<**** "BBB@ HHHH **** "O<_A;_P B;:_[[_\
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MS,/,-P8<A2YR,@AFR.YP>V#1TGX:6FFFSC2^E>TA^:2(Q@&1O(D@ZC[HV2=
M.H% '0ZIXGLK/PS<:Y!FZLX<<K\H<%@,@GJ.<YZ$=*R]3\<10^(H-&TNU34+
MB;RR)$N56,;EG8Y.#R! ?^^A5^Z\,_;/![>'[N\:2+8D2S"( [%(*@CH3A0"
M>_H*HZEX TF_\26^JRQPB*'RR;00)Y3E%G4$C'7]^?\ OD4 7;'Q;:WNF"]A
MMYP'BMY8HW #R"? 3C_>R#]#52[\=65I?Z]:7%M/')I4MK!\S*//DN.(PO/
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MD\!%QDX7!)Z<T78/,L:DVXI6\CT+_A8.A_WKG_OS_P#7H_X6#H?]ZY_[\_\
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MCR8?^?6/_OA:/)A_Y]8_^^%I<IE_8+_Y^?A_P3YWR/449'J*^B/)A_Y]8_\
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M,XRBNVN/!45M':/<W5Q$'24SJ45F0I%YG&#@],41>$;"Z9DLKZ[>01QS;6A
MRLD;.@&#U^7!^M%A?4:U[6U]5ZG$T5V%GX4MO]'&H7-U;R3?94"+""5DFW<$
M$C &VH)O#=G:Z-#>W=[,KNP)40DIL\S81N[-@$T6)^J5;7:_%'+45U7BFSTV
MWT^W:UC@CF(7'E2;MV<[OJ -OS>I/X<K095:3I2Y6PKW/X6_\B;:_P"^_P#Z
M$:\,KW/X6_\ (FVO^^__ *$::/3R3_>7Z/\ -#]0\6)ID,KZ@L</V6>873'.
M$A0;E<>[!X@!ZN?2H+?XA:1<B4P17D@AMY;F9HT5Q&D9PW*L0W)&-N<Y]CC;
MO?#NF7MS>SW5L))+R 6TQ+$90'(QZ'IR.?E7T%$>@VJ7 N?,NFNQ:M:>>TS%
M]A;=U]<]ZH^L*6I>,-.TR'3Y;P2)'>[-A#QMM+?=! <DY(QE<CU..:S[3XBZ
M1<0"7[/J$2F(RCS(E!_X]_M 'WNICR1[@@X.,VO^$#T(0I$L$RQJ(]RK,P#F
M-RZLW/)#,Q_$U-;^"M#@\K;:LRQ[<*\C,"%MS;@$$\CRR1^O6@")_&NGBZAM
MH[>]EGF:!(T1%^8S1/*@R6 'RQMG/0X^M0V'Q"T&_P!0L+.VFD:>\5"JX7*,
MZEE5ESNS@'D @<9(R,W+'P;I%G<03QI<--#)%(C23LQ!CC>-.IZ!9&%3Z+X8
MTW19(VTU9H D8B*"9BL@&<%@3R1D\_X"@#*\-^*[K5=9N+>:S6*U\U8HF .[
M)A$I)YY SM/ PV!SVI>(/'ATF3Q5 T(-QI8C-L!!*ZR;HE?YV48')(ZCBNUA
ML;2"XEN(+:&.>7[\BH S?4U0N_#NG7<>KI/$Y75@HNL2$;\($&/3@#I0!R.@
M>.=0OW626*QGM1-(MPULK V@6X\D*_S-EB#O[<*>.]=E8:HLME=WMV8K>TBE
MD5)&; \M#M+L3T&0Q^F*6UT2QMM%DTJ*(_8I!*&1F))$C,S<]>K&K=A:0V%E
M!:6R[(((UC1<YPH&!0!G>'?$FE^(-,:_TRZCEMT9E<AU)3:2#G!..F1[5S\W
MCZ**^25[*X&CMIQU#SM@W^7YBJ),;ON;6W8^]QTKL+.RMK*T%K:PK';@L=@Y
M'S$D]?4D_G6&W@O1VMI;=XYWADM&L=K3L=L!(.Q>> ,#'I0!1U'XC:'9:P=,
MS/<7?VE;,);A7)E+*NW&[(P7&20!UP20:L:?XZTF]L+B[5;J*.&&&?;)& SK
M*S(@4 G)+JRX]1Z$$Z$WAG3I;B25EF DN8[QHEE8)YR,K!]O3.57/KCW-06O
M@[1;:UEMX[9S%+;QVS!I6/R1N[I@YX(9V.1ST]* -'1]5AU1;D)'+!/:R^3/
M!-C?$^U6P=I(/RLIR"1S6A5'2=,M]+AE2W\QGF?S9997+O*^ -S$]3A0/H!5
MZ@ HHHH **** "BBB@#F_&.OW6AW7AV.VMX98M2U..PE:1B#&&5VRH'4_)W-
M5K[QK$FFV=[I^G7=ZMQJ*Z<(U>-'!)(+89ACD8PV#Z@#FMS6-&L]7?3VOHV<
MV-TMY!ARNV50P!..HPQX-4F\*Z8R76Y9S-<7*W;SF4^8)5 ",&[8  'M0!D7
MWCNTM]8ECAE@N-.2"W?SK<B5O,EG,17A@,# ^F>_2IU\?Z/_ &:UY<"XM4\F
MVGC6X"(9$N,^402V!DJP.XC&TYXYK4U?PQIFK737%]$[RLD,9(D9>(I#(G3_
M &CGWJ%?"&D+"L:0RKLM[>V1EE8,BP%C$5.>&!8\]^] %/4?&L$.D:-J6GV%
MU?V^I7)MU$;(C)A9&)^9@#_JR.#@^O3,<?Q"T5FTM9//ADU&*&>*.0('$<K;
M8V*[LX)] 2,$D #-;NJ:):ZG8PVMV9F$+B2.42$2*P!&X-ZX9A]":BL_#MA8
MR6+V8FA:SMTM$V2L-\2?=5_[V.>OJ?6@#&UCQY:V5Q-:6EC<7M]#<6T301R1
M#*S2^4K@[\?>!&#@]. .:72?B#I>I26B+:ZA ;DQ!#-$H \PR*A.&/5HG7C/
M(ST(-6H?!&BPH5CBF7]W'%'^^;]TL<AECV>FUSD4ZS\%:+:?9?)AES;>3Y9:
M9B?W3R.F>>>97^N?:@"A9_$?0[^>.'3_ +1=R33)#$(0C"0L)"ISNP ?*;[V
M#T)&#FK?A[QA'KVM?9++3[K[(;**\%V[( -[2+M*[MP(,9'0\Y[8)NV_AC3H
M$M$19O*L[@75M&9F*PL%9<*,\+AVXZ?D*=H_AK3M'FADT])8C%!]GQYA(= S
M, V>N"[8_P!XT 8.N>/X+70;F]TVSN)YC!]HLQ(%"W,?F)&9%^;[H,BG!VD@
MC'7-7KCQ0UCKMU8WT.5CM;1XUC7]Y+--)*FP MC_ )9COQSDX&:F;P9HS6\T
M#0RM#(GE*AF;$,>]7*)S\JEE4X'H.PJYJ'A[3K^[N+JXC?[1,D*&19"I7RG9
MXRN.A#.QR* *^C^*K+5[Z>TLXK@SVN1=A@H%JP+#8YW=25/W<COG!!KE]<^)
M(AU"WMM)@BD<3>3<K,0Q0F2W"X*,5.5G)Z]0,XY%=3;^$]*M_/\ +BE_TF)X
MKH&5L7(;=DR?WF^=N>O/TJDW@#0GG6:6*XDF4H=[W#$_)Y>WOV\F/\O<T ;F
MGZK!?RF.!90PC\QMZ8V?,RX/OE6X]O<5BQ^-],FUM]'@CN)M37#"WB,;%H^?
MWF0^ HVG()#<CCD9U-$TD6$=XTYC>>\F::;RU*IDC& "2<=_J2>]9EKX&T6U
MNH+FW2YCN+>)((9%N'!CB4MB,<_=^<C'T]!0 SPEXOBUGP[IU[=1-%=7$'F2
MQHN%0B,.3DG[N&7!)[_6JUG\1M&N[N[MXHKS=9RPPW3!49(6ED,:Y96(/S 9
MVYQD>^-.#P;HL.GM9):L;=K-+$JTC']TO09SUZ<]>!Z5##X&T2*;4IO*G>;4
M7@DN7>=B9&A8.AZ\<CMUH ;>>.=)L]*M]0N/-CMKJ0QVI<QI]H 4L73+ ;<
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MXK^;\$>JK\3K(#_D'7/_ 'VM+_PL^Q_Z!US_ -]K7E-%%V']KXK^;\$>K?\
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M^%&9?[L?_?1_PH DHJ/,O]V/_OH_X49E_NQ_]]'_  H DHJ/,O\ =C_[Z/\
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MV/\ [Z/^%&9?[L?_ 'T?\* .%\.:YK]]KFF6MY-8FSGAN+CS;;]Z7"& *I;
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MJ7_0/O/^_+?X5]#;I?1/^^C_ (4;I?1/^^C_ (4<H?V##^=_<?//]DZE_P!
M^\_[\M_A2?V3J(ZV%W_WY;_"OH?=+Z)_WT?\*CD:3/1?^^C_ (4<H?V##^=_
M<?/G]E:C_P ^%W_WY;_"D.E:CC_CPN_^_+?X5] YD]%_.C,GHOYT6#^P8?SO
M[A(>(8\_W1_*GTS+^B_G1E_1?SJCWT3Q5)4$9D[*G_?7_P!:GYE_NI_WT?\
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MHKA_"D>OKXAO&U*2Y,;2KE9 WEJGDC=M)X),O3;T7KR<#%\5:MKEO_PL 6+
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MKME>)<H%Z<GICG'I0!P$/Q'U.WLY&U#2+1I88G=FANFVOLM([HX!3C*N1WY
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MMJAMY'4(!$I.2C'L.>A]: ,&/Q?J%Q&D']D-:7DB32H;EVC0Q1JA+J2N2<R
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M!)[#-0R^+M/1 0ER[,\R(BH,OY6=Q'/< D>N*NQZ5%<QWG]HPJXNY?,:(G(
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M2WMQML742VB^6SWOR^6TB@\(?F./NCG=QBNQVR_WT_[X_P#KT;9?[Z?]\?\
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M2H(UD_OK_P!\_P#UZDVR?WU_[Y_^O0 ^BF;9/[Z_]\__ %Z-LG]]?^^?_KT
M/IT?WQ46V3^^O_?/_P!>EC63>/G7_OG_ .O0!;JM]AM_M'G>6/,W;NIQNZ;L
M=,^]/8NGWY8U^JX_K3?-_P"GB'\O_KT7"Q8HJ!79L;9XCDX&!_\ 7I^V7^^G
M_?'_ ->@"2BH]LO]]/\ OC_Z]&V7^^G_ 'Q_]>@"2H_^7G_@']:-LO\ ?3_O
MC_Z]-4,+CYV!^3L,=Z )J*** "OE?XE?\C[KG_7P?Y"OJBOE?XE?\C[KG_7P
M?Y"DSR\V_A+U.:HHHI'@!1110 4444 %%%% !1110 5])_!7_DG]E_UTE_\
M0S7S97TG\%?^2?V7_727_P!#--'I95_&?I_D=SN&,Y&.G6EK@-=M=;MY-3@T
M>V=_L8DU"R=ERC22#&P<\E29FV].4]J@M$\4M<2++JER+<:=--#.+)]JR[P$
M#JR[V8#)Q@$\<4SZ$]&HKS/4M7\4/9Z8UAIVIVUP@@\P2*9?-1G*R$X08( 5
MOFVGYON\&JFF2^-_(A1Y-1>:2(1EIH%4!FT_>6)V@#%P /0$D4 >KT5YK:WG
MB>_U*S3_ (FEO9O-9I,S6VPA3;3>=U7C]X(\GUQC@\KX6N/&5YJ>F?VM*]I
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MW,EFR3S1BX#30MD9F&TEMP!R,KR>H!ZON7Y?F'S=.>M-DFBB0M+(B*IP2S
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ML[:1H)IC(@*NJ*VX+OW%6+<#:.,')S@==48@A%P9Q%&)F7:9-HW$>F>N*DH
M**** "OC7QI=W*^+M:"W$X NY0 )",?,:^RJ^+_&W_(X:U_U^2_^A&K@>9F?
MPQ,S[9=?\_4__?QO\:/MEU_S]3_]_&_QJ"BM#Q[LG^V77_/U/_W\;_&C[9=?
M\_4__?QO\:@HH"[+'VVZ_P"?J?\ [^'_ !H^VW?_ #]3_P#?PU7HH"[+'VV[
M_P"?J?\ [^&C[;=_\_4__?PU7HH"[+'VV[_Y^I_^_AI/MMU_S]3_ /?P_P"-
M044!=D_VRZ_Y^I_^_C?XT?;+K_GZG_[^-_C4%% 79/\ ;+K_ )^I_P#OXW^-
M'VRZ_P"?J?\ [^-_C4%% 79[1^S?/-+J^LB6620"W3&]B<?-[U[S7@7[-?\
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ME_5*/\IY;_PH_P ._P#/[J7_ 'VG_P 33)/@CX=!_P"/S4O^^U_^)KU78?\
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M>"*3W/4PR4Z$7);2LM+WNM5;K:R^_P S5#^-9#))LBA(9S'%F,JREDVACU!
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M\Q\E9HS7UK_PC&A?] FQ_P"_*T?\(QH7_0)L?^_*T6#^R)?S'R5FOI/X*_\
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M?H?S-'D1^A_,T 251E^_^ JUY$?H?S-)Y$?]T_F: *=%7/L\?]T_F:/L\?\
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&T444"/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256442326352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PDS Biotechnology Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001472091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-4231384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">303A College Road East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">208-3343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00033 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PDSB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,819,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256442193728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,733,724<span></span>
</td>
<td class="nump">$ 56,560,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,427,752<span></span>
</td>
<td class="nump">2,494,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,161,476<span></span>
</td>
<td class="nump">59,055,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">152,938<span></span>
</td>
<td class="nump">134,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease right-to-use assets</a></td>
<td class="nump">181,533<span></span>
</td>
<td class="nump">200,873<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">60,495,947<span></span>
</td>
<td class="nump">59,390,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,252,490<span></span>
</td>
<td class="nump">6,982,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,947,221<span></span>
</td>
<td class="nump">2,424,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Note payable - short term</a></td>
<td class="nump">10,416,667<span></span>
</td>
<td class="nump">4,166,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease obligation-short term</a></td>
<td class="nump">58,396<span></span>
</td>
<td class="nump">55,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,674,774<span></span>
</td>
<td class="nump">13,629,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Notes payable, net of debt discount</a></td>
<td class="nump">13,810,194<span></span>
</td>
<td class="nump">19,506,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease obligation-long term</a></td>
<td class="nump">93,109<span></span>
</td>
<td class="nump">122,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,578,077<span></span>
</td>
<td class="nump">33,259,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00033 par value, 150,000,000 and 75,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 36,779,275 and 33,094,521 issued and outstanding at June 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">12,137<span></span>
</td>
<td class="nump">10,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">194,337,722<span></span>
</td>
<td class="nump">170,620,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(163,431,989)<span></span>
</td>
<td class="num">(144,500,615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">30,917,870<span></span>
</td>
<td class="nump">26,130,947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 60,495,947<span></span>
</td>
<td class="nump">$ 59,390,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256442189136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00033<span></span>
</td>
<td class="nump">$ 0.00033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">36,779,275<span></span>
</td>
<td class="nump">33,094,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">36,779,275<span></span>
</td>
<td class="nump">33,094,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440788576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 4,527,698<span></span>
</td>
<td class="nump">$ 8,004,852<span></span>
</td>
<td class="nump">$ 11,231,862<span></span>
</td>
<td class="nump">$ 13,848,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,156,606<span></span>
</td>
<td class="nump">4,691,321<span></span>
</td>
<td class="nump">7,550,069<span></span>
</td>
<td class="nump">8,270,049<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,684,304<span></span>
</td>
<td class="nump">12,696,173<span></span>
</td>
<td class="nump">18,781,931<span></span>
</td>
<td class="nump">22,118,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,684,304)<span></span>
</td>
<td class="num">(12,696,173)<span></span>
</td>
<td class="num">(18,781,931)<span></span>
</td>
<td class="num">(22,118,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Interest income (expenses), net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">675,209<span></span>
</td>
<td class="nump">750,654<span></span>
</td>
<td class="nump">1,344,104<span></span>
</td>
<td class="nump">1,479,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,187,971)<span></span>
</td>
<td class="num">(995,397)<span></span>
</td>
<td class="num">(2,362,716)<span></span>
</td>
<td class="num">(1,962,242)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expenses), net</a></td>
<td class="num">(512,762)<span></span>
</td>
<td class="num">(244,743)<span></span>
</td>
<td class="num">(1,018,612)<span></span>
</td>
<td class="num">(482,247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(9,197,066)<span></span>
</td>
<td class="num">(12,940,916)<span></span>
</td>
<td class="num">(19,800,543)<span></span>
</td>
<td class="num">(22,600,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="nump">869,169<span></span>
</td>
<td class="nump">1,406,021<span></span>
</td>
<td class="nump">869,169<span></span>
</td>
<td class="nump">1,406,021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,327,897)<span></span>
</td>
<td class="num">(11,534,895)<span></span>
</td>
<td class="num">(18,931,374)<span></span>
</td>
<td class="num">(21,194,813)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (8,327,897)<span></span>
</td>
<td class="num">$ (11,534,895)<span></span>
</td>
<td class="num">$ (18,931,374)<span></span>
</td>
<td class="num">$ (21,194,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">36,693,561<span></span>
</td>
<td class="nump">30,802,498<span></span>
</td>
<td class="nump">35,754,715<span></span>
</td>
<td class="nump">30,616,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,693,561<span></span>
</td>
<td class="nump">30,802,498<span></span>
</td>
<td class="nump">35,754,715<span></span>
</td>
<td class="nump">30,616,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256436681152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,956<span></span>
</td>
<td class="nump">$ 145,550,491<span></span>
</td>
<td class="num">$ (101,558,417)<span></span>
</td>
<td class="nump">$ 44,002,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">30,170,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,080,319<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,080,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock from the Sales Agreement, net</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">4,588,339<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,588,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="nump">553,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,659,918)<span></span>
</td>
<td class="num">(9,659,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 10,139<span></span>
</td>
<td class="nump">152,219,149<span></span>
</td>
<td class="num">(111,218,335)<span></span>
</td>
<td class="nump">41,010,953<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">30,723,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,956<span></span>
</td>
<td class="nump">145,550,491<span></span>
</td>
<td class="num">(101,558,417)<span></span>
</td>
<td class="nump">44,002,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">30,170,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,194,813)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 10,188<span></span>
</td>
<td class="nump">155,187,231<span></span>
</td>
<td class="num">(122,753,230)<span></span>
</td>
<td class="nump">32,444,189<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">30,868,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,956<span></span>
</td>
<td class="nump">145,550,491<span></span>
</td>
<td class="num">(101,558,417)<span></span>
</td>
<td class="nump">$ 44,002,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">30,170,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,642,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 10,921<span></span>
</td>
<td class="nump">170,620,641<span></span>
</td>
<td class="num">(144,500,615)<span></span>
</td>
<td class="nump">$ 26,130,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">33,094,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 10,139<span></span>
</td>
<td class="nump">152,219,149<span></span>
</td>
<td class="num">(111,218,335)<span></span>
</td>
<td class="nump">41,010,953<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">30,723,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,105,538<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,105,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options (in shares)</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting agreement</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">609,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting agreement (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock from the Sales Agreement, net</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">243,729<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">243,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="nump">43,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,534,895)<span></span>
</td>
<td class="num">(11,534,895)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 10,188<span></span>
</td>
<td class="nump">155,187,231<span></span>
</td>
<td class="num">(122,753,230)<span></span>
</td>
<td class="nump">32,444,189<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">30,868,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 10,921<span></span>
</td>
<td class="nump">170,620,641<span></span>
</td>
<td class="num">(144,500,615)<span></span>
</td>
<td class="nump">26,130,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">33,094,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,630,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,630,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">531,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">531,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options (in shares)</a></td>
<td class="nump">156,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock from the Sales Agreement, net</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">19,493,342<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,494,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="nump">3,428,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
<td class="num">(10,603,477)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 12,104<span></span>
</td>
<td class="nump">192,275,033<span></span>
</td>
<td class="num">(155,104,092)<span></span>
</td>
<td class="nump">37,183,045<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">36,679,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 10,921<span></span>
</td>
<td class="nump">170,620,641<span></span>
</td>
<td class="num">(144,500,615)<span></span>
</td>
<td class="nump">$ 26,130,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">33,094,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,428,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,931,374)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 12,137<span></span>
</td>
<td class="nump">194,337,722<span></span>
</td>
<td class="num">(163,431,989)<span></span>
</td>
<td class="nump">30,917,870<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">36,779,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 12,104<span></span>
</td>
<td class="nump">192,275,033<span></span>
</td>
<td class="num">(155,104,092)<span></span>
</td>
<td class="nump">37,183,045<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">36,679,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,795,722<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,795,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting agreement</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">266,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting agreement (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,327,897)<span></span>
</td>
<td class="num">$ (8,327,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 12,137<span></span>
</td>
<td class="nump">$ 194,337,722<span></span>
</td>
<td class="num">$ (163,431,989)<span></span>
</td>
<td class="nump">$ 30,917,870<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">36,779,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256441013600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,327,897)<span></span>
</td>
<td class="num">$ (10,603,477)<span></span>
</td>
<td class="num">$ (11,534,895)<span></span>
</td>
<td class="num">$ (9,659,918)<span></span>
</td>
<td class="num">$ (18,931,374)<span></span>
</td>
<td class="num">$ (21,194,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,425,733<span></span>
</td>
<td class="nump">4,185,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of shares in consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">283,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554,010<span></span>
</td>
<td class="nump">233,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,194<span></span>
</td>
<td class="nump">7,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,339<span></span>
</td>
<td class="nump">20,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,806<span></span>
</td>
<td class="num">(65,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,730,334)<span></span>
</td>
<td class="nump">3,195,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(477,471)<span></span>
</td>
<td class="num">(4,937,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(179,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,796,097)<span></span>
</td>
<td class="num">(18,003,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531,091<span></span>
</td>
<td class="nump">8,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,261)<span></span>
</td>
<td class="num">(33,253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,494,473<span></span>
</td>
<td class="nump">4,832,265<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,998,303<span></span>
</td>
<td class="nump">4,807,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173,207<span></span>
</td>
<td class="num">(13,195,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,560,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,820,160<span></span>
</td>
<td class="nump">56,560,517<span></span>
</td>
<td class="nump">73,820,160<span></span>
</td>
<td class="nump">73,820,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of period</a></td>
<td class="nump">$ 57,733,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,624,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,733,724<span></span>
</td>
<td class="nump">60,624,991<span></span>
</td>
<td class="nump">$ 56,560,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental information of cash and non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,362,716<span></span>
</td>
<td class="nump">$ 1,962,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440931248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211; </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br/>
            </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">PDS Biotechnology Corporation, a Delaware corporation (the &#8220;Company&#8221; or &#8220;PDS Biotech&#8221;), is a clinical-stage immunotherapy
                            company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome limitations of current immunotherapy and vaccine technologies. The Company develops proprietary platforms designed to train and
                            enable the immune system to attack and destroy disease; Versamune&#174;, and Versamune&#174; in combination with PDS01ADC for treatments in oncology and Infectimune&#174; for treatments in infectious diseases.&#160; When paired with an antigen,
                            which is a disease-related protein that is recognizable by the immune system, Versamune&#174; and Infectimune&#174; have both been shown to induce, <span style="font-style: italic;">in vivo</span>, large quantities of high-quality,
                            highly potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of
                            Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the limitations of cytokine therapy which previously has resulted
                            in high toxicity and limited therapeutic potential.&#160; The Company&#8217;s infectious disease candidate, Infectimune&#174;, is of potential interest for use in universal influenza vaccines. and is designed to promote the induction of
                            disease-specific neutralizing antibodies.&#160; The Company&#8217;s immuno-oncology product candidates are of potential interest for use as a component of combination product candidates (for example in combination with other leading
                            technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage
                            disease.&#160; The Company is developing targeted product candidates to treat several cancer tumors, including Human Papillomavirus (HPV) associated cancer in head and neck squamous cell carcinoma, melanoma, colorectal, lung, breast
                            and prostate<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.<br/>
                            </span></span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256445276032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 2 &#8211; Summary of Significant Accounting
            Policies</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> unaudited financial
                statements for all periods presented are referred to as &#8220;Condensed Consolidated Financial Statements&#8221;, and have been prepared by the Company in United States (&#8220;U.S.&#8221;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. Accordingly, these notes to the unaudited condensed consolidated financial statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities
                and Exchange Commission (&#8220;SEC&#8221;) on March 28, 2024. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited
                consolidated financial statements for the year ended December 31, 2023. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ent of the Company&#8217;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.</span></span></span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the condensed consolidated financial
            statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the condensed consolidated financial statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to complete clinical trials necessary to obtain regulatory <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">product licenses, the regulatory approvals needed to pursue </span>development







                          of its clinical and product candidates<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company&#8217;s adherence to covenants under its debt agreement, the Company&#8217;s</span> ability to preserve its cash resources, the Company&#8217;s ability to add clinical and product
                          candidates to its pipeline, the Company&#8217;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.<br/>
                        </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
        </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.</span> The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they
              occur.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,563,211</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,324,402</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">466,112</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">506,229</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">6,029,323</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,830,631</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div><br/></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <br/>
            </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div>
                          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> <br/>
                </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(L)</div>
                            </td>

    <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">New accounting standards:</span></div>
                            </td>

  </tr>


</table>

<div> <br/>
                      </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Recently Adopted Accounting Pronouncements</div>

<div><br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Recently issued accounting pronouncements did not, or are not believed by the Company to, have a material effect on our present or future Condensed Consolidated Financial Statements.</span></div>

<div><br/>
                          </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none;">Recent Accounting Pronouncements Not Yet
                            Adopted</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023, the FASB issued ASU 2023-09, Improvements to
                              Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative
                              threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that
                              adopting this standard will have on the consolidated financial statements and disclosures.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256540139792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiquidityAndCapitalResourcesTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 &#8211; Liquidity <span style="font-family: 'Times New Roman'; font-size: 10pt;">and </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Capital Resources</span></span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">As of June 30, 2024, the
              Company had $57.7 million of cash and cash equivalents. The Company&#8217;s primary use of cash is to fund operating expenses, primarily
              research and development expenditures. Cash used to fund operating expenses is impacted by <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">the level of activities undertaken, as well as</span> </span>the timing of when the Company pays these expenses, as reflected in the change to the Company&#8217;s outstanding accounts payable and
              accrued expenses.<span style="font-size: 10pt; font-family: 'Times New Roman';"> Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman';">year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable.<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In addition, the Loan and Security Agreement allows for the lenders to call the outstanding balance of the term loans if the minimum
                cash balances outlined in the Loans and Security Agreement are not maintained.</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company funds its operations through equity and/or debt financings such as the following:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $150
              million, $50 million of which covers the offer, issuance and sale by the Company of its common stock under the Sales Agreement (as
              discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
              Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
              having an aggregate offering price of up to $50 million, or the Placement Shares, through or to the Agents, as sales agents or
              principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in
              Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#8217;s common stock. The Agents will use commercially
              reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
              Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under
              the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of Placement
              Sh<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ares pursuant to the Sales Agreement will terminate upon the
                earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. For the year ended December 31, 2023, the Company sold 2,642,269 shares of common stock for a net value of $16.1 million pursuant to the Sales Agreement. During the three and six months ended June 30, 2024, the company sold 0 and 3,428,681 shares, respectively, of its common
                stock with a net value of $0.0 million and $19.5 million, respectively, pursuant to the Sales Agreement.</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders. The Loan and Security Agreement provides for the following 6 separate and independent term loans: (a) a term loan in the amount of $7,500,000,
                or Loan A, (b) a term loan in the amount of $10,000,000, or Loan B, (c) a term loan in the amount of $3,750,000, or Loan C, (d) a term loan in the amount of $3,750,000, or Loan D, (e) a term loan in the amount of $5,000,000, or
                Loan E, and (f) a term loan in the amount of $5,000,000, or Loan F, (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and
                Loan F, individually a Loan and, collectively, the Loans). Loan A, Loan B, Loan C<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">, and Loan D were delivered to the Company on August 24, 2022.<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In total, the Company received $24.6 million in net proceeds.</span> </span>Loan E and Loan F <span style="font-size: 10pt; font-family: 'Times New Roman';">were</span> uncommitted Loans that could have been advanced by the lenders upon the parties agreement prior to July 31, 2023 upon the satisfaction of certain conditions. <span style="font-size: 10pt; font-family: 'Times New Roman';">At</span> this <span style="font-size: 10pt; font-family: 'Times New Roman';">time, the </span>option<span style="font-size: 10pt; font-family: 'Times New Roman';"> to advance
                  Loan E and Loan F has expired and Loan E and Loan F are </span>no <span style="font-size: 10pt; font-family: 'Times New Roman';">longer available</span> to the Company <span style="font-size: 10pt; font-family: 'Times New Roman';">under







                  the Loan and Security Agreement</span>. The Company may only use the proceeds<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> of the Loans for working capital or general corporate purposes. Each Loan matures on the 48-month
                  anniversary following the applicable funding date unless accelerated pursuant to certain events of default.</span> Payments on the principal balance begin on October 1, 2024 and are paid monthly over the succeeding 24 months. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) </span>the per annum rate of
                interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;<span style="-sec-ix-hidden:Fact_422456f8ef2547ffa808d9e7f65aa170">prime rate</span>&#8221; then in effect, plus (b) 5.75%; provided that, in the event such rate of interest
                is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding the preceding month. The Company, at its
                option upon at least ten (10) business days&#8217; written notice to the lenders, may prepay all (and not less than all) of the
                outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an amount equal to (A) if such Loan is prepaid on or before the
                Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, 3% of the then outstanding
                principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan, but on or before the date that is 12 months after such Loan Amortization Date, 2% of the then outstanding principal balance of
                such Loan, or (C) if such Loan is prepaid more than 12 months after the Loan Amortization Date but prior to the stated maturity
                date applicable to such Loan, 1% of the then outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iii)
                the outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iv) all other sums, if any, that shall have become due and payable thereunder. No prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Loan and Security Agreement contains customary representations, warranties and covenants, including <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">maintenance of minimum cash balances as well as</span> </span>covenants






















              by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates, and
              fundamental changes.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2023, the Company received approximately $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company&#8217;s participation in the New Jersey Technology
                Business Tax Certificate Transfer NOL program for tax year 2021.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2024, the Company received approximately $0.9 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to its participation in the New Jersey Technology Business Tax Certificate
                  Transfer of Net Operating Loss (NOL) program for tax year 2022.<br/>
                </div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Going Concern</span></div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br/>
              </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its
                  ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, the Company has experienced net losses and negative cash
                  flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In addition, the Loan and Security Agreement allows for the lenders to call the outstanding balance of the
                    term loans if the minimum cash balances outlined in the Loan and Security Agreement are not maintained.</span></div>

<div><br/>
                </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s estimated cash requirements in 2024 and beyond include expenses related to continuing development and clinical trials as
                  well as payments on its debt. The Company plans to execute its operating plan by obtaining additional capital, principally through issuance of equity through separate offerings or an at-the-market facility, issuance of debt, or by
                  entering into collaborations, strategic alliances, or license agreements with third parties. However, there is no assurance that sufficient additional capital and/or financing will be available to the Company, and even if available,
                  whether it will be on terms acceptable to the Company or its existing shareholders. The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale
                  of additional equity would result in dilution to the Company&#8217;s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants
                  that would restrict its operations. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects,
                  grant rights to third parties to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself, or cease operations entirely. Any of these actions could harm its business, results of operations
                  and prospects. Failure to obtain adequate financing may also adversely affect the Company&#8217;s ability to operate as a going concern.</div>

<div><br/>
                </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As a result of these uncertainties, and as its plans are outside of management&#8217;s control, the Company has concluded that substantial doubt
                  exists about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements. The unaudited Condensed Consolidated
                  Financial Statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256445304432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 4 &#8211; Fair Value of Financial Instruments</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">There were no transfers among Levels 1, 2, or 3 during the
            three and six months ended June 30, 2024 or 2023.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
           </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of June 30, 2024: (unaudited)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">57,733,724</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">57,733,724</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">56,560,517</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">56,560,517</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
           <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;">The carrying value of the <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Loan and Security Agreement</span> approximated its fair value as of June 30, 2024 due to its variable rate.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256445130224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 5 &#8211; Leases</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Operating Lease:</span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 with a term of forty (40) months with an option to renew through October 31, 2027. The sublease term expired on August 31, 2023, and was not renewed. Upon inception of
              the sublease, the Company recognized approximately $0.7 million of&#160; ROU assets and operating lease liabilities. The discount
              rate used to measure the operating lease liability as of May 1, 2020 was 9.15%. Throughout the period described above, the Company
              has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Supplemental cash flow information related to operating
            leases is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="7" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Cash paid for operating lease liabilities</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">179,136</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Financing Lease:</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="7" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34,925</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">$ <br/>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">43,221</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liabilities is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31,</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34,925</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,850</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,108</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">26,723</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2028 and after</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">171,607</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(20,102</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">151,505</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company entered into four
              financing leases for laboratory equipment with a total cost of $251,959 with <span style="-sec-ix-hidden:Fact_1d2392fd0bf043fea9df39565196af84">four</span> to five-year terms and a capitalized interest rate of
              9.15%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $6,000. During the year ended December 31, 2023, the Company exercised the bargain
              purchase option, which resulted in recognition of property and equipment of $151,490.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256446040480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 6 &#8211; Accrued Expenses</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses consist of the following:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2024</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2023</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">200,699</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">&#8211;</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">556,385</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">827,863</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">892,894</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,289,690</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">296,875</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">306,771</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="background-color: #CCEEFF; vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">Accrued rent</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,947,221</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">2,424,692</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256439989584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Note 7 &#8211; Stock-Based Compensation</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">In 2014, the Company&#8217;s stockholders approved the 2014
              Equity Incentive Plan (the &#8220;Original Plan&#8221;) pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and
              restricted stock units (&#8220;RSUs&#8221;), subject to increases as hereafter described (the &#8220;Plan Limit&#8221;). In addition, on January 1, 2015, and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the
              terms of the Original Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common
              Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors (&#8220;Board&#8221;) may determine in its discretion. In March 2019, the Board adopted and the Company&#8217;s stockholders approved the Amended
              and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Prior Plan&#8221;) which amended and restated the Original Plan in order to remove the annual increase component and was limited to 826,292 shares.</div>

<div style="text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;">On </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">December 8, 2020,
                      the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Restated Plan&#8221;), which amended and restated the Prior Plan. The Restated
                      Plan is identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock authorized for issuance under the Restated Plan was increased from 826,292 shares to 4,165,535 shares, plus the total number of
                      shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on December 7, 2030, unless
                      earlier terminated.&#160; On May 19, 2023, the Board adopted, subject to stockholder approval, the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Third Restated Plan&#8221;). At the 2023 annual meeting
                      of stockholders held on July 14, 2023, the stockholders approved the Third Restated Plan, which amended and restated the Restated Plan to increase the total amount of shares authorized for issuance thereunder. The Third Restated Plan
                      is identical to the Restated Plan in all material respects, except, the number of shares of Common Stock authorized for issuance under the Third Restated Plan increased from 4,165,535 to 6,565,535. As of June 30, 2024, there were 2,301,167 shares available for grant under the Third Restated Plan.</span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;"> <br/>
              </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Pursuant to the terms of the Third Restated Plan, stock options have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a
            four-year period.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). On December 8, 2020, the Company amended the
                Inducement Plan solely to increase the total number of shares of common stock reserved for issuance under the Inducement Plan from 200,000
                shares to 500,000 shares. On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number
                of shares of Common Stock reserved for issuance under the Inducement Plan from 500,000 shares to 1,100,000 shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common
                Stock reserved for issuance under the Inducement Plan from 1,100,000 shares to 2,100,000 shares. The Inducement Plan provides
                for the grant of non-qualified stock options. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder
                approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq
                  Listing Rules, non-qualified stock options under the Inducement Plan may only be made to an employee who has not previously been an employee of the Company or member of the Board of Directors of the Company (or any parent or subsidiary of
                  the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into
                  employment with the Company or such subsidiary. As of June 30, 2024, there were 969,407 shares available for grant under the
                  Inducement Plan.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations and
              comprehensive loss for the three and six months ended June 30, 2024 and 2023:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months Ended June 30,<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six months ended June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock-Based Compensation</div>
                  </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Research and development</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">609,828</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">806,548</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,161,746</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,607,312</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">General and administrative</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,185,894</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,298,990</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,263,987</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,578,545</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,795,722</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,105,538</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3,425,733</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,185,857</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span>
            <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <br class="Apple-interchange-newline"/>
            </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The Company granted options to purchase 254,000
              and 1,192,648 shares during the three and six month periods ended June 30, 2024, respectively, and granted options to purchase 29,900 and 1,154,500 shares during
              the three and six month period ended June 30, 2023, respectively. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400;">The fair value of options granted during the three and six months ended June 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model utilizing the
              following assumptions:</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months Ended June 30</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six Months Ended June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">106.26</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">143.87</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">137.07</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">142.07</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.26</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.59</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.04</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.05</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.96</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.06</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2.86</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.09</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.71</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">10.64</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,029,345</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.43</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.42</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,395,227</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,192,648</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.12</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.70</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(156,073</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.40</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Forfeited and expired</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(502,709</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">8.68</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,563,211</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.03</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.46</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">899,228</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,563,211</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.03</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.46</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">899,228</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3,043,575</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.79</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.25</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">837,670</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br class="Apple-interchange-newline"/>
          </span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">As of June 30, 2024 there was approximately $14,042,395 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 2.84 years.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256445104592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 8 &#8211; Income Taxes</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company records a valuation allowance against its deferred tax
                assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized</span>. I</span>n assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and
            negative evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the
            generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for <span style="font-size: 10pt;">2024</span> and therefore there will be <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">no</span> current income tax expense.&#160; The Company recorded a full valuation allowance against the net deferred tax assets as of June<span style="font-size: 10pt;"> 30,
              2024</span> and December 31, <span style="font-size: 10pt;">2023</span>. Consequently, the Company recorded <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">no</span> income tax benefit due to realization uncertainties.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is subject to a U.S. federal statutory income tax rate of 21%. The primary factor impacting the effective tax rate for the three and six months ended <span style="font-size: 10pt;">June 30, 2024</span> is the anticipated full year
                operating loss which will require a full valuation allowance against any associated net deferred tax assets.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Entities are required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their
                income tax returns. The Company has analyzed its tax positions and has concluded that as of <span style="font-size: 10pt;">June 30, 2024</span>, there were no uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date
                because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties
                for the three and six months ended June<span style="font-size: 10pt;"> 30, 2024</span> or for the year ended December 31, <span style="font-size: 10pt;">2023.<br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In accordance with the State of
                  New Jersey&#8217;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL
                  carryforwards, resulting in the recognition of $0.9 million and $1.4 million of income tax benefit, net of transaction costs in the six months ended June 30, 2024 and 2023, respectively.</div>

<div><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440040768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 9 &#8211; Commitments and Contingencies</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Rent</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br/>
      </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and six months ended June 30, 2024 was $66,000 and $132,000 respectively, compared to the three and six months ended June 30, 2023 of $126,532 and $253,202.</span> </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Exclusive License Agreement</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In January 2023, the Company entered into an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting IL 12 fused antibody drug conjugate, M9241 (the &#8220;Merck KGaA License Agreement&#8221;).
            Pursuant to the Merck KGaA License Agreement, the Company agreed to make (i) development and first commercial sales milestone payments totaling up to $11
            million upon the achievement of certain milestones, including the dosing of the fifth patient in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up
            to $105 million upon achieving certain aggregate sales levels of the product.</span> </div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of 10% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) ten years after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in the event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or if
            the Company obtains a license to any intellectual property owned or controlled by a third-party which, but for such license would be infringed by making, using or selling the compound.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> <span style="font-size: 10pt;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Legal Proceedings</span><br/>
      </span> </div>

<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company is currently not a party to,</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and the Company&#8217;s</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> property is not currently the subject of,</span><span style="font-family: 'Times New Roman';"> any <span style="font-size: 10pt;">material </span>pending <span style="font-size: 10pt;">legal proceedings.</span> The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes that may not be predictable with assurance.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256541131568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Venture Loan and Security Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Venture Loan and Security Agreement</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">Note 10 &#8211; Venture Loan and Security Agreement</div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company entered into a Venture Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Horizon
            Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#8220;Collateral Agent&#8221;), and the other persons party thereto from time to time as lenders (&#8220;Lenders&#8221;).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Term loan Amounts</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for the following six (6) separate and independent term loans: (a) a term loan in the amount of $7,500,000
            (&#8220;Loan A&#8221;), (b) a term loan in the amount of $10,000,000 (&#8220;Loan B&#8221;), (c) a term loan in the amount of $3,750,000 (&#8220;Loan C&#8221;), (d) a term loan in the amount of $3,750,000
            (&#8220;Loan D&#8221;), (e) a term loan in the amount of $5,000,000 (&#8220;Loan E&#8221;), and (f) a term loan in the amount of $5,000,000 (&#8220;Loan F&#8221;) (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a &#8220;Loan&#8221; and, collectively, the &#8220;Loans&#8221;). </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Loan A, Loan B, Loan C, and Loan D were
            delivered to the Company on August 24, 2022. </span><span style="font-size: 10pt; font-family: 'Times New Roman';">Loan E and Loan F were uncommitted Loans that could have been advanced by the Lenders upon the parties agreement prior to July
            31, 2023 upon the satisfaction by the Company of certain agreed upon conditions. At</span> this <span style="font-size: 10pt; font-family: 'Times New Roman';">time the </span>option<span style="font-size: 10pt; font-family: 'Times New Roman';"> has expired and Loan E and Loan F are</span> no <span style="font-size: 10pt; font-family: 'Times New Roman';">longer available</span> to the Company <span style="font-size: 10pt; font-family: 'Times New Roman';">under the Loan and
            Security Agreement</span>. <span style="font-size: 10pt; font-family: 'Times New Roman';">The Company may only use the proceeds of the Loans for working capital or general corporate purposes.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-style: italic;">Maturity</span>. Each Loan matures on the 48 month
                anniversary following the applicable date on which a Loan is made to or on account of the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>under the Loan and Security Agreement (the &#8220;Maturity Date&#8221;) unless accelerated pursuant to agreed upon events of default. All amounts outstanding under each Loan will be due and payable upon
                the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.</span> Payments on the principal balance begin on October 1, 2024 and are paid monthly in the succeeding 24 months<span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<div><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Interest Rate</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall
            Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;<span style="-sec-ix-hidden:Fact_89027c97a3984c949cabb17cf3986c08">prime rate</span>&#8221; then in
            effect, plus (b) 5.75%; provided that, in the event such rate of interest is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of
            calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding during the preceding month.</span></div>

<div style="text-align: justify; color: rgb(0, 0, 0);"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Amortization.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;Each Loan shall commence amortization upon the date set forth on the promissory note executed in connection with the respective Loan, upon which the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>is required to commence making equal payments of principal plus accrued interest on the outstanding principal amount of the respective
            Loan (the &#8220;Loan Amortization Date&#8221;), and continuing thereafter on the first business day of each calendar month through the Maturity Date.</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Prepayment Premium.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;The <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>may, at its option upon at least ten (10) business days&#8217; written
            notice to the Lenders, prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each Lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an
            amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date applicable to such Loan, three percent (3%) of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan,
            but on or before the date that is twelve (12) months after such Loan Amortization Date, two percent (2%) of the then outstanding principal balance of
            such Loan, or (C) if such Loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated
            Maturity Date applicable to such Loan, one percent (1%) of the then outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iii) the outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iv) all other sums, if any, that shall have become due and payable hereunder. No prepayment premium will be
            applied to any outstanding balance of any Loan paid on the stated Maturity Date.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Security</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">.</span><span style="font-family: 'Times New Roman';"> The Company&#8217;s obligations are secured by a security interest in all of the assets of the Company, subject
            to limited exceptions and excluding the Company&#8217;s intellectual property.</span></div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman';"> <br/>
          </span></div>

<div><span style="font-family: 'Times New Roman';"> </span>
       <span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Covenants; Representations and Warranties; Other Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement contains customary representations, warranties and covenants, including
            maintenance of minimum cash balances as well as covenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans,
            certain corporate changes, transactions with affiliates, and fundamental changes. As of June 30, 2024, the Company was in compliance with all covenants in all material respects.</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Default Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment,
            breaches or defaults in the performance of covenants, insolvency, and bankruptcy by and/or of the Company.</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Warrant and Debt Discount.</span><span style="font-family: 'Times New Roman';"> In connection with the Loan and Security Agreement, the Company issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of 381,625 shares of the Company&#8217;s common stock at an initial exercise price of $3.6685 per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) 10 years from the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or
                substantially all of the Company&#8217;s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other
                reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of, in
                each case, for cash or for marketable securities meeting certain requirements as described in the applicable warrants. The key assumptions used in the Black-Scholes option pricing model were (i) expected term of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">10</span>
                years, (ii) a risk-free rate of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">3.11%</span>, (iii) expected volatility of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">93.8%</span>, (iv) and <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">no</span> estimated dividend
                yield. In addition, the Company incurred third party and lender fees of $449,329 during the nine months ended September 30, 2022.
                These proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrant and fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the
                Loan and Security Agreement using the effective interest method. The unamortized debt discount was $1,710,639 as of June 30,
                2024.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"><span style="font-family: 'Times New Roman';"> <span style="font-family: 'Times New Roman';"><br/>
                </span></span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company
                recognized interest expense of $1,184,294 and $2,355,053, and $961,753 and $1,952,272 for the three and six months ended June 30, 2024 and 2023, respectively and $283,774 and $554,010, and $121,997 and $233,523 was related to the amortization of
                the debt discount for the three and six months ended June 30, 2024 and 2023, respectively.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256540124192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Note 11 &#8211; Retirement Plan</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
                Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $46,995 and $113,483 for the three
                and six months ended June 30, 2024, respectively, compared to the three and six months ended June 30, 2023 of $36,863 and $131,769, respectively.<br/>
              </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256439969728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440814736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> unaudited financial
                statements for all periods presented are referred to as &#8220;Condensed Consolidated Financial Statements&#8221;, and have been prepared by the Company in United States (&#8220;U.S.&#8221;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. Accordingly, these notes to the unaudited condensed consolidated financial statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities
                and Exchange Commission (&#8220;SEC&#8221;) on March 28, 2024. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited
                consolidated financial statements for the year ended December 31, 2023. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ent of the Company&#8217;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.</span></span></span></span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the condensed consolidated financial
            statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the condensed consolidated financial statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Significant Risks and Uncertainties</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to complete clinical trials necessary to obtain regulatory <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">product licenses, the regulatory approvals needed to pursue </span>development







                          of its clinical and product candidates<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, the Company&#8217;s adherence to covenants under its debt agreement, the Company&#8217;s</span> ability to preserve its cash resources, the Company&#8217;s ability to add clinical and product
                          candidates to its pipeline, the Company&#8217;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#8217;s ability to raise capital.<br/>
                        </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents and Concentration of Cash Balance</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.</span> The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they
              occur.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,563,211</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,324,402</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">466,112</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">506,229</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">6,029,323</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,830,631</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div>
                          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(L)</div>
                            </td>

    <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">New accounting standards:</span></div>
                            </td>

  </tr>


</table>

<div> <br/>
                      </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Recently Adopted Accounting Pronouncements</div>

<div><br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Recently issued accounting pronouncements did not, or are not believed by the Company to, have a material effect on our present or future Condensed Consolidated Financial Statements.</span></div>

<div><br/>
                          </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none;">Recent Accounting Pronouncements Not Yet
                            Adopted</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                          </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In December 2023, the FASB issued ASU 2023-09, Improvements to
                              Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative
                              threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that
                              adopting this standard will have on the consolidated financial statements and disclosures.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for significant risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256540191296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2024</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,563,211</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,324,402</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">466,112</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">506,229</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">6,029,323</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,830,631</div>
                </td>

    <td colspan="1" style="font-family: &amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256439955296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
           </div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of June 30, 2024: (unaudited)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">57,733,724</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">57,733,724</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;">Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">56,560,517</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">56,560,517</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440048352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock', window );">Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text">
<div>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Supplemental cash flow information related to operating
            leases is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="7" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Cash paid for operating lease liabilities</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">179,136</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock', window );">Supplemental Cash Flow Information Related to Financing Lease</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="7" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34,925</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">$ <br/>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">43,221</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Payments for Financing Lease Liability</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liabilities is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31,</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34,925</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,850</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,108</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">26,723</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2028 and after</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">171,607</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(20,102</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">151,505</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440032192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses consist of the following:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2024</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2023</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">200,699</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">&#8211;</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">556,385</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">827,863</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">892,894</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,289,690</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">296,875</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">306,771</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="background-color: #CCEEFF; vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">Accrued rent</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,947,221</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">2,424,692</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256445251680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations and
              comprehensive loss for the three and six months ended June 30, 2024 and 2023:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months Ended June 30,<br/>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six months ended June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2024<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock-Based Compensation</div>
                  </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Research and development</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">609,828</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">806,548</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,161,746</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,607,312</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">General and administrative</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,185,894</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,298,990</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,263,987</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,578,545</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,795,722</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,105,538</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3,425,733</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,185,857</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options Granted</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400;">The fair value of options granted during the three and six months ended June 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model utilizing the
              following assumptions:</span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Three Months Ended June 30</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six Months Ended June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">106.26</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">143.87</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">137.07</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">142.07</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.26</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.59</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.04</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.05</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                    </div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.96</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.06</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2.86</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.09</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.71</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                    </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                    <div>
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">10.64</div>
                    </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;">  </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2023</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,029,345</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.43</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.42</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,395,227</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,192,648</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.12</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.70</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(156,073</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.40</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Forfeited and expired</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(502,709</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">8.68</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,563,211</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.03</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.46</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">899,228</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,563,211</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.03</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.46</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">899,228</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">June 30, 2024</span></div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3,043,575</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.79</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.25</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">837,670</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256435992192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">6,029,323<span></span>
</td>
<td class="nump">5,830,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">5,563,211<span></span>
</td>
<td class="nump">5,324,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">466,112<span></span>
</td>
<td class="nump">506,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256439628384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Loan </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Loan </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,733,724<span></span>
</td>
<td class="nump">$ 57,733,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,560,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ShelfRegistrationStatementAvailableForFutureSale', window );">Registered securities in Shelf Registration Statement available for future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PlacementSharesAvailableForFutureSale', window );">Placement Shares included in at-the-market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_CommissionPercentage', window );">Commission paid on Placement Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,428,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,642,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,494,473<span></span>
</td>
<td class="nump">$ 4,832,265<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards', window );">Proceeds from sale of tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans', window );">Number of independent term loans | Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured loans</a></td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance', window );">Period after October 1, 2024 for making monthly payments on principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:PrimeRateMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentMinimumVariableRate', window );">Minimum base rate used to compute floating interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1', window );">Prepayment premium paid if loan is prepaid on or before Loan Amortization date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentThresholdPeriod', window );">Threshold period after Loan Amortization Date used to determine prepayment premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2', window );">Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3', window );">Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4', window );">Prepayment premium paid if loan is paid on stated maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment', window );">Written notice period for prepayment of outstanding loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember', window );">Loan A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember', window );">Loan B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember', window );">Loan C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember', window );">Loan D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember', window );">Loan E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember', window );">Loan F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentMinimumVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum base rate to be used in computing the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentMinimumVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of independent term loans provided for under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentNumberOfIndependentTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after October 1, 2024 for making monthly payments on the principal balance of the debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PlacementSharesAvailableForFutureSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PlacementSharesAvailableForFutureSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ShelfRegistrationStatementAvailableForFutureSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the "2020 Shelf Registration Statement") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf Securities") that are available for future sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ShelfRegistrationStatementAvailableForFutureSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256442284032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,733,724<span></span>
</td>
<td class="nump">$ 56,560,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">57,733,724<span></span>
</td>
<td class="nump">56,560,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Quoted Prices in Inactive Markets (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256436616688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Operating Lease (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space under sublease | ft&#178;</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of sublease agreement</a></td>
<td class="text">40 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate used to measure operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Supplemental Cash Flow Information Related to Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 179,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440794336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Financing Lease (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract', window );"><strong>Supplemental Cash Flow Information Related to Finance Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeasePrincipalAndInterestPayments', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">$ 34,925<span></span>
</td>
<td class="nump">$ 43,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future Payments for Finance Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">34,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">69,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">40,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">26,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter', window );">2028 and after</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">171,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(20,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Remaining lease liability</a></td>
<td class="nump">$ 151,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseNumberOfLeases', window );">Number of financing leases entered into | Lease</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeaseCost', window );">Total cost of financing leases</a></td>
<td class="nump">$ 251,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance lease liability capitalized interest rate</a></td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseMonthlyRentalExpense', window );">Aggregate monthly rental payments</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Recognition of property and equipment from bargain purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of financing lease</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of financing lease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for finance lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeasePrincipalAndInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal and interest payments on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeasePrincipalAndInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseMonthlyRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated aggregate monthly rental expense under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseMonthlyRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of finance leases entered into by the lessee during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256541115280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 200,699<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">556,385<span></span>
</td>
<td class="nump">827,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">892,894<span></span>
</td>
<td class="nump">1,289,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on debt</a></td>
<td class="nump">296,875<span></span>
</td>
<td class="nump">306,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,947,221<span></span>
</td>
<td class="nump">$ 2,424,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256435988560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Equity Compensation Plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>Dec. 08, 2020</div></th>
<th class="th"><div>Jun. 17, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember', window );">The Plans [Member] | Incentive Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember', window );">The Plans [Member] | Incentive Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of option</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,565,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,165,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PercentageOfCommonStockOutstanding', window );">Percentage of Common Stock outstanding used to determine annual increase in the plan limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">2,301,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member', window );">2019 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">969,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pdsb_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pdsb_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256435485904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock-Based Compensation Expense (Details) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,795,722<span></span>
</td>
<td class="nump">$ 2,105,538<span></span>
</td>
<td class="nump">$ 3,425,733<span></span>
</td>
<td class="nump">$ 4,185,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">609,828<span></span>
</td>
<td class="nump">806,548<span></span>
</td>
<td class="nump">1,161,746<span></span>
</td>
<td class="nump">1,607,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,185,894<span></span>
</td>
<td class="nump">$ 1,298,990<span></span>
</td>
<td class="nump">$ 2,263,987<span></span>
</td>
<td class="nump">$ 2,578,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440426672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions Used in Determining Fair Value of Stock Options and Warrants Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">106.26%<span></span>
</td>
<td class="nump">143.87%<span></span>
</td>
<td class="nump">137.07%<span></span>
</td>
<td class="nump">142.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.26%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">4.04%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 11 months 15 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of option on grant date (in dollars per share)</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 5.09<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 10.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">254,000<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">1,192,648<span></span>
</td>
<td class="nump">1,154,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256441549680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock Option Activity (Details) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,029,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">254,000<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">1,192,648<span></span>
</td>
<td class="nump">1,154,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(502,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">5,563,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,563,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,029,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">5,563,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,563,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">3,043,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,043,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,395,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue', window );">Granted, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 899,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,395,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value</a></td>
<td class="nump">899,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">837,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unamortized Stock Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock compensation expense</a></td>
<td class="nump">$ 14,042,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,042,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options granted (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256436427008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Income tax benefit due to realization uncertainties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiabilityForUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="num">$ (869,169)<span></span>
</td>
<td class="num">$ (1,406,021)<span></span>
</td>
<td class="num">$ (869,169)<span></span>
</td>
<td class="num">$ (1,406,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiabilityForUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiabilityForUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256440426384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="nump">$ 126,532<span></span>
</td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">$ 253,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember', window );">Merck KGaA License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales', window );">Milestone payments for development and first commercial sales</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct', window );">Royalty percentage paid on net sales of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_TermOfRoyaltyPayment', window );">Term of royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember', window );">Merck KGaA License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels', window );">Milestone payments for aggregate sales levels of product</a></td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to be made for development and first commercial sale milestones detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage paid on net sales of the product detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_TermOfRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_TermOfRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256436436672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Venture Loan and Security Agreement, Term Loans (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Loan</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans', window );">Number of independent term loans | Loan</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance', window );">Period after October 1, 2024 for making monthly payments on principal balance</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on variable rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">us-gaap:PrimeRateMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentMinimumVariableRate', window );">Minimum base rate used to compute floating interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1', window );">Prepayment premium paid if loan is prepaid on or before Loan Amortization date</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentThresholdPeriod', window );">Threshold period after Loan Amortization Date used to determine prepayment premiums</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2', window );">Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3', window );">Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date.</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4', window );">Prepayment premium paid if loan is paid on stated maturity date</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment', window );">Written notice period for prepayment of outstanding loan</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember', window );">Loan A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember', window );">Loan B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember', window );">Loan C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember', window );">Loan D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember', window );">Loan E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember', window );">Loan F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentMinimumVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum base rate to be used in computing the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentMinimumVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of independent term loans provided for under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentNumberOfIndependentTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after October 1, 2024 for making monthly payments on the principal balance of the debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256435263632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Venture Loan and Security Agreement, Warrant and Debt Discount (Details) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock that can be purchased with warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">$ 1,710,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,710,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">1,184,294<span></span>
</td>
<td class="nump">$ 961,753<span></span>
</td>
<td class="nump">2,355,053<span></span>
</td>
<td class="nump">$ 1,952,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 283,774<span></span>
</td>
<td class="nump">$ 121,997<span></span>
</td>
<td class="nump">$ 554,010<span></span>
</td>
<td class="nump">$ 233,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PercentageOfVotingPowerDisposedOff', window );">Percentage of voting power disposed off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Estimated Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PercentageOfVotingPowerDisposedOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting power disposed of in a transaction (including a merger or other reorganization) or series of related transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PercentageOfVotingPowerDisposedOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140256434044464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">401(k) employer contributions</a></td>
<td class="nump">$ 46,995<span></span>
</td>
<td class="nump">$ 36,863<span></span>
</td>
<td class="nump">$ 113,483<span></span>
</td>
<td class="nump">$ 131,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M53/#!Q"43<#QN91F'=@:VSZI\3]02P,$%     @ QX -6=F(IPJK!0  H1D
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M2=UC'9@K)966#@A.!DQP9NG0Q7FN"VMS8,G0Q?G< V4#7 79JB '5?A3&]!
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MGP -08N/#U)G N2#E3'\/!$R8.H-D0';<(Q,-"*088PP-DH^R X(D\,5&#T
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M]V_:ZKY_%.7GJFVK;?_RKBQ4)-D9J.]OJJK]_J9[NN7Q>:G7_P=02P,$%
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M2-@*"#80JG,2JJ,M'2\U2[Y,Q1(^-1*VY^<U5=R<&="OXC55J4]+O%5]D+
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M:4TQK%% 'Z7K6FU IJV<8CTVM%QWAL#!=!U^^%9IQ^S.SI^];N%VC<-C_.7
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M.I(<$7_X=L.?&L];[]LU_[DRJ&<[6H#WBQ:E7/A!!Z1OSU_^&U!+ P04
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M M,Q^S3SM+X1=>AW@["[C1#)L1%TR-N.\\GX67[Z;!3%S;L4R@DVWW:3+&C
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M)DB66U -_GN3YNS_D^:[)\W9G9-F\?"D^1L'S8FPD&F8'>([%$LS9LM'T)B
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M1YZ%R%[ZN)3A3J155C<B'\6>[%<:"A-,M,BAL=W$"T RVP:>)3!5%5#"\B.
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MCX<]IMW'8G=AU,I^H)TI8U1NETN!$5K3!CR?*V6:"Q*P_6)_^3]02P,$%
M  @ QX -65B3-J<;!   X0@  !D   !X;"]W;W)K<VAE971S+W-H965T,30N
M>&ULC59-<]LV$+W[5^PP:4ZN*,F*X]J29FRWF2;3N)XX:0^='B!R*:(& 08
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MXQN$O0C@OG((\68C#VR_:N;? %!+ P04    " #'@ U9D\S.TW,%  "*#
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M ?I6.FTI-<T:2:F^-&OA9$37K^/%C%ZP/G,?3T\?K/TW/B\R.WTYWKMIC&V
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MLL2.#>\'TE/BP6 7&^N?B5^(H&Q"%=_Q$O*7C%HV$% $IJJ^D8R("A^V6I6
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M7)1M &$SZMICOW]P)FZV66#L)(.%?6GK[OM4_+U[Q_3BN6 EFV_*<6["G;4
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M06[?X !XOS20UOHON$#\T='UOP!02P,$%     @ QX -66>^0O/% @  $08
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M-?5L5#: OE>2SO(PL0+C7R#_#5!+ P04    " #'@ U9A6! ]KX"  !?!@
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MR!M0,EZAT%P*4)BOW:O@XCJQ^]L-?W#<ZQ,;;"9;*3_9P8=L[?J6$):8&HO
MZ/4%;[ L+1#1^-QCND-(ZWAJ']%OV]PIERW3>"/+/WEFBK6[="'#G#6E>93[
M7['/)[9XJ2QU^X1]MS>)7$@;;635.Q.#BHONS;[V.IPX+/V?.(2]0]CR[@*U
M+-\SPS8K)?>@[&Y"LT:;:NM-Y+BPA_)D%*UR\C.;.Z24-+Q]9ML2];N59PC4
M+GEI#W#= 80_ 4C@7@I3:/A%9)A]Z^\1F8%1>&1T'4X"_M:(,XC\&81^.)_
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M&IP(W;+$$0S*)N#S0DJSW]@#AJ&^^ -02P,$%     @ QX -61K/NOP\!0
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M'(N=N8#O$*ZL XS/I#2;&YM@^V4S^1=02P,$%     @ QX -6<8XWF05 P
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M>5I_7+$P8H5<0?R^S'.^^2(+V+X%_?[_4$L#!!0    ( ,> #5DA7IVU#@,
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MKV(?OD2G\VE#%7\R]0?CXWI1>S.[:G /EL\IR(W=ABAB7\URE5J7UEN=&[O
M/RE?^-?+<L/R@BGW3[=4;EBF4%2"2.]R@E.7++<DY8D6N5VDKX3&);\]W.(V
M#J2I@-<3(?3^Q-R@WAB&/P%02P,$%     @ QX -66RA+2-B!0  ]A\  !D
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MJC"F%L;(Y\[+D+ %)"R A(60L @2%D/"$B!8Q_+#UO)#L-1B"&EA2-@"$A9
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MT+N?WU^/N*AAYF?D%[6Y.]0&GZF-@3XG,5^GR(T7=-%B[ZCM[4OVGMI>QPJ
MD0AM&5]\C.\=5B+^L8V'R- ^(*QALZ5"\^[F1EL\WN;=?9MW3VWN4%^8ZVWF
M4BR-,E>-',\X@_?7-DLPE"S1XYHP*E+N(0E#)'J8/6&+[VWI=@ TVP&S7OLJ
MW1"?W@Q$MYQ2MJ.#V2\_Z;;V:QM5D& .))@+">8!@4D4FR7%I@I]=NQ,Q!B8
M<A(O@GCU 3W151#'XE*,(2&)?8K>!3%*\QQH[624/OJR#@GF',"L'"P;]'<S
M2\-3P[2N1[LZH9!./2 PB5"K)-12$OH;(S$78\L%QJR3N&#+U#1-#LN\I=AT
MVBSEG);2]2FVS4DCR&WE+--JXGG*+WQE_.PR?K8R?NXS97Z07HZ@$J9OSD."
M.?9)F#_JEJV-C08=D$X](#")LW')V5C)F1B0EC3(LE[T8(@^;P)VF3\E9%_^
M(,&<\2E_HM,::],&?Y!./2 PB;])R=^D_R!$\]^N(]#DM)^W; /K>J-#4U:D
M+U$=G;J03KT6IXT13>)@6G(P57+PE::U!B26H>*&)V@G'E^*_;1C[)45Z!O[
MCDY=2*<>$)A$D*Y5*T>MR]!$GL*+S:% JH?'T$S#&C?F/7.UR[ZD='7K@KKU
MH-!D7FHK>EVY3/J6JRFBO=SN*",KBHYS"'3/ M%U75XU%0Z !B-0- <4S05%
M\Z#09.)Q13R&6CPM1 H0EJ*-6$_G[;:]V2K]]<X#2#2G0)O4VK8]-)MS2E"?
M'A2:S&\E?^C*I;>TENI((*C^ 8KF%&BZ7A\SASIN,@BJ;4"AR0Q6ZH:NEC?D
MU5Q'#D'5#% TIT#3<7V$'9I-"D'5#"@TF<)*S]#5@L;YQ5U'.H'4A().2#2G
M0).:Y&1H-W434*<>%)K,9Z6OZ&J!I>MBKR.[=LNHI!G-62ZHOE*@2:R=.G5!
MG7JM'UH;?F4V*N5$5TLGEY9]'5D8=XG(7%V7WC1T<NJ".O6@T&2Z*J%$5RLE
MS25@1WHF)[EC#<?3)CN@VD@GGRZH3P\*32:G4E#T:;]UX /-MAID'=L\B3DC
M/M^2$/T9+&G>X&Y7*T97A%/T2;P-XC3PT5<2;L6*\?8IS<NWKQ8A-8TY*)H#
MBN:"HGE0:/+_I2OY!JOEF]:!;W_,&5+D#"MSQJ_E3"ARIBT5U"[[I@(HFG,A
M'&/T0K.NRT+180> ;J$%>4E;_VL.*A?UKEA6+U4*5$H15@H2QP7EVVD'U8M
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MK'CWZGTG-R,.K8.@- ^4YH/2 E!:"$7K"H6T0B%O;.W4'4#)")+F@=)\4%H
M2@NA:%T9M08A-AI(LRO]=JZE0A?EJ_D]5TF^0"N^T:_CNB:L>.'G\/F\5S^@
MWB HS:MI[E;ML(Z<W0(#ZOJ!TD(H6E<6K?&'S<Z?KY_4(J5S7[Z4&XL1J&\'
M2O- :3XH+0"EA5"TKEQ:CP\[;UV,0%T]4)H'2O-!:0$H+82B=674&H#X_SN
M+R!,%J Y]&!5O-X$!!U( $H+H6A=";1&(#8[@=>)O/MIKN<,=$T5,U<>4#L0
ME.:!TGQ06@!*"Z%H7;VTUB&>OG7E@?39+D!I'BC-!Z4%H+00BM:54>M08K-%
M^?7Q;Y(9HU+KJ=1-DJ_6_8Y8!<.CSNN%96.\:XE!^H;>OMWZH-T&H+00BM;]
M45/K?A*S^]F\V'SA*55)6LP4IB)CQATZ.X#2/%":#TH+0&DA%*TKFM:4)?B-
MBPP!M6Q!:1XHS0>E!:"T$(K6E5%KV1*CEW=@D:EAV.G,]JX]<;?_[10<\P@.
M5L8KAN"##B$ I850M*X 6K.5F,U67ZHDHT7U\9+[)&9Z)ODS86ELKD"@-BLH
MS0.E^:"T )060M&ZRFG]6#)ZZPH$ZM."TCQ0F@]*"T!I(12M*Z/6IR7F'V,>
M6(&<)[^BL';K#:C1^G*'/FB' 2@MA*)5R1UN+8C)F%B4:YTD*G^F4:T :(XV
MZZG.RE5$.\?/\?$%[CGNX6._6BW5XJO%6Y=4+))<HI3-=5?6T42?F*C60U4[
MBJ_*Y3BW7"F>E9M+1F,FB@;Z^SGGZG&GZ*!9E3;[#U!+ P04    " #'@ U9
M:WH+_XL"  "W!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6RM56U/
MVS 0_BM6-DT@;>25 %T:B39%VR2D"L3V8=H'-[DV%HZ=V4X+_WZVDV8%0E5M
M?&GL\_,\Y[MS[Y(-%_>R!%#HH:),CIU2J7KDNC(OH<+RA-? ],F2BPHKO14K
M5]8"<&%)%74#SXO="A/FI(FUS46:\$91PF ND&RJ"HO'"5"^&3N^LS7<D%6I
MC,%-DQJOX!;473T7>N?V*@6I@$G"&1*P'#N7_F@6&;P%?">PD3MK9")9<'YO
M-E^+L>.9"P&%7!D%K#]KF *E1DA?XW>GZ?0N#7%WO56_LK'K6!98PI33'Z10
MY=@Y=U !2]Q0=<,W7Z"+Y]3HY9Q*^XLV+3:,'90W4O&J(^L;5(2U7_S0Y6&'
MH'6&"4%'")X3HE<(84<(#_40=83H4 ^G'<&&[K:QV\1E6.$T$7R#A$%K-;.P
MV;=LG2_"S#NY54*?$LU3Z0TH(D 77J$YQ0P=9: PH?(8?4)WMQDZ>G^<N$H[
M,G W[T0GK6CPBFB(KCE3I40S5D QP,_V\^,]?%<'V$<9;*.<!'L%OS7L!(7>
M1Q1X031PG^GA]' HG/_S/OMG[T^2$?8E#ZU>>&#)?UXNI!+Z'_MKJ-*M5C2L
M9;K82-8XA[&CVY0$L08G_?#.C[W/0VE^2['L+<5F;R3VI"!17Y!HGWH:>?[1
M_3&"JJ;\$03*]>,79-&83BJ':M+*Q5;.#()U&L47%Z>)N]Y-]DM4&)_'X5-4
M]A+E^V%T_@PV&X"%_EE\T</:R-V=3E2!6-D1('5$#5/M"^VM_92YM,WUF7WB
MCZ;^@#W34ZD=(G_EVY%VC<6*,(DH++4K[^1,-TK1CHEVHWAM^^""*]U5[;+4
MDQ6$ >CS)>=JNS$.^EF=_@%02P,$%     @ QX -69H[DLAA P  FA8   T
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M3.A@Y,1);E$18J]SZ$3OGV=,/G0/JM.VMH?>1>A;;$,.ZF(=#;)";&HV\FU
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MYJWO1/HHIX]R+,N%C,T'R^/F)/IPCS1)HBB.L1D=CYT.QMB\Q3'\N=4P;\#
M\D"FE\TUOMIXA>RO VQ-]U4(-E*\$K&1XG,-B'O>@)$D[M7&\@ #6P6L=B"_
M.P_4E)L31;"JF#?L#L:1),$0J$5WC<8Q,CLQ?-SK@]TE490D;@0PMX,HPA"X
M&W$$<P >,"2*S._@SN]1L/Z="C;_C1[]!5!+ P04    " #'@ U9EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,>
M#5FB6*@;I ,  &H:   /    >&PO=V]R:V)O;VLN>&ULQ9G;;N(P$$!_Q<I3
M5^HN)*'THE*)WG:1JK8J%:\KDPQ@U;%9V^GMZW><%*W3RVA?+)Y([&!.QGB.
M)SE^TN9AKO4#>ZZDLJ-DY=SZJ->SQ0HJ;G_H-2CL66A3<8>G9MFS:P.\M"L
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M7EK44IYAVXW"\)2;5R6;USPG?P%02P,$%     @ QX -64"[PRV' 0  O!<
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W8RV[",!"%X5=!>0"<
MF>%: :MNV%:\0 3F(G)3[*KP]HU@ 0=UT0WR646VE<F_^A1Y\>7+(IZ:.AQ/
M;1A<JK(.R^P88_OA7-@>?56$8=/ZNC_9-UU5Q'[9'5Q;;,_%P3O-\XGKGF=D
MJ\7SS,'FVOK_3&SV^]/6?S;;[\K7\8_![J?ISN'H?<P&FZ([^+C,W*5\; =W
M>\BPGYP-UKMEUJUWDKG400I!FC[((,C2!XT@:)0^: Q!X_1!$PB:I ^:0M T
M?= ,@F;I@^80-$\?)#G*F!,DO6!-H+4@UT+@M2#80B"V(-E"8+8@VD*@MB#;
M0N"V(-Q"(+<@W4)@MR#>0J"WHMY*H+>BWDJ@M[[\;!/HK:BW$NBMJ+<2Z*VH
MMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NAMJ+<1Z&VHMQ'H;:BW$>AM+Y<E!'H;
MZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM[]0[Q&OIPZ/GOL;;R'=2'?MW
M_>/SM^5]$W$>W7!V<%F_^@502P,$%     @ QX -6?]Y:I*? 0  '1@  !,
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M0E:)0E:)0E;YGV3]T'KYUQ^LVS6I5=D<_%GW5V#V!5!+ 0(4 Q0    ( ,>
M#5D'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ QX -6;I#E<3N    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ QX -69E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #'@ U96%'S+]@%  #G'@  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ QX -6?C7> B]!0
M#Q8  !@              ("!&PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( ,> #5F?$GH2J@(  %X'   8              " @0X4
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #'@ U9V8BG
M"JL%  "A&0  &               @('N%@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ QX -647+?*^!"@  .U4  !@
M ("!SQP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,>
M#5G(Y^TIX0@  #I%   8              " @88G  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " #'@ U9L=U'#G<#  "E!P  &
M        @(&=,   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ QX -6>0!F+NZ$   ARX  !@              ("!2C0  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,> #5D"%E"C/0X  $$G   8
M              " @3I%  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " #'@ U9X!:4*!8#   6!P  &0              @(&M4P  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,> #5D.0,8O[@0
M "H+   9              " @?I6  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ QX -6:Y5%*RS @  ]P4  !D              ("!
M'UP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #'@ U9
MU/J+"3\+  "]'P  &0              @($)7P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,> #5E8DS:G&P0  .$(   9
M      " @7]J  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ QX -69/,SM-S!0  B@P  !D              ("!T6X  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #'@ U9BT77<H<)  "J%P
M&0              @(%[=   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( ,> #5F,.7P/PP(  "H&   9              " @3E^  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ QX -6328%.%&
M @  K 8  !D              ("!,X$  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " #'@ U9'CNQFL01  " -   &0
M@(&P@P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,>
M#5EGOD+SQ0(  !$&   9              " @:N5  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ QX -685@0/:^ @  7P8  !D
M         ("!IY@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " #'@ U9C'&"7VP#  "/"   &0              @(&<FP  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,> #5ER""SQLP(  . %
M   9              " @3^?  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ QX -61K/NOP\!0  Y0P  !D              ("!*:(
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #'@ U9QCC>
M9!4#  !2"P  &0              @(&<IP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( ,> #5D*2S&%0@L  !%]   9
M  " @>BJ  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MQX -62%>G;4. P  : T  !D              ("!8;8  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " #'@ U9:/\ @(4#   D#@  &0
M            @(&FN0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( ,> #5ELH2TC8@4  /8?   9              " @6*]  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ QX -62R)P#>^ @
M'0@  !D              ("!^\(  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " #'@ U9V@6)4*H%  "O+P  &0              @('P
MQ0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,> #5D1
MRA)WC@,  'X0   9              " @='+  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ QX -6:?M/A$/!   I1   !D
M     ("!EL\  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,> #5G"^+S-C@8  *$V   9              "
M@=+I  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ QX -
M66MZ"_^+ @  MP<  !D              ("!E_   'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " #'@ U9FCN2R&$#  ":%@  #0
M        @ %9\P  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,> #5F7BKL<
MP    !,"   +              "  >7V  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( ,> #5FB6*@;I ,  &H:   /              "  <[W  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #'@ U90+O#+8<!  "\%P  &@
M    @ &?^P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #'@ U9_WEJDI\!   =&   $P              @ %>_0  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     +P O , ,   N_P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>108</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LiquidityAndCapitalResources</Role>
      <ShortName>Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Venture Loan and Security Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement</Role>
      <ShortName>Venture Loan and Security Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/StockbasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails</Role>
      <ShortName>Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/LiquidityAndCapitalResources</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Leases, Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesOperatingLeaseDetails</Role>
      <ShortName>Leases, Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090502 - Disclosure - Leases, Financing Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesFinancingLeaseDetails</Role>
      <ShortName>Leases, Financing Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/AccruedExpensesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails</Role>
      <ShortName>Stock-Based Compensation, Equity Compensation Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation, Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Venture Loan and Security Agreement, Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails</Role>
      <ShortName>Venture Loan and Security Agreement, Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>091002 - Disclosure - Venture Loan and Security Agreement, Warrant and Debt Discount (Details) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails</Role>
      <ShortName>Venture Loan and Security Agreement, Warrant and Debt Discount (Details) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ef20030064_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/RetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/RetirementPlan</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ef20030064_10q.htm">ef20030064_10q.htm</File>
    <File>pdsb-20240630.xsd</File>
    <File>pdsb-20240630_cal.xml</File>
    <File>pdsb-20240630_def.xml</File>
    <File>pdsb-20240630_lab.xml</File>
    <File>pdsb-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="456">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20030064_10q.htm": {
   "nsprefix": "pdsb",
   "nsuri": "http://pdsbiotech.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "ef20030064_10q.htm"
     ]
    },
    "schema": {
     "local": [
      "pdsb-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pdsb-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pdsb-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pdsb-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pdsb-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 201,
   "keyCustom": 32,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 12,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 3
   },
   "contextCount": 108,
   "entityCount": 1,
   "segmentCount": 29,
   "elementCount": 348,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 456,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "010000 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c20221231_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "040000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTax",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://pdsbiotech.com/role/NatureOfOperations",
     "longName": "060100 - Disclosure - Nature of Operations",
     "shortName": "Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "060200 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://pdsbiotech.com/role/LiquidityAndCapitalResources",
     "longName": "060300 - Disclosure - Liquidity and Capital Resources",
     "shortName": "Liquidity and Capital Resources",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "pdsb:LiquidityAndCapitalResourcesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "pdsb:LiquidityAndCapitalResourcesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstruments",
     "longName": "060400 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://pdsbiotech.com/role/Leases",
     "longName": "060500 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://pdsbiotech.com/role/AccruedExpenses",
     "longName": "060600 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensation",
     "longName": "060700 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://pdsbiotech.com/role/IncomeTaxes",
     "longName": "060800 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://pdsbiotech.com/role/CommitmentsAndContingencies",
     "longName": "060900 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement",
     "longName": "061000 - Disclosure - Venture Loan and Security Agreement",
     "shortName": "Venture Loan and Security Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://pdsbiotech.com/role/RetirementPlan",
     "longName": "061100 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://pdsbiotech.com/role/InsiderTradingArrangements",
     "longName": "061200 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "070200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "080200 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables",
     "longName": "080400 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://pdsbiotech.com/role/LeasesTables",
     "longName": "080500 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://pdsbiotech.com/role/AccruedExpensesTables",
     "longName": "080600 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationTables",
     "longName": "080700 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "090200 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
     "longName": "090300 - Disclosure - Liquidity and Capital Resources (Details)",
     "shortName": "Liquidity and Capital Resources (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20220831",
      "name": "pdsb:ShelfRegistrationStatementAvailableForFutureSale",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails",
     "longName": "090400 - Disclosure - Fair Value of Financial Instruments (Details)",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails",
     "longName": "090500 - Disclosure - Leases, Operating Lease (Details)",
     "shortName": "Leases, Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "U006",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240630",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "U006",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
     "longName": "090502 - Disclosure - Leases, Financing Lease (Details)",
     "shortName": "Leases, Financing Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "pdsb:FinanceLeasePrincipalAndInterestPayments",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "pdsb:FinanceLeasePrincipalAndInterestPayments",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://pdsbiotech.com/role/AccruedExpensesDetails",
     "longName": "090600 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c20240630",
      "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240630",
      "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
     "longName": "090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)",
     "shortName": "Stock-Based Compensation, Equity Compensation Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "longName": "090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation, Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
     "longName": "090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)",
     "shortName": "Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
     "longName": "090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation, Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c20231231_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://pdsbiotech.com/role/IncomeTaxesDetails",
     "longName": "090800 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240630",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
     "longName": "090900 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails",
     "longName": "091000 - Disclosure - Venture Loan and Security Agreement, Term Loans (Details)",
     "shortName": "Venture Loan and Security Agreement, Term Loans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c20240630_DebtInstrumentAxis_TermLoansMember",
      "name": "pdsb:DebtInstrumentNumberOfIndependentTermLoans",
      "unitRef": "U005",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails",
     "longName": "091002 - Disclosure - Venture Loan and Security Agreement, Warrant and Debt Discount (Details) (Details)",
     "shortName": "Venture Loan and Security Agreement, Warrant and Debt Discount (Details) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c20220831",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20220831",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://pdsbiotech.com/role/RetirementPlanDetails",
     "longName": "091100 - Disclosure - Retirement Plan (Details)",
     "shortName": "Retirement Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240401to20240630",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20030064_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r36",
      "r568"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r491"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AccruedRentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRentCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued rent",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r460"
     ]
    },
    "pdsb_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r491",
      "r598"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r521",
      "r522",
      "r523",
      "r524",
      "r572",
      "r599"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r220"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r261"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r49",
      "r191",
      "r581"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Antidilutive impact to EPS (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space under sublease",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r72",
      "r86",
      "r104",
      "r131",
      "r133",
      "r137",
      "r138",
      "r140",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r297",
      "r299",
      "r329",
      "r368",
      "r420",
      "r464",
      "r465",
      "r491",
      "r503",
      "r537",
      "r538",
      "r587"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r87",
      "r104",
      "r140",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r297",
      "r299",
      "r329",
      "r491",
      "r537",
      "r538",
      "r587"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Interim Financial Statements",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liquidity [Abstract]",
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85",
      "r459"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r574"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Concentration of Cash Balance",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at the end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r51",
      "r102"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r51"
     ]
    },
    "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowFinancingActivitiesLesseeAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information Related to Finance Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information Related to Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock that can be purchased with warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "pdsb_CommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "CommissionPercentage",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.",
        "label": "Commission Percentage",
        "terseLabel": "Commission paid on Placement Shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r67",
      "r369",
      "r407"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r152",
      "r153",
      "r455",
      "r531",
      "r536"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r521",
      "r522",
      "r524",
      "r572",
      "r597",
      "r599"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r408"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40",
      "r408",
      "r426",
      "r599",
      "r600"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.00033 par value, 150,000,000 and 75,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 36,779,275 and 33,094,521 issued and outstanding at June 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r370",
      "r491"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r89",
      "r91",
      "r96",
      "r363",
      "r377",
      "r378"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current income tax expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r520"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Venture Loan and Security Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Venture Loan and Security Agreement",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r103",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r158",
      "r159",
      "r169",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r185",
      "r192",
      "r193",
      "r195",
      "r336"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r31",
      "r32",
      "r65",
      "r66",
      "r106",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r488",
      "r518",
      "r532",
      "r533",
      "r534",
      "r580",
      "r582"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Margin on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r336",
      "r337",
      "r468",
      "r469",
      "r488"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r488",
      "r518",
      "r580",
      "r582"
     ]
    },
    "pdsb_DebtInstrumentMinimumVariableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentMinimumVariableRate",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum base rate to be used in computing the variable rate on the debt instrument.",
        "label": "Debt Instrument, Minimum Variable Rate",
        "terseLabel": "Minimum base rate used to compute floating interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r106",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r488",
      "r518",
      "r532",
      "r533",
      "r534",
      "r580",
      "r582"
     ]
    },
    "pdsb_DebtInstrumentNumberOfIndependentTermLoans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentNumberOfIndependentTermLoans",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of independent term loans provided for under the debt instrument.",
        "label": "Debt Instrument, Number of Independent Term Loans",
        "terseLabel": "Number of independent term loans"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period after October 1, 2024 for making monthly payments on the principal balance of the debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Period for making monthly payments on principal balance",
        "terseLabel": "Period after October 1, 2024 for making monthly payments on principal balance",
        "verboseLabel": "Period after October 1, 2024 for making monthly payments on principal balance"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentPrepaymentPremiumPeriod1",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.",
        "label": "Debt Instrument, Prepayment Premium, Period 1",
        "terseLabel": "Prepayment premium paid if loan is prepaid on or before Loan Amortization date"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod2": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentPrepaymentPremiumPeriod2",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.",
        "label": "Debt Instrument, Prepayment Premium, Period 2",
        "terseLabel": "Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod3": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentPrepaymentPremiumPeriod3",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.",
        "label": "Debt Instrument, Prepayment Premium, Period 3",
        "terseLabel": "Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod4": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentPrepaymentPremiumPeriod4",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.",
        "label": "Debt Instrument, Prepayment Premium, Period 4",
        "terseLabel": "Prepayment premium paid if loan is paid on stated maturity date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r22",
      "r23",
      "r29",
      "r58",
      "r59",
      "r106",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r488",
      "r518",
      "r580",
      "r582"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_DebtInstrumentThresholdPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentThresholdPeriod",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Threshold Period",
        "terseLabel": "Threshold period after Loan Amortization Date used to determine prepayment premiums"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r579",
      "r580",
      "r582"
     ]
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncommitted loan",
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r158"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "DebtInstrumentWrittenNoticePeriodForPrepayment",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Written Notice Period for Prepayment",
        "terseLabel": "Written notice period for prepayment of outstanding loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentsAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Venture Loan and Security Agreement [Abstract]",
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/RetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) employer contributions",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r21"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r222",
      "r253",
      "r254",
      "r256",
      "r477"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r121",
      "r123",
      "r125",
      "r126",
      "r127",
      "r130",
      "r293",
      "r296",
      "r308",
      "r309",
      "r364",
      "r379",
      "r461"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r123",
      "r125",
      "r126",
      "r127",
      "r130",
      "r293",
      "r296",
      "r308",
      "r309",
      "r364",
      "r379",
      "r461"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss per Common Share [Abstract]",
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r129"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r270",
      "r284",
      "r481"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Abstract]",
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Stock Compensation Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized stock compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "verboseLabel": "Stock Options to Purchase Common Stock [Member]",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "pdsb_EquityCompensationPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "EquityCompensationPlansMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans).",
        "label": "Equity Compensation Plans [Member]",
        "terseLabel": "The Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r81",
      "r93",
      "r94",
      "r95",
      "r107",
      "r108",
      "r109",
      "r111",
      "r116",
      "r118",
      "r120",
      "r132",
      "r141",
      "r142",
      "r143",
      "r198",
      "r282",
      "r283",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r340",
      "r354",
      "r376",
      "r385",
      "r386",
      "r387",
      "r396",
      "r446"
     ]
    },
    "pdsb_EquityIncentivePlan2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "EquityIncentivePlan2014Member",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (\"RSUs\"), subject to increases.",
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r322",
      "r482"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r322",
      "r482"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r322",
      "r324",
      "r355",
      "r356",
      "r357",
      "r468",
      "r469",
      "r473",
      "r474",
      "r475",
      "r482",
      "r484"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r362",
      "r482",
      "r485"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quoted Prices in Active Markets (Level 1) [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r202",
      "r207",
      "r312",
      "r322",
      "r355",
      "r473",
      "r474",
      "r475",
      "r482"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quoted Prices in Inactive Markets (Level 2) [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r202",
      "r207",
      "r312",
      "r313",
      "r322",
      "r356",
      "r468",
      "r469",
      "r473",
      "r474",
      "r475",
      "r482"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Unobservable Inputs (Level 3) [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r312",
      "r313",
      "r314",
      "r315",
      "r322",
      "r357",
      "r468",
      "r469",
      "r473",
      "r474",
      "r475",
      "r482",
      "r484"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r322",
      "r324",
      "r355",
      "r356",
      "r357",
      "r468",
      "r469",
      "r473",
      "r474",
      "r475",
      "r482",
      "r484"
     ]
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiabilityAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments [Abstract]",
        "label": "Fair Value, Net Asset (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pdsb_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for finance lease contract.",
        "label": "Finance Lease, Cost",
        "terseLabel": "Total cost of financing leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future Payments for Finance Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease liability",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease obligation-short term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Payments for Financing Lease Liability",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease obligation-long term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "FinanceLeaseLiabilityToBePaidYearFourAndThereafter",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four and Thereafter",
        "verboseLabel": "2028 and after"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "pdsb_FinanceLeasePrincipalAndInterestPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "FinanceLeasePrincipalAndInterestPayments",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal and interest payments on finance lease.",
        "label": "Finance Lease, Principal and Interest Payments",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r350"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease right-to-use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease depreciation expense",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r348",
      "r490"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r430"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "pdsb_IncentiveStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "IncentiveStockOptionsMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r69",
      "r71",
      "r365",
      "r374",
      "r463",
      "r464",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r150",
      "r151",
      "r316",
      "r318",
      "r323",
      "r382",
      "r384",
      "r431",
      "r458",
      "r483",
      "r596"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r316",
      "r318",
      "r323",
      "r382",
      "r384",
      "r431",
      "r458",
      "r483",
      "r596"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r265",
      "r270",
      "r272",
      "r273",
      "r274",
      "r276",
      "r279",
      "r285",
      "r287",
      "r288",
      "r289",
      "r395",
      "r481"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest and penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefit for income taxes",
        "label": "Benefit for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r79",
      "r119",
      "r120",
      "r131",
      "r136",
      "r138",
      "r269",
      "r270",
      "r286",
      "r380",
      "r481"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r267",
      "r268",
      "r276",
      "r277",
      "r278",
      "r280",
      "r392"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit due to realization uncertainties",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r481",
      "r570"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r516"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_InducementPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "InducementPlan2019Member",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2019 Inducement Plan provides for the grant of non-qualified stock options.",
        "label": "Inducement Plan 2019 [Member]",
        "terseLabel": "2019 Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r189",
      "r196",
      "r470",
      "r471"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r515"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest income (expenses), net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r515",
      "r526"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r100",
      "r101"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest on debt",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r134",
      "r138",
      "r464",
      "r514"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares in consulting agreement",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Lease [Abstract]",
        "label": "Lessee, Finance Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability capitalized interest rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "pdsb_LesseeFinanceLeaseMonthlyRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LesseeFinanceLeaseMonthlyRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated aggregate monthly rental expense under finance lease.",
        "label": "Lessee, Finance Lease, Monthly Rental Expense",
        "terseLabel": "Aggregate monthly rental payments"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LesseeFinanceLeaseNumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LesseeFinanceLeaseNumberOfLeases",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of finance leases entered into by the lessee during the period.",
        "label": "Lessee, Finance Lease, Number of Leases",
        "terseLabel": "Number of financing leases entered into"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.",
        "label": "Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Financing Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of financing lease",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r353"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r353"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease [Abstract]",
        "label": "Lessee, Operating Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate used to measure operating lease liability",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities.",
        "label": "Lessee, Operating Lease, Supplemental Cash Flow Information Related to Operating Lease [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorOperatingLeaseTermOfContract",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of sublease agreement",
        "label": "Lessor, Operating Lease, Term of Contract",
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r31",
      "r32",
      "r33",
      "r35",
      "r36",
      "r37",
      "r38",
      "r104",
      "r140",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r298",
      "r299",
      "r300",
      "r329",
      "r406",
      "r462",
      "r503",
      "r537",
      "r587",
      "r588"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r68",
      "r372",
      "r491",
      "r519",
      "r530",
      "r578"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r84",
      "r104",
      "r140",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r298",
      "r299",
      "r300",
      "r329",
      "r491",
      "r537",
      "r587",
      "r588"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LiabilityForUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LiabilityForUncertainTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.",
        "label": "Liability for Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LiquidityAndCapitalResourcesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LiquidityAndCapitalResourcesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Capital Resources [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LiquidityAndCapitalResourcesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LiquidityAndCapitalResourcesTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResources"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.",
        "label": "Liquidity and Capital Resources [Text Block]",
        "verboseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LoanAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LoanAMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $7,500,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan A [Member]",
        "terseLabel": "Loan A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LoanBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LoanBMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $10,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan B [Member]",
        "terseLabel": "Loan B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LoanCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LoanCMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan C [Member]",
        "terseLabel": "Loan C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LoanDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LoanDMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan D [Member]",
        "terseLabel": "Loan D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LoanEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LoanEMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan E [Member]",
        "terseLabel": "Loan E [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_LoanFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "LoanFMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan F [Member]",
        "terseLabel": "Loan F [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r217",
      "r262",
      "r315",
      "r360",
      "r381",
      "r383",
      "r390",
      "r398",
      "r399",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r466",
      "r472",
      "r476",
      "r484",
      "r485",
      "r486",
      "r487",
      "r492",
      "r539",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Dividend Yield [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r575",
      "r576",
      "r577"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r484"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r484"
     ]
    },
    "pdsb_MerckKGaALicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "MerckKGaALicenseAgreementMember",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements with each of the Company's executives that generally provide for product.",
        "label": "Merck KGaA License Agreement [Member]",
        "terseLabel": "Merck KGaA License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "MilestonePaymentsAchievementOfCertainAggregateSalesLevels",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.",
        "label": "Milestone payments, Achievement of Certain Aggregate Sales Levels",
        "terseLabel": "Milestone payments for aggregate sales levels of product"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "MilestonePaymentsDevelopmentAndFirstCommercialSales",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to be made for development and first commercial sale milestones detailed in the license agreement.",
        "label": "Milestone payments, Development and first commercial sales",
        "terseLabel": "Milestone payments for development and first commercial sales"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r217",
      "r262",
      "r315",
      "r360",
      "r381",
      "r383",
      "r390",
      "r398",
      "r399",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r466",
      "r472",
      "r476",
      "r484",
      "r485",
      "r486",
      "r492",
      "r539",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://pdsbiotech.com/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r53",
      "r70",
      "r82",
      "r88",
      "r90",
      "r95",
      "r104",
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r124",
      "r140",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r293",
      "r296",
      "r309",
      "r329",
      "r375",
      "r428",
      "r444",
      "r445",
      "r501",
      "r537"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income (expenses), net",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r463",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r490"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for operating lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r350"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Abstract]",
        "label": "Other Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/RetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r475"
     ]
    },
    "pdsb_PercentageOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "PercentageOfCommonStockOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.",
        "label": "Percentage of Common Stock outstanding",
        "terseLabel": "Percentage of Common Stock outstanding used to determine annual increase in the plan limit"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_PercentageOfVotingPowerDisposedOff": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "PercentageOfVotingPowerDisposedOff",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting power disposed of in a transaction (including a merger or other reorganization) or series of related transactions.",
        "label": "Percentage of Voting Power Disposed off",
        "terseLabel": "Percentage of voting power disposed off"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_PlacementSharesAvailableForFutureSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "PlacementSharesAvailableForFutureSale",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.",
        "label": "Placement Shares, Available for future sale",
        "terseLabel": "Placement Shares included in at-the-market offering program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of secured loans",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.",
        "label": "Proceeds from Sale of Unused Net Operating Loss Carryforwards",
        "terseLabel": "Proceeds from sale of tax benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of property and equipment from bargain purchase option",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r352",
      "r366",
      "r373",
      "r491"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r200",
      "r217",
      "r248",
      "r249",
      "r250",
      "r262",
      "r315",
      "r358",
      "r359",
      "r360",
      "r381",
      "r383",
      "r390",
      "r398",
      "r399",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r466",
      "r472",
      "r476",
      "r484",
      "r485",
      "r486",
      "r487",
      "r492",
      "r495",
      "r535",
      "r539",
      "r576",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r200",
      "r217",
      "r248",
      "r249",
      "r250",
      "r262",
      "r315",
      "r358",
      "r359",
      "r360",
      "r381",
      "r383",
      "r390",
      "r398",
      "r399",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r466",
      "r472",
      "r476",
      "r484",
      "r485",
      "r486",
      "r487",
      "r492",
      "r495",
      "r535",
      "r539",
      "r576",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r458",
      "r464",
      "r595"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r60",
      "r371",
      "r388",
      "r389",
      "r394",
      "r409",
      "r491"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r107",
      "r108",
      "r109",
      "r111",
      "r116",
      "r118",
      "r120",
      "r141",
      "r142",
      "r143",
      "r282",
      "r283",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r338",
      "r340",
      "r385",
      "r387",
      "r396",
      "r599"
     ]
    },
    "pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "RoyaltyPercentagePaidOnNetSalesOfProduct",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage paid on net sales of the product detailed in the license agreement.",
        "label": "Royalty Percentage Paid on Net Sales of Product",
        "terseLabel": "Royalty percentage paid on net sales of product"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r221",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions Used to Value Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SecuredDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable - short term",
        "label": "Secured Debt, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r65"
     ]
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable, net of debt discount",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation [Abstract]",
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumptions Used in Determining Fair Value of Stock Options and Warrants Granted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r221",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited and expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited and expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options granted (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value",
        "terseLabel": "Granted, aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term",
        "terseLabel": "Granted, weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of option on grant date (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, aggregate intrinsic value",
        "periodEndLabel": "Options outstanding, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares [Roll Forward]",
        "terseLabel": "Stock-Based Compensation [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Award [Domain]",
        "terseLabel": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r226",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r257",
      "r258",
      "r259",
      "r260"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of option",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_ShelfRegistrationStatementAvailableForFutureSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "ShelfRegistrationStatementAvailableForFutureSale",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the \"2020 Shelf Registration Statement\") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the \"Shelf Securities\") that are available for future sale.",
        "label": "Shelf Registration Statement, Available for future sale",
        "terseLabel": "Registered securities in Shelf Registration Statement available for future sale"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for significant risks and uncertainties.",
        "label": "Significant Risks and Uncertainties, Policy [Policy Text Block]",
        "terseLabel": "Significant Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40",
      "r43",
      "r44",
      "r81",
      "r93",
      "r94",
      "r95",
      "r107",
      "r108",
      "r109",
      "r111",
      "r116",
      "r118",
      "r120",
      "r132",
      "r141",
      "r142",
      "r143",
      "r198",
      "r282",
      "r283",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r340",
      "r354",
      "r376",
      "r385",
      "r386",
      "r387",
      "r396",
      "r446"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r132",
      "r340",
      "r361",
      "r391",
      "r397",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r496"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r132",
      "r139",
      "r340",
      "r361",
      "r391",
      "r397",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r496"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for consulting agreement (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock from the Sales Agreement, net (in shares)",
        "label": "Issuance of common stock (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r60",
      "r393",
      "r446",
      "r454"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuances of common stock, from exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r60",
      "r232"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for consulting agreement",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuances of common stock from the Sales Agreement, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r60",
      "r396",
      "r446",
      "r454",
      "r502"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuances of common stock, from exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40",
      "r43",
      "r44",
      "r60"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r55",
      "r410",
      "r426",
      "r447",
      "r448",
      "r491",
      "r503",
      "r519",
      "r530",
      "r578",
      "r599"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental information of cash and non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "TermLoansMember",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityAndCapitalResourcesDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementTermLoansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On August 24, 2022, the Company, as borrower (the \"Borrower\"), entered into a Venture Loan and Security Agreement (the \"Loan and Security Agreement\") by and among Borrower, PDS Operating Corporation, as guarantor (\"Guarantor\", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the \"Loan Parties\" and each individually a \"Loan Party\") , the persons party thereto from time to time as lenders (collectively, the \"Lenders\"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the \"Collateral Agent\"). The Loan and Security Agreement provides for six separate and independent term loans.",
        "label": "Term Loans [Member]",
        "terseLabel": "Term Loans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pdsb_TermOfRoyaltyPayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pdsbiotech.com/20240630",
     "localname": "TermOfRoyaltyPayment",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of Royalty Payment",
        "terseLabel": "Term of royalty payment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r275",
      "r480"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r75",
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to Purchase Common Stock [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementWarrantAndDebtDiscountDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of warrants",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r127"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r127"
     ]
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001140361-24-037067-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-037067-xbrl.zip
M4$L#!!0    ( ,> #5E=48T\$*4! *67$@ 2    968R,# S,# V-%\Q,'$N
M:'1M[+UK5QO'EC_\/I^BATS.2=82=MTOQ.&_,."$&0<X@,^</&^RZFHT$1*G
M)=EF/OU3U9) 0BV00"VUH+R<6)=6=U7MO7_[4KOV?O?_OEVULB\N[S8[[5_^
M#M^ OV>N;3JVV?[\R]_WSO>/CO[^_W:_>W?9"Y>%2]O=G6\Z;S5_V;KL]:YW
MWK[]^O7KF_C)FT[^^2T" +]MMKL]U39N:WA]J]G^ZX'+X]=:=6\O_S9U_5=<
M7 VEE&^+;V\O[3;++@RWA6__]?O'<W/IKM3V_?'$Q]N['XZ/AKT=?#FZM-GM
M$ 3Y0Y,=7#'Z03?OW5[L55<7%X8/P\6(W-[UVZP;PKAZ88;N7^_//MY=WBN_
M_N[2M[U<M;N^DU^I7J!C?!K8!F@;HK&;;'>=F;A1>/_F<^?+@_>!=!N(;0Q'
M]^EWMS\K=3T]R>$7$Q.U[MXRCYX8OIBXT'3Z[5Y^4W[Q\,O)'_3S/+#IK%\,
MOYT<3"_?[MU<NV[Y8H:OW\:OXV_0-L#C<^[E,SE O@W?CBYLJZ;IE@^I^&IB
M/-VF*;\T?#%Y8>\ZGW%E^&;B4O?-7)9?&K^97$'G9RR>\Y/W-';&+8V=N/#:
M=O7ME?%-L]-SYO*-Z5P5UP&&P?#:V>(=<69K][LL>W?IE(TOPLM>L]=RN^_>
M#OX=?/8?V]O9QZ9Q[:ZS6:^SDYWWKZZ:O>Q#LQV$O:E:Q67%GX..Z5^Y=B\S
MN5.]<'F_&] M>Y]WE,V;]K/+3L].?+/E,D3>L#?H#46$W/U\OW-]DS<_7_:R
M,$2:;6=Q,N._WMX>CNG*]5069[;M_MUO?OEE:[_3[H4';U\$QMK*S.#=+UL]
M]ZWWMICIVP"M;P<S_>Z=[MB;K-N[:;E?MK0R?WW. ^?;;=-I=?*=['M?_/DY
M&[T'Q9^?PVJ]L\TO63.0Z>#\]$,S"O)O36M=>VMT-]OL7K?4S4[6[K1=^,6[
MYK>=^%27#UX65Q<OPP7'8;'RILG:ZBK^U#5W]L+JV;B"'UKJ\U;QI _*]/[T
M0"@!I$926R(44TP 9P6EW#/A(1E.^5OO+#*;*9@  MCKW+'# &M^V0KXM..;
MWYS=]JH5E,%N\<^[MQ-#FCW"_4+B>Q^:7:-:?SB5'[;M0:#UV& -L! +I1WD
MC@B&E.84:208IXPHPA8<K UWW[X*O[C<MNIF:Q>B@!ASCW?$DG<#_A ^Z8X-
M%W#DL2; QN%19;5"$CD/!5* .N$?'^YN?/7$$9V&;SOV_IB(=4I*+KV1B%BH
M%:'&*B^9A%X:,,^8_H'F'M%A.\C[S7X84ZY:1VWKOOVWNQGG/LB,Q0A8+RQ1
M@DGLN,5!1*!E%D$WQVB"_$#"$9#S46ZHXW8.G.X=!:LB+U;LGRIO*MUR1^%A
MN>OVS@)G1($__!:DO=L,WQRVXVT*E3J^F@@1RKQP'E'"O0^B)*QT07:H4I"#
M1\?_Y^0X]KXUNW]>N/SJ8R<H\=_=E7;YUNY#>OK[T[QYY>)X!U>O81&$!(@;
MR166@AA)I%%:0VY\>,\,$#5?A(^NVW5NH'/<1Q?,V/CL$Q^!/P_S@V-3A19A
MB;P%V@."?1 E&V9)&862*2]*T3).\$RU/[MB7K\WV\VK_M5H5J?DCZG!OIV$
M\]QY%TTAU]U]%RWGG6YA$X<G9(4EO7.9QX=%;;T]>N";;UV[-?PZ6D2_;'6;
M5]<M%Y15<?OQ>Q9ONYU^7KPK/(.=X2R*B9=*W? Z5\CWZ%W3QO>^Z?*L&*,K
M-57WC_Y[4FKO_WAW]-'DW:\+/!N]"_Y WHOJH8#(;0##W]'O[KZ[':8=NY1M
M8W#WB,$WH_>CA[R=6(?9RR( J\%B#-RCWG!^(DSQ]D;#;YXZOWH0>W)^X_1[
MWOPP#'_K-3^\/;1"ED,_4G.Q)>L06WR+9KB.RX+G1S.\W&4A-5^6>;EEJ<N"
M(DC\>=X+=XC6R6%P"X-)V[FZ#GY8N]<MM/I9\!J;;6</5=X.?NFMT5+M"@X7
MPGV.XQJ\M>%AWZY;3=/L#<:0V6 9M8O(X*W%\^!<MG9'EY5/ZMW;TN?<KN;M
M<!;#/;1,W$/UP_6ES@\GEEP!2RY5%<^#(N'M5:=]WNN8OUX$M:;FLPG8,8]L
M)4)MB$3M6=N,T0K5.E5->]3>5]?-GFJ]"*(].+>7(FF)@#66P/&H$$X&234&
MR3,"77B,TL\-=$T$$I)ZK(Z^:X^(X%JX3L^(B"R/[>\M2])5U>NJ#:1[4FR;
M2^G%%%NB].:JN,6,U83E+\5TO;>KD4S7ZA!\+=LSB\EUHN^FR>\]^M;--=D,
M6$N&RR8#W"(F:C)<7HK!NI@3FA3;IKF>BR%XDNN7@N>)VNO8]EIFUFB*'ZR#
M@'B)^Y8IJ%M]^A19)LE2''XU&6\KEK)DM=9 ME(\?/7Z;,D$3('M"@FU3,LQ
MA>I6HL661[*Z!)W7B1V))6N%(BD,O!9]O5HUD/1U#< _!=XWQ->LRX'52AFQ
M=O-;)OTF3F3_N1?&8)NM?J_YQ9T[T\\#X+ONX3?3ZEMG/^2=J\B^_5Y1BN3$
MCW3XJ<O/+U7NWM^4WZ 0V,.KZU;GQKF"Q4^NXQWJ+;@5+L:=V,]<E9KLNU63
M,%0UK_V/RO,@%8F_=B96HC*>6E<AF%7B5^*IU?+4:\"II!/KH1/7A5\(B+K9
MEVA0M'8Y]F68WU"6ZC+3";(7<YV/[/>696EJJR854YZ.O!/GFI^+O/,6):PG
M.$Z/?&LWE@?<N3?^38B5%?):1HLXC_<;2H>QL5=$@V6CYVP:'&PP#0Y>" WV
M-I@&>R^$!OL;3(/]S:'!3-T<Y_%A@VGP87-T\H,T.-Q@&AQN#@T"%B$R\F@0
M2=;JTYWN I]BF?TYO:^[2Y<;X$DDW+BXR>(DG%T*_H62]M$G=?/>SNVB;.W&
MMQ,K\^*89OS@%ZG%MO4SSD612LZYUG!9%CL&NLQEB<#R037S?ZI6W[V_N7WY
M6YB'RLWES4?WQ;4*2+G][JA]W>]UBR]@O0%FOIG=!>4?F.(FV&V#HI>)G.LC
MYY)+8#Y3.M'+)R=Z1=*9R/FBI!._?'+B5R2=B9QUDDX **C#GO/8_, VH&-&
M_C+09\S?5]_JZ^^7>>'CX]T$?'BDUU[]%[RJL$=U!UDX)'^>ME3[6%T-UGQP
MN."H;>)XOKCX'0K+5D\:C(!T? ;#\-:#\Z@,70'?AF1)Z H1$(DVRZ(-B)H/
MB*70!LKB7%&BS7)H ^42CZ) 4AB9B39+H@U9HL4(;[=;$I66O!D"Y]\,N4_2
M982W$R'K:-Z5T.:H;?NF.$4ZG([<.++,FL)F4.3>F9"O*K>Q1_N0.$-6&SNP
M,-IV+I&P>$(BK%=Q1")^7;)#76>/]5')FS&_F72>^XD3JW[+53/7_ND/7*53
M7HNM\57P=^+C9?/QAG);<,,8Y$F_/=OY8MN0+TV_(90H\FR+ VXCM!R*($"3
MC"PA YXN349* GN)(NL,YTV?_I^P6C;O;/6D6?#Z*H0\D9[1/NU<N=LZ2Q\[
MIK#9AC7TNB[NX^Z%D<5]VLYUO.3P6[3L7+WYX8%IC9?3>W1^2S=87Q]G/NP?
MO3K.7!H_U$<6-M27>BIGOGC.VE1ZWN].D^BY-,U1BRYBKUQS))NF#&G6U)CW
M29Q95\YZ]?1\HN9XJ4B3;-07K0-_=6V7JU98QCU[U6PWN[U<Q>V3C>#-N3AE
MKADF/5A+WWZCN;.FR/D\>7AE_F#BSE?%G>OKJ;K\B/U&<V?2[.7<N9[]I")9
M.?FUR]BXK>!\<"),[?)<[Q4F3B1:!P(N/<O_I'?I\MA?J-F+PQ^4GO_=Y>:O
M__Y5[7ULFJAU]C[GKM!9]29IV5R&J2R/S&@3Y._I]-JT[/$*Z/CHLU_&6>O)
M:$62[1?I]@^(^[M3W7Y>S+,H-7&KB>]_$3T'TW,V%@>L-XUG3>E..S\^MTV4
MTU0=X44)VD'S2UQF>Q:>7$]*/E_@IN>X&8*W$$'/FMV_/@1=<A3NDKMN[R42
M=/8<7R!!3_-@(?RSTU*]9BN,]:71LG1ZFT!&=*L0PR+6K\PLFE__A$OED_5/
MO]T<K,DG,%:$ZVI Y=WAPV.KM.[H!J/O1N_C'<KNAJ;NUNQV"()\Y]/YP:(W
MP[<WLX46&+_FN'_E<M7KY$]\WM3OXX<'KMVY:K;+;COOHDS<XNWDZ!^9+IE!
MB>OP<M&EHU/WNNUSL.BMV-2M^KU\I_MOWUOT3GS&H,*;1R;XMOEM)RQ\IY\;
MUQV\O73*%C(65G?WNW?A_UFW=],*LMIJMMWVI6M^ONSM9,%N[#55Z^>MW>^R
M+/P=O] 'J=CVZJK9NMG)_GX1D+&;';NOV5GG2K7__G-6?-]M_I_;R2"X[OV<
M11G:5JWFY_9.UG(^?&(ZK4Z^D^6?]8^@D<6_/PT>5=63O@?%G]%#PF/^8WL[
MTV$%L\O<^?"H9LL%I'J[O_/V4]?EW;?GZD:=OMV[O@X H=[&S:#6VPMW=?WV
M].PD7OS6]_ZZ:?5@_@;?T+<!O%7;OBT H]U[ZSOY%03_?G/9N]K*MK=O'QH7
M?;CTX^,8.L8VZW5VLO=Y1]F\:3^[[$.0B+8)=,C..['M8J?='?XL_#GHF'[4
M#)G)7< PF_6[S?;G[/#@U[VS,,#8NC$;CC7C;^@;\ ;<_7B_<WV31U)G4$J:
M;6<!&^'XH^\-^O:7[R[S$75T)P^LM).U.VWW<S9XMZT[O5[G*M#C^EO6[;2:
M-M,M9?ZZ_;[7N=[)R/TO1VP7J/CMCF:^^!-^&J[YG'?Z;;M]_ZMQ@L=#V"[_
M.;M2^>=F>SO2?R=3_5[G]J-\\)3BLZVW8Y.:F.(D#S[PA.'MV!L6>6^<&<GM
M!U^',].=EAU^-)NAMW8_'1]='!YDYQ=[%X?GDYQRQT#=P&MSBLC6;O;N;;Q^
MM_QF\\^2O^%+F^7YX?ZGLZ.+H\/S;._X(#O\U_YO>\>_'F;[)[__?G1^?G1R
MO.:IC\\2/766_Z.ZET$*>YUV(SMXL_\FR!@E<@4S"U\O=+=W.G\[SO[9Z/99
MC<@@GDJ&#R=GOV?O@NH+.%68+TV3M56T3JUK[HQ0-%KO6X7&_:!,[T_,J).
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M^:R*002Z>+D44V(8T0[V0TM==\,UHU<KMS+B:,H4X^/B,51\B^AA-O-I][8
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M5V&F-U$9AKL%K1$/!'[./N>=K[W+B14>7ODFZ$E7#-,Z7U2][+2+Y)RXAXG
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MO^JWXH918"G?-,T**M)N8EVC%U'+:!7GNLN%[+DP^^/#.'OF>JK9=O90Y>W
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M"]?T.EGOTD5F"X9TUQ7E?(M(8Y&JY0=]*XL-NO!!40_Q3?E %JRP<'^>D\<
M9TS2M)S*"TZYO#7U>YWK>YTW1]PRZ-J4F9;J!O%X?W;ZX51]=N]SI_[:"_^[
M!P;%<^Y=>]R/YQN+B\OXV(3E</F"Q27&^TJ)6^_DJXO(%SDQR&UK=%&\X>UG
M6[MXYB)-+M-U&/JVCO/<5CZ,<$>UOJJ;[HRUF +%=Y?YZ$Z#%1W +B@VTH?"
M"< =-@\_ S]GE\-9%/'+H?!]#XH_97)Y^]4X78LJES/F=V_XOSD5GG]+FO&Q
M34^J8%&57>81.[\_.CXX_%<9X>X39DB#F%W;-.&V1T%.OMW2097&)DO'/\W8
MTY_\Q_;VZ=F);[;<'?>=N:[K_1!>_T!^^.&'[>W[0##^[N[UW:OO%L*)Z7:V
MT\!]CWK#I9[5;&TH))DI*]ZR\&@FA$4'W1H>?WIPGKT_.KDXW/_M^.3CR:]_
M9/LG9Z<G9WL71R?'V=[Q07;^Z?WYT<'1WMD?$ZOU\(@7K1DSS@EEF+V^!0IL
M'^V._8#]N;L,,-_\XCYVNMWP3>"XO;:Y[.2!L0IV7K!,SDAK[(]KC?-;79%U
M_'?CW'W[K)-KEQ?]CP>AEHFA97%L]T8VD+>)SV:_>8TT_O%36_5ML&GL3_,,
MJ)#DI<^^L(#"9%O1_(OMK@M;-+X?6G(#*W792'0O47A<#8Q4AO&]8G"W>N&6
M+:>CGT^->SXVH?(<_'*3\ZECF#_[;=Q(7_(@[OEL0T4QW,">9T2LS#:K6JRV
M=B^"<>"RW\/GE]WL,$";S88U,AI3?M&B:S6__U,+$M9B$)O*1^?-;R^)BZ9<
MWY</F6OEZK&'H_4P\&)F05$7J-0-*J_LLQ%,G_AIG?R$$S\E?DKXE/BIIOST
M\O"I.B-O3I(.9CIW2X4E47X8AVI_SMRWZQC*ZNX\FWZ/C6+6.E4H@X_Q](0$
M/NW1C\UZ@0W B@ QT271)=$ET:7>=*DPVC*,C%-46L;H^_W]P\,/'\KT==EF
MZG-T."1OR!*5>-PB5;FY++:2K/OB6IWKN/UTJ]-+LEJ6:J7-G\;VP+(O06R>
MEH VYY 6XHHE4;8L&^W9E%M6W:_Z+--CU28&XK'7M@=WPG$XD(V)M%NM* &*
M044(Q%X9XYV2'BM'O( E?1<(( #V.DM-P(U%T7F#23%/;MH*?:VY)*8R79S0
M)J%-799I.6CC+66(>XR D(1AK!07#%@GC$)8R)(D?WR+-GAI:",: )"&H',5
M-DUHD] FH<U&H@T#Q@GAG'8.$ >Q0!!CZ2&%3'%+2M+M ]8LW;:!L($P; B6
MX";!38*;.B[3<N#&*84DH80[@(DR0@2;A5/KN# 6*E]2"A3?PLWRC!N(&X*(
M!L6OR9=:4?QLCH+*&Q Y^]6U7:Y:1>!,V:MFN]GMQ?VP+ZZ&L;.J-JZ7<6SS
MP5WMI8?!%SHR^=C0ZH>R0ZX,(+LWP9/3.$LU%UX@BB0C1 ,BE#; "*H)5H[I
MDAY#U82L(&4-!EA]87:EF2=)O)-X+T6\O0$2$^JL\9Q("S66B$*'O5(0>US6
M0JR"&!%I, D;>+Y^8DF\DW@G\9Y/O!T,KI&&CE.(B0WZVG& +304(,>M,*L)
MRO &C<W/V5S]$I)X)_%.XCVG>!-+G%%" B6(!TA[@:$T6C$/@TK7JPF"B ;B
M0;S)ZQ#O"J(?5TUK6^[QZ,=Z4XJ6FQ8\* C8F4H.KG<PI)8A\4?/<%8[Z(I0
M>H-CV+<I[T/$[HY!ME3.4V@MP=@$"RN^]0SS +Y.8R%+(+N*>(IH,$$:P97;
M,,C>F*VS!!X)/)8/'I1K0C#0C'E.K/0:<N^")!/&#<&4K"9: U&#2=: '"?T
M2.B1T&-3T$,R3(7E@"M/"%=4.F>Y1%1Y@Q"1=$49.J+!!6Q(O&G!WH0>"3U>
M,7I8Y14E,C898@12*:SPD@3XT,!23,O*Z580:T*H 0."4#%7\?"7C!X59N$\
MVA7C+DZUBC. <R/?*HYD/H4CUGA4]&$PJ^N"K>W ;6*[Q':)[1+;);9+;)?8
M[M563UCN5F<LMIWYO',UVN[LM&NTS5G'P$ =W?X:._4_SNG5'[5-YVI0EWZ\
M?;" %%KC(2/$6"HUYY0CZ:62 ,EG)W@7)-A^23N3SW+EU\$?/R6T26A3#[2A
MSFK)),>:!_1 7!/J)9; (X:5Q.ZY.Y@+HLTF;&4FN$EPD^#F:7"#O7"":*65
M-X00*PDPD#H!K!=2"?7<+<]%X68#]CX3W"2X27#S1.N&>N@<X%!12;A" BI&
MG78>0Z2U>O8>Z8)PLPF;I:\!;FJR59OEG:_UC"B/#:RFP=)5C_&)D>;Z+^0,
MJ5[?P!.;)C9-;)K8-+%I8M/$IK5ETWK8T(MM2\]VC&;[(A.^QD+;VDOR;XYB
MWR?7[67-PL/-?AR=S/VID;5=KPK'L1* J3CR48F8K'?(U09S-F*9-RL5ZV6M
M?6+QQ.)UXY?$XINXS(G%$XLG%E]?\N[F56F^-[HEN6^+-;T=T.N>^U76!;<8
MWXQ.N(/O:K(?OJY-[[7M;*]_=_+AW>NC]I? 6K&@_F#[>L1L8UO8QEMAI2?&
M*$@T]$(+:95!C"$ N"_-F%E^?2+&:0.!&A>4J]6)_R1GFR=GGA+FB,&$(D2"
M=&E".=)&4N004;:D%6 5I7PX!0U&:YQKG^0LR=GS]!F/A?4PAY *0J#1V'JD
ME7:&$N=L2<)Y)45O&IB0!JSSJ98D:4G2GB5ID"B J(=".$X,@)I;Z QA%@%&
MN<4KZLC4(%PVI*0O3=)6X[HO7CQJ/*EP*3N@"W'M8*7&_Y_=>M##C<N:;D\^
M9Z%K&Z]Z5FVL#4BVJ&B&CR2=CSAZ6)7KN-.^K9L]?M9%:D8%DPIX0["(-HYR
M%EE!O(@5AU?CN<,&%+PA>=D)EQIPZ')J<\VBXT\)6A*TO$!H880) 1CC4'KB
MN13(20,(]98"KNF*@A7!J&M@67:6I0;\F8!E_7*7@&73@$5XKRTU0$FOB*=
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M#8I) -2R(MX)4!.@)D!]N8 J(%#:0"D8P40YK##@TDCJI+'6^Q(LJC3$^#1
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MI9YB*Q_I^+JBV.5TGH1(V)"P(6%#M=@03 6L-;6.1U.!(HD49HYJZ36'&&U
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M)L<,,4P1"WQD.IB?(UQ7IPXVD(Y,$YEN;=K\L+R@AFU//+NN3G,(;'?-@CW
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MF!R>__ [_BGAW"*_R"?[NX(1?MSP,K>P U_]"G)$[GO>>61_[O1G/]XSII$
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MGOWA@#G]Q @%<RX?9G54U8D(V2?:- 6]^OOW']Z\_=^Z!=I>@)S6<$:- O[
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M_TSIF *6=@B6MA:FR4Q+%BPE$D$V6$:/T3)BV0^]+J@B-LKIA:V-5ANBUF4
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M%BL\!'+?4@%6(%PFM>75*]$M$@Q\4?<O#=?RV EO>4C)+.,"&,?P6/XF<%]
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MHE'")'^12 N<B(Z2-V'*V-;D ;N5+_-2 YQ969$!>8.,__ 4L9C>7O8 OG$
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MSX\:IW.<H_ ()'HPS<0/;#VAC>A/B;PDVU0^">"DXNX(PGU:N-J D6)?%U
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M99XP"!=5GK6NKMLQ]EX5L1)HE?V:*R()P,&T7X0:Y^?\#Q]_+M&D1'$<OU
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MO6EWV\B9*/R]?P7&2=_C/H=2JE +JMQY?8Z\99S;W?:UW9F93SFU04*:(CD
M:5OY]6]5 2!!$B0H<!$HP>G8$D$ 54\]^QKA0ZB.$ABJ8Q@I(",,.&-$,Q!"
M%L<1#[$;@K<7FO^P=&"U"N&12* VE;M1KP3/MJ#-3K#*0W'*#(=%/H<OPW>_
M3UP0J_C]:$95L*6V=\6UXDSA:;KN L]-OZEV(]_LBUR%LRL=GR_ZJ\L\5F)8
MKB.__'-0[&]>:5XM:7YH]E%TFOC+5#^)_;IE./K[_Y[!X^R]*'HOMUY@7^"=
MUAX0U27@C37F6WH'= 22+RO&UZ]&."N_*)J<%FE_3L'QO6U^S^R/I<=I=;-/
M!/-6T]:^I6*R,SK^X.&TQI&>#I^JA]X38UY[H= 1.5K3NL)SYG)?W"",)\Z[
MCH]CW=U[3W0/0'3_;S9V8?^/U@HR+H]T _V=S7Z"*Y\'&/SJ4Z:R<]_.<^_/
M"N!//5_L^6+/%WN^V)HOOA^)Q\@9PYXS]IRQYXPG)+S/=E$^3]/-$CMO'O+[
M:"Q=785WE[\?36:/ABVBI\X6S\$)6.]I:\"]3D#79^B/X^5(^8O@^3R/_#3H
MUPU8'%W>=&V;X2/>Y@.I%)W8^]/;9H_)CW/O3V^;/28_SKT_O6WVF/S 5DF>
MO$7"']?M.^SLNPW55@!;,P"QHMIJ\TB'FL\[:.&4(TM<@MN+@/NJY->N[XJO
M574_N!X07]VXX&U.@U-8066VW5[GU0WZ.#ZWJP!K@QO/%7P/S2;0_>GUZ[=O
MW[U;6>EYV.Q_/@DZ5IUCOEO&'.C\*0)]^YAKQU*N1MK]\W;!3VK*^JK#O4!(
M0T$(1Q''3!.!C,(PLI]%)@P5J<O(IEN;%8,-T[IJ)E='@PBA012N]WSO>=U9
M:+6/"(*]M.BEQ2,#^N&E!0Q)J!C"E$*& 6'",*&$CF.J,0B9V2 M_EDI%9K_
M^)^)25VSK3L?9/)#(>?7\O"9OP#K!D3V N>AL:L7.+W Z3+OZP7.HQ X"%%D
MH('"DC V1$J&()2 0V,HT)$X@L )VPN<./EN],6_33IV!.U[7?2"IA<T#TV7
MO:#I!<WC OKA!8V0($("$1-K@W'(1"Q)+&-E?V32A#7S#_<6-*@7-%UBD^<6
M3NL$T(XN3[JQRU-*T">RX^T2[8D H6O'_O#*=B? T.^XI_<G<>P]O3_1@^_I
M_4D>>T_O3_3@>WI_DL=^;CZ-_;*!]W%2/MNU2>P1"A_?&.4]@0&"OO@1K0Q[
M6-WJT7SWY^.L.VU,HX?+SI&('E3GCD(/KR.>$;!ZN/1\J/.@.D\4ZOE0CT1G
M )>>#SUR%.KY4(]$9P"7G@\]<A0Z-U]>73[8>>07'J)<_[1I=IT 6\?RC,\Q
MK_4\DHG/$;*'SQB.#:%<X%!@K3&))8]#(PB.-*%:Q BO9PPC:/\[3"$C'1 *
M!@1&W4S[[<2A/[SBWEW8]+RZY]6=A>SA>36E3!K B)$ 8\: T)Q:YAD2Q;0F
MB&W@U9VI6^_9?<_N>W;?L_M'"=DCM"F)F3 19I1A@B4.F5$ $ 6,IA&*470$
M=O\4JL8[@2\]F^_9?,_FSQ"RAV?SDG!F#-<*8X,E,X(@##E&*%*<0'8,K?XI
MU&QW E\.'^VH_/*#O>K&]+S\P9^ PY)D-!/%$:Q]LO*!1\ O=M'_1#A6@  !
M8JXQ,48@(+")I>824* T!#D*VCN-OIKN>I<CZ;7NQDOIR0VG\>QEL)Q"O+ZI
MRJ/WV!]LM;^PW-^.*=>G95,R_<LRXA2@#(X,R[ 5+%$M+ ^+'QN&5;GP6(L3
MVA!R)<1'6\N0J[_MFW&R<7%D6[+RVS,:_VDRTL9]%5$?[5L^__9G6IY."3Z=
M9).AN'M1Q;7R"$XGL5?!6CW4?\VR:1+?U8/ERXT)E$C3.RLSG-29&5>^,+6?
M/B@EUVYJ:*93JT0Y 6)76[_9'(.7=@J<!-P@D:Q:MG@>J!G-E[]A-P3W[[!J
MPSCU2%7N-+%Z13)?9^5Z\:CY]1*5["?#9&2"_PB2V\DXG5K(6(@,QV(Z9VF_
MC.W9N-CU9Z-F:3*]"ZZN4V-NC1NZE_,V,9FDX^]6A7%S2I-I%L16^2F.6*Q/
MYPJT_7PZ]M_TQ^$44[M0<[D30UE@?$NV57W8/GQOA<O=<S6-HF(#$U5#(U*O
MC]W,<PVFXTF)^,4GI4[F/[2R82@RJUZ^^O3QW4=Q;5ZE1OQQ9?]:95;N/2O?
M_6WF=%;_Y2U#!Y_=:_=5>F5S<ETEPAH:?O82PHV'L RGB5W[A70;O1"Q7>*+
M0 R_B;ML S36#*&_WJ3EHPJ3JE!]/>W6G()7@ O*+I1D *R:?%-LJSJ1L+#*
M:CMK%9>>_67S%E<V\)]&:&=6%,NMOGU]6QY317"3.OOC3^]_>_/VO^L.;_5P
M2@XSM>>N[&/?6Y;W?7X4H@:=@QI$KOOL(-2TII(L/_/03SSL\UH][0$*#BL<
M:JG$<+&7'Y9I\-YB>UV^UFW-K>2\038_]L-#:LX_#J':5]']<(\K,3[W7U@!
M8])$K;AT?C%99LR'B7$:S.CZ%R,RDSF]^=5PK/YXME"CC30406;_T0QC'LD(
M,@ 18SJ$G-?Y<3"  $['BVD4)E-BXN1:.C-U=I1!.C+(/MC$&,<<267_KR$W
M!!..['OV@_62;;@ R&Z68?/:6FPH7+$\EL2S' ]U1_P\SU[^-IZ:@ 2%2RS(
MT60_6[L9."T@>@I+N_6.4)L=X78[.I:'I'FY+?9(3N,?V=5CT+S<%GND*[2^
MFPB^-ZFOZ)@K!NJ+P&K )G6VJ/WFG.OG]/SB/N!<5R9;@Y.V 6?4%F56Z.(
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M($UC]H)LJ_0DN#4_J1E(+2 [3QC8,U]Z-[%U-'"W2M>!6_-UFB'7 MQGES,
M6R6^P*V9+SL!:;>D@1/E"*PE)YP^:> A0PG_8T0:&"OX=/#&*#_#U+7T/9P%
MM^,Q;K3A]AKJ?+Q@>,.ZPGW7U?3^>UC!^X[%/G$PCK'[MP@X$;%T/*Y?L_WC
M%;P>D 9/4H+7-!B[ZV'#_?RHYP"L[06OM6Z(TC'ZR;AFU-JD'^)WB?-=.K%6
M\9;2R" L.51$$ZQ-S"$&R"HW"(01%23<:;)!5\-1#T9%W9,;#RD<+-*0CO#R
M3C+LA]+DMG/&1\'^WLS,;W:77[Z9X5?SZ]A-^Z@P/RDQ4"I&'!.%K3TF":4
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M-G%YCU!2_F<]BK;ET]:6<NU4NJ:;^+.NFL!UV3&UGH^=/!Z-V5O[0)ZW2N
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M,-%.RUV]>^ C>\&U&9G4JF]WP5??3>JK4]?7O+S;<:*-U/)__<.^TFK>.5;
M:GR*PI!#AB$@#(<(<@-YC)A5!R*"0UC;>?OX:+']^./Q++UPY[]V_!._OYV<
MZGOD:X%6' W696S=,TUC+0G]M/D:L%6J&FPYK;J[F4>U(8 E5^UZGK=;<4B(
MU5:+O\IUKZ; 'R=Y]L.2+[<^U%D$X[DU^?5,>::R;O.O7%O8^Q]&:VZ4I>R5
MA=]D+8X?K+TQ&P^=@Z;>%J\S<%5NX.8RUXUM2[]N-F]7W[:#05L)]+\6$Y<:
MGUL!GXI762/@W6PZ2\W[XG55BTMIB6,1ZE"Z659,B @3B>(PII2 :+V2%')
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MKN#.VD%_G/J7%\NN67+P+;'7W<T5H%P&7Q8[SY^3/\ B;I;5/B9Q'T^,)Y3
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M;&Q5U<5M[N$U(%AZG3.OLMG0JZ7)J- ]YR4Y3G5MJ/=J#L(CKJV*X#1%H+&
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M0\%CJ\UI'DH*@.% TA@Q59LOXSK>?G!90U6OMVM\ZX'E8%6 :@ZIQO;&&_L
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MUQ<-A\9/ZW,OGECY:;_^;63\<AR:I6/[A6)+TYLDU1?N_7=YYOL@D+-<-_)
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M]/^S]Z;-C1M7P^CW_ I<QTY1%9)#<*<G294L:6PE'LV\(\7.K5OW P@T)61
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MV=_/!AX.9^U!?U:UXHRFY6!O"54:BH! U\4JI3M5J1S];@78H#(EQBQY4G_
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MY,JMR1_&I5=2?'IK.)=.=63\$$75B7PC*E*H7D4A[-A\Z'!9BO7VQ7PT&PA
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MU;8.CX\.\B!KEZL5B\-];AB&!G 0W:NA6#Y()S^(']8 )^G67?03X8(LEI$
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MCX""S<=XSP4J0TT2![]J8C%@ +_"A2B?G\ AA3OAJ<3*>A1P@B3"F:7 0]@
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M[K\^NN?P09\,M:<)']BTUOW"!_L'$!Z*0)]Z*/QQ%BM7O0HPJ/C!366H,>A
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MZ#X7JY33F]G;?2,L3V#L%"-3ZTY_=G3:QG,D(D"GA(IQU^BN,JMOE0>/=(X
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M2*?5;@+DC0HI8Q&S6X(FZZI!YYW1&?FG=,HK).8(=L+#F%@WQVQR[O5!KFC
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MIX%%ER$PVKRFADTQ/(7X@DR=I@W7UE?4U4LDE<PI,^4'7:!1".O.XPA,"8R
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MIW$@N-(<2(M'T1(M([11<YM/6MI.F@(1@U:)&41IKJT>)K5[;1N ,*^19ZR
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MPD%MFLM.).*;AJ)A"J0TL()]"-3/HV*TJ"';U*56=G. SX!.762GFM'*ABL
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MQR/\P>= 5@<^K WO;/D';'ZBPHG@AU]4P5_D/>5EHMB 0LN7;U3K2K6W[H?
M!1S7!1V$9!E=!N(I\;:N]4XRWUO8KK2)CX7+ZN? 9H<9R4G"CGY[/,28S\P0
M! 5PT^L=K#-%=W;&)JD][MI:.=\"SJYUS#X=.ATA-C%F_XOIA5IGP@_SK?8V
MR*KZ;>8&!*XX: _[T_9X:M_Y/?:L.\J%FY35)-/;CWMZXZ*&@[9=N*4=0=#M
M%X PFHS;PW&?WU-Z3>T+AMWIOD>O4V=+^N,V;?'Q]4/K&OZ>Q9@8YH12@R*)
M"C*]HA_^JIXY5\^4=<5?HMC_'\#R0KA7(6SF\M9Z!^2,A'H4Q:LHEC(7Q',@
MB),I-1%83>SD$I&4'Y*B0-MH?>)S9/>2+.(?)RQ1-VQ+\>]$V_@+6"NZ090<
MPU%1DJ6,DPC)E2!P$B\AB"0_@FU\ &#2GU@^<T/#;I^T1[U>&P!.@*+='+:M
MUGS;[VS^D?E#??Z?X 7NMA<,VI-1:6%0PUO>'K\[AM^);;\;5?9KG;#,;"WV
M^.T[6).PA@R':*$/KT!(__VIK4^F=FJNK-X$U^?#36>D/#D:)]H%&Z2MT3@!
M[63=,OJUQT OL5!Z-HMH]*WD1#64#@VY)6-'_-,L)/V&U&%:%C8 ZJX;9<#3
M2,N8"Y'?NN-=(ZV0ZDP[933/93"Y,,DVR!'<9QOBGQD<7$FX_!<8GT@PLH L
M4+[V*%JN2(4%82?BU$&)BB^4RF*NT'71>DRO_$1JEDA_*WK3%5"P^++R$2KZ
MT(7SLZH#Z!!>(IE?.WZ@?+WF'DB?T0#8PF5(AR*#+PQN26<FH!B*H+Y?(OB;
M*/Z,I.Y*)1X^NI2N?U>R(X%\'-759 ^OU'W9\PDB/IUWZ2 7)MS"(PRG'9**
M (<0<2]!13-G741;JU4 *B>"= % Q(\]TM="$$,)JD@BP$YH<$&FI#(O6ERS
MA;E "\O) H#O1^=VR1]*A%.F)U@3 >*FOJJYN 2\@<<^N&F$VA6CWI"#*C'B
MJN^Q; ]N%4-(,A>O"C<+3[+@9R9>60BW)31\YJ#.P:&L!; 7LK=\V12$?ZW^
M9M&- KZZ3N!F'+_S0U^Z_8D?H/P0Y :3'@MX%,@,M$4)\43N=$F:KL-ZZ8I$
M59@M]?EC=@?D2U>=#JL,E/ODBBU7W.;OJ"B?IW #J?5/4#TP" #KH;4@EBO>
MKB+]3;(VBME*0&@F"7H(<"5I?] !TZBM3B*M; R]"-JU,K'A2^+4[*P%A28
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M!J0Z3%]S:+/0%X/A,$G0):GU6*$7?=WOH2=6J>WU<K7ZIY*\0=0 QMH? E3
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MQ;-N!45*7>L,9X:=SQ@>J*VS8C"P.+]2;8^CLS9F=3.!5ROEJGKH+3GH0]N
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MT9.^^D&^_/N';N".\?]^/!Q\^G]02P,$%     @ QX -60ZX$3'J"0  CC,
M !4   !E9C(P,#,P,#8T7V5X,S$M,2YH=&WM6VU/(SD2_G[2_0=?1KO#2$GH
M]Q=@D#(0;CF-@ 7FM/=IY&Y7)SXZ[:S=#61__97=G:0AX0BSK":CF0B)?K&K
MRDX]?IYR=P[&Y20__/O?"#D8 V7F"(]+7N9P>+!;_V\N_J/7(Q]Y"H4"1DJQ
M1ZZJR82774+)!RDHDYR-@!R)R906L[J/^1R+M)I 49)4 BVQ;Z5X,6KWN;@\
MSW@.Q/'Z0=_I^X[GM?H?B>E,\M&X)'8<^Z1'',OQVMU[O7H$N\T0#A+!9B09
MI2(7\GWG368^':+*60[O.YDHREY&)SR?[9&WUWP"BIS!';D4$UJ\W2?FON)_
MP!ZQK6FY3TJX+WLTYZ-BC^20X15C>8^\L<QGOU/[9_QV/E=C20JAQI2AO^:@
M0XR)]QV<P1+D(IPQZ+'M$6]ZOV*8)#2]&4E1%:SW^%8[JMKD/IE0.>)%3P>Y
M1VA5BL4E63NIKR5",D!;A2B@"?Y!^/7)/,"V(V-F-4PS97?-0!*1,[0ZO!_S
MA)?$M?OVP>YCXX<'B5Q>6+F]SO=\D)LX/QI>7I^>G!X-KD_/S\CY"3F@I* 3
MM/C'YW3Z69O];']V7;N#64X/+RY/SXY.+P8?R?"WX=&GZ]-_#Y_JX=0]!F?'
MY.3T;(#=L-?Y"?H:7K[^."X^75Y]&IQ=D^MS#.WHE\'9/X=D<'1-+C]]'!+;
MI3W;VZ'O=FV?U4>O'\+@B@R.SR^NA\>D'<W5\,C,K6LYK^\3O[#K7X;D:G#Y
M87 VO.J=__9Q^!\S;KSC6.M</I-0AP?:SSRN%?R>=K&/;G%X(FEQ0SX JWH#
MQL3_[]8E%^/^<;^+@Y,ESV:D'--RK['TLAA+FN *F$*>JRE-<8%\W[$ZYGQ*
M&9N?<X;Y&,5N'"2AE;#$\IB5Q;@@!ED<>7[FQY'E8[><*O6^<WQU<?*1J_):
MV_[R]>^.LW*L3ZR?-EX,ZT]K%<<1RL/VN;["YC'-743:WZV>S)3F<S>EF*[Q
M8O>1G]BS)NL5;ZW)]E#^6RG]!3Z(?C6?FR#D*-FQND3_O=/)0\;T%HB$6PYW
MFAO'7)%?*RHQW_,9N82ID"41!3D1<H+3V/N5B(Q<'%^1#UR4D(X+-#N:(=%)
M;$E+CDTS(=$.D"E(+AB!@J'A?U4%(."ZA@'W'R;0/*D>30E>D&N^$+RL<^*O
MR$[7MB.:)HX+(7A.R&@&5N1$D%%FA[9C?Q_9Z7R][%P&\8%JJ8;9-)F1FT+<
MY8!RJ5OGIZRSD@F<WT*@.,-YI;P@J-U(592R C2+<LTH-TQ7BDH"\YG3G&0T
MQ4N2"%1_&&O=;J5! 2DH1>5,-YG0&S#YO+"I\!K#8-!E;L0=^M -4BY1+F*S
M KMC)"A4R-V8IV.BJG3\>/BD;? .)#16]8@F7.4H"+76O./E&$>LII":B%O(
M2@7./LY2,FO/R[:"*XT#/[#"$ )PO=AE21*Y5I9"!+9#'?:=@,O=9FSI$@BS
MUE1)>*1$SIDI>S)>8%)K?"QS%HNG JU@+]FZSPM<_B<U$? BS2N]^"-06@G:
M19!QS2Y33&L-40W=/%]BL,EV92):FD:8,ZX-=W6+*L<&(EM%E4!T&/_*!)A2
M-299+N[4'*821IA=J)5*0O7%>B 8=K<%+C6/;B7\;<67Z_@IRQ(G<CS?2QR?
MLB!R:)A%D1<&:9A^'_CRMH&\KA]DV<]O(L<.]U6#E49OZ[5=9!G'4Y-_IX1*
M,*F/F<OUMZYU%"B= 5R-=7/=;()$I\E.GS.NTERH"OMI"I0BKU-^*D6*10#:
M(CN8X0P00W4:#^_3,2U&0 9()I=5CBU,(>;OP#O3U11C^JP^Y;KN*6KL:?MK
MT';[ /XU1'1P&WO.'GC.T/-<0+:!BBVT4MW;4O#1&#S+BJD;1-1#2-#,B4.'
MQH'%?-\/HF\9?'T'/78>3-03\[ZV?]A_ 7SU+L!7A^\Q*.R.>:MEVP8HZVI%
MF=)*;=Y%*[D$$""-IUHLBDJB 22@6ZX,SV$K9&-M1U?G2X9LLZR$G!K$->)P
MB9INP\!X<Q6X'.DS;7.\JA+%&:>2ZQ'Q6N0:?5!HTY72.M,L8<J(4L.*0@%&
M6"(MZTY3JK^0*J>:W7&<)JJE7L4>M1QNJW@\2D W1+[%_L"VE5]M)T@BVZ8^
MV*&7AG:2A%:4Q8X?L,#V(N\'Q#>#>+)]$'],<T^RV@K2-^ZY.>!QD;CE3..8
M*E&8_,2TJJ2N*C6XJ61S7"'T.4UXSLO96BF\+@Z]#AE,&KC52P@*XW0A_-/G
MA'\M3.Z;@4\K.<550!D5GZ9",A.H*5M'4* 6SW$QP#LPU09U$ZS1:\#C\L2G
M* 6V%O)V%"6!&P +4\]E412!E7HT\$([QJ+5_0'YS2"?;@/DA[<TKTQ2Z_2'
M+,,2D]]BAJHUE>%"LV] Y?7I^F+1(!P[(@VKNB1-1%4^'<$F8H,N6H,NP-?@
M_MD](I+,MP#,*@;UU&" ^]K;EJ(QBB%S[3#Q=(&;@I.$X/L.M2(_MB,:_M#8
M&Z*1;0,:C^M$7P6,WL1M2D5S9RTJ7T"[6C>+-*VD1D%+DZZQ.A&JQ.OZ:1_:
M4CAJ\GO]**0V,Z9J(<$UIQD  S.BP R@(>S9*B)S?@-YLYW\R$#W3P]RFT'K
M,LJ\V$+%K%^-8'["(M^WP]AE5NB'KO,M@W9SR/G;MROU]MG]*/-DD,UQVEUR
MAN:T-E:6]*&)Z05B>J5BQ: HUJNED&HA5,T%-*9?V"D!&NY;A=@#*XE F:R;
M,HY!&GL[B%(D1:59&/_K GJ^%L#O%<<Q&-Q716HVC]]MZU:3:T?,\6B49&'H
M^8Z=.('M,K!9;*4V.-\T#?XI$OS6MID&.595:( CZ/0>I]XM33D@2AI1N=CN
MN0-ZHU5B7649G6CJ2/,D<_ZXXT78:S9BZBWG.6VU6(HR[*A@05)K<-K4G=@8
M$89E7W<5DD:U*I2LJII,J,2D,N-JF'[M0Z-MYK* QB&U_<ASP/42&D<0A7C(
M L\/[,B)?R#O&]G]&:#&S"022Q=Q (8%A:P?O#>0Z]:*CQ>W(K\%+?L*.FI>
M*) -<<)DFHL9X-V[L:C9DCX - )PC8A]^P)EU]\^)-0O8+8%G@>6FS''33T/
MDC "B ++\C(KB8!Y[)72OW:KWR3-Z51AF_G17XP,W^H[]D_K4_%+7K@ZUCL0
M>V10C3!UB>W6+T1M]#6O"\^)^U'P1'CS.4M$68K)8CJ(,[TG9H?OF0%L\ 9D
MYW!7[9+'[QU^Z6#LN!^[3\[USV_LP-I_+OE?XUM]PM-+Y__%L]MY_ 9G\X[F
MCPG5;]?J)'Z-C+V0J)T8- ^5C\8<,C*\A[32>W'DO"Z!7GW*%_%_I[.^<U'O
M]B.[K4SVNZ\]VU_*F!O<7CKYDA]6.%_MAQ7MH2R/YT<'N_IW*N:@^17._P!0
M2P,$%     @ QX -638K?&29"0  "S,  !4   !E9C(P,#,P,#8T7V5X,S$M
M,BYH=&WM6VMOVS@6_;[ _@>NBYFV@)WH:4M)&L!)W)DL@B23N,#LIX(O6=S*
MHH>4['A^_5Q2LJW$#N*TF:F+UE^B!WGO)74/S[F4<I06X^SXW_]"Z"CEF-DC
M."Y$D?'CH_WJ;WWQ/YT.NA"4YYHS5,@#=%N.QZ)H(XQ.E,1,"3;BZ%2.)SB?
M5WWL[TS2<LSS E'%<0%]2RWR4;//]<U5(C*.O&"ON^?MA5X0-/J?RLE<B5%:
M(#>.0]1!GN,%S>Z=3C6"_7H(1T2R.2(C*C.IWK5>)?;70KJ89_Q=*Y%YT4GP
M6&3S _1Z*,9<HTL^0S=RC//7A\C>U^)/?H!<9U(<HH+?%1V<B5%^@#*>P!5K
M^0"]<NSOL%7Y9V*ZF*M4H5SJ%#/P5Q^TD#7QK@4S6'"U#"?E9FP'*)C<K1E&
M!--/(R7+G'4>WFI&59D\1&.L1B+OF" /$"X+N;RD*B?5-2(5XV KESFO@[\7
M?G6R"+#IR)I9#]-.V:P>")$9 ZN#NU0042#?W?..]A\:/SXB:G5A[?8FWXM!
M;N/\=' S/']_?MH?GE]=HJOWZ BC'(_!XI\?Z>2C,?O1_>C[80NR'!]?WYQ?
MGIY?]R]0__3TZL/E\/SR%^@%!@8W+Q_<]8>;VP_]RR$:7J'![Z>_]B]_&8#C
M(;KY<#% KH\[;O &O]UW0U8=O7P(_5O4/[NZ'@[.4#.:V\&IG3#?V?#(OM0G
M/(7AKP-TV[\YZ5\.;CM7OU\,_F?'#7<\9Y/++;-D#8[G;72!E48GDNL1QHJU
M(5)5B&2.BA07!\_S5& "BQ/E6:8GF,+:]:[EM.SY!#.V.!<,DBL,.>MAA@,W
M[ 9)Q$@O)O! NV'B=[TX=*%;AK5^USJ[O7Y_(70Q-+8_?VF:"5:DYL3Y:>MU
MJOHU%E@8H3INGILK;!'3PD5D_$W-+%*<+=P4<K+!B[L'U,&>-%DM1AM--H?R
M_U*;)W<O^FUR *5XRI'B4\%GAK%2H=%O)5:0L-D<W?")5 62.7HOU1AFL/,;
MD@FZ/KM%)T(6G*8Y6!S-@7X4M,2%@*:)5&"'HPE70C+$<P:&_UOF'!#3MKQT
M>#]W%OGT8#;@@MKP+."R28>_(S'C;DQ=+R:QTZ,!BX(HBC$/(LRZ"2$N][Z/
MQ/1V(3%/L!%0D$WC.?J4RUG&0<2TJ_Q4558R6+> G4$RP;QBD2-05*C,"U5R
M, LBRNHI2%<,_ [Y+'"&$DSADD(2-!G$6K5;:Y!SRK7&:FZ:C/$G;O-Y:5/#
M-0;!@,O,2B[P81I0H4#$0;,<ND,D(!_0+!4T1;JDZ</AHZ;!&5>\MFI&-!8Z
M YEF%.!,%"F,6$\XM1$WD$4ES#[,$IDWYV57P15BAP"L7.*%3A!X'@X2[+NA
MRWS>Y5'L?!_@\G<96Z8P@:RUM0L<:9D)9HN11.20U 8?JYR%DB8'*]!+->Z+
M');_<44$(J=9:19_ $HC0=L ,F'890)I;2!JH)ME*PS6V:YM1"O3 ',FC.&V
M:5%FT$ FZZB2@ [K7]L *=8I2C(YTPN8*CZ"[%(8/&-SL1H(A-UN@$LOHEL+
M?U?Q19CK]3BC+&9>@)V(Q(0Z2>"%- G=R"'?![Z"72"OX;TL^_E5Y+F]0UUC
MI=;89FV722+@U.;?.<**V]2'S!7FJ1L=Q;7) *%3T]PT&P/1&;(SYTQHFDE=
M0C]#@4IF5<I/E*2<P66-WD"&,PX8JM)X<$=3G(\XZ@.9W)09M+"55/B&O[5=
M;35ESJI380J7O,*>L;\!;=-[\*\@8H+;VG-RSW,"GA<"L@E4:&&4ZL&.@H^S
M@#L>3MQNCP<]VL7,=UP2AMTPH%#H?.ODUKHW38_,^I="UY3P7QVZ9UQ#=\A9
M(]FV0%C;J$F*2[U]%Z/B" =PU)XJH2A+!0: ?*9"6XZ#5L#$QHZIQE?LV&18
MQ3-LT58+PQ5BVC7[PLUUT J@3MKD=UT2+9C 2I@1B4K@6FV0&].E-AK3+E_:
M"E++B%)SB+  2C:=)M@\D#+#AMEAG#:JE5:%'I44;BIX."+<- 2NA?Z<[2JW
M^I'K)Z!5J>< T"DA4!IZ/'+"'@$AV_W6=RS^$7B3W8/W0WI[E,W64+YUS^W!
M#@O$5#"#8:QE;G,34JI4IIHTP,:*+3 %L!>8B$P4\XT2>%,<9@VR>+10JY8/
M$,1T*?CI4X*_$B1W]< GI9K "J"M>J=4*F8#M>7JB.>@P3-8". .GQB#I@G4
MYA7886D2$Y  NPIW$C''I0[!&+M!Z &!8R?HQ5Y"L1O!$O #[D_#G>X"W =3
MG)4VH4WJ\R2!LE),(3OUAFIPJ=.WH/#J='.!:-$-'8%^=56&$ED6CT>PC<C
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MH_H# E43)Q]/,CGG<'>6RHHM\3U  P WB-C7SU!V>[N'A.HSR,96*/8Y<8S
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M85^P-EVY'Y>C_K'Y()@-BL^=_P%02P,$%     @ QX -69/!?'%;!0  '!4
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M)E)O-L;L)>LIC95=GPX=^(JR25"P *&RU%C-_-)8Z95C)X_[0E%#,J,)??K
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ME2^M%\'TZZ5 X'B3K:LXGU27JJ7(RE"AQ#%\5KPL4'T9NMTOS_@N* V#YQ9
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M/*;R=Z#%6DSI8-2G4R2JZM<SF_@#A\6/[8[7^+=^1TC]9L%YM@>.5822M<3
MJ8>_6A"T@##2^)7,2_\(7%MWJ_F@D3DBZ7Q9O'@[!0^[TI9A!;-:3?&]KI7B
M0 ),;T-HI?!,*UO![Z*+0*+D3;/YZT&+O2PQI:RGG%$C4]VWT&RX.K'MB=PH
MIHX,:7SSK#>NP5GFB0Q#.@H;)>U+I2%"_= [+I*XV?-VG1%CYQ^F>CPX?T9!
M; %/5>'G-R#VQYYE8[' T0T/C<>S[[$=N7LKQ6:O"=7:IY*9,#_GS<4!V9[9
M,CQR;?Q*C62T+$/7; Y9KK$*HR.&=3@TQ=W$S_!'GF<GAW6P>X1+NSO_%!_#
MB"XCQ?QI56#Z75KOT!!#(L$]'['3S;&6TS(PE['X3/.&>\$C$_WE8IEFX\#C
MJ37?/L-XN]CN*_ 'SA(LO4'.$JZ"-K28ZJ,FA;N\7FG=DR3#:[8?[VAF*C[0
M*?C)RM=<*])!+LX1>G^QM==V5A27*)*T+Q?C0*2S4QQA_KL;GG5%TZ7='/7*
M5(S)UI-OO[_.7@YY>YIW>;YY?S$#PKFI25+<4_AHRM#\\.IMYHPS6A]%G_O,
M;]F_,[%DF6#XRI@RAQ0T?CBMT9HC,S5]!RM*^#5//#ZQGVO#6NI(W0*3TW#W
MO1U.#36QPL">VY,&(%Z#;YS&?3&)4H:[B9&S5K_)+ SF^2MQ"QJ3DY*XJ:IO
MKCNY+565G\,^7[R#/4WZC.>S'-&6Q>^[\$TX=S5J[=60\;""M'AZ0;IFYS15
M .73-P-&JE"\?C0*>H,:KM=U<TI72XC"2.:G$WS$QNIA^,,[>T96]I)H"2W5
M[9WONQ-&6X4TS^(JGD:1M\KK%%<Z)WB89IEG\VW%0?$V7C\V4+ MBF+IK'@(
M^\XL.=YQQ-L[:#GXNTD&):;@S;;WO1%KKNV$E&I"_FJ8SHH_8Q *%<0!KZ8&
M?\^B:/]2.'7?.;;H6V9[*[^M%+OT>"N^Q]M)-I??F<J83S_JB9(]LSGF0MAE
M=EM=?9A,N$'X.%_S)U<C]TF?P0$W=X*%'\XQC"-ZFQDHK[+NQG7-EJ +\T L
M:7-6,&)(8\6/K^Y+DFY.YQ80L:*T1W"U]H<J4#5H+PE6P\8 O:+"F[A9BT#4
M-K^,E?U5#,D6E1%L'P$9@H <<=4$N_BATXAN?-RZ;T\LPYO*$@.FJ0Z9,[V^
M#UG0V*([FNR"P>CV\S6D(VSF=/]0J#C%?#;V9R#IP5J;W&[6PA *2T9!:R71
M-]>@'_JT#1'Z('--"'5Q1K!+A.8?TTG'S<F?7*N!"K[/0MR6(?NY3M"+'6,X
M "$X?ZFY4/N]QJ0(,:3O')R/,&[K#W]L"I,^O5GYTV)UC%,!JJ*K/D9$\>KP
M#;%N6X*N=NH:(V D/[ZK%\^! WM%")VB_QXB9NOX@-+SY)=95?]YS)#X"[/L
M)W[\?VJ& R>;SPHA7I ?W (2@283H-JZL[X_UIF?9_]XX_;GA2C^"->+L3]D
M]:-5YIY208K=9M6.!*TW[:J^;#OVU8A_S)R+XK_, ^4*]L"!S \0+E@-&0XI
MRU>2B8)2UQ!%= R$E*1_I2<6R]?3WT0H\A,H3 <R3S?ZKQ6/7PH'FN![(8KK
M\M>+KRN0 -U#B:VDDWU(:'[V/[KI?5P"L-LGPMDLJ6'S?WQ^]NOAQ;P/ALG?
M1-\X1L,!*?XCXW^>X!O8,-9M]4Y:=A'UYPT+23"W]!FS<JIRXQ?B\S"%% 3P
MXS ;=_*%X[ZF/E2)B;/YO[KY[K@FF^7?4 1>I8E4:4I >I,NH?E*%T*3T!'I
MA-!!BA":](Z U*#2JPBA"R*]=Y#0>Z^AEW!1SWM/N[_[.?>?\\?][]F=G=G9
MG=DGW\DS.ZJ:J,P*,#FR)9PGWXF[+5UPH(\+8=-=CTM<5#?AV]F&!7)\?GYO
M,*]48 0))Y?(>#]VWRT7YN!/PJ>08RQ$T]6A2OK2EZ(!EKMR47\_/T=Y$<Y$
M[B%$E:(0:)[CIX4'D_)XY>;+[P XQ(V59BB5]2@N7@W=/>(4O :$9G]-[;6(
M%]"W?:A2,?/ZQ>*)/PAA8!K0=:JWV 9)R4B^*N9$2<>T]'W1*T.W42M6^R$9
MW9[$MO$1JP \G]0*/"YD-[_XQB _YK\A8OX.=C%U>#Y.,6],9'/?/H1GIR3K
M52E'39([DRQI( >^<?(UP-TYR@'/<XPUK,+;;15S#_T*4%FK4_G4%B5?TUJ+
ML_S9<>KNP $;SO"G#/8[!,MR'&XQ1<0DV8HQSE'3T*Y+@7GQ"]A#I.(#?:]-
M71XS?Q1;&&AV74[:;+TFK&3TV'GS!B8'F<1)\(&=HNE[%Y$C>3=OC#MI;R4W
MZB![F41Z9L/RMP,$0ZE9 >58\3J4BRW&>RD&9VW#%SA;G<MS]),GBHA32F'+
M2OZH(_EVE/E8;IZ["8R;>T>;\XS!N*+%+$SH0K"[QO?D 8D3&TX1>AY=CQ"6
M$BGI;7Z]K+PJG\3PRD+2>(61=WRHOA"\M_X9N:^:0)0P<E[#+YN[08;ZS*4]
MA*O[YO+E+5?FR(DS,+GANF?DUSH=Z\KR*>N]&=34]%2G12=H,-QW^.D$S7L8
M2Q7 Z7%]1B9#:8V/\?LWTV*;*G%6'Y\.=804."CS >X?>(L_&[6U?X/C[&KI
MROZE;F0YJ3L"P80?Y7R;;\NA(]-S3E,()JX3>3@V5F$B5#QZ257U:D1B95P;
MMCP@1T"KJ^6]>V2*4"/11YL>U$^O+R^*H]LDG,&XI 0/ CJ8ZC<6E:L-K8QH
MV<%!DC^^"(5]:]G'X4U>\DNOZ[JL[I.V=32T#\'[< T@Z!W86Y"E/YF8W%IG
M2D"YI0'$&=[W,U1@E?10[9**M3]*,8_@UUBC?AF;(><) 9:@-L:-* ?C,!0(
M-96G;;ICTXH KOURD3DLYL.Y,>ZV9(<W0$?K1^F@E+5&?^7DMW6,HMY(1J<&
MONX*2YHSZ28<<JQUI8V>)AVR7$*L=67=)ZJAE*D%-DF=H /)#TQ=&]L)3\G9
MVN>H2CP]'?5&L%8P0O6C5&UQK::NCKBDUI_[S/3]RR;OB1<J[1_&P.@"?O@(
M<;='"1EO<^9]&%J(ZK17\9_J9\*Z$TJ!&_7AA,(V3O(%AD%U*VI!<>OMTN=.
MED94(A9SB,(,4R<@X\*)=K+8LB1_?C*PX9WA>AR7]GZGV^3 ]MLD)ZIK@%DI
M$/3*E\\>9.X,S>\V&T0)Y&33OW\08R1<+G#F:WGQS6\29ZP\<W^F2+"&U[*\
M_)U\EJZ-G.AKG-KY=+?E5"R(%4NT[>&F82-*\/5(!M&QBA>N5[J/QG[FT2%
M9'-7O:3P0_''*>[1D*J8<%>';F39('X>#<AK )_1?-$;NCU^U^:):W:MON&$
M_N-@PH/BEDAJ1^0$A)$3UOV:9E?[<)?,9F MJ>I^8*7S%-Q6,;?EV2/!*G"%
MH,W!FW8@X.ZP&!TZ91M8CHS$;H5A9T[ZEOE*&M>=N1WFTNH[KUH01",P54N,
M]8N,(J4WINXX-6X5.6\/91DV"QI]6.F7H?A.9#>LEUD_/H-\"S_MA.ZH*'@?
MDTUQV<F2'5NEG RD5;9CJUH87Z\.TCZD!C8R1!+5\VT?F$1)Y $-"_#(77 F
M43$H_7N]]:RL4@YPK]?HU<U>@$=_&,A\X9:*JPN4NGCQ<TSS<?)WL:?9DDZI
M)Z1-49)J@*;.OENI_;2SK7FIG-0PWNE,A&U8@U+H!ZLQ59J#YE5F8OPN@&E:
MU%'Q2VL&.7\@<VC9C\QNW@\2[4C9JV23LJ0MX3I=-[X#R"T'/!)Z/L#E+8!#
M)8;_:Y).G5E#!>R)%_31\,!$]>LX<],, \>##&+^;QT2CI?B^S@Z(TA]K_"\
M[<C(EC"F\DCJYXUK<4INGVTE]1Y7/XCRW#<J%$HH:J$ISHPIV+JUB'\GQO&P
M W_O@RV,TFI97P>W+#)O@>]VM+27JU0ZP+'AX3CO[+QW6QGN'LM2K"R7Q>CG
M>\ZLG=6K:73WV@<@X@O<4/W4!:*H=$>*J_K'W@AA;9$"&C3]/'<=&SY_CAS<
MUW7=J*BR<O/.L\_/F%[IQCQ *8HQ1QL,IQ#HF7#*TKQS<?KDL#F[+Y6<2<S/
MXYKZJ&Q(B+-?0'/D855+AR@Q8O\ <K.7)';Z8:O(:-)-[0SF?>_LKTM?9.EW
MXF%W7Q5P+:0MR.'3.7BF95P5CJ8(6D+,-3;3B^2!$H[/H5:,?=.X*JM$7Y:Q
M9O@C?OG&=Q(:L/4<#5+?FV?^5H$HVFX'-U: N0V(3D13TU$20G!?#O."[/-D
M"FPJ&0R#7$Z7:JA4JF6="F*KWJ5= XK.]E15^8B)'<0-]94J1@7S!3>K^R>8
M;V>3;G_#)<5[XD(A\@-&J$B##.B61U. RM[:KCK01]V<@GLW<5[Z2,IT>N#8
MX&2WQ!9;3!FLFS!6H6G"KPDV&*/F%T&W&J#+0+[?]EG^4A73[C)K'B5GI?Z1
M$]CYA(EBZAO9X*T^K+/V7,F,RL1N3@7N>3*!8$N"QSJ$V. 2T5XAKF+U)9=*
M/R,YXBT@H XG!IR/GP)8<9$BLTF)#BVQ97RN55X9FYEBRH1=DE=<S7/5JE.%
M8[6(SRI*[RKW(-" ID4]--DM63BRQ=.RA$/I=R+GHO%]PZG2<&1FU3U?GF7
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M[A:&$'""OFH5$JH=!Q7C%:EY"2D,=<Q0%:/#B8&&!']'O4,]L7&\8^$WW$O
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M[J?[!'I(>*]/H7+>B2OGS:+_7:-RF?H+G$51(7^0W 5Q=)U62VB%V+UUVGN
M\8?B'#R ["4.P1W(8AC=@Q ^E58H5@P[6-@5N\HE]MEYB=0=6UD,?/L"57%T
MZK0;NT9H#:*+=486;PM!>ZE<EZ]X[A0CT!T;*==O=H+#ZGL)75T[2':APSA4
MX/K),W"5W8D&NB0(\.'%)3 F?,E;0AE@7!85PG[V#&%%4)0_XPE#U03W9Z\*
M=26:+4K=,4%*2G^]YHI"O0+2WSP#4@E^120)*LLT42/'DIP%-)LF-IK^PS,T
M%>"_!=^++T.:HUX=B6:H46=,D.'JJ]?L-*A6 /G%,X"4@!Z($$8EF>9EI!CA
M:ZS9G/11\O&#*YC<@KS,?6OF)E1HH'ZK3-#YYJ5O>?*+7=BI77O*X7)P)661
MSLO:)VE][.Z15!]M.JN1 B 7?ARY9<*L7;UV4K'BFW_\-4P@GD1\>I=G9"6$
M_ #3'+SFETE1Z],[!)Z:N;&./+H]$@73(BWV-69NA/'*=OU-+VO3_9S]]0X<
MV@Z'PS2D(J.@V$(%G9+K?9V.5!>M%(_*W=PRE1$89:PVQ8S$E(YON1Z$<MI1
M74PC3#S.(#A:3_]U[)6OVVE3)IS=4U#?W82DZPT_<K2A.KW[N35<J9S-_%Y9
M@?+=T<B*'Z)0K$K3H51BQ)$4(JYCEK$'0W6G5-G-AANWK*]N'J*BE,L%!%U'
M\#TY;IJ"Z#+(4CQM0U2_\PM5UF 5\M734DI)N9A%J;^C_]M1QPAX=/_-66X<
M_02$21E$YT5,\E(Y06.2O_R)(Y-<!QW(,JHNY7":2?K<\W=&<2-Q]M D/^;1
M2[/!+WGFU"3300=R33+F'5+>?1-COZE1/P:_PZ;'-GOV30L6FR';[.0OV]@]
MGNJ;25Q,4K @49RL\_@%5.T*%NCR-4S66,\K/. CYEKGA;7FBWH@=@>R8@?B
MAI%M;YIL/?4Q1M;)(DY'G NB"8CF^3/(R$V#"42XD4>S1QSI09AW3*I8NU[V
M&5K;T>3".'"@KN6:$Q53TA5+3T.E<KZ>H:?\;$E:/;/M1)NFF4:BIKE' 6##
MRK;"PI"LKE=_R*W,T3K!(SA-A:A[M%:(UWM^AHGO=(_81O18M;:M,#(M='/%
MS?OM<$V5S][H!"B;Z3O@9*97XW-RNY%O)[[T^[T!WFEM.AK5QT"?R-?#SV'E
M;; $U%UNV>+<L&D6=Y?EL MX,J. :3&#/1)/0C:NFY+M&3A[R0K>P).6F.$)
M/KD9'HX1ZD.JR.5RE< WT#Q81]UK%I:KEXK8Y;R:$U-:,"BOI1A$6_K%<@V;
MKNM&JGJW@.ITZK?*!)UO(W N3YNA#NW0ZD?Q+E,*9.Y?=X L\@;.=N.)M=@O
M*%7YAUG*1<B<K1$6 "'<.3S&:=$YD&2..*JR*;Y@:* %R#(0,9;C-2A4!E&B
MX"A(12Z&)@S2C& &0Q*X2HQ<M]$D):B(;?1,LIU>@J3((,C/<2OTAD<DM(L\
M!M6I\S[EZO@+(Q6E)8$C25IS/->_+9/\\M?#,T@6]^ I)H@DHFX2QF8ON'DG
M4_TKF%VM29['0]!?\E6LOKG_9VAU?Q&B:0I)L SGHGG-$ ,W=TD0%FS+$W]2
M8!E4IS*+9!U_8:&BM"06)$EKWH_# $"1<(;(+!U/6D,L1/#4ZR@X11KG ?I%
M_/6FA$JRK3Z5DM?7S?Q(AZIE&GS=D]6\9G[8\6IGE\?<93 $($)D18O(1&ZJ
MG2\:IUZZ78!L^;KY%Y?W%R!#E95M]L5D-:^"833Y;9ENU\0H\\5U&H$5659H
MO.+*G8G+5*1.SOD5_<6!LOJ2@!A"W_6U+FU9K_  AIJ )2I&Q4>SV%C0P%1-
MR?=-:J[O9VE+]D>Z1B Z@UD&O^/N[#Q8!2%95Q0[7ZHF%0^"FF.!R! #**%&
MP,#Y%2[T#J]80 ?%>^A2@PQ*>>X@HU7>7ZP,559KD-$BZ_S"F+;XI)/C-B3-
M M3VHBS@KZN%ZBA%?TFG=;&,K2%C.8FY@MGGX!MN:#[#-'].WNZ"M_* :GJ'
M9SIAO J2ZLT+KCM5B5%=/YS86&"B:28E2 WG6<//V67H;07. A2CAU4&@FB>
M?@VRF"RKW0<Y^,B%I+@:%7R\:F.!F;3J2H#B4:^AX^S^[[:HM737:0XR@'(B
MY1?,_9+LO:,8?[E,<<&L]<@9%4U*E*@ &TAI+)C3,9 2# <RK)&INIHKU:=^
MQFHLU\MF4'!1Q2E/Q0ZU_%@0(E96"0=4LK6W5==BI;S]9Q;G&&NW,-\\B("[
MV;L,K,K.E>MZV<I4'(@KCP44 \V@A! QCQHN5M=HMPSQ7\MXO2Q%X8]B1)7H
M VAFI;' 0E)MM0$QDW8- ]4%62D8?,%E$7DZJF3+GR73R](GS-VR8_$U7TFU
M:7279.U9U058G0 _5@GP;CZ[;*6Q.%U2;9,!WDC#5UT]U8'!B0H,3E1@<#)Z
M&'35-@F#DRT,5!=+=6!PJ@*#4Q48G(X>!EVU3<+@= L#P\NLS=5ZDO0U7Y1[
M.K<@KV[B2Y_(+>]%2NFB?/^SNTFO18.RDS* AK^8,6$4A1V7 :QJ1'FR<DJ[
M%X)3@CZL='!#P_ AI.#6!/F!8^LF@^/345QET%:!<@,!NP#5Y1Z<]^>YM^=]
MP5E["JV^X_TXY]Y)'F(=(185HR=L>7&>G>.Y?G*6S/'S/D%*%I9'I\4U7=P[
MZ.S<R;13X6I>YA[B'N9G V>N&:.[3?H>]2@MXVNE3^^K%V,M^C%:OB9LS[0/
MT/:H:(8?PRG%I;=4AU"^5"JTOCAR!,O(D"=XT_8= L3DK8KVS'W&-/<9T]QG
M?IN;+KB$N<\ZYC;<Y! 6YTQSGS/-?>ZWN>F"2YC[O&-NPZ?I"(L+IKDOF.:^
M\-O<=,$ES'W1,;?ALVN$Q273W)=,<U_Z;6ZZX!+FONR8VW#" F%QQ33W%=/<
M5WZ;FRZXA+FO.N8V>WH+97EC4H#_M9T0X'_\=1^D3X R8>_]7K_RLOW=Y^DY
M2WR)67FCJI4[DV0<0G^%I_^EZ92=1 =W9MTW.N1)W?3%INK& U:O+3+A@]Y<
MT847:%-?D1NXDUR6(ZQ=(29P195;174&]5NE4^>;HRZ#!G[(%[SGC&UGT:G6
MCXQ=W@4E>/W#X750&\EF"('B_9N;.'B,D^)VK<\@(!?61_/TGAQ>(6>I<8%;
MF&;U/XODXAO&)5)6:%>>-TS;Q=+B1H5;D!=:U!J\,>ZGDJ_0-1*G@J-@MX,-
MJ&"D9AMB5"K2"LE(XWJ)FWZ'TD;R[<,5'3@.KL>]SXI:;]_ J6HRJQ@=()3K
M>U%-Z$[;93=.UV OY6)'WW[K;-C0NVG$]84>U9L+&[W/WC9__F<,,@R;Y[<;
M\ (2REK(L$K=.!%4<KJ*8AZ[4-%<IM&^6<Z1E<;UD&4C7*7@LM5C;22F;M4K
MU>WB5*ZNN]6E@;"">F:AXI'+N04V.8X_#.9Z2TY^HHZVFF89=MS%.$O \^$Y
M@(ULU^EJG:-"F8_453Z)DEU0T4JZGG<-:H/@$+6IB)%AUP(.C8TW[5-#N&-I
MD!Q+@^1XGT!"5]LX2(X[(/&J)3F1!LF)-$A.]@DD=+6-@^2D Y(3-WL5Y5/A
MVV,3Y)_U!H7E]\FKO9$.4P=A<@/P9 I44J PBU>5FM1]#LG2=7:&J+2+=J$4
MJK1_3S;&=L2@.BWEA74<M1JRCH1JRC=;# &K(MU%CH6EG-$>\_INU#)4A5B@
M%V?"H%M\C C@JJSM_"YU.\FK38[G$/6V(!F?ZZ% [[/_?A2H--!O?6J:6:\6
MFG:26D<NO4Z+%J1[H8ET>68L]\K[#X*A2FM'<X^\9K:NC1% C$)RBRWE6BRY
MPNP^OU5XC.C@J*O?R[=H6THK[G&M+IJ\QS.7(+E\78$4B;W.J\3T/KW2&%$@
MH;XV&N@\/'B[ D\0\[>[)$CS61J1Q(%5<=(OB@IM*3<D2%;87H<@K. _9@:K
M/1 O,O0U'[2P-)FFI6%(E.1.HEVD2@QN0&344VHU&(2;KU:X23G8TU,5,NZ4
M/%W!(44_9>%?AC_-2=,IB^F4Q73*XH<^9;$#=P2O;'?0OM7N:'_SS!T<P7GN
M:%=S^P#Z+ SQ&".JYBS(^AY2\7[;(^Y"HW.X)#R+J\3)B#A_:_Y"QLHNC]P4
M#Q&>=>6<D:?KGXHQV-G;MDCU\,.,W%C6&U1N'A(V17#SM+ ^01<SC<OE*H%O
M #R ["4. 4.-IZ<,/ 5Y([$=,7:XC-&K[&J GJ-FRB#$H'F[-EM$?4E)0VI
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M3]E[ZX.QU4_-#)$J6V_;\LLZ&A<S @<.TXWFM^TQ90$E.T</2Z;7*5F\CU\
MX7C\X>,IQXV"LBTW,LLZ<J.<L^ P59M>Y3+8.IE)V(Z3K]-H'1:=<<7O%ZI_
M1<4J?=G%?/>JI(*#',JFZ?KZB7*0A1E01KC4;Y7ZG6_[-\;E*6]MD-MAZAH<
MZAIM%4DC[C#,)@O9968E%N[&[71DRBP>Z]NRB?R6'%+KP4K\7<\B1AH$O?G
MJ,. -B_::1QPIU<[B00?KKW;)&$6:3O%D2CZ)$!4KIM^VR_GZ]Z&3AL*Y2TS
M: E70:962FU?%EM3C&I&T^!(7PR0*+F9:'!*NIIK")T,AZC8FFJP2)?3# Y)
M9V?D1GB0U,J,0N;8J='91/^0JMFLRNF0ZG1(U>H(;[\.J4ZG(@6G(AT]!48_
MI<@XNU@>G71X5E'N'%12,,=_S1?W((1/*3FD4:9:D3O0F ^$6:(^Z+3= .H>
MK0?0SRO*%>;/T%V?-+2%"?9,77RFT+!,G#F[-Z<'*VU 1!>4?D'8L$KUVKYD
MI?W#HY*Y+.-25B;7:T/;J8L9(_#3$2WPZ*4F&N6QTS1%FTWV#EQ@NZ6WH\*H
M7A+;KWU?&U!4V@,V* A[/WC:"IOV@QMA,.T'3T$P[0=/^\'3?O"T'^SI?K V
MT*[3$"ZQ8'@>3)2YJ<9/E,&K1,GMSC&[Y'X/;.6-M)-A+E<<UVT<0SAJQRU5
ME@\_]^-)&7"P,20<)G+(<[#@R^C/&!IZ P@_\$ ;6)D !'>\I ,)'X9!Y& X
MMN4S[E4OR+N!L+CPOUJ9I>^^R]>H]^1E:C@:),DU!5!%;0F8; <P4N1=MR"_
M@Q1D08)EG$5+K!O97R(Y6SRX#*I364ZRCN^045%]$&@D&;B]N9F>C3!#:+TL
ML_S^P)^^P.(!TV;R'];JSX!,#')4W.\%HNF:Y3V\9EE9[@HFC1L8[V&27,&,
M?#1E;2DFNAX0,/%U^6 WMT,-\8!']T0)Q';=D^OJ5;3(Z+JZ1>[W#")C#9R8
M@Z%XHW*8@DW*]OY%&E5FU[.KZ6ZKZ6XKJT%C_&ZK*05D]ROE!@_J>'3TW]^Q
MC9^[W/NTQSVE>DQ!,*5Z3*D>?NQQ3*D>/VRJA_N%[H:8LS"/7^+\;5K'GM:Q
MIW5L;]K&:1W[QUW';NCU)XB?GG,0S5Y %CR!RU<\?8\1N,OB$!"=%[8C<J
MYJ-56H IDDUXSNLHEU;)]>!>5^=9%!4^"!+Q$[X[X64HK@6\IA >Z __HE4@
MO>O7**42K6]A^@(0:6>(8N@+S(.D^9TD6]_"_'] ODW#UGE?VP2_(3>"Z/';
MBR#=M5\<O=^MIX'KIRNMJ=C,Z-M5P-)XV@[:-L\I<!7],Z+@;6OA^AE-:VJ6
M^31XPE_]1,IU']ITP]QV2#.83[&MZ[$1!3E#'=</?A8*]K8:)-[_%4[T[P%!
M(/[]'*;%V&0=)%] MCRF387=2*#[>K6.!'L1_.Y]Y]&+V#HZ:3Z=RKAJ7'==
MH#HM(ZF&C;3MP<Q-9G0/8+X_T>S*8_ZMB@U5I_FFZQB[\J_ED":-R*&_,"^.
MTN&?AK=GW4&]?X(9ZOA-"K8_+8@G!O5\F&!2U:KE^66L+4^U)TBRP!TU,1H2
M&&I+E"28&@TCOO.O=5#2J4ZA^3#6'?1&XW>-E8M3%(?%:7Y[J3)T/N8S8KI\
M]B=R=^ '_^8&',GK*#3\;)BAV4Q]K-5J?$GQ,CM39_&:XFR@/_R+-8'T=;R-
M-F],/!.8/3UEX"G(@=6HU9;#4$1KR#%%NT$_^M<2:&A6MQ+.DM@,S@C:NEF<
M"C,8F9_Q]ACM3R#OPA->SU][HM>AZ"Q%S>#@GY?<[N9\AYM#'?L4L3OWD7\=
MK;0>=2P[RU83:LH\&TR][<ED/)OGK'V3@0+G'R.NK?G*06R;U*6.;[?Y:3K:
MU@HY"7$EYJ:B?"#S*=!U/>9AK ]4IPYWU3PTYT/S*Y@M0)P7Y]>*98(X*RA8
MB?Y=R&)H&*\IRX_1-NS0G_X-^36UJUL.M]EO5M<6=]ATF!%F9^OQ4^.Q6X_Z
MUWKHJE<W'VY3V#0,P$[8L=E.#.1JJ$&0YCI%OK*/_ MQ:3WJ>USV(0WM=DVY
MW=$:??-K]C7]*1(E[.Y?S%$DKJ-KM!>E30]^['.,[=V#'^[2RLBM$-<(K4%T
ML<YP"U"*5VB"FE=&U-UO[T)!90)UE"@0V(\@T+6<!8PKB%1#V&W.D\TUJ5VO
MV.YZ579?XFG'?O&OBY'0H([6T:9%B=> K,RFAK+=V:KH-/?2]Y)_D2RO2!W0
M_N9&R:_X6(E<)GWSZY13+ ZPNW]!1Y&XCBYWF4G3BXS3BXPV8\;XBXS'?YN>
M9#0#TNE)1F_'-'Z^1F<LMY/'8GJ2L27']"2C9T$P/<EHUYS3DXS3DXQ#V]#I
M2<;B5^&3C-<I_A-\"5X!JA]=K*4PS@N;=!GGA16QD<@]3S&V:AK&6]X. FV>
M/X.L(5IO>E4%FK!<!2=..1?M2%<<QMLPHF(,Y9R_Q"+V"I16KMD0,.F2:&;3
M<SV"FN/Y6T#"Z@;@!HK<U][U,[- [6%* :]]*U)(WJL42IJC ,:=5Y_C!* <
MIJ#J0'#S]P(2N"HZDS2ZBC.4$RG)XF"0/ 2X=,>-&A0JLRA1\!D(^B:11HH2
M*\W7QF2A- N?8RP-^7N^. <9[E?3S>TQA2@W1%@AH(;28<%*GLZHP*5H'G6(
MR3/4?"F+ ;1[^!8D^=L=QC06(7C"@L71/+T%><%\OKC+8+3NC2N&5JOL)%_-
M9]0H*B\-$GGZFH\O,3!![F>=+VHI2J!V_,\K4JE++^*S7R64DO8AG9;KYW.Z
M(M,V]+AE&/,%%QMM2E,$T5[8H/E!>[MJ'+M5O3E.?].*5X0U7W2_A<7W-&VV
MR-^5HM*CSA*]V&CJ2D5=)><78OC6_78-UW,4SPKW76@$::[U90-%P[F]57?'
M[J5M0ZCYE[N?,,S#!C8&6/,XW&A]^Z_?@]E-C,=R",SPR+[H!JB+_I*EZSF9
MJ+0G8ZW^$OXP/7E^W2[%"VE:"6*4Y8T QO_:!B_^QU_W9'^!TL7V?J_G1]O?
M_>Y,60I(]:"-RE:VXV2<0HT_RI>F8W825]R>L&]VR).ZZ8U-U8T'G >&R >]
M%MZ%%V@=EL@-W*Z)Y0AKN],"5WP.7N/E>DGOD&C?ZNZG_<U19T,#/^0+WG-&
M6:KH1-K5W.[A?L6-YCH#-S!(9VGT ,)U%N=OFWZ-K#"0;RXW62_ 8WZ=(CS5
M)1+U9N 5B@2E*K<P2[D8<;>%8>VN"DI1%7._MRIR!Y15K!E(#*(DJ)C$-#L>
MQI"[S:[,OY\OKG'HK4C\-0*'ZTV9BE0'\RN.Q><#U%>" 9^^ZRRMMJQ700AF
M2[CNK8*+BE'QT2PV%C0P55/R?9.:YO:I84__D:X1B,Y@EL'OY,VZ8!6$I,\5
M.U^J)A4/@IIC@<@0 RBA1L! <WO4,) H#XRS"U!AX?2A[L'>%[R0+>WDUM/4
MAK<UVYS*<^Q7,/L<?,-P^@S3_#FI=^K0/+W+XC2,5T%R%B1!VKL*SPPQJN>'
M$QL+2C3-I(2HX3Q=;]*VY3\+4(P>5AD(HGGZ-<ABLHIV'^2]AY2&5J-BCU=M
M+"B35ET)3SSJS9U@]\BIA;M.<Y !E!,A22;[)5F(0#'^<IGB@N7-'EPP*5&B
MXFL@I;% 3L= 2B@<R+ "INIMUU(=ZF>LQ7*];(8$%U2<\E3H4,N/!2!B995@
M0"5;.5OU;F(I9_^9Q3E&VBW,XQ!LNMB[#*RHZ6)JE:DP$%<>"R8&FD$)(&(>
MNJ^PRPVV-PSQ7\MXO2Q%X0]A1)7H@V=FI;' 0E)MM<$PD[:E9\ [LSM<%CW#
M)*)>AR=5ECY7[I8=BZ_Y2JK-H+LD=1^<U@GP8Y4 [VZ>RE8:B],EU389X-NM
M9>47A75@<*("@Q,5&)R,'@9=M4W"X$3_-5L=&)RJP.!4!0:GHX=!5VV3,#CU
MX"'43J=%.8? *4$?!#@X@S"\PQ></Y#OYEMG#\H'+[T_?-!6@9(7R2Y =;D'
MF9(\]_:\+TB8I-#J.]Z/XP:=S7S6M3RB8O0$"B_NB.)XKI\L(7/94Y\@)2O"
MHUN;-%W<RX%T[F1:)J>:E[GYG</\;._HP2:=AIK9R?C:.+O9^NK%:(I^'Q!?
M$[9GVC?Y]*C824XKDCFI#J%\J51H?7'D"):1(4_PINT[!(C)6Q7MF?N,:>XS
MIKG/_#8W77 )<Y]US&VXR2$LSIGF/F>:^]QO<],%ES#W><?<AM=>"(L+IKDO
MF.:^\-O<=,$ES'W1,;?A-0["XI)I[DNFN2_]-C==< ES7W;,;3A=B["X8IK[
MBFGN*[_-31=<PMQ7'7.;S4_:TX.,@NFYS#%&QJQ\.L0X'6*<#C%Z<XBQ3(2A
M'V*D?=O<:Y9Z?(B1(SCO$&.[FM>'&/\,R!V\Y'8]TLQ>Q"@DV?S5B<;I8.-T
ML/%'/-BH[>3S)$!HOJB":Y[=D_?/ZQ-W50S& )T'20*BL[>J'*H*=E%NB%IE
M6VUJ_H++K*$D0:C-U/592ZH"];.P=UD<@LW'C=3=Q$$M&CQ@BFF,#(X#C:(#
M0C$KUX<_:Y'P\*.4J?$L(N4$GVSQRG;BXOYB9Z"JDC 14[6S<K>]276^^ K)
M7>!W\#O(\'!S1=(EYHM%Q]/R%2H#R%3PU]N#U97TMPQ=S<5#JVW 9Q @/'DA
M>EVGJW5WE*Q25:)MZ%?U%SD:)C#09O0YN#Z[N3E7NBA40FA-SI221P>ZHVJ)
MDG7;PBOI+S3D%91M37@$_3IZ^4<:+&&6Q_\$4;VFP9UA<\HS[HR@E/<7"D.5
M5;P?@D)6\^"C-BSJ\YGD]>T4 2)Q!PB<$I4UJ"7\=;98(4GW4@EI'F[4?^VU
MQ%AQKK9LB&JP52G6'?=*EZ]?A167]]?U0Y65!(($6=U3C%,^NU_Y[!]'D<_>
M'7\6[P3V-\E%Q3;W.;.*^;R%+JF<Q(XZFY+K]72:9-1D:'%!CJ_=Y[P+?<GP
MMS#WG468Y79?<N -.+ZWC>Z!ZVGI 'J^YR8+J'G?A]=ZN]*1H6B8@X@L5C)N
M\)>MP$ #K8*C 9]$I%,P(=18A(SFE?YBTKZU$/<Q^G:5@=;%/%)($5=D((97
M<53(D;: .H)X+'QK:XIMLZ\PP=.>),[?I$#$K</ #Z/.J* CH[<Z:AC47>]>
MLIK'B_@ECD :23<]XHJ"SHI6<53XD;: ?N=%8V'E[MHIHWO@_'/*Z)XRNJ>,
M[BFC>\KHYF9TWX,\+ONUNR1(ZQSM6A M=KU14,$0@&AY1+W8]";>[(%7%B#_
M>0P0^/O_ U!+ P04    " #'@ U9V[EJ=3*&  #IVP< %0   '!D<V(M,C R
M-# V,S!?;&%B+GAM;.R]:W/<.)HN^'TC]C_@U)Z(KHI(5Y5<[NZMWID\(<MR
MC\ZH+(VDJMY>QXD.*A.2>(I)9)-,V>I?OP (,GG!E0 (9-H1,UU6\KV Q/.\
M>''_M__Q>9.!9UB4*<K__9N3[W_\!L!\A=9I_OCOW^S*5TFY2M-O_L?R__P_
M_NV_O7KU5YC#(JG@&MR_@+<%2M9%NGZ$X/KFZB'-('C]YOL_??_Z^S^^?O.F
M\_C5*Z*>I?GO?R'_<Y^4$&"W>?F7SV7Z[]\\5=7V+S_\\.G3I^\__?0]*AY_
M>/WCCR<__+^_7-ZNGN F>97F997D*_@-P/)_*>F/EVB55+3,'?7/]T76&/CI
MA]:74(+\]:H1>T5^>G7R^M5/)]]_+M??L"*2QQI.&O'/(WGV3B<___SS#_1I
M*XH-I1+3[6OCKP= _?T*E,$;^ #(?W^]N1!J__P#D?@AA]5E<@\S[)*J5R];
M^._?E.EFF\'FMZ<"/O#M9$71FB%?YV?R=4[^1+[._[6W_(--\1X)F.Y0E61N
MRDGMC<LZ<F-?Z ^N/JVLR!]<?F5,<CC#5^ZXL2_T-2Q2M#[/U_X+/G3EJO"W
M55+, )6Q,_L7\%]J3E$S\M,E_E?/+_Q<P7P-UXUG8EL2.ZEK&FRIY=8V6O6L
M9J050<7X=4ILE5HLX>K[1_3\ URML>77;\@_7I%_T+? ?_SC(B_3-2SNBH0T
MFJ=%@<L.+RJX*1NS](W^_1NU8)56Y*UD@C_TWX=8[KU1 4NT*U9PX%NOH%H?
MM8>)NL!*ZYL,%X1D%#!_]>OM-R!=*Y66[!E@#P%^BDW #<RK$GPD@H!*_J]_
M^V'_IN.O<UKTJSPI5DWI\3\5;\PD?E@AW YOJU>]EW\HT$:K5I'N]V>?DWKY
M"Q#+@PH!E<4?O /_9I?!DQ_O_WB"'9^NT1;3^7V6/ Z0IY!BKRR4LL"[PK,-
MV,6F14@7:2S) T">O#KI0APP(?"1B 7&N*H.D=8'[Z-;(-Q 6Q<0GG%]5VSR
M2@7KL1 'U5TA1Z >^W6%Z9YE'4AW%(2(QIGA)LV3&$'-J4$.IH7US('T7I:'
M: D8/ #Z \KU8K5:D+VP3- "W&K_-@"76A>!7**TQ,]>'4+XUJA6I%L!?<2+
MY1O4&R#%/_*%T5PIQ\>]HYBN].X0]5J17:PCQ7QD 5Y=J7S4J\*\4%R >9?!
M_B$I[^E'V)6O'I-DRW"?567SRYX [(=_G*Y6:(<[3=?)2W*?P=-\C7\I=KCS
MG2;W:996*2S?I>4J0^6N@'>XI_T6%^3W 5 MK;!/.-G*1'HY^@8Z!*S&XVOU
M.]N7@<=36ZM+)@;./V]A7L(R+%EMX86<U76?[!.-D5!@79XPF/]'=I^=V+8\
MCLK@ ?BUZ66C#9@Z2/(U:"C1L0#V)L!'8@10*X&;MO!LZ:$D%LJP0@5I9-?K
ME,Q')MEUDJXO\K-DFU9)-FQ$Y5)-(RF2L@T(<N]N&CFA#RF7!5K+_0.PQ4]>
MI3E8U<\"$U!1D4C[JP^XPQ?N<6->=+AM#N0^)D"D">=[G)#' ./D[#AP(@NT
MD\$2,%"^@]L"KE*Z>&. 1-XC]L;]1Y9(Y_EQ$OP&AF5P[HDNNW\!6"?D88'+
MK0LD_X9]=/;>J0-);U7I-%+Q#.O6)XM)W9\.IS(E\4:G1@-&EHNRW)'U4E</
MMQ5.!G'2^+>$C$Y5Y7M4W,+B.5W!\JHXRY)T/#<_1;>9KC?3M43\I)+:LL'4
MJ8PI9K:6C3A #Z!\2O#7(8T[!GNYRRJR+B!Y+" =?PR\#F 2@I!EQ0Y6#)B8
MZ#+8#L*SL/NV2BI:S5</[],<%S;%.0TJ:79S>E]61;*J!I0Q46$?4D_%DL(F
MY;)EKJ8O&6&U3"S/4+XF:<L:X'^5*$O7="+@;9)1]MX^04C6[30*@0=0C*"!
MIE5=GYLZFEU*3D+B+$P\3XH<!][R&A:W)""_3<IT-8"Z5(9]&(&,);FDGFW9
M)#(NHP]?9_D!5B!#90FVL*@;M@6X)X_ M[A]6Z,L2XK.P^_"\D5>GTCS\_<9
MP17M4D /(/,,[VU04:7_HBGNU<,[>%^1X4<R1GE=P$VZVPP'^G3EFR$_M;SM
M\(YNB:S'>#0<20=ZE/K+K@C)"]=8"*R95. !'^V*1Q/J9C#^HU+KC009(VP6
M8ITEY1-.-\E_SO^Y2Y^3C*SO/:W.</[Y@LG_6Y+MAI VTF&?3%/'DF1&);,E
MFJXS&=GT;"S)<SI#MB+_@'O)L&0S P*:6$]]TFFI=HDW#7D!R7>-D_?5BV@=
MB)&.E'PC'2_D$Y3,R7BOKD=S!@YMU SL"% VGA%JY+@KT#2$5(IUN6*DI@@F
M2FK*\26EYD!53<T@N'0Z>&WDT1J<;+B[;2.&4%V 6@%\9/^-9AF%7Y!*1M+]
M(#7DV'N.@R4L*S++B'NVP]%U_M-VN]O@J>T(.=^;]1CXR*QTE'L@7=.#K&$
M#Z@ *7L<>N\:OUZ0\F,.=ZKUA'HCRXK*G0F=JP(F)7P'Z_]>Y+C/0^KB'7R
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M0A\!:$(E#:BC4NO1*3S4W*:JNMZLT-8DHATY=EP2^):)?A=/RND%>[*$TBD
MX]B.1J[!VA6%^+1F+=GQQC.>K+OM/.*2N-YBQO6DN6>'H[O<_];=3QQX%$.O
MCOG;<92@&&^_&:L(]MS,#2)?&\'$GB8C:;SEJ[[2CF$KEACM%EEZN[LLX!4P
M)E_U&PM.1UXBP;X%5\*2,!*O3KKV?/LR7O TEK0[U1TE1GG@[J*LNI#6]^TC
MG"/8Q?5,=>\T1$KL&P* A<.K4=9*'GYWJ$"0Q#MS- 2,;=?D+@J4G^;KJ^H)
M%M<(1UM8I06]B>$MS.%#6I7J0])MS; O.-V,)9ULRV]+-PO_,CI.-KN\:<7
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MZX=(;^ZZD74^LL\3B_=K+\[J/6?#("H4:*(?1\ V; E].LF:N>:ET6*LL/R
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M?=F5Z)QIM !$*)(+7;4K'YE7T&#B1*'5FU(QQ=B,LZG2<P&D!P(XW@3N\0@
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M/;4":N\FW%59$[<2T:Q=GPHF"9G-\"C@M<*(C.>1(=IK Z3IVR&H)0T4TUP
MJMLY??L+1KM!4^8/\B&/46P[7>>;;89>(.YP%<\IV?3;W%_1O>'B-*/%H-TN
M=K_ZO^ :OV:*ZFLOY(,]'GR,QGR<^G V]./AS=V- +DMG-Y D$N?JBMS%LU^
MC36[DV";5DE&3#6K0V,;(?)!%.Y D3]&CL:+'+KB#QOY9/X\M_/0#)1NM[Y.
MBJN"GE>ZIH<Q-"W)(- 8:#0W\NAHV%YXHE\JZUM.M%Q)KS;1L+!D?8.22"W
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MDXI$97KZ5> @:H<JY*J.!Q%KDJU>J#DDH+O-I:R*X![M3?92*R\ 4Z=I1]]
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MB5J-4MA"6.Y"AF>9YK+SD';]5MW'X-L/J(+@Y\#S'SIUC(PJH\\%B4*7&"8
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M6I+9G8N\*M*\3%=T?/.$UV_RZJC;??+DR$4 ]_H-W'6F?!53&<G].%YVGBU
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M']O -+ IBR$]T26]!9O\B1F-?PC,9FX5(/FGZW.D*]&%L[0&9T7>.[1)TER
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M=1ZCS2$\>])-.ZU7#[^6D*Y/EV39 DE.6CV2=)A'"TKA,G$>N]#-E(>:RQ8
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MG'C02,_*8,_6&FX+N$KKHWZB..?2%"!ZYX](L,7AHT19\UR2$*CTUA9H^'0
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M"0&U<2:@I%A?1E(#D :E[1TL-D9T'2LH:-I5\$3/<9E\T;+G:0H=.P:6S6^
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MSMV,JJ/N=!NB?GG=;DW4\JN_75'#W&BG:Q1W/T]&CW!CHS$"&9M-K8AW04X
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M($I:51X!]5^[I,#=U>SE!FY1,0Q<"JD!S$92#A G\.P"?&/3*AP.-?:0;)^
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M)-'J]]NG!".H<_,4MS^MH]#K5\L5[-=W:93'P2HON1?%6B^9<KOBBPH!*K4
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M'4G& "5Z%.+D-[ 7J]O@+3E2F&SP)*,-I#VF8PHDM<Y1_FH_B-"; @D^8Z$
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MM@ P63U1CZ18].$*91E<D>GIK#Y&C3XJF6'\=ENV]@AK)=4K+/%J4Y<5/3Q
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M+)4E7:7*<Y]%7:W[2)=U9QXV6I=W9QHWC"SS[,VKJ:6>E1&>/&9T7?+5HL+
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MY_N>L_]#MO<YG<3)]$SZ3'_?D6^]/I]C>6VG>V=?^M D)'.;(C0DY=C]UR_
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MDYY)F=]J9?2^N6=,4>,EENP5;8)D7-Z6:\!W\1*6P=6,[7812:^3=DG<LRU
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MR=6%/8]K^4P<FYN7L;]]6<[C9%,,8C@E5!QD;*F\P@9;-GUT;/GYF]D),+P
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M#N':T>[;VGW:6^1JZ\8$<E4J'S&[/8!9 GP<,C)+$%;G97P>1]#JG'7$! '
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MI-ES$"?4O5[B[')3;#)T'PSO[F@6WSY^HUK<5TB.5)01=*JWP;5=[]LDJ/*
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MQ$GHM]'S>(I)CGJ,'S-,>$9DHJV&IYE[-+^AZW%XNOM@7=./:V]I;W/M-'3
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M3>8/EKC":2*GS<_?=$A=F;ZFFQQ%ISC+\#?ZL&^P#D)ZABN'#J@D$TV2DOX
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M,# V-%]E>#,Q+3$N:'1M4$L! A0#%     @ QX -638K?&29"0  "S,  !4
M             ( !7:\! &5F,C P,S P-C1?97@S,2TR+FAT;5!+ 0(4 Q0
M   ( ,> #5G_@0[8!P4  /<4   5              "  2FY 0!E9C(P,#,P
M,#8T7V5X,S(M,2YH=&U02P$"% ,4    " #'@ U9D\%\<5L%   <%0  %0
M            @ %CO@$ 968R,# S,# V-%]E>#,R+3(N:'1M4$L! A0#%
M  @ QX -6<!DGON*8P  D70   L              ( !\<,! &EM86=E,#$N
M:G!G4$L! A0#%     @ QX -6;X<D%6/#   \H$  !$              ( !
MI"<" '!D<V(M,C R-# V,S N>'-D4$L! A0#%     @ QX -6=]_3UW<"@
M>H8  !4              ( !8C0" '!D<V(M,C R-# V,S!?8V%L+GAM;%!+
M 0(4 Q0    ( ,> #5FO=Q6"LR(  )M. @ 5              "  7$_ @!P
M9'-B+3(P,C0P-C,P7V1E9BYX;6Q02P$"% ,4    " #'@ U9V[EJ=3*&  #I
MVP< %0              @ %78@( <&1S8BTR,#(T,#8S,%]L86(N>&UL4$L!
M A0#%     @ QX -6:%[.?*=0   VF\$ !4              ( !O.@" '!D
I<V(M,C R-# V,S!?<')E+GAM;%!+!08     "P + - "  ",*0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>ef20030064_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pdsb="http://pdsbiotech.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pdsb-20240630.xsd" xlink:type="simple"/>
    <context id="c20240101to20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="c20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240401to20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20240630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220801to20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240630_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20240630_DebtInstrumentAxis_LoanFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240630_DebtInstrumentAxis_LoanEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20220824to20220824_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-24</startDate>
            <endDate>2022-08-24</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="c20240630_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240630_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20230714_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-14</instant>
        </period>
    </context>
    <context id="c20201208_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-08</instant>
        </period>
    </context>
    <context id="c20190331_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c20141231_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20240630_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240630_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20190617_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-17</instant>
        </period>
    </context>
    <context id="c20240122_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c20220517_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="c20201208_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-08</instant>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240101to20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240101to20240630_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20220101to20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>pure</measure>
    </unit>
    <unit id="U005">
        <measure>pdsb:Loan</measure>
    </unit>
    <unit id="U006">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U007">
        <measure>pdsb:Lease</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20240101to20240630"
      id="Fact_f08a809b29bd48a6a680ed8557f68f14">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20240101to20240630"
      id="Fact_c0d138abe17e4862ab752b2867564a46">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20240101to20240630"
      id="Fact_072f3b40d75645adba292ef182a05e8f">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20240101to20240630"
      id="Fact_4dea9979fc924d1ba45cdaf9691f9c0f">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20240101to20240630"
      id="Fact_f16cd320df8d4a8693e7d3fff1d6d21e">0001472091</dei:EntityCentralIndexKey>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_422456f8ef2547ffa808d9e7f65aa170">http://fasb.org/us-gaap/2024#PrimeRateMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_89027c97a3984c949cabb17cf3986c08">http://fasb.org/us-gaap/2024#PrimeRateMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="c20240630_RangeAxis_MinimumMember"
      id="Fact_1d2392fd0bf043fea9df39565196af84">P4Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <dei:DocumentType
      contextRef="c20240101to20240630"
      id="Fact_365e905914894c9e87dfc63bc0d433c1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20240101to20240630"
      id="Fact_5ca304fb07da461ca129d06543e993cd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20240101to20240630"
      id="Fact_7d81142ab3ad40e2949129fd6cbb370f">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20240101to20240630"
      id="Fact_00ee2abdf8c8430681efab904ca8da03">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20240101to20240630"
      id="Fact_7ddc5e54b9cf466fa1169764ce556209">001-37568</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20240101to20240630"
      id="Fact_f964a16257724463a8445f1887e2c1d2">PDS Biotechnology Corp</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240101to20240630"
      id="Fact_108477a6b87d42e491b88f5ec1126bba">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240101to20240630"
      id="Fact_a54f2ecdd73e4f5191235f88796cbca0">26-4231384</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240101to20240630"
      id="Fact_d6aff782196d4c94a68ccf91f13cbf93">303A College Road East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240101to20240630"
      id="Fact_4a7f1ed407d44ee2817b8b1928611841">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240101to20240630"
      id="Fact_e13ebfad41454ddebb7fbbbc352058cf">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240101to20240630"
      id="Fact_3494373f1a774d2499fe5604a0e79984">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240101to20240630"
      id="Fact_c9ad349634274b8bbc9b705b9b76ed96">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240101to20240630"
      id="Fact_5ce13dd8645e4ba9b7d5201a109d382a">208-3343</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20240101to20240630"
      id="Fact_d8e50348cbed49ef98d75054f982159e">Common Stock, par value $0.00033 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240101to20240630"
      id="Fact_60d9272f8d054c4da2408f1fb2c4a4c0">PDSB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240101to20240630"
      id="Fact_96d178427bee42eea07fbee625cea55e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20240101to20240630"
      id="Fact_0661ef6d819f41afa5efab5e655a882e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20240101to20240630"
      id="Fact_72ac275f41424fea87c6d34a99561711">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20240101to20240630"
      id="Fact_62016895bcd1415d9bc1f508ea7b9d22">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20240101to20240630"
      id="Fact_418a1a222fc545eaa32b66f2d8a1aacd">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240101to20240630"
      id="Fact_8eeeb46ff3834f038c54e85e0d37d14b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20240101to20240630"
      id="Fact_8e85e7ac1d4f4fa18774ed0f798706ac">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20240806"
      decimals="INF"
      id="Fact_4eff5ee365bd4e319dcd0de8ed2bda73"
      unitRef="U001">36819810</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20240630"
      decimals="0"
      id="Fact_58cd4bde50064e879484494d9c2b33ff"
      unitRef="U002">57733724</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="0"
      id="Fact_2c5533225ad44d25b51f3b96b8ebdedf"
      unitRef="U002">56560517</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_ba5045bb2b1146809daf8b45a5ff6b4d"
      unitRef="U002">2427752</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_a6f868956f5141c3b6d5dfba703002a3"
      unitRef="U002">2494558</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_8e82065c38b4463cb75c905e217dc8bd"
      unitRef="U002">60161476</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_de9ac827d7464354846d0e8450cfce8f"
      unitRef="U002">59055075</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20240630"
      decimals="0"
      id="Fact_1610703be8d14131b468dd1feb95d5b8"
      unitRef="U002">152938</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="0"
      id="Fact_e3123f90e91241e09fb614e4acf21877"
      unitRef="U002">134132</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="c20240630"
      decimals="0"
      id="Fact_ec51644928f342fab65fffab15c9344e"
      unitRef="U002">181533</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="c20231231"
      decimals="0"
      id="Fact_79bdfa67c2564faea68c946258c3b0f4"
      unitRef="U002">200873</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="c20240630"
      decimals="0"
      id="Fact_4281ffb1886b4fcf81a360ce214507dc"
      unitRef="U002">60495947</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231"
      decimals="0"
      id="Fact_9e0f5b2a7aae49e0a944cd5525cb1a74"
      unitRef="U002">59390080</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_46d1f113f7064383b9c0a53ae3c621cb"
      unitRef="U002">3252490</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_786bc17e06704462a43e5cc423205c58"
      unitRef="U002">6982824</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_77f4221a3d974b8d89b110b90f8789c8"
      unitRef="U002">1947221</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_f5980f0733194e649c543011e04d0352"
      unitRef="U002">2424692</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_ce14fa90f5494ac79cfdd63233ef9645"
      unitRef="U002">10416667</us-gaap:SecuredDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_94d908d2f64f4532b23ca882e0b2309c"
      unitRef="U002">4166667</us-gaap:SecuredDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_c3b204cfdc6b4f5caed50e956c265830"
      unitRef="U002">58396</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_c4ead7d41220453493b668ae358966dc"
      unitRef="U002">55794</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_c9c498fc16054a4aa66ae8b81d8ce318"
      unitRef="U002">15674774</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_265b5300de1f4c238f300aa6f6149985"
      unitRef="U002">13629977</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="c20240630"
      decimals="0"
      id="Fact_e79f4575e7a24f05a2aa0ae73e620e02"
      unitRef="U002">13810194</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="c20231231"
      decimals="0"
      id="Fact_b4272ad0792244358be9eed96e8c20d7"
      unitRef="U002">19506183</us-gaap:SecuredLongTermDebt>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_68f4c5b4c5504fbdad7e92f20176f50c"
      unitRef="U002">93109</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_5099de4cb3a24d3389dd6cb3fde33fbc"
      unitRef="U002">122973</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20240630"
      decimals="0"
      id="Fact_ee4953fdccaa4d9f83a899fd467ecb68"
      unitRef="U002">29578077</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20231231"
      decimals="0"
      id="Fact_d48a783ef7c34207b4346111c6e48cd0"
      unitRef="U002">33259133</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20240630"
      id="Fact_b89f2e2578874178bf16bcc1e04dd3a1"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20231231"
      id="Fact_5aa038bc69c34112a5aef9902797a2cd"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="5"
      id="Fact_7fc4e9303fe54351bb936ee19fac6ba4"
      unitRef="U003">0.00033</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20240630"
      decimals="5"
      id="Fact_7d30ba7895bd44b5a86d32726ade556b"
      unitRef="U003">0.00033</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20240630"
      decimals="0"
      id="Fact_9ea3813345f04264ae05aad2f019aed8"
      unitRef="U001">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_c1d6edd4a74946dc86d394f8a8266b47"
      unitRef="U001">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20240630"
      decimals="0"
      id="Fact_f0f11dbb8be043328c4a902918a9f7f1"
      unitRef="U001">36779275</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20240630"
      decimals="0"
      id="Fact_60c96c45e048489194d15ac4f738b38d"
      unitRef="U001">36779275</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20231231"
      decimals="0"
      id="Fact_c505db1117d54edd9e5e1185e5b97229"
      unitRef="U001">33094521</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_4bb1937319384ea08ca73051de15f9c3"
      unitRef="U001">33094521</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="c20240630"
      decimals="0"
      id="Fact_a47bde7256bc458086cdb2556c8d25ed"
      unitRef="U002">12137</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20231231"
      decimals="0"
      id="Fact_b828a76b6b95439bbd99e74407b29be2"
      unitRef="U002">10921</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20240630"
      decimals="0"
      id="Fact_50674871eb3e46a584b9df2dbdafd92d"
      unitRef="U002">194337722</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20231231"
      decimals="0"
      id="Fact_d9f9ca9030864b54a06a464ad811e628"
      unitRef="U002">170620641</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20240630"
      decimals="0"
      id="Fact_7f6e65f53dea4969ada42ab21649e6c6"
      unitRef="U002">-163431989</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20231231"
      decimals="0"
      id="Fact_e5fa26da84dd45efbe0ac5bc5ebaa25f"
      unitRef="U002">-144500615</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20240630"
      decimals="0"
      id="Fact_08b733a4e2414b378a9aed24878392b1"
      unitRef="U002">30917870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="0"
      id="Fact_89d2a3f6b0aa42899a92a6294c698b6d"
      unitRef="U002">26130947</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20240630"
      decimals="0"
      id="Fact_8b3940b36839447b938cbc07d93e5530"
      unitRef="U002">60495947</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20231231"
      decimals="0"
      id="Fact_3180b1082b314039be709c6632793839"
      unitRef="U002">59390080</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_8bba540a61a4413faccfea9f3ae4f817"
      unitRef="U002">4527698</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_fd5627f320894633aa7860de8ca23890"
      unitRef="U002">8004852</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_60ce88eebee04e13821339f1516a7d49"
      unitRef="U002">11231862</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_eaa294547e034ac8802375de78cd1af6"
      unitRef="U002">13848538</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_5b78f82529644b048abc0c85b43ae6b2"
      unitRef="U002">4156606</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_fc09345edcf749d1b39251e3faa13f32"
      unitRef="U002">4691321</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_e1ac8b1e75134de6be703d1c502e7d8c"
      unitRef="U002">7550069</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_e4d4eca890a84f02bf8319cba6f1edcb"
      unitRef="U002">8270049</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_9aef51dd433c4069aeff637002eb389b"
      unitRef="U002">8684304</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_57b4430b66f74d9fb17fe684467c4354"
      unitRef="U002">12696173</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_96358d707af447a59eed7925afc22495"
      unitRef="U002">18781931</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_dafa5490aa4641598d8f94925b0d5359"
      unitRef="U002">22118587</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_898151dcf1644cd59b775729f9a90292"
      unitRef="U002">-8684304</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_5edb96973b724027b45f9390f263a93e"
      unitRef="U002">-12696173</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_3f8e84babafc444d940c15e80df89a8a"
      unitRef="U002">-18781931</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_55f1ee071a5947a281a65ebef312bba9"
      unitRef="U002">-22118587</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_cfd8d9f4cca14b1f8b89dac2662007fa"
      unitRef="U002">675209</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_f546e4c345224266b4572bc952e24ad7"
      unitRef="U002">750654</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_c72eb3371158441cb3df2babec54eede"
      unitRef="U002">1344104</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_14a025f188e74c01b7d1ec46d20657d3"
      unitRef="U002">1479995</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_39b65869a0fc438babeaed2d84f851dd"
      unitRef="U002">1187971</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_64688066719f4f7982e9c045fd507b57"
      unitRef="U002">995397</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_8ffbd5c0a9fa4f50a7ff8cfde83aeb44"
      unitRef="U002">2362716</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_db6c0fb8bd79405faf92eace357936b8"
      unitRef="U002">1962242</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_48abaa1ffa8c41c7ad6a9669ab79c8e0"
      unitRef="U002">-512762</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_c71b680948334f36a50bc3ef78b3b47c"
      unitRef="U002">-244743</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_cf42185cfb204234b631c15914d37691"
      unitRef="U002">-1018612</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_669db3e4ba764a36b50546bf4b19c450"
      unitRef="U002">-482247</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_f3b6d2ac2b544885b1b78ad1cb9eb5ad"
      unitRef="U002">-9197066</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_7b7e2675a18a4381a66dfdf14bf04af0"
      unitRef="U002">-12940916</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_c8a061bd96cd48d590b05fe5911f2dc6"
      unitRef="U002">-19800543</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_36345dc525824836b021e79d677f162b"
      unitRef="U002">-22600834</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_741a3bc5ce42437ebf5bde3b6ca22418"
      unitRef="U002">-869169</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_2fbc1f6ec23f4cab9be6dbe965034b63"
      unitRef="U002">-1406021</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_8875565866f04fad97fede3b00df085b"
      unitRef="U002">-869169</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_41e3216bba3f491b9fdee385492ef66e"
      unitRef="U002">-1406021</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_377ea27d197048f5942f829f477da39b"
      unitRef="U002">-8327897</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_c8e74a3f54754ac39f048f57d5655ce4"
      unitRef="U002">-8327897</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_168c4bd943c74e22990b18bddbaea573"
      unitRef="U002">-11534895</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_26f7a6d1b18248619a757ae546ef3889"
      unitRef="U002">-11534895</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_810abc1986434ae3a3079c95e9cddff9"
      unitRef="U002">-18931374</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_31fde16c696c42ba979f6f8f06f778cd"
      unitRef="U002">-18931374</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_9de7ba64ee8e4fa182f316fcfb74a14d"
      unitRef="U002">-21194813</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_fa688cb517e6427aa1dfb4e6dfc0cdd1"
      unitRef="U002">-21194813</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240401to20240630"
      decimals="2"
      id="Fact_843d6131b1344b5abc58409f48041fad"
      unitRef="U003">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240401to20240630"
      decimals="2"
      id="Fact_524e9b25a74a44b499d2bf8b8b6e73f6"
      unitRef="U003">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230401to20230630"
      decimals="2"
      id="Fact_00d43245b3ca4deba80dcfa6b75e1d6e"
      unitRef="U003">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230401to20230630"
      decimals="2"
      id="Fact_0f2d6c5a0b3f41c2a504bf9a4dd94a10"
      unitRef="U003">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20240630"
      decimals="2"
      id="Fact_01b8a864ef314062b7cb0c77d1e0cff7"
      unitRef="U003">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20240630"
      decimals="2"
      id="Fact_4d64c8a7c73f4f298033d85bb655d9e2"
      unitRef="U003">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230101to20230630"
      decimals="2"
      id="Fact_33ef74912c5b40c697f7297fd319b8ad"
      unitRef="U003">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230101to20230630"
      decimals="2"
      id="Fact_d8e5cb42cc494cb89598ace68a4074a5"
      unitRef="U003">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_c191ceb8a4e9404c8a7243fc8090441f"
      unitRef="U001">36693561</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_185868c66f3d4f17bf5677657b204c94"
      unitRef="U001">36693561</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_58fa32f85fbf475f99e3641379dcde87"
      unitRef="U001">30802498</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_68db77a33a334551993cf150bb508a98"
      unitRef="U001">30802498</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_7af4ec41069a445bb2fcfd3f8290a668"
      unitRef="U001">35754715</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_89edddddde5a47439dbc98e49215eb5d"
      unitRef="U001">35754715</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_16be6bf8c60f44d19a8ef1f960cd84c3"
      unitRef="U001">30616310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_dfb97dd9234e4da1961c0bbfecef1e66"
      unitRef="U001">30616310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a17f18e557ee453eb9b345ee86e10817"
      unitRef="U001">30170317</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6c87cf06e4344f1d9211f5c112e479dc"
      unitRef="U002">9956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_511f41f42528440ea8325a94861d1ca2"
      unitRef="U002">145550491</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_d34bac104ab2426ea302532f79b45316"
      unitRef="U002">-101558417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="0"
      id="Fact_3a31dea4cc304adab1341e91f0accd27"
      unitRef="U002">44002030</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_8b4457e26a7b4ffebca507e9cdc2c09c"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_b7cc6b9c7ea74b4f994c8650dcaeebdf"
      unitRef="U002">2080319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_1b297cf17dbf4fbbb2aaaf7d27b7277a"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_690ed19515384e1c9157b25169bb7314"
      unitRef="U002">2080319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b40f15915a074a118366ae28a34dc4df"
      unitRef="U001">553293</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_85dffa3f4df549eb9ab5c8f4d5f53d95"
      unitRef="U002">183</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_3663bb5de7dc4d5292a36e5b9fb7132f"
      unitRef="U002">4588339</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b5033d45247441a2a56c0d7283db88c8"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_9680e474dfb24de897c9bb3db591ef97"
      unitRef="U002">4588522</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ff7cc99dd1814c8bb80dff7a88d65f26"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_8d587fa7eb16423783d2f39dd1e6e0f2"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_426b3e6a049a42128e770a0f1ad0ffa1"
      unitRef="U002">-9659918</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_8f9c7a771886444fae5fbfca75bb2256"
      unitRef="U002">-9659918</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f2b6d1fb9ee8400296441c92c3c97e32"
      unitRef="U001">30723610</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_86cd78018b2e4add888676bb01f5cb1d"
      unitRef="U002">10139</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_d413b1cf114a40af8421545e281be822"
      unitRef="U002">152219149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_65d0918c4cc84c86a0047b04359965a0"
      unitRef="U002">-111218335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="0"
      id="Fact_c85a1a5e4a554f6a96a46409d5b9e36f"
      unitRef="U002">41010953</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b85c7ec911b3480ebf5444cad3d1d0bd"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_1f3370fc68d14f888eb92a8e8abed6a3"
      unitRef="U002">2105538</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_bb7476561dbe46cd954c1ffa0311a444"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_bee912fdb9e74e2d800f3a005cd60d64"
      unitRef="U002">2105538</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b5e1bccf07d8419b87791f922445e2ab"
      unitRef="U001">1409</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_dc6899b61ec746b4a51cde21f8c57655"
      unitRef="U002">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_f369d9748bd44041b7ff93f6b3bab9e2"
      unitRef="U002">8848</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_6ade92214ef94d5ca736adc32e0bff2b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_0086ef5ffd6442fa966e61209177fbf4"
      unitRef="U002">8849</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_63510e87950048a68de6da465788a29e"
      unitRef="U001">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_96edb979f57a43518642c7423961f938"
      unitRef="U002">33</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_0b8515dc5ce74900b86af418de4b306b"
      unitRef="U002">609967</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_3cafb53ffece480c9a4769a605221ed4"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_741c3fb923734502ac34386f608b3b70"
      unitRef="U002">610000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2c9e059cbabe4a36bf3394344aa007a6"
      unitRef="U001">43169</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e46106bc44ec4ecf96b32b8d97703e74"
      unitRef="U002">14</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_4e1430e0dbfe477aa807b82022c617f4"
      unitRef="U002">243729</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_40f0e21ea0ba4d3596d326d2c6148be1"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_b47f196eedb148be8d5c2d5119073abf"
      unitRef="U002">243743</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7f502060fb224d63aed8d554784d1dd3"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_e41678e80515408c8bbcf24adfb9ab6a"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_e786e9af6dc547679a1c10fa8746d577"
      unitRef="U002">-11534895</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_449bf0e5bb824f9584f29a3881304880"
      unitRef="U002">-11534895</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3ceef7e34b454135a68b80a937afd5ed"
      unitRef="U001">30868188</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5ba641eef356458187afee7cc0b888d3"
      unitRef="U002">10188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_db53b31ccb6c419bbba68b32b23752c3"
      unitRef="U002">155187231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b3b0f61b06724ac68b273da4d2c64a72"
      unitRef="U002">-122753230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630"
      decimals="0"
      id="Fact_40e6a6c748d04c0087ac656e02ac8e7d"
      unitRef="U002">32444189</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_072bee52c106457c86537fd1b853f60e"
      unitRef="U001">33094521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d4b889cfacc346acb1a8e5dfe4b8e3b7"
      unitRef="U002">10921</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_c22de3d64b7d4909a6392c3016acac01"
      unitRef="U002">170620641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_e6d4f19c24454031acd521ec311b58e8"
      unitRef="U002">-144500615</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="0"
      id="Fact_aca96ffd59e9401394bb5c370ade91da"
      unitRef="U002">26130947</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d56e24862104405ba96c470b0c5a507e"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_4d56635128854c1e8cddbd744611499b"
      unitRef="U002">1630011</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_23dba73f6ee84414871e4385d8fb7c7a"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_03688abcd4da4b7aa2305dea2d82322b"
      unitRef="U002">1630011</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_33b829a3541d4a8a86b8158acb78b304"
      unitRef="U001">3428681</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4dfa382e0007474085c3b1ad4b320dfb"
      unitRef="U002">1131</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_3a02eb81c3994f40bac63d6a55ce06ff"
      unitRef="U002">19493342</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_d8b1ee21a0cb42c98450ef64468ea012"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_f150f45c2e50497788e728e25403d1cd"
      unitRef="U002">19494473</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_48937b3ee3a54b7c8f4482535451f19a"
      unitRef="U001">156073</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f1b973da455f4f12805872dec6d2f301"
      unitRef="U002">52</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_190d16b1c2484a1c86dc05498b366de2"
      unitRef="U002">531039</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_3d1dbb0554d64eecbc503b6b78975a0a"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_407b79332b4d4a62aa0c02901e0f1878"
      unitRef="U002">531091</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_94d3fd92b5064269bde0299620830d7c"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_a794180720ef4128b5b6d4fc2446190a"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b8147a09fd0442e78e62f4df4ed9d3b0"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331"
      decimals="0"
      id="Fact_e157fabb85b745e1932a472cbf7796e5"
      unitRef="U002">-10603477</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_83f27d7992ca4ce38ae96a66f6d63597"
      unitRef="U001">36679275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4c499ff1726c4752b57aa3059e2d7833"
      unitRef="U002">12104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_6ba72e7db42744c2af96276ec0f7f0e9"
      unitRef="U002">192275033</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_4821885b92004a529b329ab49377a98f"
      unitRef="U002">-155104092</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331"
      decimals="0"
      id="Fact_6d2558224bab4ed88eefcd02275acf18"
      unitRef="U002">37183045</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_55e84919f4d447e6871c51d747267c5b"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_cb691ab584cd41d9bce0e3d5ed1143a4"
      unitRef="U002">1795722</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_09f20ccd89394565bce47b581e9f910a"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_feba92dd57fa49c381ae4bc87588edd5"
      unitRef="U002">1795722</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_77c4e1bf646a44b6970417d5b414bd8b"
      unitRef="U001">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f9a8f7d0af8444f0a05172e33d0b5ab1"
      unitRef="U002">33</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_e1e4d1ecb1374d57880d742101331383"
      unitRef="U002">266967</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_e796889cbc5148e991f85c5faeafabb1"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_0e871a26d44b4bfda5ebbc687e88f187"
      unitRef="U002">267000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f06854d265a5405f98b10984b0e5c414"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_bfd14e1d54624ce1aab7d2dd30f71798"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_25cbc41faaed41c1b338609faac4adbc"
      unitRef="U002">-8327897</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_6403afe5eab345149fe7550a2a19a897"
      unitRef="U002">-8327897</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9cce72280d284a9599dc859108110d3b"
      unitRef="U001">36779275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fba67b7742be4d77a97121246f69178f"
      unitRef="U002">12137</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_d5a9819ca3984b069f6b69b6182d72e2"
      unitRef="U002">194337722</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_1b2529990feb492a92e7726e8e52c909"
      unitRef="U002">-163431989</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240630"
      decimals="0"
      id="Fact_4de60f016f7f4195a01e8f656e3da696"
      unitRef="U002">30917870</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_d371d6fbe1354307a068ad80d618fff1"
      unitRef="U002">-18931374</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_94324c0eb01f4d78ab4b8a7ab7648aa5"
      unitRef="U002">-21194813</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_19524dc183204ac1b88f093e14182f09"
      unitRef="U002">3425733</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_7a171c8858d841dbad59a31eb2bc56ed"
      unitRef="U002">4185857</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_9ce9a1b0760740348462701707abc445"
      unitRef="U002">267000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_7c38ed89148044379746f406ebb4109b"
      unitRef="U002">610000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_37285b0b0389433395bf5663b8bb67de"
      unitRef="U002">554010</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_311932628c8646a6a3621521ecbf96f5"
      unitRef="U002">233523</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:Depreciation
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_9fd022416b1f49e79fdbcaed89bec187"
      unitRef="U002">10194</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_5bfa810d6a294d5ba208c0bcac554954"
      unitRef="U002">7891</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_54f58908287d426daaabae3c8f08cc91"
      unitRef="U002">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_75dc8cdf88624289874cc5c58695b644"
      unitRef="U002">120514</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_f9f9eb8d87ed45ef9b05ab7106143ce6"
      unitRef="U002">19339</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_9cdb85ab45414581b426c66fffd02146"
      unitRef="U002">20627</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_858f426ff4c74716a781aa7e8902fa7f"
      unitRef="U002">-66806</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_ab269d9c446b4856834a99390a2a02eb"
      unitRef="U002">65728</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_87b046b4525c476c995ef62d960b674d"
      unitRef="U002">-3730334</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_11bb94511a874f9ea2829ea6780ffdca"
      unitRef="U002">3195618</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_6364081558654232864d83f82cf9070a"
      unitRef="U002">-477471</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_05fb6f2adfcd48fbb150347bcfd8059e"
      unitRef="U002">-4937383</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_d7fcc916ba3847ecab7cda9d4a04f771"
      unitRef="U002">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_606bab05064b4b0692cae6a09cbd5760"
      unitRef="U002">-179136</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_4e49e35b1f0c44c28361e9edacc7f926"
      unitRef="U002">-18796097</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_9cb099844ff24203bf74c4e5bfd94901"
      unitRef="U002">-18003030</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_482967e9f8f3417f868054fa9dc1e163"
      unitRef="U002">28999</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_1ef334a8d6ad44f18c0a587db76f62dc"
      unitRef="U002">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_4fd31d7799e54baca82c7034ffbae15c"
      unitRef="U002">-28999</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_1f95d420f0244007b8d59ed3792534c0"
      unitRef="U002">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_cc415224efb04d25ba05cc173d5caabc"
      unitRef="U002">531091</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_4ba380215ecf48b8b842cf784e297b25"
      unitRef="U002">8849</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_11d1a799fb194ab6936a7c8ece91fa36"
      unitRef="U002">27261</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_218e611bada94a729337f19ad71e93a3"
      unitRef="U002">33253</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_dba17d320dfc44b99bfb3c92ff3af270"
      unitRef="U002">19494473</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_be8c38940bc141a8bd95dc5072e3760a"
      unitRef="U002">4832265</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_445ab690f49748789b8fedc0156e06b0"
      unitRef="U002">19998303</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_5bc4bc501f644d5bb90284b0e1ae8215"
      unitRef="U002">4807861</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_5ebec0ba6e744fe6866f6d146f5845e7"
      unitRef="U002">1173207</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_bedab34420c148fab5f78ba13a80b8e8"
      unitRef="U002">-13195169</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="0"
      id="Fact_16d44bf0396249b5961782ff1359c1bf"
      unitRef="U002">56560517</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="0"
      id="Fact_769d18960d694648b7413513b3783c55"
      unitRef="U002">73820160</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20240630"
      decimals="0"
      id="Fact_da0da21904364fa99772b2598d26579f"
      unitRef="U002">57733724</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230630"
      decimals="0"
      id="Fact_2ee0b3c36cbf4ef2bcba60cc7c318854"
      unitRef="U002">60624991</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_31fc71d4c27340618443e63d4280769b"
      unitRef="U002">2362716</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_cc599f1b77cb4715a59577a5d57ffda0"
      unitRef="U002">1962241</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="c20240101to20240630"
      id="Text_f99c036f06914cada08548bd403cf17e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;Note 1 &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013; &lt;/span&gt;Nature of Operations&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"&gt;&lt;span style="font-size: 10pt; font-style: normal; font-weight: bold;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;PDS Biotechnology Corporation, a Delaware corporation (the &#x201c;Company&#x201d; or &#x201c;PDS Biotech&#x201d;), is a clinical-stage immunotherapy
                            company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome limitations of current immunotherapy and vaccine technologies. The Company develops proprietary platforms designed to train and
                            enable the immune system to attack and destroy disease; Versamune&#xae;, and Versamune&#xae; in combination with PDS01ADC for treatments in oncology and Infectimune&#xae; for treatments in infectious diseases.&#160; When paired with an antigen,
                            which is a disease-related protein that is recognizable by the immune system, Versamune&#xae; and Infectimune&#xae; have both been shown to induce, &lt;span style="font-style: italic;"&gt;in vivo&lt;/span&gt;, large quantities of high-quality,
                            highly potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of
                            Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the limitations of cytokine therapy which previously has resulted
                            in high toxicity and limited therapeutic potential.&#160; The Company&#x2019;s infectious disease candidate, Infectimune&#xae;, is of potential interest for use in universal influenza vaccines. and is designed to promote the induction of
                            disease-specific neutralizing antibodies.&#160; The Company&#x2019;s immuno-oncology product candidates are of potential interest for use as a component of combination product candidates (for example in combination with other leading
                            technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage
                            disease.&#160; The Company is developing targeted product candidates to treat several cancer tumors, including Human Papillomavirus (HPV) associated cancer in head and neck squamous cell carcinoma, melanoma, colorectal, lung, breast
                            and prostate&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;.&lt;br/&gt;
                            &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="c20240101to20240630"
      id="Text_b2e98eba8f0e4774b2d74a1c8f25a31f">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 2 &#x2013; Summary of Significant Accounting
            Policies&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(A)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Unaudited interim financial statements:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; unaudited financial
                statements for all periods presented are referred to as &#x201c;Condensed Consolidated Financial Statements&#x201d;, and have been prepared by the Company in United States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. Accordingly, these notes to the unaudited condensed consolidated financial statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities
                and Exchange Commission (&#x201c;SEC&#x201d;) on March 28, 2024. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited
                consolidated financial statements for the year ended December 31, 2023. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;ent of the Company&#x2019;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(B)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Use of estimates:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the condensed consolidated financial
            statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the condensed consolidated financial statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(C)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant risks and uncertainties:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#x2019;s ability to complete clinical trials necessary to obtain regulatory &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;product licenses, the regulatory approvals needed to pursue &lt;/span&gt;development







                          of its clinical and product candidates&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the Company&#x2019;s adherence to covenants under its debt agreement, the Company&#x2019;s&lt;/span&gt; ability to preserve its cash resources, the Company&#x2019;s ability to add clinical and product
                          candidates to its pipeline, the Company&#x2019;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#x2019;s ability to raise capital.&lt;br/&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#x2019;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(D)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash equivalents and concentration of cash balance:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#x2019;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(E)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#x2019;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(F)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Patent costs:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(G)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock-based compensation:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#x2014;Stock Compensation
              (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.&lt;/span&gt; The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they
              occur.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(H)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Net loss per common share:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2023&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,563,211&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,324,402&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;466,112&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;506,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;6,029,323&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,830,631&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(I)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Income taxes:&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;(J)&lt;/div&gt;
                                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;Fair value of financial instruments:&lt;/div&gt;
                                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 1 &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;(K)&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;Leases:&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#x201c;ASC 842&#x201d;). Both financing and operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#x2019;s condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; &lt;br/&gt;
                &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(L)&lt;/div&gt;
                            &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;New accounting standards:&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
                      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Recently issued accounting pronouncements did not, or are not believed by the Company to, have a material effect on our present or future Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none;"&gt;Recent Accounting Pronouncements Not Yet
                            Adopted&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to
                              Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative
                              threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that
                              adopting this standard will have on the consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_ae15636a958f48f590ed8b2b8efa9524">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(A)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Unaudited interim financial statements:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; unaudited financial
                statements for all periods presented are referred to as &#x201c;Condensed Consolidated Financial Statements&#x201d;, and have been prepared by the Company in United States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S. generally accepted accounting
                principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements.
                Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. Accordingly, these notes to the unaudited condensed consolidated financial statements should be
                read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities
                and Exchange Commission (&#x201c;SEC&#x201d;) on March 28, 2024. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited
                consolidated financial statements for the year ended December 31, 2023. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statem&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;ent of the Company&#x2019;s financial position and results of
                  operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other subsequent interim period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20240101to20240630"
      id="Text_8e8f7dfa7f71490682a0f73c10591bb1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(B)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Use of estimates:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The preparation of the Condensed Consolidated Financial
            Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the condensed consolidated financial
            statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the condensed consolidated financial statements. Actual results could differ from those estimates. The most significant estimate
            relates to the fair value of securities underlying stock-based compensation.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_c545e5abd9404e599145b2e2902aa2a4">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(C)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant risks and uncertainties:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the Company&#x2019;s ability to complete clinical trials necessary to obtain regulatory &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;product licenses, the regulatory approvals needed to pursue &lt;/span&gt;development







                          of its clinical and product candidates&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, the Company&#x2019;s adherence to covenants under its debt agreement, the Company&#x2019;s&lt;/span&gt; ability to preserve its cash resources, the Company&#x2019;s ability to add clinical and product
                          candidates to its pipeline, the Company&#x2019;s ability to protect its intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if
                          approved for sale, the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company&#x2019;s ability to raise capital.&lt;br/&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#x2019;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.&lt;/div&gt;
</pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_01bbd76af7a6433f8426790f730739da">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(D)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash equivalents and concentration of cash balance:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company considers all highly liquid securities with a
            maturity of less than three months to be cash equivalents. The Company&#x2019;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20240101to20240630"
      id="Text_17d0a550b2da44a2a4ae7181cf80533c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(E)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#x2019;s research and development projects as well as fees paid to consultants and vendors that perform certain research activities and
            testing on behalf of the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for
            these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs incurred.&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_d55a0bcd06fb41e088a5e0ddd7a36446">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(F)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Patent costs:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/div&gt;
</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20240101to20240630"
      id="Text_b1e49b3b2a11499ea3e20799bd91936b">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(G)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock-based compensation:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#x2014;Stock Compensation
              (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the condensed consolidated statements of operations and comprehensive loss based on their grant date fair values.
              In order to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free
              interest rate and dividend yield. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;While the risk-free
                interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of judgment.&lt;/span&gt; The
              Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they
              occur.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_267cafa3f35f467f880e864ab04514b9">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(H)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Net loss per common share:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2023&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,563,211&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,324,402&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;466,112&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;506,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;6,029,323&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,830,631&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20240101to20240630"
      id="Text_bd6c17c1239342398b7bffdd5d70af4d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp;amp; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2023&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,563,211&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,324,402&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;466,112&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;506,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;6,029,323&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,830,631&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_aac1457e1cae4c8797be9a328686ddb5"
      unitRef="U001">5563211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3df308594a5642929508521c9449f647"
      unitRef="U001">5324402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20240630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_053877254e9b4087845f1c3083ffd80a"
      unitRef="U001">466112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_053064ddb00f45bdbea9fef6ff02a7f3"
      unitRef="U001">506229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_3fbb9c257ee148939e9aac3f79f48205"
      unitRef="U001">6029323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_f77aa823c9474205afaba74a4409de95"
      unitRef="U001">5830631</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_947124b4214a4a51a357f82d9362a009">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(I)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Income taxes:&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20240101to20240630"
      id="Text_9d8ae5da59e54622be3ed11c8b60726e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;(J)&lt;/div&gt;
                                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;Fair value of financial instruments:&lt;/div&gt;
                                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 1 &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_c4f1c03d02eb48d48ca03d4b57b9c3d2">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;(K)&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;Leases:&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#x201c;ASC 842&#x201d;). Both financing and operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#x2019;s condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s
                  obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the
                  portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.&lt;/div&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20240101to20240630"
      id="Text_1ab6e075e98548aa9c38121d7d665840">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(L)&lt;/div&gt;
                            &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;New accounting standards:&lt;/span&gt;&lt;/div&gt;
                            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
                      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Recently issued accounting pronouncements did not, or are not believed by the Company to, have a material effect on our present or future Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-variant: normal; text-transform: none;"&gt;Recent Accounting Pronouncements Not Yet
                            Adopted&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to
                              Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative
                              threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that
                              adopting this standard will have on the consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <pdsb:LiquidityAndCapitalResourcesTextBlock
      contextRef="c20240101to20240630"
      id="Text_3c4156a7dd5c4ae7a6d201702ce741d3">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 3 &#x2013; Liquidity &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;and &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Capital Resources&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;As of June 30, 2024, the
              Company had $57.7 million of cash and cash equivalents. The Company&#x2019;s primary use of cash is to fund operating expenses, primarily
              research and development expenditures. Cash used to fund operating expenses is impacted by &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;the level of activities undertaken, as well as&lt;/span&gt; &lt;/span&gt;the timing of when the Company pays these expenses, as reflected in the change to the Company&#x2019;s outstanding accounts payable and
              accrued expenses.&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal&lt;/span&gt;&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable.&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In addition, the Loan and Security Agreement allows for the lenders to call the outstanding balance of the term loans if the minimum
                cash balances outlined in the Loans and Security Agreement are not maintained.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company funds its operations through equity and/or debt financings such as the following:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $150
              million, $50 million of which covers the offer, issuance and sale by the Company of its common stock under the Sales Agreement (as
              discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
              Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
              having an aggregate offering price of up to $50 million, or the Placement Shares, through or to the Agents, as sales agents or
              principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in
              Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#x2019;s common stock. The Agents will use commercially
              reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#x2019;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
              Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under
              the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of Placement
              Sh&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;ares pursuant to the Sales Agreement will terminate upon the
                earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. For the year ended December 31, 2023, the Company sold 2,642,269 shares of common stock for a net value of $16.1 million pursuant to the Sales Agreement. During the three and six months ended June 30, 2024, the company sold 0 and 3,428,681 shares, respectively, of its common
                stock with a net value of $0.0 million and $19.5 million, respectively, pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders. The Loan and Security Agreement provides for the following 6 separate and independent term loans: (a) a term loan in the amount of $7,500,000,
                or Loan A, (b) a term loan in the amount of $10,000,000, or Loan B, (c) a term loan in the amount of $3,750,000, or Loan C, (d) a term loan in the amount of $3,750,000, or Loan D, (e) a term loan in the amount of $5,000,000, or
                Loan E, and (f) a term loan in the amount of $5,000,000, or Loan F, (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and
                Loan F, individually a Loan and, collectively, the Loans). Loan A, Loan B, Loan C&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;, and Loan D were delivered to the Company on August 24, 2022.&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In total, the Company received $24.6 million in net proceeds.&lt;/span&gt; &lt;/span&gt;Loan E and Loan F &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;were&lt;/span&gt; uncommitted Loans that could have been advanced by the lenders upon the parties agreement prior to July 31, 2023 upon the satisfaction of certain conditions. &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;At&lt;/span&gt; this &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;time, the &lt;/span&gt;option&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; to advance
                  Loan E and Loan F has expired and Loan E and Loan F are &lt;/span&gt;no &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;longer available&lt;/span&gt; to the Company &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;under







                  the Loan and Security Agreement&lt;/span&gt;. The Company may only use the proceeds&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; of the Loans for working capital or general corporate purposes. Each Loan matures on the 48-month
                  anniversary following the applicable funding date unless accelerated pursuant to certain events of default.&lt;/span&gt; Payments on the principal balance begin on October 1, 2024 and are paid monthly over the succeeding 24 months. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) &lt;/span&gt;the per annum rate of
                interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#x201c;&lt;span style="-sec-ix-hidden:Fact_422456f8ef2547ffa808d9e7f65aa170"&gt;prime rate&lt;/span&gt;&#x201d; then in effect, plus (b) 5.75%; provided that, in the event such rate of interest
                is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding the preceding month. The Company, at its
                option upon at least ten (10) business days&#x2019; written notice to the lenders, may prepay all (and not less than all) of the
                outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an amount equal to (A) if such Loan is prepaid on or before the
                Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, 3% of the then outstanding
                principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan, but on or before the date that is 12 months after such Loan Amortization Date, 2% of the then outstanding principal balance of
                such Loan, or (C) if such Loan is prepaid more than 12 months after the Loan Amortization Date but prior to the stated maturity
                date applicable to such Loan, 1% of the then outstanding principal balance of such Loan;&#160;&lt;span style="font-style: italic;"&gt;plus&lt;/span&gt;&#160;(iii)
                the outstanding principal balance of such Loan;&#160;&lt;span style="font-style: italic;"&gt;plus&lt;/span&gt;&#160;(iv) all other sums, if any, that shall have become due and payable thereunder. No prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Loan and Security Agreement contains customary representations, warranties and covenants, including &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;maintenance of minimum cash balances as well as&lt;/span&gt; &lt;/span&gt;covenants






















              by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates, and
              fundamental changes.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In April 2023, the Company received approximately $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company&#x2019;s participation in the New Jersey Technology
                Business Tax Certificate Transfer NOL program for tax year 2021.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In April 2024, the Company received approximately $0.9 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to its participation in the New Jersey Technology Business Tax Certificate
                  Transfer of Net Operating Loss (NOL) program for tax year 2022.&lt;br/&gt;
                &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its
                  ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, the Company has experienced net losses and negative cash
                  flows from operations each fiscal year. The Company has no revenues and expects to continue to incur operating losses for the foreseeable future and may never become profitable. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In addition, the Loan and Security Agreement allows for the lenders to call the outstanding balance of the
                    term loans if the minimum cash balances outlined in the Loan and Security Agreement are not maintained.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s estimated cash requirements in 2024 and beyond include expenses related to continuing development and clinical trials as
                  well as payments on its debt. The Company plans to execute its operating plan by obtaining additional capital, principally through issuance of equity through separate offerings or an at-the-market facility, issuance of debt, or by
                  entering into collaborations, strategic alliances, or license agreements with third parties. However, there is no assurance that sufficient additional capital and/or financing will be available to the Company, and even if available,
                  whether it will be on terms acceptable to the Company or its existing shareholders. The Company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization. The sale
                  of additional equity would result in dilution to the Company&#x2019;s stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants
                  that would restrict its operations. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects,
                  grant rights to third parties to develop and market immunotherapies that the Company would otherwise prefer to develop and market itself, or cease operations entirely. Any of these actions could harm its business, results of operations
                  and prospects. Failure to obtain adequate financing may also adversely affect the Company&#x2019;s ability to operate as a going concern.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As a result of these uncertainties, and as its plans are outside of management&#x2019;s control, the Company has concluded that substantial doubt
                  exists about the Company&#x2019;s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements. The unaudited Condensed Consolidated
                  Financial Statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
</pdsb:LiquidityAndCapitalResourcesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20240630"
      decimals="-5"
      id="Fact_9955260197d743888d4cca1dd369702a"
      unitRef="U002">57700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <pdsb:ShelfRegistrationStatementAvailableForFutureSale
      contextRef="c20220831"
      decimals="-6"
      id="Fact_710c6c366f93414fa1c39e3bff61a838"
      unitRef="U002">150000000</pdsb:ShelfRegistrationStatementAvailableForFutureSale>
    <pdsb:PlacementSharesAvailableForFutureSale
      contextRef="c20220831"
      decimals="-6"
      id="Fact_6b522faf850b4f94a418be586f4d2c8e"
      unitRef="U002">50000000</pdsb:PlacementSharesAvailableForFutureSale>
    <pdsb:PlacementSharesAvailableForFutureSale
      contextRef="c20220831"
      decimals="-6"
      id="Fact_2665b6875c894711877e6ea794fd90b8"
      unitRef="U002">50000000</pdsb:PlacementSharesAvailableForFutureSale>
    <pdsb:CommissionPercentage
      contextRef="c20220801to20220831"
      decimals="2"
      id="Fact_50ac525485634764ab592c355f7198f0"
      unitRef="U004">0.03</pdsb:CommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_8fa3752f833a45a2b39d68d8c78f1fe1"
      unitRef="U001">2642269</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_25d09146f7c84a529f0f9dbade4972e1"
      unitRef="U002">16100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_342229c574364f5796bb42324c157d0a"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_7ebc0eb766b54c79a999988fe70a47bd"
      unitRef="U001">3428681</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240401to20240630"
      decimals="-5"
      id="Fact_d4b59f780dc04e2bbc03e860cb5f38bc"
      unitRef="U002">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20240630"
      decimals="-5"
      id="Fact_68d4eca5736742ef930c000325165aad"
      unitRef="U002">19500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pdsb:DebtInstrumentNumberOfIndependentTermLoans
      contextRef="c20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_80bcd4963d084d8ca38b95c1d6988c8c"
      unitRef="U005">6</pdsb:DebtInstrumentNumberOfIndependentTermLoans>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanAMember"
      decimals="0"
      id="Fact_a72c635b19fd47bc8440f1c38bb35ab1"
      unitRef="U002">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanBMember"
      decimals="0"
      id="Fact_10ef9d1a844f468b84eb8111885e1a33"
      unitRef="U002">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanCMember"
      decimals="0"
      id="Fact_fca85b253a8947579723127eee15bfca"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanDMember"
      decimals="0"
      id="Fact_27e20ebff30544cb88d718435d5dbaec"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20240630_DebtInstrumentAxis_LoanEMember"
      decimals="0"
      id="Fact_f028c1bf3abe447292b5a9d0d57a8b28"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20240630_DebtInstrumentAxis_LoanFMember"
      decimals="0"
      id="Fact_73a94544ccc74bbd8e4ceb25771a5c05"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="c20220824to20220824_DebtInstrumentAxis_TermLoansMember"
      decimals="-5"
      id="Fact_c870a63c32cf4e06af15becab34aa190"
      unitRef="U002">24600000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_7205ebdef8854f8492ba9bbdab1fa024">P48M</us-gaap:DebtInstrumentTerm>
    <pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_0adfb56132e140cba0f3d2c4194ff386">P24M</pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="4"
      id="Fact_178a4bdbf571470fa22199f7546d883b"
      unitRef="U004">0.0575</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <pdsb:DebtInstrumentMinimumVariableRate
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="4"
      id="Fact_b4828118bc2449d290594ffd59af6bb6"
      unitRef="U004">0.04</pdsb:DebtInstrumentMinimumVariableRate>
    <pdsb:DebtInstrumentMinimumVariableRate
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="4"
      id="Fact_2ddc8f2e87e3414fb814b97f0f43190c"
      unitRef="U004">0.04</pdsb:DebtInstrumentMinimumVariableRate>
    <pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      id="Fact_f64fd241826842079b8530f30c998727">P10D</pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod1
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_aab36050e8b64e34a5b2213be97703b1"
      unitRef="U004">0.03</pdsb:DebtInstrumentPrepaymentPremiumPeriod1>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_86915a0f1d9e4c3589ba7497d5f33bc0">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod2
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_daa28246c4fe4146807689479fd27bd6"
      unitRef="U004">0.02</pdsb:DebtInstrumentPrepaymentPremiumPeriod2>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_34abab4d1da74f43952d29b79bab39bd">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod3
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_b71d39a87b0f4f6185a2c6ea68eb2a67"
      unitRef="U004">0.01</pdsb:DebtInstrumentPrepaymentPremiumPeriod3>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod4
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_33c9969ab5e44e80b39cab83536419cf"
      unitRef="U004">0</pdsb:DebtInstrumentPrepaymentPremiumPeriod4>
    <pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
      contextRef="c20230401to20230430"
      decimals="-5"
      id="Fact_b7d2e6593e2e461c96a0808d75382653"
      unitRef="U002">1400000</pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards>
    <pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
      contextRef="c20240401to20240430"
      decimals="-5"
      id="Fact_b945e7b0a8224bd4a18d617b95f911ab"
      unitRef="U002">900000</pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20240101to20240630"
      id="Text_73560b82835844c09425c66d391eb93d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 4 &#x2013; Fair Value of Financial Instruments&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;There were no transfers among Levels 1, 2, or 3 during the
            three and six months ended June 30, 2024 or 2023.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Fair Value Measurements at Reporting Date Using&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Active Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Inactive Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Unobservable Inputs&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 3)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of June 30, 2024: (unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;57,733,724&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;57,733,724&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;56,560,517&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;56,560,517&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
           &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;The carrying value of the &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Loan and Security Agreement&lt;/span&gt; approximated its fair value as of June 30, 2024 due to its variable rate.&lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="c20240101to20240630"
      id="Text_95e08fa664cb47879671c705ca11674d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Fair Value Measurements at Reporting Date Using&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Active Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Inactive Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Unobservable Inputs&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 3)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of June 30, 2024: (unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;57,733,724&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;57,733,724&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; margin-left: 9pt;"&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;56,560,517&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;56,560,517&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20240630"
      decimals="0"
      id="Fact_30262a55937948d5a3ec41762a7e22c5"
      unitRef="U002">57733724</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_1252c83466184058ae8acadff6d4028e"
      unitRef="U002">57733724</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_3363e1e1a2044e5bb8311b091ee60d7a"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20240630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_ab073a35efde4428afb5fbfc4288be23"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231"
      decimals="0"
      id="Fact_fe569a42a4dd45fb9f2ea547d56daf34"
      unitRef="U002">56560517</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_668be085eb044880ad9651725c8dd538"
      unitRef="U002">56560517</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_1f8ae74868454b428ec005c0ed673f37"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_b598ee9dc44e4b8ea534194337c95188"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20240101to20240630"
      id="Text_ebe6318ebed84497b71801388d219988">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 5 &#x2013; Leases&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Operating Lease:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 with a term of forty (40) months with an option to renew through October 31, 2027. The sublease term expired on August 31, 2023, and was not renewed. Upon inception of
              the sublease, the Company recognized approximately $0.7 million of&#160; ROU assets and operating lease liabilities. The discount
              rate used to measure the operating lease liability as of May 1, 2020 was 9.15%. Throughout the period described above, the Company
              has maintained, and continues to maintain, a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Supplemental cash flow information related to operating
            leases is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="7" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Cash paid for operating lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;179,136&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="c20240630"
      decimals="0"
      id="Fact_7cddf27e8fff4bbebe3595f9943b04f1"
      unitRef="U006">11200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="c20240630"
      id="Fact_7ffb3691adaa4de892aa46f62cb456dc">P40M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20200501"
      decimals="-5"
      id="Fact_a8e35e4a7c794dffaa95c6047074ca30"
      unitRef="U002">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20200501"
      decimals="-5"
      id="Fact_5f36a6ab264545e0af62254dc09deef6"
      unitRef="U002">700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c20200501"
      decimals="4"
      id="Fact_060db95296534a09b19b139870a9fcd0"
      unitRef="U004">0.0915</us-gaap:LesseeOperatingLeaseDiscountRate>
    <pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock
      contextRef="c20240101to20240630"
      id="Text_e53fc6fae7d04841af06125cd44cb1e0">
&lt;div&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Supplemental cash flow information related to operating
            leases is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="7" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Cash paid for operating lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;179,136&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_373734314b5f4d689f1d3eae81d11487"
      unitRef="U002">0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_3bad8866750347ccacc9545e39524ae0"
      unitRef="U002">179136</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="c20240101to20240630"
      id="Text_41fd09658afd4ab184eb1cf9960421fd">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Financing Lease:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The Company has financed certain
              laboratory equipment as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="7" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash paid for finance lease liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;34,925&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;43,221&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"&gt; Maturity of the Company&#x2019;s financing lease liabilities is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended December 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;34,925&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;69,850&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2026&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,108&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2027&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;26,723&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2028 and after&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total future minimum lease payments&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;171,607&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Less imputed interest&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(20,102&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining lease liability&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;151,505&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;The Company entered into four
              financing leases for laboratory equipment with a total cost of $251,959 with &lt;span style="-sec-ix-hidden:Fact_1d2392fd0bf043fea9df39565196af84"&gt;four&lt;/span&gt; to five-year terms and a capitalized interest rate of
              9.15%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $6,000. During the year ended December 31, 2023, the Company exercised the bargain
              purchase option, which resulted in recognition of property and equipment of $151,490.&lt;/div&gt;
</us-gaap:LesseeFinanceLeasesTextBlock>
    <pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock
      contextRef="c20240101to20240630"
      id="Text_b073d91e77ab4362937f69077b4cbdb8">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The Company has financed certain
              laboratory equipment as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="7" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash paid for finance lease liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;34,925&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;43,221&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock>
    <pdsb:FinanceLeasePrincipalAndInterestPayments
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_0c10c947a5a44051a08fe5806c47b3c5"
      unitRef="U002">34925</pdsb:FinanceLeasePrincipalAndInterestPayments>
    <pdsb:FinanceLeasePrincipalAndInterestPayments
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_1bf5435942e741d080c5f8e845bc79f1"
      unitRef="U002">43221</pdsb:FinanceLeasePrincipalAndInterestPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="c20240101to20240630"
      id="Text_b058af5d7b1f4beda78c3242f6dbdf5d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"&gt; Maturity of the Company&#x2019;s financing lease liabilities is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended December 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;34,925&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;69,850&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2026&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,108&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2027&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;26,723&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2028 and after&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total future minimum lease payments&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;171,607&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Less imputed interest&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(20,102&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining lease liability&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;151,505&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20240630"
      decimals="0"
      id="Fact_67e34b91c5d54def9140387930276a52"
      unitRef="U002">34925</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20240630"
      decimals="0"
      id="Fact_bb40ccf3945c46ddb566015b44c9e24b"
      unitRef="U002">69850</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20240630"
      decimals="0"
      id="Fact_dfd0bc168b4644ba9a651749777fe53b"
      unitRef="U002">40108</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="c20240630"
      decimals="0"
      id="Fact_86b681387e7f4961a8b785dd950af103"
      unitRef="U002">26723</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <pdsb:FinanceLeaseLiabilityToBePaidYearFourAndThereafter
      contextRef="c20240630"
      decimals="0"
      id="Fact_4094e13f7e754a3e871a092479348f3d"
      unitRef="U002">1</pdsb:FinanceLeaseLiabilityToBePaidYearFourAndThereafter>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="c20240630"
      decimals="0"
      id="Fact_a46a17cbf611417b83c0d12cb0b98625"
      unitRef="U002">171607</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20240630"
      decimals="0"
      id="Fact_5c853d4b574c4fa8ac554e529cd90662"
      unitRef="U002">20102</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="c20240630"
      decimals="0"
      id="Fact_964abaef68fa4215b3a64504b837136c"
      unitRef="U002">151505</us-gaap:FinanceLeaseLiability>
    <pdsb:LesseeFinanceLeaseNumberOfLeases
      contextRef="c20240101to20240630"
      decimals="INF"
      id="Fact_6d95c0c36aad49c79e15e7f07e043a75"
      unitRef="U007">4</pdsb:LesseeFinanceLeaseNumberOfLeases>
    <pdsb:FinanceLeaseCost
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_05386836a411454985f996e8e94fa755"
      unitRef="U002">251959</pdsb:FinanceLeaseCost>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="c20240630_RangeAxis_MaximumMember"
      id="Fact_e719eb706b0a415c82cc2e8827d3e8b8">P5Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="c20240630"
      decimals="4"
      id="Fact_56d50fa0256b4c1d9b4b14666c1f68ec"
      unitRef="U004">0.0915</us-gaap:LesseeFinanceLeaseDiscountRate>
    <pdsb:LesseeFinanceLeaseMonthlyRentalExpense
      contextRef="c20240101to20240630"
      decimals="-3"
      id="Fact_9e8de6d9265b4f919da10405e937ceb0"
      unitRef="U002">6000</pdsb:LesseeFinanceLeaseMonthlyRentalExpense>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_7cbeb32ac61b419b8ee3f58fdc73d8ed"
      unitRef="U002">151490</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20240101to20240630"
      id="Text_32a268bf225b4809b33cf77488db16a5">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 6 &#x2013; Accrued Expenses&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Accrued expenses consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;June 30, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Accrued research and development&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;200,699&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&#x2013;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;556,385&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;827,863&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;892,894&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,289,690&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued interest on debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;296,875&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;306,771&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="background-color: #CCEEFF; vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued rent&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
                &lt;div style="margin-left: 9pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,947,221&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;2,424,692&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20240101to20240630"
      id="Text_c8d65d70ec0f4b9390897c4a8e85dfdd">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Accrued expenses consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;June 30, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Accrued research and development&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;200,699&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;&#x2013;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;556,385&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;827,863&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;892,894&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,289,690&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued interest on debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;296,875&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;306,771&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="background-color: #CCEEFF; vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued rent&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
                &lt;div style="margin-left: 9pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,947,221&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;2,424,692&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pdsb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_9f220b571cbc49d2a314ed90b57adbb6"
      unitRef="U002">200699</pdsb:AccruedResearchAndDevelopmentCostsCurrent>
    <pdsb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_3fb4405d0a1942d09e6809280b787f32"
      unitRef="U002">0</pdsb:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_cc894b495b3d4cc6a089474c2af46ff2"
      unitRef="U002">556385</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_48edbadd582d4c0990552189f2e90b27"
      unitRef="U002">827863</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_c4edf79801a44fe9a7443eb4ef920921"
      unitRef="U002">892894</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_15f1a7f50f4b43d88762d0a6165a3ad8"
      unitRef="U002">1289690</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_8541f296d2f443238b7031adfb98e770"
      unitRef="U002">296875</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_2af6bc4ced454a7388ab0cdc477ae675"
      unitRef="U002">306771</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_2729008833b244faaffb5db99728bcc6"
      unitRef="U002">368</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_ecd353adc79d4d2791b6b80348f7b45d"
      unitRef="U002">368</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20240630"
      decimals="0"
      id="Fact_bc20ff5666434347b3ab09fb51b9e15a"
      unitRef="U002">1947221</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="0"
      id="Fact_4161dc5efc4647d38716fdb67d903da5"
      unitRef="U002">2424692</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20240101to20240630"
      id="Text_c437c32b26e1418682eb12f87af9e911">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Note 7 &#x2013; Stock-Based Compensation&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;In 2014, the Company&#x2019;s stockholders approved the 2014
              Equity Incentive Plan (the &#x201c;Original Plan&#x201d;) pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and
              restricted stock units (&#x201c;RSUs&#x201d;), subject to increases as hereafter described (the &#x201c;Plan Limit&#x201d;). In addition, on January 1, 2015, and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the
              terms of the Original Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common
              Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors (&#x201c;Board&#x201d;) may determine in its discretion. In March 2019, the Board adopted and the Company&#x2019;s stockholders approved the Amended
              and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#x201c;Prior Plan&#x201d;) which amended and restated the Original Plan in order to remove the annual increase component and was limited to 826,292 shares.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;On &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 8, 2020,
                      the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#x201c;Restated Plan&#x201d;), which amended and restated the Prior Plan. The Restated
                      Plan is identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock authorized for issuance under the Restated Plan was increased from 826,292 shares to 4,165,535 shares, plus the total number of
                      shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on December 7, 2030, unless
                      earlier terminated.&#160; On May 19, 2023, the Board adopted, subject to stockholder approval, the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the &#x201c;Third Restated Plan&#x201d;). At the 2023 annual meeting
                      of stockholders held on July 14, 2023, the stockholders approved the Third Restated Plan, which amended and restated the Restated Plan to increase the total amount of shares authorized for issuance thereunder. The Third Restated Plan
                      is identical to the Restated Plan in all material respects, except, the number of shares of Common Stock authorized for issuance under the Third Restated Plan increased from 4,165,535 to 6,565,535. As of June 30, 2024, there were 2,301,167 shares available for grant under the Third Restated Plan.&lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Pursuant to the terms of the Third Restated Plan, stock options have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a
            four-year period.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). On December 8, 2020, the Company amended the
                Inducement Plan solely to increase the total number of shares of common stock reserved for issuance under the Inducement Plan from 200,000
                shares to 500,000 shares. On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number
                of shares of Common Stock reserved for issuance under the Inducement Plan from 500,000 shares to 1,100,000 shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common
                Stock reserved for issuance under the Inducement Plan from 1,100,000 shares to 2,100,000 shares. The Inducement Plan provides
                for the grant of non-qualified stock options. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder
                approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq
                  Listing Rules, non-qualified stock options under the Inducement Plan may only be made to an employee who has not previously been an employee of the Company or member of the Board of Directors of the Company (or any parent or subsidiary of
                  the Company), if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into
                  employment with the Company or such subsidiary. As of June 30, 2024, there were 969,407 shares available for grant under the
                  Inducement Plan.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations and
              comprehensive loss for the three and six months ended June 30, 2024 and 2023:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Three Months Ended June 30,&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six months ended June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Stock-Based Compensation&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Research and development&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;609,828&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;806,548&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,161,746&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,607,312&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;General and administrative&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,185,894&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,298,990&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,263,987&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,578,545&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Total&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,795,722&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,105,538&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3,425,733&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,185,857&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;
            &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt; &lt;br class="Apple-interchange-newline"/&gt;
            &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;The Company granted options to purchase 254,000
              and 1,192,648 shares during the three and six month periods ended June 30, 2024, respectively, and granted options to purchase 29,900 and 1,154,500 shares during
              the three and six month period ended June 30, 2023, respectively. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400;"&gt;The fair value of options granted during the three and six months ended June 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model utilizing the
              following assumptions:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Three Months Ended June 30&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six Months Ended June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;106.26&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;143.87&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;137.07&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;142.07&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Risk-Free Interest Rate&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.26&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3.59&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.04&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.05&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Expected Term in Years&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.96&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.06&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Fair Value of Option on Grant Date&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2.86&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.09&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.71&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;10.64&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Number&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;of Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Contractual&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Life in Years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Intrinsic Value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,029,345&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.43&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.42&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,395,227&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Granted&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,192,648&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.12&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9.70&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(156,073&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3.40&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Forfeited and expired&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(502,709&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;8.68&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at &lt;span style="text-indent: 0pt;"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,563,211&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.03&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.46&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;899,228&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,563,211&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.03&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.46&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;899,228&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercisable at &lt;span style="text-indent: 0pt;"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3,043,575&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.79&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.25&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;837,670&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br class="Apple-interchange-newline"/&gt;
          &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;As of June 30, 2024 there was approximately $14,042,395 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 2.84 years.&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_c6aef12ea95f44d4a7f0a391a79c7dd0"
      unitRef="U001">91367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <pdsb:PercentageOfCommonStockOutstanding
      contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="2"
      id="Fact_4112a691f84744918df79867720b18af"
      unitRef="U004">0.04</pdsb:PercentageOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_3c2698f281fd414aaa21a5d25ba0a9f7"
      unitRef="U001">826292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_a8d54a70b2e64630952f1a757c504547"
      unitRef="U001">826292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_f28c4b6ba18140a2aebd4562ac2d5f0f"
      unitRef="U001">4165535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20201208_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_6964c627afb240a78c987cec7e504a88"
      unitRef="U001">4165535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20230714_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_a17a417db0f04da5893bc3fc5fadda59"
      unitRef="U001">6565535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20240630_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_fc157376d4ee4898970544b23f300256"
      unitRef="U001">2301167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember"
      id="Fact_6d46dfdc4d3b4301b67ba2333c878b09">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20240630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember"
      id="Fact_46129184105842319e19f38fc5754212">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20190617_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_acdb4fa2d2b14ed8aa745b3f2f66507a"
      unitRef="U001">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201208_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_59f088e58ce0464d8d2ac39892cf38d6"
      unitRef="U001">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201208_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_3a3b958fc2f74c3fa5089c8a9e2c08ec"
      unitRef="U001">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20220517_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_40e55844e5c040b6b8dcc73950cfc15b"
      unitRef="U001">1100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20240122_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_096fe0152ad547eab6e0105108614494"
      unitRef="U001">2100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20240630_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_031ab312b56340cc90126fa8f65541b2"
      unitRef="U001">969407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20240101to20240630"
      id="Text_0d4ff581aa6d4e7f9a24f2a492e60771">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations and
              comprehensive loss for the three and six months ended June 30, 2024 and 2023:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Three Months Ended June 30,&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six months ended June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Stock-Based Compensation&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Research and development&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;609,828&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;806,548&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,161,746&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,607,312&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;General and administrative&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,185,894&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,298,990&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,263,987&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,578,545&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;Total&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,795,722&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,105,538&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3,425,733&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,185,857&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_b38cc47944d946e89c5643ee4e0c239f"
      unitRef="U002">609828</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_d7a18c3cd4084cdc9218b2a3714c908f"
      unitRef="U002">806548</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_ecccb889ca024a509a5ba7e22f882240"
      unitRef="U002">1161746</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_ac36d3e8fb2445828215f8880840b556"
      unitRef="U002">1607312</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_419201a8b7c04b06b383da94655d2680"
      unitRef="U002">1185894</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_b75938fa8f334097b7dd2d2c0bd06652"
      unitRef="U002">1298990</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_074ca782ad564117a2981a188960f3ce"
      unitRef="U002">2263987</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_3cd0cac24cdd40cb85afd9338e160965"
      unitRef="U002">2578545</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_7ec2276d54ec4ed08faf6c888eaa0b08"
      unitRef="U002">1795722</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_2e7030e205724ae5857338cc2d0f6555"
      unitRef="U002">2105538</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_2c84403a28554ac38c456ffaf5bf28d4"
      unitRef="U002">3425733</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_1e4d41af35984ef1a2d0fc6af723e90f"
      unitRef="U002">4185857</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240401to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_69ee1788d7c64c50a34e3396151cb8e0"
      unitRef="U001">254000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_96487fb65f274d8787d08f9a9715bb8e"
      unitRef="U001">1192648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_a041a66a99dd43b4bd56dbdc385d49d4"
      unitRef="U001">29900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_556b98cc356744fcb83a0675a342ae88"
      unitRef="U001">1154500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20240101to20240630"
      id="Text_d4a54fba219547c5b0abbd8dacdbbc9e">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400;"&gt;The fair value of options granted during the three and six months ended June 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model utilizing the
              following assumptions:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Three Months Ended June 30&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six Months Ended June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;106.26&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;143.87&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;137.07&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;142.07&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Risk-Free Interest Rate&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.26&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3.59&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.04&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.05&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Expected Term in Years&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.96&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.06&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Fair Value of Option on Grant Date&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2.86&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.09&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.71&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;10.64&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240401to20240630"
      decimals="4"
      id="Fact_73622b901ffc40199b5d2b83695fd94f"
      unitRef="U004">1.0626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230401to20230630"
      decimals="4"
      id="Fact_1d0c0f5e187f4a9e88269e7aa21cd68f"
      unitRef="U004">1.4387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20240630"
      decimals="4"
      id="Fact_5eaca980cc4f465ba490e1b729fccf93"
      unitRef="U004">1.3707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230630"
      decimals="4"
      id="Fact_692a1462b6924ec79eac451855dbabd4"
      unitRef="U004">1.4207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240401to20240630"
      decimals="4"
      id="Fact_dd775fd838eb408b9799a75c8e4d4f80"
      unitRef="U004">0.0426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230401to20230630"
      decimals="4"
      id="Fact_65ce4b27490c4c2880eb7cb172c90986"
      unitRef="U004">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20240630"
      decimals="4"
      id="Fact_81db045f554e4a28a310ef860ecd6aea"
      unitRef="U004">0.0404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230630"
      decimals="4"
      id="Fact_ea0a2cb99e6f443595d11302498977ea"
      unitRef="U004">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240401to20240630"
      id="Fact_7c76ab7d9e3b41b58c43f775e541e24b">P5Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230401to20230630"
      id="Fact_20bd16180c9d404f8bbb46156077d83b">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20240630"
      id="Fact_0f048e98534b4214b1b3de890ecb3cf8">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230630"
      id="Fact_fdb0468f70fd41e2a8885ac64d21471c">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_1f400578de334d9c840187a133f579ce"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_70e152a0c2b1442fb6331e1b621923ff"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_45fde375ecf34b45afd6500fcdfde907"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_ed168608831e45019c838f376ccc2f8f"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240401to20240630"
      decimals="2"
      id="Fact_33107a0632ab4ac7a1b166e875e8131a"
      unitRef="U003">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230401to20230630"
      decimals="2"
      id="Fact_6337f650cd6e4903b0626219468c8c15"
      unitRef="U003">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240630"
      decimals="2"
      id="Fact_9264aaadb0d641a4b50da31033d6c9bf"
      unitRef="U003">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20230630"
      decimals="2"
      id="Fact_ce7708181dec4d729cf1cf75899088a6"
      unitRef="U003">10.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20240101to20240630"
      id="Text_eb6c618c5c0b416c89868fac25211833">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Number&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;of Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Contractual&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Life in Years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Intrinsic Value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,029,345&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.43&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.42&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,395,227&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Granted&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,192,648&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.12&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9.70&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(156,073&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3.40&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Forfeited and expired&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(502,709&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;8.68&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at &lt;span style="text-indent: 0pt;"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,563,211&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.03&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.46&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;899,228&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,563,211&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.03&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.46&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;899,228&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercisable at &lt;span style="text-indent: 0pt;"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3,043,575&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.79&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.25&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;837,670&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3dd20bac58f0403da7572a3f59eae646"
      unitRef="U001">5029345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_d4fcfe57034d4e2a8d07ad2bc03991aa"
      unitRef="U003">6.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_87239619c2f64f5bb86bd7d3e5e312d2">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_de5a1dd188134a2f80be658bfbb74bf6"
      unitRef="U002">4395227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_0d2a50d28f274e059d0737f958e99ebb"
      unitRef="U001">1192648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_ca5a83bb9e92485296629d8fdfe0b320"
      unitRef="U003">5.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_3e83006f28cd411eb5321d03e01c8caa">P9Y8M12D</pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_00d006b726e8467db892c02e1eada1a5"
      unitRef="U002">0</pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_e92a47b51a9544b4b96861a9a96718b2"
      unitRef="U001">156073</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_f67fa6be0add49c88512759e93933567"
      unitRef="U003">3.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_c318d1367dc74985a8f1bb10824503e3"
      unitRef="U001">502709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_fbda28039a2e471983f7d83d43c85b18"
      unitRef="U003">8.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_b6651365b81e4cc3a84255f68399c23f"
      unitRef="U001">5563211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_cdb9ab2cabec4ebfb5ad1da6e72a5762"
      unitRef="U003">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_253b8a81d7954c2783c63ce97640507c">P7Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_20c27b33baad4447a9cc3013dace4779"
      unitRef="U002">899228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_05e0c3e590ff4980bf6d3f5073dcbf1d"
      unitRef="U001">5563211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_a1ea890e70ea41aaa549c03df5a95b19"
      unitRef="U003">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_250806dfa0ca4930b910b9ecd357d214">P7Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_25211783475d4d4aace4f3867cb2414c"
      unitRef="U002">899228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ac186c6db3ec470aaa0489c182741184"
      unitRef="U001">3043575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_3c69fce0ae8342bdb77e7deb88ce0619"
      unitRef="U003">5.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_84a7e0113abf4eb5a64b3549108ffab4">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ad817bc788c44c32875ccbb51ed49b77"
      unitRef="U002">837670</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20240630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_f9b4306c2f61451a912edea622bfae4b"
      unitRef="U002">14042395</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20240101to20240630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_9d7edcc5adc946f39e9abe55dd612e45">P2Y10M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20240101to20240630"
      id="Text_860d2874450e4ff6950d5ae9c0b7d227">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 8 &#x2013; Income Taxes&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company records a valuation allowance against its deferred tax
                assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized&lt;/span&gt;. I&lt;/span&gt;n assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and
            negative evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the
            generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for &lt;span style="font-size: 10pt;"&gt;2024&lt;/span&gt; and therefore there will be &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt; current income tax expense.&#160; The Company recorded a full valuation allowance against the net deferred tax assets as of June&lt;span style="font-size: 10pt;"&gt; 30,
              2024&lt;/span&gt; and December 31, &lt;span style="font-size: 10pt;"&gt;2023&lt;/span&gt;. Consequently, the Company recorded &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt; income tax benefit due to realization uncertainties.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is subject to a U.S. federal statutory income tax rate of 21%. The primary factor impacting the effective tax rate for the three and six months ended &lt;span style="font-size: 10pt;"&gt;June 30, 2024&lt;/span&gt; is the anticipated full year
                operating loss which will require a full valuation allowance against any associated net deferred tax assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Entities are required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their
                income tax returns. The Company has analyzed its tax positions and has concluded that as of &lt;span style="font-size: 10pt;"&gt;June 30, 2024&lt;/span&gt;, there were no uncertain positions. The Company&#x2019;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date
                because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties
                for the three and six months ended June&lt;span style="font-size: 10pt;"&gt; 30, 2024&lt;/span&gt; or for the year ended December 31, &lt;span style="font-size: 10pt;"&gt;2023.&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In accordance with the State of
                  New Jersey&#x2019;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL
                  carryforwards, resulting in the recognition of $0.9 million and $1.4 million of income tax benefit, net of transaction costs in the six months ended June 30, 2024 and 2023, respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_7b74f8e6f3dc432db12c79bffdb66310"
      unitRef="U002">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20240101to20240630"
      decimals="-6"
      id="Fact_0dc632c800e04dfb94cfa339ab97b85d"
      unitRef="U002">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20240401to20240630"
      decimals="2"
      id="Fact_644149ac2fad41c998494f1685361914"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20240101to20240630"
      decimals="2"
      id="Fact_150aa9db59e94b9d90086c9325dbed09"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <pdsb:LiabilityForUncertainTaxPositions
      contextRef="c20240630"
      decimals="0"
      id="Fact_d754d07f16e848afb90e73d87b794abf"
      unitRef="U002">0</pdsb:LiabilityForUncertainTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20240630"
      decimals="0"
      id="Fact_82f50ea5cc3f402b91f4ad510a0f9f86"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20231231"
      decimals="0"
      id="Fact_238fe5654c6846bf976d007b353e1400"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="c20231231"
      decimals="0"
      id="Fact_b5e6c3a52ce24dad89b1a7a50ce42f4a"
      unitRef="U002">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="c20240630"
      decimals="0"
      id="Fact_a9c30f66831b4350a2f71b2be9cf54aa"
      unitRef="U002">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20240630"
      decimals="-5"
      id="Fact_39d231b91f0d4a179688098fed546635"
      unitRef="U002">-900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20230630"
      decimals="-5"
      id="Fact_7e243093c14e421fbddf06ab7aa4e0c6"
      unitRef="U002">-1400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20240101to20240630"
      id="Text_52ee43536ad149dfb48cd95e38b71a8a">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 9 &#x2013; Commitments and Contingencies&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
    &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Rent&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and six months ended June 30, 2024 was $66,000 and $132,000 respectively, compared to the three and six months ended June 30, 2023 of $126,532 and $253,202.&lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Exclusive License Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In January 2023, the Company entered into an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting IL 12 fused antibody drug conjugate, M9241 (the &#x201c;Merck KGaA License Agreement&#x201d;).
            Pursuant to the Merck KGaA License Agreement, the Company agreed to make (i) development and first commercial sales milestone payments totaling up to $11
            million upon the achievement of certain milestones, including the dosing of the fifth patient in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up
            to $105 million upon achieving certain aggregate sales levels of the product.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of 10% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) ten years after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in the event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or if
            the Company obtains a license to any intellectual property owned or controlled by a third-party which, but for such license would be infringed by making, using or selling the compound.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;span style="text-decoration: underline;"&gt;Legal Proceedings&lt;/span&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
    &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is currently not a party to,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; and the Company&#x2019;s&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; property is not currently the subject of,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; any &lt;span style="font-size: 10pt;"&gt;material &lt;/span&gt;pending &lt;span style="font-size: 10pt;"&gt;legal proceedings.&lt;/span&gt; The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes that may not be predictable with assurance.&lt;/span&gt;&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_0cc599e7eec14e9292f25f7ea1e11749"
      unitRef="U002">66000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_8a0e82f619704fbe9dcd1cf1f830fe76"
      unitRef="U002">132000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_aa6a6b8e8b3a444cbb32d2e8706e1f80"
      unitRef="U002">126532</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_58363d72c87a4c359724dc959bf67ba8"
      unitRef="U002">253202</us-gaap:OperatingLeaseCost>
    <pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales
      contextRef="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      decimals="-6"
      id="Fact_1e7f44d12a9f406d92b600e90b6f38c5"
      unitRef="U002">11000000</pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales>
    <pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels
      contextRef="c20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember"
      decimals="-6"
      id="Fact_137cb8f125b54b6aa8f70165da80571d"
      unitRef="U002">105000000</pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels>
    <pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct
      contextRef="c20240101to20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      decimals="2"
      id="Fact_65a9466def21466f91f757b2ab743d3b"
      unitRef="U004">0.10</pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct>
    <pdsb:TermOfRoyaltyPayment
      contextRef="c20240101to20240630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      id="Fact_8fa6563452bb4940a933a76552adad4b">P10Y</pdsb:TermOfRoyaltyPayment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20240101to20240630"
      id="Text_1e66b360307945beae775da6db05f15a">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;Note 10 &#x2013; Venture Loan and Security Agreement&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In August 2022, the Company entered into a Venture Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;) with Horizon
            Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#x201c;Collateral Agent&#x201d;), and the other persons party thereto from time to time as lenders (&#x201c;Lenders&#x201d;).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Term loan Amounts&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The Loan and Security Agreement provides for the following six (6) separate and independent term loans: (a) a term loan in the amount of $7,500,000
            (&#x201c;Loan A&#x201d;), (b) a term loan in the amount of $10,000,000 (&#x201c;Loan B&#x201d;), (c) a term loan in the amount of $3,750,000 (&#x201c;Loan C&#x201d;), (d) a term loan in the amount of $3,750,000
            (&#x201c;Loan D&#x201d;), (e) a term loan in the amount of $5,000,000 (&#x201c;Loan E&#x201d;), and (f) a term loan in the amount of $5,000,000 (&#x201c;Loan F&#x201d;) (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a &#x201c;Loan&#x201d; and, collectively, the &#x201c;Loans&#x201d;). &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Loan A, Loan B, Loan C, and Loan D were
            delivered to the Company on August 24, 2022. &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;Loan E and Loan F were uncommitted Loans that could have been advanced by the Lenders upon the parties agreement prior to July
            31, 2023 upon the satisfaction by the Company of certain agreed upon conditions. At&lt;/span&gt; this &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;time the &lt;/span&gt;option&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; has expired and Loan E and Loan F are&lt;/span&gt; no &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;longer available&lt;/span&gt; to the Company &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;under the Loan and
            Security Agreement&lt;/span&gt;. &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;The Company may only use the proceeds of the Loans for working capital or general corporate purposes.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt;Maturity&lt;/span&gt;. Each Loan matures on the 48 month
                anniversary following the applicable date on which a Loan is made to or on account of the &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Company &lt;/span&gt;under the Loan and Security Agreement (the &#x201c;Maturity Date&#x201d;) unless accelerated pursuant to agreed upon events of default. All amounts outstanding under each Loan will be due and payable upon
                the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.&lt;/span&gt; Payments on the principal balance begin on October 1, 2024 and are paid monthly in the succeeding 24 months&lt;span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Interest Rate&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall
            Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#x201c;&lt;span style="-sec-ix-hidden:Fact_89027c97a3984c949cabb17cf3986c08"&gt;prime rate&lt;/span&gt;&#x201d; then in
            effect, plus (b) 5.75%; provided that, in the event such rate of interest is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of
            calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding during the preceding month.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0);"&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Amortization.&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&#160;Each Loan shall commence amortization upon the date set forth on the promissory note executed in connection with the respective Loan, upon which the &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Company &lt;/span&gt;is required to commence making equal payments of principal plus accrued interest on the outstanding principal amount of the respective
            Loan (the &#x201c;Loan Amortization Date&#x201d;), and continuing thereafter on the first business day of each calendar month through the Maturity Date.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Prepayment Premium.&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&#160;The &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Company &lt;/span&gt;may, at its option upon at least ten (10) business days&#x2019; written
            notice to the Lenders, prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each Lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an
            amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date applicable to such Loan, three percent (3%) of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan,
            but on or before the date that is twelve (12) months after such Loan Amortization Date, two percent (2%) of the then outstanding principal balance of
            such Loan, or (C) if such Loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated
            Maturity Date applicable to such Loan, one percent (1%) of the then outstanding principal balance of such Loan;&#160;&lt;span style="font-style: italic;"&gt;plus&lt;/span&gt;&#160;(iii) the outstanding principal balance of such Loan;&#160;&lt;span style="font-style: italic;"&gt;plus&lt;/span&gt;&#160;(iv) all other sums, if any, that shall have become due and payable hereunder. No prepayment premium will be
            applied to any outstanding balance of any Loan paid on the stated Maturity Date.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Security&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company&#x2019;s obligations are secured by a security interest in all of the assets of the Company, subject
            to limited exceptions and excluding the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
       &lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Covenants; Representations and Warranties; Other Provisions&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The Loan and Security Agreement contains customary representations, warranties and covenants, including
            maintenance of minimum cash balances as well as covenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans,
            certain corporate changes, transactions with affiliates, and fundamental changes. As of June 30, 2024, the Company was in compliance with all covenants in all material respects.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Default Provisions&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The Loan and Security Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment,
            breaches or defaults in the performance of covenants, insolvency, and bankruptcy by and/or of the Company.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Warrant and Debt Discount.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; In connection with the Loan and Security Agreement, the Company issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of 381,625 shares of the Company&#x2019;s common stock at an initial exercise price of $3.6685 per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) 10 years from the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or
                substantially all of the Company&#x2019;s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other
                reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of, in
                each case, for cash or for marketable securities meeting certain requirements as described in the applicable warrants. The key assumptions used in the Black-Scholes option pricing model were (i) expected term of &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;10&lt;/span&gt;
                years, (ii) a risk-free rate of &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;3.11%&lt;/span&gt;, (iii) expected volatility of &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;93.8%&lt;/span&gt;, (iv) and &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt; estimated dividend
                yield. In addition, the Company incurred third party and lender fees of $449,329 during the nine months ended September 30, 2022.
                These proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrant and fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the
                Loan and Security Agreement using the effective interest method. The unamortized debt discount was $1,710,639 as of June 30,
                2024.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The Company
                recognized interest expense of $1,184,294 and $2,355,053, and $961,753 and $1,952,272 for the three and six months ended June 30, 2024 and 2023, respectively and $283,774 and $554,010, and $121,997 and $233,523 was related to the amortization of
                the debt discount for the three and six months ended June 30, 2024 and 2023, respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <pdsb:DebtInstrumentNumberOfIndependentTermLoans
      contextRef="c20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_20b962accd3141e689bdfbb169e051d6"
      unitRef="U005">6</pdsb:DebtInstrumentNumberOfIndependentTermLoans>
    <pdsb:DebtInstrumentNumberOfIndependentTermLoans
      contextRef="c20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_3736d53918fc4c31b65025cdd16a00bd"
      unitRef="U005">6</pdsb:DebtInstrumentNumberOfIndependentTermLoans>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanAMember"
      decimals="0"
      id="Fact_f4d7a72863124a92b63d6636eaecbe62"
      unitRef="U002">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanBMember"
      decimals="0"
      id="Fact_2598f545f00c4d849365747be3cb073d"
      unitRef="U002">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanCMember"
      decimals="0"
      id="Fact_fd8f24a09d7e45fda32db3a43fd05c16"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanDMember"
      decimals="0"
      id="Fact_4e6fa4b7814e4868b94615f1f4977ace"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20240630_DebtInstrumentAxis_LoanEMember"
      decimals="0"
      id="Fact_d9c43f4090204364b6ea8d2fa54ca47f"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20240630_DebtInstrumentAxis_LoanFMember"
      decimals="0"
      id="Fact_c394293bc8a548bf9ae743476745cc12"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_98c0875d08c8476abf8fdc195f485bea">P48M</us-gaap:DebtInstrumentTerm>
    <pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_2e7a6319159c4e51af4f181dda9b3895">P24M</pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="4"
      id="Fact_ca83be1c21ff459d94c8d76aba7e3692"
      unitRef="U004">0.0575</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <pdsb:DebtInstrumentMinimumVariableRate
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="4"
      id="Fact_6339d404263c446f9815295df936f308"
      unitRef="U004">0.04</pdsb:DebtInstrumentMinimumVariableRate>
    <pdsb:DebtInstrumentMinimumVariableRate
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="4"
      id="Fact_ed3682dd8d2e4ea8b224716235316f53"
      unitRef="U004">0.04</pdsb:DebtInstrumentMinimumVariableRate>
    <pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      id="Fact_2a5e5626da0946349c64a0704271738d">P10D</pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod1
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_697fd35d900543ad9404f3365000416e"
      unitRef="U004">0.03</pdsb:DebtInstrumentPrepaymentPremiumPeriod1>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod1
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_c4029ad6060643f68be8d73f66bcb90d"
      unitRef="U004">0.03</pdsb:DebtInstrumentPrepaymentPremiumPeriod1>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_0f5aa54f278a4772af6b1e50e9bebe8a">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod2
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_e6f619f0422843669eae8f93528c42a6"
      unitRef="U004">0.02</pdsb:DebtInstrumentPrepaymentPremiumPeriod2>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod2
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_31cf549d4dbb43429751829ab5c76c64"
      unitRef="U004">0.02</pdsb:DebtInstrumentPrepaymentPremiumPeriod2>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_0bea390f660c404ca08ac7e5b087bf06">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod3
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_24651e45dbe741dd834a0cd540b31cf3"
      unitRef="U004">0.01</pdsb:DebtInstrumentPrepaymentPremiumPeriod3>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod3
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_979dc69d94a14e06a971273c6e72f94a"
      unitRef="U004">0.01</pdsb:DebtInstrumentPrepaymentPremiumPeriod3>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod4
      contextRef="c20240101to20240630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_0e9aee95847d4b66b8a8ad9ace42217a"
      unitRef="U004">0</pdsb:DebtInstrumentPrepaymentPremiumPeriod4>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220831"
      decimals="0"
      id="Fact_ed2f30ff2c8542778fb1e7b754510893"
      unitRef="U001">381625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220831"
      decimals="4"
      id="Fact_7d306780cb664bb39d2fabf80065c90b"
      unitRef="U003">3.6685</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20240630"
      id="Fact_696abf53c34740be9e514b8cd5f4ae02">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pdsb:PercentageOfVotingPowerDisposedOff
      contextRef="c20240101to20240630_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_a64577487c654e08898a33712b9b40fa"
      unitRef="U004">0.50</pdsb:PercentageOfVotingPowerDisposedOff>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_6fbeade6f579427f81deb0ca14e26b7a">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_37503b5edd4b4110982a8f67ed265905"
      unitRef="U004">0.0311</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="Fact_b6fd6cac954c4f4a8941661a2d573458"
      unitRef="U004">0.938</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20240630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="0"
      id="Fact_a8de3c7b652d4c0ca73ff79de2aa0388"
      unitRef="U004">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c20220101to20220930"
      decimals="0"
      id="Fact_3519c2c4ed944bb998f5e81c9eac0fa2"
      unitRef="U002">449329</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20240630"
      decimals="0"
      id="Fact_f18071a71cff464bb6101c1847ebf1f3"
      unitRef="U002">1710639</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_6f024079c07344daa6048911035ee179"
      unitRef="U002">1184294</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_3e0bb71891ed462d8cf7c722c04b388d"
      unitRef="U002">2355053</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_ba20457f91744e31b589ab92918e68b2"
      unitRef="U002">961753</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_f04b61add8724e5fb4105ce2087612c9"
      unitRef="U002">1952272</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_9e1984055b2c4ab4aec36369d170cfc4"
      unitRef="U002">283774</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_19173240c273496080b2332af033408a"
      unitRef="U002">554010</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_a09eddb5e2354ceba4144a9fce5ea34a"
      unitRef="U002">121997</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_e50680fe25a742a38d4221d8e69d175c"
      unitRef="U002">233523</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="c20240101to20240630"
      id="Text_a6cabaaa720442fdb8bc1481eada5813">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 11 &#x2013; Retirement Plan&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"&gt;The
                Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $46,995 and $113,483 for the three
                and six months ended June 30, 2024, respectively, compared to the three and six months ended June 30, 2023 of $36,863 and $131,769, respectively.&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20240401to20240630"
      decimals="0"
      id="Fact_2eb593eb78ab40028861b7fe47008ed4"
      unitRef="U002">46995</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20240101to20240630"
      decimals="0"
      id="Fact_805668b1ef6e444fbfbffd866e916b0c"
      unitRef="U002">113483</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_5e0c1bd3ea104148ae0635853cf0f140"
      unitRef="U002">36863</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_59fcd1af036a4e6f8e1113af5f54f06c"
      unitRef="U002">131769</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="c20240401to20240630"
      id="Fact_dd7a3b2cdaeb446fafcba81314d7e6d4">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="c20240401to20240630"
      id="Fact_c1ab8f79ebcf4a3eb66f08d804e25338">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="c20240401to20240630"
      id="Fact_92e765a356ea4642b594db621e952dca">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="c20240401to20240630"
      id="Fact_23d9d23af62443049bf70dfcce0911cb">false</ecd:Rule10b51ArrAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
